Datasets:

sabareesh88

/

FNSPID_nasdaq

like 0

0.0

2023-12-16 23:00:00 UTC

Interesting A Put And Call Options For August 2024

A

https://www.nasdaq.com/articles/interesting-a-put-and-call-options-for-august-2024

Investors in Agilent Technologies, Inc. (Symbol: A) saw new options begin trading this week, for the August 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the A options chain for the new August 2024 contracts and identified one put and one call contract of particular interest. The put contract at the $125.00 strike price has a current bid of $4.50. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $125.00, but will also collect the premium, putting the cost basis of the shares at $120.50 (before broker commissions). To an investor already interested in purchasing shares of A, that could represent an attractive alternative to paying $138.99/share today. Because the $125.00 strike represents an approximate 10% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 77%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 3.60% return on the cash commitment, or 5.45% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for Agilent Technologies, Inc., and highlighting in green where the $125.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $150.00 strike price has a current bid of $8.10. If an investor was to purchase shares of A stock at the current price level of $138.99/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $150.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 13.75% if the stock gets called away at the August 2024 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if A shares really soar, which is why looking at the trailing twelve month trading history for Agilent Technologies, Inc., as well as studying the business fundamentals becomes important. Below is a chart showing A's trailing twelve month trading history, with the $150.00 strike highlighted in red: Considering the fact that the $150.00 strike represents an approximate 8% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 53%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 5.83% boost of extra return to the investor, or 8.83% annualized, which we refer to as the YieldBoost. The implied volatility in the put contract example is 32%, while the implied volatility in the call contract example is 29%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $138.99) to be 27%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of Stocks Analysts Like » Also see: • Canadian Stocks Crossing Below Their 200 Day Moving Avg • Funds Holding SNUG • CCE Insider Buying The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Because the $125.00 strike represents an approximate 10% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. Of course, a lot of upside could potentially be left on the table if A shares really soar, which is why looking at the trailing twelve month trading history for Agilent Technologies, Inc., as well as studying the business fundamentals becomes important. Below is a chart showing A's trailing twelve month trading history, with the $150.00 strike highlighted in red: Considering the fact that the $150.00 strike represents an approximate 8% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected.

The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 77%. Below is a chart showing the trailing twelve month trading history for Agilent Technologies, Inc., and highlighting in green where the $125.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $150.00 strike price has a current bid of $8.10. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 53%.

Below is a chart showing the trailing twelve month trading history for Agilent Technologies, Inc., and highlighting in green where the $125.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $150.00 strike price has a current bid of $8.10. Below is a chart showing A's trailing twelve month trading history, with the $150.00 strike highlighted in red: Considering the fact that the $150.00 strike represents an approximate 8% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted).

At Stock Options Channel, our YieldBoost formula has looked up and down the A options chain for the new August 2024 contracts and identified one put and one call contract of particular interest. Should the contract expire worthless, the premium would represent a 3.60% return on the cash commitment, or 5.45% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing A's trailing twelve month trading history, with the $150.00 strike highlighted in red: Considering the fact that the $150.00 strike represents an approximate 8% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected.

1.0

2023-12-12 00:00:00 UTC

Wolfe Research Initiates Coverage of Agilent Technologies (A) with Outperform Recommendation

A

https://www.nasdaq.com/articles/wolfe-research-initiates-coverage-of-agilent-technologies-a-with-outperform-recommendation

Fintel reports that on December 13, 2023, Wolfe Research initiated coverage of Agilent Technologies (NYSE:A) with a Outperform recommendation. Analyst Price Forecast Suggests 1.04% Downside As of November 27, 2023, the average one-year price target for Agilent Technologies is 132.34. The forecasts range from a low of 101.00 to a high of $157.50. The average price target represents a decrease of 1.04% from its latest reported closing price of 133.74. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 4.35%. The projected annual non-GAAP EPS is 5.77. Agilent Technologies Declares $0.24 Dividend On November 15, 2023 the company declared a regular quarterly dividend of $0.24 per share ($0.94 annualized). Shareholders of record as of January 2, 2024 will receive the payment on January 24, 2024. Previously, the company paid $0.22 per share. At the current share price of $133.74 / share, the stock's dividend yield is 0.71%. Looking back five years and taking a sample every week, the average dividend yield has been 0.72%, the lowest has been 0.44%, and the highest has been 1.14%. The standard deviation of yields is 0.14 (n=235). The current dividend yield is 0.12 standard deviations below the historical average. Additionally, the company's dividend payout ratio is 0.22. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5. The company's 3-Year dividend growth rate is 0.22%, demonstrating that it has increased its dividend over time. What is the Fund Sentiment? There are 1945 funds or institutions reporting positions in Agilent Technologies. This is an increase of 30 owner(s) or 1.57% in the last quarter. Average portfolio weight of all funds dedicated to A is 0.31%, a decrease of 2.75%. Total shares owned by institutions increased in the last three months by 1.25% to 300,740K shares. The put/call ratio of A is 1.01, indicating a bearish outlook. What are Other Shareholders Doing? Massachusetts Financial Services holds 11,076K shares representing 3.79% ownership of the company. In it's prior filing, the firm reported owning 11,037K shares, representing an increase of 0.35%. The firm increased its portfolio allocation in A by 546.51% over the last quarter. Wellington Management Group Llp holds 10,256K shares representing 3.51% ownership of the company. In it's prior filing, the firm reported owning 8,736K shares, representing an increase of 14.81%. The firm increased its portfolio allocation in A by 15.48% over the last quarter. T. Rowe Price Investment Management holds 10,122K shares representing 3.47% ownership of the company. In it's prior filing, the firm reported owning 9,968K shares, representing an increase of 1.53%. The firm decreased its portfolio allocation in A by 2.00% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,113K shares representing 3.12% ownership of the company. In it's prior filing, the firm reported owning 9,177K shares, representing a decrease of 0.70%. The firm decreased its portfolio allocation in A by 4.15% over the last quarter. Price T Rowe Associates holds 7,386K shares representing 2.53% ownership of the company. In it's prior filing, the firm reported owning 8,054K shares, representing a decrease of 9.05%. The firm decreased its portfolio allocation in A by 10.32% over the last quarter. Agilent Technologies Background Information (This description is provided by the company.) Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits. Click to Learn More This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Fintel reports that on December 13, 2023, Wolfe Research initiated coverage of Agilent Technologies (NYSE:A) with a Outperform recommendation. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

T. Rowe Price Investment Management holds 10,122K shares representing 3.47% ownership of the company. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,113K shares representing 3.12% ownership of the company. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more.

Agilent Technologies Declares $0.24 Dividend On November 15, 2023 the company declared a regular quarterly dividend of $0.24 per share ($0.94 annualized). In it's prior filing, the firm reported owning 11,037K shares, representing an increase of 0.35%. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,113K shares representing 3.12% ownership of the company.

The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 4.35%. At the current share price of $133.74 / share, the stock's dividend yield is 0.71%. Additionally, the company's dividend payout ratio is 0.22.

2.0

2023-12-12 00:00:00 UTC

Agilent Technologies Reaches Analyst Target Price

A

https://www.nasdaq.com/articles/agilent-technologies-reaches-analyst-target-price-0

In recent trading, shares of Agilent Technologies, Inc. (Symbol: A) have crossed above the average analyst 12-month target price of $132.36, changing hands for $133.74/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 14 different analyst targets within the Zacks coverage universe contributing to that average for Agilent Technologies, Inc., but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $100.00. And then on the other side of the spectrum one analyst has a target as high as $146.00. The standard deviation is $12.779. But the whole reason to look at the average A price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with A crossing above that average target price of $132.36/share, investors in A have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $132.36 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Agilent Technologies, Inc.: RECENT A ANALYST RATINGS BREAKDOWN » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 7 9 9 9 Buy ratings: 0 0 0 0 Hold ratings: 7 5 5 4 Sell ratings: 0 0 0 0 Strong sell ratings: 1 1 1 1 Average rating: 2.2 1.93 1.93 1.86 The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on A — FREE. The Top 25 Broker Analyst Picks of the S&P 500 » Also see: • PXMD Insider Buying • ETM Insider Buying • Funds Holding FXG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In recent trading, shares of Agilent Technologies, Inc. (Symbol: A) have crossed above the average analyst 12-month target price of $132.36, changing hands for $133.74/share. And so with A crossing above that average target price of $132.36/share, investors in A have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $132.36 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? The Top 25 Broker Analyst Picks of the S&P 500 » Also see: • PXMD Insider Buying • ETM Insider Buying • Funds Holding FXG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In recent trading, shares of Agilent Technologies, Inc. (Symbol: A) have crossed above the average analyst 12-month target price of $132.36, changing hands for $133.74/share. » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 7 9 9 9 Buy ratings: 0 0 0 0 Hold ratings: 7 5 5 4 Sell ratings: 0 0 0 0 Strong sell ratings: 1 1 1 1 Average rating: 2.2 1.93 1.93 1.86 The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. The Top 25 Broker Analyst Picks of the S&P 500 » Also see: • PXMD Insider Buying • ETM Insider Buying • Funds Holding FXG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. There are 14 different analyst targets within the Zacks coverage universe contributing to that average for Agilent Technologies, Inc., but the average is just that — a mathematical average. » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 7 9 9 9 Buy ratings: 0 0 0 0 Hold ratings: 7 5 5 4 Sell ratings: 0 0 0 0 Strong sell ratings: 1 1 1 1 Average rating: 2.2 1.93 1.93 1.86 The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell.

When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 14 different analyst targets within the Zacks coverage universe contributing to that average for Agilent Technologies, Inc., but the average is just that — a mathematical average.

3.0

2023-12-07 00:00:00 UTC

Agilent (A) Enhances BioTek Cytation C10 With New Technology

A

https://www.nasdaq.com/articles/agilent-a-enhances-biotek-cytation-c10-with-new-technology

Agilent Technologies A is enhancing its BioTek product line on the back of portfolio expansions and technology upgrades. Notably, Agilent enhanced the BioTek Cytation C10 confocal imaging reader with the addition of water immersion and confocal spinning disk technology. Further, the water immersion technology can be used in light microscopy to increase numerical aperture, reduce z-axis distortion, and improve image quality by placing water between the objective lens and sample. Additionally, the technology aids researchers in reducing exposure times in live-cell applications, thereby reducing the traditional phototoxic effects associated with these experiments. Moreover, this addition offers a deep-sectioning spinning disk technology, enhancing microscopic images by blocking out-of-focus light, resulting in clearer, more quantitative results. Agilent is anticipated to gain significant traction among researchers utilizing live-cell and 3D applications on the back of its latest move. Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote Growth Prospects The latest move positions the company well to strengthen its footing in the global microplate reader and live cell imaging markets. Per a Grand View Research report, the global microplate reader market is expected to grow at a CAGR of 7.6% during the forecast period 2023-2030. A Mordor Intelligence report indicates the global live cell imaging market size will reach $2.95 billion by 2028, exhibiting a CAGR of 7.06% between 2023 and 2028. We believe the company’s solid prospects in these promising markets are expected to instill investor optimism in the stock. However, the company has been suffering from macroeconomic uncertainties, weak momentum in China, rising inflationary pressure and geo-political tensions. Agilent has lost 13.9% in the year-to-date period against the industry’s growth of 0.9%. ACG Segment in Focus The latest move bodes well for the company’s growing efforts toward bolstering its Agilent CrossLab Group (ACG) segment. Notably, Agilent Technologies launched Gen6 software for all Agilent BioTek detection instruments, offering automated optimization tools and improved navigation through built-in data analysis functions. Further, the company introduced the Agilent BioTek 406 FX washer dispenser, a compact tool that combines reagent dispensing and plate-washing, suitable for automated systems and benchtop use. All the abovementioned endeavors are likely to aid the performance of the ACG segment in the days ahead. In fourth-quarter fiscal 2023, the ACG segment revenues increased 6% year over year to $404 million, accounting for 24% of total revenues. Our model projects fiscal 2024 ACG segment revenues at $1.64 billion, indicating growth of 4.7% from 2022. Strong momentum in the underlined segment will likely aid its overall financial performance in the upcoming period. Zacks Rank & Stocks to Consider Currently, Agilent carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader technology sector are Badger Meter BMI, Arista Networks ANET and Adobe ADBE. While Badger Meter currently sports a Zacks Rank #1 (Strong Buy), Arista Networks and Adobe carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here. Shares of Badger Meter have gained 37.8% in the year-to-date period. BMI’s long-term earnings growth rate is currently projected at 20.39%. Shares of Arista Networks have surged 75.9% in the year-to-date period. The long-term earnings growth rate for ANET is currently projected at 19.77%. Shares of Adobe have gained 84.3% in the year-to-date period. ADBE’s long-term earnings growth rate is currently projected at 13.54%. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Badger Meter, Inc. (BMI) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Adobe Inc. (ADBE) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Per a Grand View Research report, the global microplate reader market is expected to grow at a CAGR of 7.6% during the forecast period 2023-2030. A Mordor Intelligence report indicates the global live cell imaging market size will reach $2.95 billion by 2028, exhibiting a CAGR of 7.06% between 2023 and 2028. Some better-ranked stocks in the broader technology sector are Badger Meter BMI, Arista Networks ANET and Adobe ADBE.

Notably, Agilent enhanced the BioTek Cytation C10 confocal imaging reader with the addition of water immersion and confocal spinning disk technology. While Badger Meter currently sports a Zacks Rank #1 (Strong Buy), Arista Networks and Adobe carry a Zacks Rank #2 (Buy) at present. Click to get this free report Badger Meter, Inc. (BMI) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Adobe Inc. (ADBE) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report To read this article on Zacks.com click here.

Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote Growth Prospects The latest move positions the company well to strengthen its footing in the global microplate reader and live cell imaging markets. Zacks Rank & Stocks to Consider Currently, Agilent carries a Zacks Rank #4 (Sell). Click to get this free report Badger Meter, Inc. (BMI) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Adobe Inc. (ADBE) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report To read this article on Zacks.com click here.

Notably, Agilent enhanced the BioTek Cytation C10 confocal imaging reader with the addition of water immersion and confocal spinning disk technology. Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote Growth Prospects The latest move positions the company well to strengthen its footing in the global microplate reader and live cell imaging markets. All the abovementioned endeavors are likely to aid the performance of the ACG segment in the days ahead.

4.0

2023-12-07 00:00:00 UTC

Pre-Market Most Active for Dec 7, 2023 : SQQQ, PLTR, TQQQ, ALT, UBER, PFE, GILD, MRK, AMD, NIO, JBLU, AI

A

https://www.nasdaq.com/articles/pre-market-most-active-for-dec-7-2023-%3A-sqqq-pltr-tqqq-alt-uber-pfe-gild-mrk-amd-nio-jblu

The NASDAQ 100 Pre-Market Indicator is up 70.21 to 15,858.26. The total Pre-Market volume is currently 39,237,818 shares traded. The following are the most active stocks for the pre-market session: ProShares UltraPro Short QQQ (SQQQ) is -0.15 at $16.37, with 2,061,124 shares traded. This represents a 6.64% increase from its 52 Week Low. Palantir Technologies Inc. (PLTR) is +0.32 at $17.45, with 1,538,113 shares traded. PLTR's current last sale is 109.06% of the target price of $16. ProShares UltraPro QQQ (TQQQ) is +0.42 at $42.94, with 1,408,932 shares traded. This represents a 166.71% increase from its 52 Week Low. Altimmune, Inc. (ALT) is +0.04 at $6.92, with 1,312,522 shares traded. As reported by Zacks, the current mean recommendation for ALT is in the "buy range". Uber Technologies, Inc. (UBER) is -0.1504 at $59.60, with 1,305,966 shares traded. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2023. The consensus EPS forecast is $0.15. As reported by Zacks, the current mean recommendation for UBER is in the "buy range". Pfizer, Inc. (PFE) is +0.08 at $28.87, with 1,143,924 shares traded. PFE's current last sale is 78.03% of the target price of $37. Gilead Sciences, Inc. (GILD) is unchanged at $79.36, with 1,093,482 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2024. The consensus EPS forecast is $1.82. As reported by Zacks, the current mean recommendation for GILD is in the "buy range". Merck & Company, Inc. (MRK) is -0.25 at $105.38, with 1,073,394 shares traded. As reported by Zacks, the current mean recommendation for MRK is in the "buy range". Advanced Micro Devices, Inc. (AMD) is +3.53 at $120.35, with 917,522 shares traded. As reported by Zacks, the current mean recommendation for AMD is in the "buy range". NIO Inc. (NIO) is +0.0803 at $7.83, with 865,295 shares traded. NIO's current last sale is 66.64% of the target price of $11.75. JetBlue Airways Corporation (JBLU) is +0.39 at $5.12, with 842,311 shares traded. JBLU's current last sale is 89.04% of the target price of $5.75. C3.ai, Inc. (AI) is -2.88 at $26.28, with 641,132 shares traded. AI's current last sale is 95.56% of the target price of $27.5. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

ProShares UltraPro Short QQQ (SQQQ) is -0.15 at $16.37, with 2,061,124 shares traded. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2023. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2024.

As reported by Zacks, the current mean recommendation for ALT is in the "buy range". Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2023. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2024.

The total Pre-Market volume is currently 39,237,818 shares traded. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2023. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2024.

The NASDAQ 100 Pre-Market Indicator is up 70.21 to 15,858.26. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2023. C3.ai, Inc. (AI) is -2.88 at $26.28, with 641,132 shares traded.

5.0

2023-12-05 00:00:00 UTC

A Quantitative Stock Analysis

A

https://www.nasdaq.com/articles/a-quantitative-stock-analysis-2

Below is Validea's guru fundamental report for AGILENT TECHNOLOGIES INC (A). Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. AGILENT TECHNOLOGIES INC (A) is a large-cap growth stock in the Scientific & Technical Instr. industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: FAIL CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks Financial Planning Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.

Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks Financial Planning Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends.

Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks Financial Planning Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends.

Below is Validea's guru fundamental report for AGILENT TECHNOLOGIES INC (A). Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing.

6.0

2023-11-24 00:00:00 UTC

The Zacks Analyst Blog Highlights Visa, Marriott International, Parker-Hannifin, FedEx and Agilent Technologies

A

https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-visa-marriott-international-parker-hannifin-fedex-and

For Immediate Release Chicago, IL – November 24, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa Inc. V, Marriott International, Inc. MAR, Parker-Hannifin Corp. PH, FedEx Corp. FDX and Agilent Technologies, Inc. A. Here are highlights from Wednesday’s Analyst Blog: Top Research Reports for Visa, Marriott International and Parker-Hannifin The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc., Marriott International, Inc. and Parker-Hannifin Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today's research reports here >>> Visa's shares have outperformed the Zacks Financial Transaction Services industry over the past year (+20.9% vs. +15.7%). The company's stock prices has consistently outperformed the industry, driven by strategic acquisitions and alliances fostering long-term growth. The fourth quarter fiscal 2023 earnings beat estimates, fueled by increased payments and sustained investments in technology. The ongoing shift to digital payments is advantageous for Visa, with strong domestic volumes supporting overall performance. A robust cash position enables the company to enhance shareholder value. However, elevated operating expenses pose margin challenges. Increased client incentives may impact the top line. Additionally, it is witnessing a declining cash volume from the Asia Pacific and CEMEA regions. As such the stock warrants a cautious stance. (You can read the full research report on Visa here >>>) Shares of Marriott International have outperformed the Zacks Hotels and Motels industry over the year-to-date period (+40.6% vs. +22.9%). The company's upside was backed by robust leisure demand and solid global booking trends. Also, substantial RevPAR growth in international markets added to the upside. In the quarter, RevPAR for worldwide comparable system-wide properties increased 8.8% year over year. Also, the emphasis on expansion initiatives, digital innovation and the loyalty program bode well. During the quarter, the company added 97 properties to its worldwide lodging portfolio. However, challenging macroeconomic conditions and high debt remain a concern. Earnings estimates for 2023 have declined in the past 30 days. (You can read the full research report on Marriott International here >>>) Shares ofParker-Hannifin have outperformed the Zacks Manufacturing - General Industrial industry over the year-to-date period (+51.1% vs. +12.0%). The company is benefiting from higher demand from distributors and end users across the oil and gas, material handling, cars and light trucks, and farm and agriculture markets in the North American region within the Diversified Industrial segment. Higher volume across all businesses, especially the commercial and military aftermarket businesses bolstered the company's Aerospace Systems unit. Synergies from the Meggitt buyout (September 2022) are also aiding the company. Benefits from the Win strategy are driving Parker-Hannifin's margins. The company's measures to add shareholder value hold promise. However, the escalating cost of sales and rising selling, general and administrative expenses pose a threat to its bottom line. Foreign currency headwinds may dent PH's top line. A weak liquidity position is also worrisome. (You can read the full research report on Parker-Hannifin here >>>) Other noteworthy reports we are featuring today include FedEx Corp. and Agilent Technologies, Inc.. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@zacks.com https://www.zacks.com Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Visa Inc. (V) : Free Stock Analysis Report Marriott International, Inc. (MAR) : Free Stock Analysis Report Parker-Hannifin Corporation (PH) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report FedEx Corporation (FDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stocks recently featured in the blog include: Visa Inc. V, Marriott International, Inc. MAR, Parker-Hannifin Corp. PH, FedEx Corp. FDX and Agilent Technologies, Inc. A. The company is benefiting from higher demand from distributors and end users across the oil and gas, material handling, cars and light trucks, and farm and agriculture markets in the North American region within the Diversified Industrial segment. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security.

Stocks recently featured in the blog include: Visa Inc. V, Marriott International, Inc. MAR, Parker-Hannifin Corp. PH, FedEx Corp. FDX and Agilent Technologies, Inc. A. Here are highlights from Wednesday’s Analyst Blog: Top Research Reports for Visa, Marriott International and Parker-Hannifin The Zacks Research Daily presents the best research output of our analyst team. Click to get this free report Visa Inc. (V) : Free Stock Analysis Report Marriott International, Inc. (MAR) : Free Stock Analysis Report Parker-Hannifin Corporation (PH) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report FedEx Corporation (FDX) : Free Stock Analysis Report To read this article on Zacks.com click here.

Here are highlights from Wednesday’s Analyst Blog: Top Research Reports for Visa, Marriott International and Parker-Hannifin The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc., Marriott International, Inc. and Parker-Hannifin Corp. Click to get this free report Visa Inc. (V) : Free Stock Analysis Report Marriott International, Inc. (MAR) : Free Stock Analysis Report Parker-Hannifin Corporation (PH) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report FedEx Corporation (FDX) : Free Stock Analysis Report To read this article on Zacks.com click here.

Here are highlights from Wednesday’s Analyst Blog: Top Research Reports for Visa, Marriott International and Parker-Hannifin The Zacks Research Daily presents the best research output of our analyst team. A robust cash position enables the company to enhance shareholder value. In the quarter, RevPAR for worldwide comparable system-wide properties increased 8.8% year over year.

7.0

2023-11-22 00:00:00 UTC

3 Biotech Stocks With Big-Time Breakthrough Potential

A

https://www.nasdaq.com/articles/3-biotech-stocks-with-big-time-breakthrough-potential

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In a world in constant evolution and growth, more and more companies are needed that are committed to development and research in the health area. These biotech companies are not only doing the job, but also have potential for future growth. Let’s take a quick look at these biotech stocks to buy. Agilent (A) Source: Michael Vi / Shutterstock.com Agilent Technologies (NYSE:A) is a key player in the life sciences industry, providing vital solutions for laboratories and research facilities. Although it is not a traditional biotech company, its impact on the biotech and healthcare sectors is notable. In their recent third quarter report, they faced a 2.7% decline in year-on-year revenues, reflecting weaker market conditions. However, the company demonstrated its resilience, showing a 7% increase in non-GAAP net income. Despite these challenges, Agilent adjusted its outlook for the year, anticipating a 0.7% decline to flat growth. One positive aspect of the report is Agilent’s commitment to shareholders, as evidenced by the 5% increase in the quarterly dividend, reflecting confidence in the company’s financial position. This move may appeal to investors looking for stable returns. On the biotech front, they received FDA approval for their PD-L1 IHC 22C3 pharmDx PD-L1 IHC 22C3 pharmDx as a diagnostic tool. This approval is crucial for identifying patients with gastric or gastroesophageal junction adenocarcinoma eligible for treatment with KEYTRUDA, an anti-PD-1 therapy developed by Merck (NYSE:MRK). The significance lies in the fact that PD-L1 IHC 22C3 pharmDx is the only FDA-approved companion diagnostic for this purpose, demonstrating Agilent’s leadership in the development of companion diagnostics. Exact Sciences (EXAS) Source: Tada Images / Shutterstock Exact Sciences (NASDAQ:EXAS) stands out as a key player in the field of cancer detection and diagnostics, attracting the attention of investors seeking innovative opportunities. Its recent financial report for the third quarter of 2023 reveals impressive growth, with total revenues of $628 million, a significant 20% increase over the same period last year. Core revenues, excluding exceptionals, showed an even more remarkable increase of 23%, driven by a 31% increase in the Screening segment and a 3% increase in Precision Oncology revenues. In particular, Exact Sciences made waves with the groundbreaking BLUE-C assay results presented at the 2023 Annual Meeting of the American College of Gastroenterology. The next-generation Cologuard test showed an exceptional sensitivity of 94% for colorectal cancer with a specificity of 91%, outperforming fecal immunochemical tests (FIT) in detecting cancer or pre-cancer. In addition, the test demonstrated higher sensitivity for advanced precancerous lesions compared to FIT. Beyond the financial success, they showed their commitment to advancing cancer detection and treatment at the European Society for Medical Oncology Congress 2023. The company presented data on its blood-based early detection program for multiple cancers and results from OncoExTra, which provides information on actionable fusions in people with solid tumors. Soleno Therapeutics (SLNO) Source: aslysun / Shutterstock.com Soleno Therapeutics (NASDAQ:SLNO) is like a medical beacon working passionately in the field of rare diseases. Its flagship, diazoxide choline extended-release tablets (DCCR), has recently achieved great success in the treatment of Prader-Willi syndrome (PWS). In a long-term study, DCCR showed a statistically significant improvement over placebo, bringing hope and good vibes to those suffering from this difficult syndrome. What is even more encouraging is that DCCR is not only effective, but also a good teammate, as it is generally well tolerated and has no unexpected safety issues. These findings, presented at the Prader-Willi Research Foundation Symposium, are like a victory cheer for both the scientific community and the individuals and families affected by PWS. But these are not just victories on the medical front. Soleno, as a company, is making strategic moves on the financial front. Closing a round of funding to the tune of $129 million is like giving a strong dose of energy to their research and development efforts. They have even welcomed new members to their board, such as industry veteran Matthew Pauls, and added Dr. Mike Huang to their clinical development team. Looking at their playbook, Soleno is not slowing down. They have published results, are making financial moves, and with an NDA submission for DCCR on the horizon, it looks like they are gearing up for a groundbreaking chapter in their journey to make a meaningful impact on rare diseases. As of this writing, Gabriel Osorio-Mazzilli did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines (no position) Gabriel Osorio is a former Goldman Sachs and Citigroup employee. He possesses discipline in bottom-up value investing and volatility-based long/short equities trading. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors The post 3 Biotech Stocks With Big-Time Breakthrough Potential appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This approval is crucial for identifying patients with gastric or gastroesophageal junction adenocarcinoma eligible for treatment with KEYTRUDA, an anti-PD-1 therapy developed by Merck (NYSE:MRK). The company presented data on its blood-based early detection program for multiple cancers and results from OncoExTra, which provides information on actionable fusions in people with solid tumors. In a long-term study, DCCR showed a statistically significant improvement over placebo, bringing hope and good vibes to those suffering from this difficult syndrome.

Exact Sciences (EXAS) Source: Tada Images / Shutterstock Exact Sciences (NASDAQ:EXAS) stands out as a key player in the field of cancer detection and diagnostics, attracting the attention of investors seeking innovative opportunities. Beyond the financial success, they showed their commitment to advancing cancer detection and treatment at the European Society for Medical Oncology Congress 2023. Soleno Therapeutics (SLNO) Source: aslysun / Shutterstock.com Soleno Therapeutics (NASDAQ:SLNO) is like a medical beacon working passionately in the field of rare diseases.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In a world in constant evolution and growth, more and more companies are needed that are committed to development and research in the health area. One positive aspect of the report is Agilent’s commitment to shareholders, as evidenced by the 5% increase in the quarterly dividend, reflecting confidence in the company’s financial position. Exact Sciences (EXAS) Source: Tada Images / Shutterstock Exact Sciences (NASDAQ:EXAS) stands out as a key player in the field of cancer detection and diagnostics, attracting the attention of investors seeking innovative opportunities.

Let’s take a quick look at these biotech stocks to buy. One positive aspect of the report is Agilent’s commitment to shareholders, as evidenced by the 5% increase in the quarterly dividend, reflecting confidence in the company’s financial position. Soleno, as a company, is making strategic moves on the financial front.

8.0

2023-11-22 00:00:00 UTC

Top Research Reports for Visa, Marriott International & Parker-Hannifin

A

https://www.nasdaq.com/articles/top-research-reports-for-visa-marriott-international-parker-hannifin

Wednesday, November 22, 2023 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Marriott International, Inc. (MAR) and Parker-Hannifin Corp. (PH). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>> Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the past year (+20.9% vs. +15.7%). The company’s stock prices has consistently outperformed the industry, driven by strategic acquisitions and alliances fostering long-term growth. The fourth quarter fiscal 2023 earnings beat estimates, fueled by increased payments and sustained investments in technology. The ongoing shift to digital payments is advantageous for Visa, with strong domestic volumes supporting overall performance. A robust cash position enables the company to enhance shareholder value. However, elevated operating expenses pose margin challenges. Increased client incentives may impact the top line. Additionally, it is witnessing a declining cash volume from the Asia Pacific and CEMEA regions. As such the stock warrants a cautious stance. (You can read the full research report on Visa here >>>) Shares of Marriott International have outperformed the Zacks Hotels and Motels industry over the year-to-date period (+40.6% vs. +22.9%). The company’s upside was backed by robust leisure demand and solid global booking trends. Also, substantial RevPAR growth in international markets added to the upside. In the quarter, RevPAR for worldwide comparable system-wide properties increased 8.8% year over year. Also, the emphasis on expansion initiatives, digital innovation and the loyalty program bode well. During the quarter, the company added 97 properties to its worldwide lodging portfolio. However, challenging macroeconomic conditions and high debt remain a concern. Earnings estimates for 2023 have declined in the past 30 days. (You can read the full research report on Marriott International here >>>) Shares of Parker-Hannifin have outperformed the Zacks Manufacturing - General Industrial industry over the year-to-date period (+51.1% vs. +12.0%). The company is benefiting from higher demand from distributors and end users across the oil and gas, material handling, cars and light trucks, and farm and agriculture markets in the North American region within the Diversified Industrial segment. Higher volume across all businesses, especially the commercial and military aftermarket businesses bolstered the company’s Aerospace Systems unit. Synergies from the Meggitt buyout (September 2022) are also aiding the company. Benefits from the Win strategy are driving Parker-Hannifin’s margins. The company’s measures to add shareholder value hold promise. However, the escalating cost of sales and rising selling, general and administrative expenses pose a threat to its bottom line. Foreign currency headwinds may dent PH’s top line. A weak liquidity position is also worrisome. (You can read the full research report on Parker-Hannifin here >>>) Other noteworthy reports we are featuring today include FedEx Corp. (FDX), América Móvil, S.A.B. de C.V. (AMX) and Agilent Technologies, Inc. (A). Mark Vickery Senior Editor Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Visa (V) Rides On Growing Cross Border Volume, Expenses High Solid Demand & Expansion Effort Aid Marriott (MAR), High Debt Ail Aerospace Systems Unit Aids Parker-Hannifin ( PH ), Costs Hurt Featured Reports FedEx (FDX) Benefits From Dividends & Buyback, Expenses Ail The Zacks analyst likes the shareholder-friendly measures adopted by FedEx. However, capital expenditures are concerning as they are likely to keep the bottom line under pressure. America Movil (AMX) Benefits from Increasing Subscriber Base Per the Zacks analyst, America Movil's performance is gaining from growing subscriber base. However, stiff competition and high debt load are major concerns. Sluggishness in LSAG Segment Hurts Agilent Technologies (A) Per the Zacks analyst, Agilent Technologies is suffering from weak Life Sciences & Applied Markets Group (LSAG) segment owing to soft market conditions in China and a sluggish pharma market. Decent AUM & Organic Growth Aid Carlyle (CG), High Costs Ail Per the Zacks analyst, Carlyle's decent AUM balances and organic growth support its top-line expansion. However, escalating expenses are likely to impede bottom-line growth. Focus on R&D Aids Inspire Medical (INSP) in Stiff Competition The Zacks analyst is upbeat about Inspire Medical's focus on research and development despite its operation in a highly competitive market. RingCentral (RNG) Rides on Strong Portfolio, Partner Base Per the Zacks analyst, RingCentral benefits from solid demand for its Unified Communications as a Service and contact center software-as-a-service solutions. TreeHouse Foods (THS) Gains from Efficient Pricing Efforts Per the Zacks analyst, TreeHouse Foods has been gaining from its pricing efforts. Net sales advanced 3.6% year over year in Q3, driven by favorable pricing actions undertaken to recover inflation. New Upgrades Mobileye (MBLY) Rides High on ADAS Technology's Design Wins The Zacks analyst is optimistic about Mobileye's Advanced Driver Assistance Systems (ADAS) Technology's design wins, which is likely to generate a $17 billion revenue pipeline through 2030. UK Nod to CRISPR's (CRSP) Casgevy Gene Therapy Encouraging Per the Zacks Analyst, the U.K. approval to CRISPR Therapeutics' Casgevy is a major scientific breakthrough as it marks the first ever regulatory authorization for a CRISPR/Cas9-based gene therapy. Improved Menu Strategies & Expansion Plans Aid Brinker (EAT) Per the Zacks analyst, Brinker is benefiting from improved menu pricing, a favorable menu item mix and sales leverage. Also, expansion plans and digital enhancements bodes well. New Downgrades Seasonality & Strong Competition Ail UGI Corporation (UGI) Per the Zacks analyst, UGI's seasonal business operations may reduce demand and adversely impact its overall performance. Strong competition from other clean sources may lower profitability. JetBlue Airways (JBLU) Reels Under High Operating Expenses The Zacks analyst is worried about the elevated expenses on fuel. High non-fuel unit costs represent another headwind at JetBlue. RPC (RES) Likely to Suffer From Aggressive Capital Budget Per the Zacks analyst, RPC is anticipated to face challenges due to its increased capital expenditure, impacting its profitability. Additionally, rising costs of revenues are a cause for concern. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Visa Inc. (V) : Free Stock Analysis Report Marriott International, Inc. (MAR) : Free Stock Analysis Report America Movil, S.A.B. de C.V. Unsponsored ADR (AMX) : Free Stock Analysis Report Parker-Hannifin Corporation (PH) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report FedEx Corporation (FDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The company’s stock prices has consistently outperformed the industry, driven by strategic acquisitions and alliances fostering long-term growth. The company is benefiting from higher demand from distributors and end users across the oil and gas, material handling, cars and light trucks, and farm and agriculture markets in the North American region within the Diversified Industrial segment. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Visa (V) Rides On Growing Cross Border Volume, Expenses High Solid Demand & Expansion Effort Aid Marriott (MAR), High Debt Ail Aerospace Systems Unit Aids Parker-Hannifin ( PH ), Costs Hurt Featured Reports FedEx (FDX) Benefits From Dividends & Buyback, Expenses Ail The Zacks analyst likes the shareholder-friendly measures adopted by FedEx.

If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Visa (V) Rides On Growing Cross Border Volume, Expenses High Solid Demand & Expansion Effort Aid Marriott (MAR), High Debt Ail Aerospace Systems Unit Aids Parker-Hannifin ( PH ), Costs Hurt Featured Reports FedEx (FDX) Benefits From Dividends & Buyback, Expenses Ail The Zacks analyst likes the shareholder-friendly measures adopted by FedEx. Click to get this free report Visa Inc. (V) : Free Stock Analysis Report Marriott International, Inc. (MAR) : Free Stock Analysis Report America Movil, S.A.B. de C.V. Unsponsored ADR (AMX) : Free Stock Analysis Report Parker-Hannifin Corporation (PH) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report FedEx Corporation (FDX) : Free Stock Analysis Report To read this article on Zacks.com click here.

If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Visa (V) Rides On Growing Cross Border Volume, Expenses High Solid Demand & Expansion Effort Aid Marriott (MAR), High Debt Ail Aerospace Systems Unit Aids Parker-Hannifin ( PH ), Costs Hurt Featured Reports FedEx (FDX) Benefits From Dividends & Buyback, Expenses Ail The Zacks analyst likes the shareholder-friendly measures adopted by FedEx. Click to get this free report Visa Inc. (V) : Free Stock Analysis Report Marriott International, Inc. (MAR) : Free Stock Analysis Report America Movil, S.A.B. de C.V. Unsponsored ADR (AMX) : Free Stock Analysis Report Parker-Hannifin Corporation (PH) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report FedEx Corporation (FDX) : Free Stock Analysis Report To read this article on Zacks.com click here.

A robust cash position enables the company to enhance shareholder value. Also, substantial RevPAR growth in international markets added to the upside. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Visa (V) Rides On Growing Cross Border Volume, Expenses High Solid Demand & Expansion Effort Aid Marriott (MAR), High Debt Ail Aerospace Systems Unit Aids Parker-Hannifin ( PH ), Costs Hurt Featured Reports FedEx (FDX) Benefits From Dividends & Buyback, Expenses Ail The Zacks analyst likes the shareholder-friendly measures adopted by FedEx.

9.0

2023-11-21 00:00:00 UTC

Tuesday Sector Leaders: Healthcare, Consumer Products

A

https://www.nasdaq.com/articles/tuesday-sector-leaders%3A-healthcare-consumer-products-1

In afternoon trading on Tuesday, Healthcare stocks are the best performing sector, up 0.8%. Within that group, Agilent Technologies, Inc. (Symbol: A) and Waters Corp. (Symbol: WAT) are two large stocks leading the way, showing a gain of 8.8% and 5.7%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.8% on the day, and down 2.87% year-to-date. Agilent Technologies, Inc., meanwhile, is down 16.88% year-to-date, and Waters Corp., is down 20.21% year-to-date. Combined, A and WAT make up approximately 1.1% of the underlying holdings of XLV. The next best performing sector is the Consumer Products sector, not showing much of a loss. Among large Consumer Products stocks, Tesla Inc (Symbol: TSLA) and Clorox Co (Symbol: CLX) are the most notable, showing a gain of 2.4% and 2.2%, respectively. One ETF closely tracking Consumer Products stocks is the iShares U.S. Consumer Goods ETF (IYK), which is up 0.2% in midday trading, and down 5.05% on a year-to-date basis. Tesla Inc, meanwhile, is up 123.25% year-to-date, and Clorox Co is up 1.76% year-to-date. CLX makes up approximately 0.8% of the underlying holdings of IYK. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Tuesday. As you can see, one sector is up on the day, while six sectors are down. SECTOR % CHANGE Healthcare +0.8% Consumer Products -0.0% Materials -0.0% Industrial -0.1% Utilities -0.2% Financial -0.2% Services -0.3% Energy -0.4% Technology & Communications -0.8% 25 Dividend Giants Widely Held By ETFs » Also see: • Funds Holding AB • NYCB Historical Stock Prices • SAPE Videos The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In afternoon trading on Tuesday, Healthcare stocks are the best performing sector, up 0.8%. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Tuesday. Healthcare +0.8% Consumer Products -0.0% Materials -0.0% Industrial -0.1% Utilities -0.2% Financial -0.2% Services -0.3% Energy -0.4% Technology & Communications -0.8% 25 Dividend Giants Widely Held By ETFs » Also see: • Funds Holding AB • NYCB Historical Stock Prices • SAPE Videos The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In afternoon trading on Tuesday, Healthcare stocks are the best performing sector, up 0.8%. Within that group, Agilent Technologies, Inc. (Symbol: A) and Waters Corp. (Symbol: WAT) are two large stocks leading the way, showing a gain of 8.8% and 5.7%, respectively. Among large Consumer Products stocks, Tesla Inc (Symbol: TSLA) and Clorox Co (Symbol: CLX) are the most notable, showing a gain of 2.4% and 2.2%, respectively.

Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.8% on the day, and down 2.87% year-to-date. One ETF closely tracking Consumer Products stocks is the iShares U.S. Consumer Goods ETF (IYK), which is up 0.2% in midday trading, and down 5.05% on a year-to-date basis. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Tuesday.

Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.8% on the day, and down 2.87% year-to-date. Among large Consumer Products stocks, Tesla Inc (Symbol: TSLA) and Clorox Co (Symbol: CLX) are the most notable, showing a gain of 2.4% and 2.2%, respectively. One ETF closely tracking Consumer Products stocks is the iShares U.S. Consumer Goods ETF (IYK), which is up 0.2% in midday trading, and down 5.05% on a year-to-date basis.

10.0

2023-11-21 00:00:00 UTC

A Quantitative Stock Analysis

A

https://www.nasdaq.com/articles/a-quantitative-stock-analysis-1

Below is Validea's guru fundamental report for AGILENT TECHNOLOGIES INC (A). Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. AGILENT TECHNOLOGIES INC (A) is a large-cap growth stock in the Scientific & Technical Instr. industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: FAIL CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.

Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends.

Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends.

Below is Validea's guru fundamental report for AGILENT TECHNOLOGIES INC (A). Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing.

11.0

2023-11-21 00:00:00 UTC

Agilent (A) Q4 Earnings & Revenues Beat Estimates, Down Y/Y

A

https://www.nasdaq.com/articles/agilent-a-q4-earnings-revenues-beat-estimates-down-y-y

Agilent Technologies A delivered fourth-quarter fiscal 2023 earnings of $1.38 per share, which beat the Zacks Consensus Estimate by 2.99%. The bottom line decreased 10% from the year-ago quarter. Revenues of $1.69 billion surpassed the Zacks Consensus Estimate of $1.67 billion. However, the top line was down 8.7% on a reported basis and 9.7% on a core basis from the respective year-ago levels. The decline was attributed to broad-based weakness across all the end markets, especially in Chemistry & Advanced Materials, Pharma, Food and Diagnostics and Clinical markets. Also, weak momentum in China was a major concern. The company witnessed a year-over-year decline of 31% in its business in China in the reported quarter. Agilent Technologies, Inc. Price, Consensus and EPS Surprise Agilent Technologies, Inc. price-consensus-eps-surprise-chart | Agilent Technologies, Inc. Quote Segmental Top-Line Details Agilent has three reporting segments, namely, Life Sciences & Applied Markets Group (“LSAG”), Agilent Cross Lab Group (“ACG”) and Diagnostics and Genomics Group (“DGG”). LSAG: The segment accounted for $928 million or 55% of its total revenues, down 17% on a reported basis and 18% on a core basis from the respective prior-year fiscal quarter’s levels. This was due to macroeconomic uncertainties, soft market conditions in China and sluggish capital spending by the customers. The reported figure came ahead of the Zacks Consensus Estimate of $925 million. ACG: Revenues from the segment were $404 million, accounting for 24% of total revenues. The figure surpassed the consensus mark of $401 million. The top line improved by 6% from the prior-year fiscal quarter’s reading on a reported basis and by 4% on a core basis, demonstrating solid momentum across all end markets and regions except China. DGG: Revenues increased 1% from the prior-year fiscal quarter’s figure on a reported basis to $356 million, accounting for the remaining 21% of total revenues. The figure remained flat year over year on a core basis. The figure came above the consensus mark of $345 million. Segmental growth was attributed to strength in the NASD business. However, weakness in the genomics business was a negative. Operating Results For the fiscal fourth quarter, gross margin in the LSAG segment contracted by 100 basis points (bps) to 59.6% from the prior-year fiscal quarter’s number. ACG’s gross margin expanded by 180 bps to 50.4%. DGG’s gross margin expanded by 90 bps from the year-ago fiscal quarter’s actuals to 51.9%. Research & development (“R&D”) costs were $114 million, down 4.2% from the prior-year fiscal quarter’s number. Selling, general & administrative (“SG&A”) expenses were $393 million, down 6.9% from the year-earlier fiscal quarter’s figure. As a percentage of revenues, R&D expenses expanded by 40 bps year over year to 6.8%. SG&A expenses expanded by 50 bps year over year to 23.3%. Operating margin for the fiscal fourth quarter was 24.2%, which declined 130 bps from the year-earlier fiscal quarter’s figure. Segment-wise, the operating margin in the LSAG segment contracted by 460 bps to 28.1% from the prior-year fiscal quarter’s number. ACG’s gross margin expanded by 430 bps to 31.7%. DGG’s gross margin expanded by 300 bps from the year-ago fiscal quarter’s actuals to 22.5%. Balance Sheet & Cash Flow As of Oct 31, 2023, Agilent’s cash and cash equivalents were $1.59 billion, up from $1.33 billion on Jul 31, 2023. Accounts receivables were $1.29 billion at the end of fourth-quarter fiscal 2023, down from $1.33 billion at the end of third-quarter fiscal 2023. Long-term debt was $2.735 billion for the reported quarter compared with $2.734 billion in the prior fiscal quarter. Agilent generated $516 million in cash from operations during the reported quarter, down from $562 million generated in the previous quarter. The company made dividend payments worth $66 million and repurchased shares worth $80 million during the fiscal fourth quarter. Guidance For the fiscal first quarter of 2024, management expects revenues of $1.555-$1.605 billion, suggesting a decline between 11.4% and 8.6% on a reported basis from the year-ago fiscal quarter’s actuals. The Zacks Consensus Estimate for the same is pegged at $1.69 billion. Non-GAAP earnings per share are expected to be $1.20-$1.23. The consensus mark for fiscal first-quarter earnings is pinned at $1.33 per share. For fiscal 2024, management expects revenues in the band of $6.71-$6.81 billion, implying a fall of 1.8-0.3% on a reported basis from the respective fiscal 2023 figures. The Zacks Consensus Estimate for the same is pegged at $6.81 billion. Fiscal 2024 non-GAAP earnings per share are projected in the range of $5.44-$5.55. The consensus mark for fiscal 2024 earnings is pinned at $5.41 per share. Zacks Rank & Stocks to Consider Currently, Agilent carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader technology sector are Badger Meter BMI, Arista Networks ANET and Salesforce CRM. Badger Meter sports a Zacks Rank #1 (Strong Buy), and Arista Networks and Salesforce carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here. Shares of Badger Meter have gained 24.8% in the year-to-date period. BMI’s long-term earnings growth rate is currently projected at 20.39%. Shares of Arista Networks have surged 56.4% in the year-to-date period. The long-term earnings growth rate for ANET is currently projected at 19.77%. Shares of Salesforce have gained 57.4% in the year-to-date period. CRM’s long-term earnings growth rate is currently projected at 22.54%. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.” Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Salesforce Inc. (CRM) : Free Stock Analysis Report Badger Meter, Inc. (BMI) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Agilent Technologies A delivered fourth-quarter fiscal 2023 earnings of $1.38 per share, which beat the Zacks Consensus Estimate by 2.99%. Some better-ranked stocks in the broader technology sector are Badger Meter BMI, Arista Networks ANET and Salesforce CRM. Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests.

Operating Results For the fiscal fourth quarter, gross margin in the LSAG segment contracted by 100 basis points (bps) to 59.6% from the prior-year fiscal quarter’s number. Badger Meter sports a Zacks Rank #1 (Strong Buy), and Arista Networks and Salesforce carry a Zacks Rank #2 (Buy) each. Click to get this free report Salesforce Inc. (CRM) : Free Stock Analysis Report Badger Meter, Inc. (BMI) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report To read this article on Zacks.com click here.

Operating Results For the fiscal fourth quarter, gross margin in the LSAG segment contracted by 100 basis points (bps) to 59.6% from the prior-year fiscal quarter’s number. Guidance For the fiscal first quarter of 2024, management expects revenues of $1.555-$1.605 billion, suggesting a decline between 11.4% and 8.6% on a reported basis from the year-ago fiscal quarter’s actuals. Click to get this free report Salesforce Inc. (CRM) : Free Stock Analysis Report Badger Meter, Inc. (BMI) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report To read this article on Zacks.com click here.

The top line improved by 6% from the prior-year fiscal quarter’s reading on a reported basis and by 4% on a core basis, demonstrating solid momentum across all end markets and regions except China. DGG: Revenues increased 1% from the prior-year fiscal quarter’s figure on a reported basis to $356 million, accounting for the remaining 21% of total revenues. The consensus mark for fiscal 2024 earnings is pinned at $5.41 per share.

12.0

2023-11-21 00:00:00 UTC

S&P 500 Movers: J, A

A

https://www.nasdaq.com/articles/sp-500-movers%3A-j-a

In early trading on Tuesday, shares of Agilent Technologies, topped the list of the day's best performing components of the S&P 500 index, trading up 8.1%. Year to date, Agilent Technologies has lost about 17.7% of its value. And the worst performing S&P 500 component thus far on the day is Jacobs Solutions, trading down 5.5%. Jacobs Solutions is showing a gain of 7.9% looking at the year to date performance. Two other components making moves today are Best Buy, trading down 4.1%, and Waters, trading up 5.0% on the day. VIDEO: S&P 500 Movers: J, A The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In early trading on Tuesday, shares of Agilent Technologies, topped the list of the day's best performing components of the S&P 500 index, trading up 8.1%. And the worst performing S&P 500 component thus far on the day is Jacobs Solutions, trading down 5.5%. Jacobs Solutions is showing a gain of 7.9% looking at the year to date performance.

In early trading on Tuesday, shares of Agilent Technologies, topped the list of the day's best performing components of the S&P 500 index, trading up 8.1%. Year to date, Agilent Technologies has lost about 17.7% of its value. And the worst performing S&P 500 component thus far on the day is Jacobs Solutions, trading down 5.5%.

In early trading on Tuesday, shares of Agilent Technologies, topped the list of the day's best performing components of the S&P 500 index, trading up 8.1%. And the worst performing S&P 500 component thus far on the day is Jacobs Solutions, trading down 5.5%. Two other components making moves today are Best Buy, trading down 4.1%, and Waters, trading up 5.0% on the day.

In early trading on Tuesday, shares of Agilent Technologies, topped the list of the day's best performing components of the S&P 500 index, trading up 8.1%. And the worst performing S&P 500 component thus far on the day is Jacobs Solutions, trading down 5.5%. VIDEO: S&P 500 Movers: J, A The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

13.0

2023-11-21 00:00:00 UTC

A Makes Bullish Cross Above Critical Moving Average

A

https://www.nasdaq.com/articles/a-makes-bullish-cross-above-critical-moving-average

In trading on Tuesday, shares of Agilent Technologies, Inc. (Symbol: A) crossed above their 200 day moving average of $124.47, changing hands as high as $124.68 per share. Agilent Technologies, Inc. shares are currently trading up about 8.2% on the day. The chart below shows the one year performance of A shares, versus its 200 day moving average: Looking at the chart above, A's low point in its 52 week range is $96.80 per share, with $160.265 as the 52 week high point — that compares with a last trade of $123.46. The A DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other stocks recently crossed above their 200 day moving average » Also see: • MOK Historical Stock Prices • Top Ten Hedge Funds Holding SWM • AIT Dividend Growth Rate The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In trading on Tuesday, shares of Agilent Technologies, Inc. (Symbol: A) crossed above their 200 day moving average of $124.47, changing hands as high as $124.68 per share. The chart below shows the one year performance of A shares, versus its 200 day moving average: Looking at the chart above, A's low point in its 52 week range is $96.80 per share, with $160.265 as the 52 week high point — that compares with a last trade of $123.46. The A DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other stocks recently crossed above their 200 day moving average » Also see: • MOK Historical Stock Prices • Top Ten Hedge Funds Holding SWM • AIT Dividend Growth Rate The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In trading on Tuesday, shares of Agilent Technologies, Inc. (Symbol: A) crossed above their 200 day moving average of $124.47, changing hands as high as $124.68 per share. The chart below shows the one year performance of A shares, versus its 200 day moving average: Looking at the chart above, A's low point in its 52 week range is $96.80 per share, with $160.265 as the 52 week high point — that compares with a last trade of $123.46. The A DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other stocks recently crossed above their 200 day moving average » Also see: • MOK Historical Stock Prices • Top Ten Hedge Funds Holding SWM • AIT Dividend Growth Rate The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In trading on Tuesday, shares of Agilent Technologies, Inc. (Symbol: A) crossed above their 200 day moving average of $124.47, changing hands as high as $124.68 per share. The chart below shows the one year performance of A shares, versus its 200 day moving average: Looking at the chart above, A's low point in its 52 week range is $96.80 per share, with $160.265 as the 52 week high point — that compares with a last trade of $123.46. The A DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other stocks recently crossed above their 200 day moving average » Also see: • MOK Historical Stock Prices • Top Ten Hedge Funds Holding SWM • AIT Dividend Growth Rate The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In trading on Tuesday, shares of Agilent Technologies, Inc. (Symbol: A) crossed above their 200 day moving average of $124.47, changing hands as high as $124.68 per share. Agilent Technologies, Inc. shares are currently trading up about 8.2% on the day. The chart below shows the one year performance of A shares, versus its 200 day moving average: Looking at the chart above, A's low point in its 52 week range is $96.80 per share, with $160.265 as the 52 week high point — that compares with a last trade of $123.46.

14.0

2023-11-20 00:00:00 UTC

Agilent (A) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

A

https://www.nasdaq.com/articles/agilent-a-q4-earnings%3A-taking-a-look-at-key-metrics-versus-estimates

Agilent Technologies (A) reported $1.69 billion in revenue for the quarter ended October 2023, representing a year-over-year decline of 8.7%. EPS of $1.38 for the same period compares to $1.53 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $1.67 billion, representing a surprise of +1.29%. The company delivered an EPS surprise of +2.99%, with the consensus EPS estimate being $1.34. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Revenue- Americas: $702 million compared to the $678.42 million average estimate based on two analysts. Net Revenue- Asia Pacific: $553 million compared to the $582.25 million average estimate based on two analysts. Net Revenue- Europe: $433 million versus $416.94 million estimated by two analysts on average. Net Revenue- Diagnostics and Genomics Group: $356 million versus $345.17 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1.1% change. Net Revenue- Life Sciences and Applied Markets Group: $928 million compared to the $924.52 million average estimate based on four analysts. The reported number represents a change of -16.9% year over year. Net Revenue- Agilent Crosslab Group: $404 million compared to the $401.38 million average estimate based on four analysts. The reported number represents a change of +6% year over year. Revenue by End Markets- Chemical and advanced materials: $381 million compared to the $379.36 million average estimate based on two analysts. Revenue by End Markets- Environmental and Forensics: $175 million versus $171.76 million estimated by two analysts on average. Revenue by End Markets- Diagnostics and Clinical: $236 million compared to the $234.25 million average estimate based on two analysts. Revenue by End Markets- Academia and Government: $150 million versus the two-analyst average estimate of $147.76 million. Revenue by End Markets- Pharmaceutical and Biopharmaceutical: $590 million compared to the $595.74 million average estimate based on two analysts. Revenue by End Markets- Food: $156 million versus the two-analyst average estimate of $152.73 million. View all Key Company Metrics for Agilent here>>> Shares of Agilent have returned +3.6% over the past month versus the Zacks S&P 500 composite's Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Revenue- Americas: $702 million compared to the $678.42 million average estimate based on two analysts. Net Revenue- Agilent Crosslab Group: $404 million compared to the $401.38 million average estimate based on four analysts. Revenue by End Markets- Diagnostics and Clinical: $236 million compared to the $234.25 million average estimate based on two analysts.

Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Revenue- Americas: $702 million compared to the $678.42 million average estimate based on two analysts. Revenue by End Markets- Diagnostics and Clinical: $236 million compared to the $234.25 million average estimate based on two analysts. Revenue by End Markets- Pharmaceutical and Biopharmaceutical: $590 million compared to the $595.74 million average estimate based on two analysts.

The reported revenue compares to the Zacks Consensus Estimate of $1.67 billion, representing a surprise of +1.29%. Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Revenue- Americas: $702 million compared to the $678.42 million average estimate based on two analysts. Net Revenue- Life Sciences and Applied Markets Group: $928 million compared to the $924.52 million average estimate based on four analysts.

15.0

2023-11-20 00:00:00 UTC

Agilent Technologies Q4 Profit Increases, beats estimates

A

https://www.nasdaq.com/articles/agilent-technologies-q4-profit-increases-beats-estimates

(RTTNews) - Agilent Technologies (A) reported a profit for its fourth quarter that increased from the same period last year and beat the Street estimates. The company's earnings totaled $475 million, or $1.62 per share. This compares with $368 million, or $1.23 per share, in last year's fourth quarter. Excluding items, Agilent Technologies reported adjusted earnings of $404 million or $1.38 per share for the period. Analysts on average had expected the company to earn $1.34 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items. The company's revenue for the quarter fell 8.6% to $1.69 billion from $1.85 billion last year. Agilent Technologies earnings at a glance (GAAP) : -Earnings (Q4): $475 Mln. vs. $368 Mln. last year. -EPS (Q4): $1.62 vs. $1.23 last year. -Analyst Estimate: $1.34 -Revenue (Q4): $1.69 Bln vs. $1.85 Bln last year. -Guidance: Next quarter EPS guidance: $1.20 - $1.23 Next quarter revenue guidance: $1.555 - $1.605 Bln The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

(RTTNews) - Agilent Technologies (A) reported a profit for its fourth quarter that increased from the same period last year and beat the Street estimates. Excluding items, Agilent Technologies reported adjusted earnings of $404 million or $1.38 per share for the period. Analysts on average had expected the company to earn $1.34 per share, according to figures compiled by Thomson Reuters.

Excluding items, Agilent Technologies reported adjusted earnings of $404 million or $1.38 per share for the period. -Analyst Estimate: $1.34 -Revenue (Q4): $1.69 Bln vs. $1.85 Bln last year. -Guidance: Next quarter EPS guidance: $1.20 - $1.23 Next quarter revenue guidance: $1.555 - $1.605 Bln The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

(RTTNews) - Agilent Technologies (A) reported a profit for its fourth quarter that increased from the same period last year and beat the Street estimates. This compares with $368 million, or $1.23 per share, in last year's fourth quarter. Excluding items, Agilent Technologies reported adjusted earnings of $404 million or $1.38 per share for the period.

(RTTNews) - Agilent Technologies (A) reported a profit for its fourth quarter that increased from the same period last year and beat the Street estimates. Excluding items, Agilent Technologies reported adjusted earnings of $404 million or $1.38 per share for the period. -Analyst Estimate: $1.34 -Revenue (Q4): $1.69 Bln vs. $1.85 Bln last year.

16.0

2023-11-20 00:00:00 UTC

After-Hours Earnings Report for November 20, 2023 : A, KEYS, ZM, BRBR, SYM, GBDC, CENTA, CENT, ENTA, XELB

A

https://www.nasdaq.com/articles/after-hours-earnings-report-for-november-20-2023-%3A-a-keys-zm-brbr-sym-gbdc-centa-cent-enta

The following companies are expected to report earnings after hours on 11/20/2023. Visit our Earnings Calendar for a full list of expected earnings releases. Agilent Technologies, Inc. (A)is reporting for the quarter ending October 31, 2023. The electrical test equipment company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.34. This value represents a 12.42% decrease compared to the same quarter last year. In the past year A has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2023 Price to Earnings ratio for A is 20.91 vs. an industry ratio of 33.10. Keysight Technologies Inc. (KEYS)is reporting for the quarter ending October 31, 2023. The electrical instrument company's consensus earnings per share forecast from the 5 analysts that follow the stock is $1.73. This value represents a 14.36% decrease compared to the same quarter last year. KEYS missed the consensus earnings per share in the 1st calendar quarter of 2023 by -1.15%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for KEYS is 17.71 vs. an industry ratio of 27.70. Zoom Video Communications, Inc. (ZM)is reporting for the quarter ending October 31, 2023. The internet software company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.36. This value represents a 71.43% increase compared to the same quarter last year. Zacks Investment Research reports that the 2024 Price to Earnings ratio for ZM is 36.23 vs. an industry ratio of -416.60, implying that they will have a higher earnings growth than their competitors in the same industry. BellRing Brands, Inc. (BRBR)is reporting for the quarter ending September 30, 2023. The medical products company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.40. This value represents a 29.03% increase compared to the same quarter last year. In the past year BRBR has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 6.25%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for BRBR is 34.63 vs. an industry ratio of 5.30, implying that they will have a higher earnings growth than their competitors in the same industry. Symbotic Inc. (SYM)is reporting for the quarter ending September 30, 2023. The technology services company's consensus earnings per share forecast from the 4 analysts that follow the stock is $-0.06. This value represents a 40.00% increase compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for SYM is -103.33 vs. an industry ratio of 13.80. Golub Capital BDC, Inc. (GBDC)is reporting for the quarter ending September 30, 2023. The financial services company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.48. This value represents a 45.45% increase compared to the same quarter last year. In the past year GBDC has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 2.33%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for GBDC is 8.61 vs. an industry ratio of 7.80, implying that they will have a higher earnings growth than their competitors in the same industry. Central Garden & Pet Company (CENTA)is reporting for the quarter ending September 30, 2023. The consumer company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.08. This value represents a 300.00% increase compared to the same quarter last year. CENTA missed the consensus earnings per share in the 3rd calendar quarter of 2022 by -233.33%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for CENTA is 15.59 vs. an industry ratio of 10.70, implying that they will have a higher earnings growth than their competitors in the same industry. Central Garden & Pet Company (CENT)is reporting for the quarter ending September 30, 2023. The consumer company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.08. This value represents a 300.00% increase compared to the same quarter last year. CENT missed the consensus earnings per share in the 3rd calendar quarter of 2022 by -233.33%. The "days to cover" for this stock exceeds 13 days. Zacks Investment Research reports that the 2023 Price to Earnings ratio for CENT is 17.17 vs. an industry ratio of 10.70, implying that they will have a higher earnings growth than their competitors in the same industry. Enanta Pharmaceuticals, Inc. (ENTA)is reporting for the quarter ending September 30, 2023. The drug company's consensus earnings per share forecast from the 5 analysts that follow the stock is $-2.11. This value represents a 66.14% decrease compared to the same quarter last year. In the past year ENTA has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 21.85%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ENTA is -1.26 vs. an industry ratio of 3.30. Xcel Brands, Inc (XELB)is reporting for the quarter ending September 30, 2023. The retail (shoe) company's consensus earnings per share forecast from the 3 analysts that follow the stock is $-0.14. This value represents a 17.65% increase compared to the same quarter last year. XELB missed the consensus earnings per share in the 1st calendar quarter of 2023 by -11.76%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for XELB is -1.43 vs. an industry ratio of 11.80. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The electrical test equipment company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.34. The technology services company's consensus earnings per share forecast from the 4 analysts that follow the stock is $-0.06. The financial services company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.48.

Zacks Investment Research reports that the 2024 Price to Earnings ratio for ZM is 36.23 vs. an industry ratio of -416.60, implying that they will have a higher earnings growth than their competitors in the same industry. Central Garden & Pet Company (CENTA)is reporting for the quarter ending September 30, 2023. The consumer company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.08.

Zacks Investment Research reports that the 2023 Price to Earnings ratio for BRBR is 34.63 vs. an industry ratio of 5.30, implying that they will have a higher earnings growth than their competitors in the same industry. Zacks Investment Research reports that the 2023 Price to Earnings ratio for GBDC is 8.61 vs. an industry ratio of 7.80, implying that they will have a higher earnings growth than their competitors in the same industry. The consumer company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.08.

In the past year BRBR has beat the expectations every quarter. In the past year GBDC has beat the expectations every quarter. The consumer company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.08.

17.0

2023-11-20 00:00:00 UTC

Agilent Technologies Q4 23 Earnings Conference Call At 4:30 PM ET

A

https://www.nasdaq.com/articles/agilent-technologies-q4-23-earnings-conference-call-at-4%3A30-pm-et

(RTTNews) - Agilent Technologies (A) will host a conference call at 4:30 PM ET on November 20, 2023, to discuss Q4 23 earnings results. To access the live webcast, log on to https://www.investor.agilent.com/news-and-events/events/default.aspx The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

(RTTNews) - Agilent Technologies (A) will host a conference call at 4:30 PM ET on November 20, 2023, to discuss Q4 23 earnings results. To access the live webcast, log on to https://www.investor.agilent.com/news-and-events/events/default.aspx The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

(RTTNews) - Agilent Technologies (A) will host a conference call at 4:30 PM ET on November 20, 2023, to discuss Q4 23 earnings results. To access the live webcast, log on to https://www.investor.agilent.com/news-and-events/events/default.aspx The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

(RTTNews) - Agilent Technologies (A) will host a conference call at 4:30 PM ET on November 20, 2023, to discuss Q4 23 earnings results. To access the live webcast, log on to https://www.investor.agilent.com/news-and-events/events/default.aspx The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

(RTTNews) - Agilent Technologies (A) will host a conference call at 4:30 PM ET on November 20, 2023, to discuss Q4 23 earnings results. To access the live webcast, log on to https://www.investor.agilent.com/news-and-events/events/default.aspx The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

18.0

2023-11-16 00:00:00 UTC

Daily Dividend Report: CSCO,CB,EXR,NOC,A,PHM

A

https://www.nasdaq.com/articles/daily-dividend-report%3A-cscocbexrnocaphm

Cisco has declared a quarterly dividend of $0.39 per common share to be paid on January 24, 2024, to all stockholders of record as of the close of business on January 4, 2024. The Board of Directors of Chubb today declared a quarterly dividend equal to $0.86 per share, payable on January 5, 2024 to shareholders of record at the close of business on December 15, 2023. The dividend will be payable out of legal reserves and will be made in United States dollars by the company's transfer agent, as described in the Chubb Limited 2023 proxy statement. This will be the third installment as approved by the company's shareholders on May 17, 2023. Extra Space Storage announced today that the Company's board of directors has declared a fourth quarter 2023 dividend of $1.62 per share on the common stock of the Company. The dividend is payable on December 29, 2023 to stockholders of record at the close of business on December 15, 2023. The board of directors of Northrop Grumman declared a quarterly dividend of $1.87 per share on Northrop Grumman common stock, payable Dec. 13, 2023, to shareholders of record as of the close of business Nov. 27, 2023. Agilent Technologies today announced the company has increased its quarterly dividend to 23.6 cents per share of common stock, a 5% increase over the previous dividend. The quarterly dividend will be paid on Jan. 24, 2024, to all shareholders of record as of the close of business on Jan. 2, 2024. PulteGroup announced today that its Board of Directors has voted to increase the Company's quarterly dividend by 25% to $0.20 per common share. The increase will be effective with the Company's next scheduled dividend, which is payable January 3, 2024, to shareholders of record at the close of business on December 19, 2023. VIDEO: Daily Dividend Report: CSCO,CB,EXR,NOC,A,PHM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Board of Directors of Chubb today declared a quarterly dividend equal to $0.86 per share, payable on January 5, 2024 to shareholders of record at the close of business on December 15, 2023. The dividend will be payable out of legal reserves and will be made in United States dollars by the company's transfer agent, as described in the Chubb Limited 2023 proxy statement. The increase will be effective with the Company's next scheduled dividend, which is payable January 3, 2024, to shareholders of record at the close of business on December 19, 2023.

The Board of Directors of Chubb today declared a quarterly dividend equal to $0.86 per share, payable on January 5, 2024 to shareholders of record at the close of business on December 15, 2023. Extra Space Storage announced today that the Company's board of directors has declared a fourth quarter 2023 dividend of $1.62 per share on the common stock of the Company. The board of directors of Northrop Grumman declared a quarterly dividend of $1.87 per share on Northrop Grumman common stock, payable Dec. 13, 2023, to shareholders of record as of the close of business Nov. 27, 2023.

The Board of Directors of Chubb today declared a quarterly dividend equal to $0.86 per share, payable on January 5, 2024 to shareholders of record at the close of business on December 15, 2023. The board of directors of Northrop Grumman declared a quarterly dividend of $1.87 per share on Northrop Grumman common stock, payable Dec. 13, 2023, to shareholders of record as of the close of business Nov. 27, 2023. Agilent Technologies today announced the company has increased its quarterly dividend to 23.6 cents per share of common stock, a 5% increase over the previous dividend.

The Board of Directors of Chubb today declared a quarterly dividend equal to $0.86 per share, payable on January 5, 2024 to shareholders of record at the close of business on December 15, 2023. PulteGroup announced today that its Board of Directors has voted to increase the Company's quarterly dividend by 25% to $0.20 per common share. The increase will be effective with the Company's next scheduled dividend, which is payable January 3, 2024, to shareholders of record at the close of business on December 19, 2023.

19.0

2023-11-16 00:00:00 UTC

What to Note Ahead of Agilent Technologies' (A) Q4 Earnings

A

https://www.nasdaq.com/articles/what-to-note-ahead-of-agilent-technologies-a-q4-earnings

Agilent Technologies A is set to report its fourth-quarter fiscal 2023 results on Nov 20. For the fiscal fourth quarter, A expects revenues of $1.655-$1.705 billion, suggesting a decline between 12.2% and 9.5% on a core basis from the year-ago fiscal quarter’s actuals. The Zacks Consensus Estimate for the same is pegged at $1.67 billion, implying a decline of 9.9% from the year-ago fiscal quarter’s reported figure. Agilent’s non-GAAP earnings are expected to be $1.33-$1.36 per share. The Zacks Consensus Estimate for earnings is pegged at $1.34 per share, indicating a fall of 12.4% from the year-ago fiscal quarter’s reported figure. Agilent’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and matched the same once, the average being 4.76%. Agilent Technologies, Inc. Price and EPS Surprise Agilent Technologies, Inc. price-eps-surprise | Agilent Technologies, Inc. Quote Factors to Note The company is expected to have gained from growing momentum across Agilent’s Cross Lab Group (“ACG”) and Diagnostics and Genomics Group (“DGG”) segments during the fiscal fourth quarter. The ACG segment is likely to have benefited from robust portfolio offerings. Strength in services and solid momentum across all regions and end markets are likely to have contributed well. The Zacks Consensus Estimate for ACG is pegged at $401 million, implying growth of 5.2% from the year-ago fiscal quarter’s reported figure. Agilent’s strength in the Nucleic Acid Solutions Division business is expected to have continued benefiting the DGG segment’s performance in the fiscal fourth quarter. Also, solid demand for diagnostic tests is expected to have aided the performance of the company’s pathology business. However, weakness in genomics and Resolution Bioscience businesses might have been a negative The Zacks Consensus Estimate for DGG is pegged at $345 million, implying a fall of 2% from the year-ago fiscal quarter’s reported figure. Strength in liquid chromatography and liquid chromatography-mass spectrometry and lab consumables is expected to have benefited Agilent’s Life Sciences & Applied Markets Group (“LSAG”) segment in the quarter under review. However, the weakening pharma market, macroeconomic uncertainties and soft market conditions in China are likely to have scaled down the LSAG segment’s revenues in the fiscal fourth quarter. The Zacks Consensus Estimate for LSAG is pegged at $925 million, implying a decline of 17.1% from the year-ago fiscal quarter’s reported figure. What Our Model Says Our proven model does not conclusively predict an earnings beat for Agilent Technologies this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Agilent Technologies has a Zacks Rank #4 (Sell) and an Earnings ESP of -0.28% at present. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Stocks to Consider Here are some stocks worth considering, as our model shows that these have the right combination of elements to beat on earnings this season. Costco Wholesale COST has an Earnings ESP of +4.26% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here. Costco is set to announce its first-quarter fiscal 2024 results on Dec 14. COST shares have gained 29.6% year to date. Synopsys SNPS has an Earnings ESP of +0.94% and a Zacks Rank #2. Synopsys is set to announce its fourth-quarter fiscal 2023 results on Nov 29. SNPS shares have declined 24.9% year to date. Snowflake SNOW has an Earnings ESP of +67.33% and a Zacks Rank #2. Snowflake is set to announce its third-quarter fiscal 2024 results on Nov 29. SNOW shares have gained 86% year to date. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Costco Wholesale Corporation (COST) : Free Stock Analysis Report Synopsys, Inc. (SNPS) : Free Stock Analysis Report Snowflake Inc. (SNOW) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Zacks Consensus Estimate for earnings is pegged at $1.34 per share, indicating a fall of 12.4% from the year-ago fiscal quarter’s reported figure. Agilent’s strength in the Nucleic Acid Solutions Division business is expected to have continued benefiting the DGG segment’s performance in the fiscal fourth quarter. The Zacks Consensus Estimate for DGG is pegged at $345 million, implying a fall of 2% from the year-ago fiscal quarter’s reported figure.

Agilent Technologies, Inc. Price and EPS Surprise Agilent Technologies, Inc. price-eps-surprise | Agilent Technologies, Inc. Quote Factors to Note The company is expected to have gained from growing momentum across Agilent’s Cross Lab Group (“ACG”) and Diagnostics and Genomics Group (“DGG”) segments during the fiscal fourth quarter. The Zacks Consensus Estimate for DGG is pegged at $345 million, implying a fall of 2% from the year-ago fiscal quarter’s reported figure. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Costco Wholesale Corporation (COST) : Free Stock Analysis Report Synopsys, Inc. (SNPS) : Free Stock Analysis Report Snowflake Inc. (SNOW) : Free Stock Analysis Report To read this article on Zacks.com click here.

The Zacks Consensus Estimate for earnings is pegged at $1.34 per share, indicating a fall of 12.4% from the year-ago fiscal quarter’s reported figure. Agilent Technologies, Inc. Price and EPS Surprise Agilent Technologies, Inc. price-eps-surprise | Agilent Technologies, Inc. Quote Factors to Note The company is expected to have gained from growing momentum across Agilent’s Cross Lab Group (“ACG”) and Diagnostics and Genomics Group (“DGG”) segments during the fiscal fourth quarter. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Costco Wholesale Corporation (COST) : Free Stock Analysis Report Synopsys, Inc. (SNPS) : Free Stock Analysis Report Snowflake Inc. (SNOW) : Free Stock Analysis Report To read this article on Zacks.com click here.

Agilent’s strength in the Nucleic Acid Solutions Division business is expected to have continued benefiting the DGG segment’s performance in the fiscal fourth quarter. Agilent Technologies has a Zacks Rank #4 (Sell) and an Earnings ESP of -0.28% at present. Snowflake SNOW has an Earnings ESP of +67.33% and a Zacks Rank #2.

20.0

2023-11-16 00:00:00 UTC

Agilent (A) Boosts DGG Offerings With PD-L1 IHC 22C3 Approval

A

https://www.nasdaq.com/articles/agilent-a-boosts-dgg-offerings-with-pd-l1-ihc-22c3-approval

Agilent Technologies A is leaving no stone unturned to bolster diagnostic tool offerings in a bid to strengthen its Diagnostics and Genomics Group (DGG) segment. Notably, Agilent received FDA approval for its PD-L1 IHC 22C3 pharmDx diagnostic tool, which helps in Gastric or Gastroesophageal Junction Adenocarcinoma diagnosis. Further, it identifies patients’ eligibility for treatment with KEYTRUDA, an anti-programmed cell death (PD1) therapy, along with chemotherapy, trastuzumab and fluoropyrimidine. Additionally, PD-L1 IHC 22C3 pharmDx aids in identifying patients with non-small cell lung, esophageal, cervical, head and neck and triple-negative breast cancer who may be eligible for KEYTRUDA treatment. We note that this approval would benefit cancer patients whose tumors express programmed cell death ligand 1 (PD-L1). Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote Growth Prospects The latest announcement bodes well for the company’s deepening focus to strengthen its footprint in the PD-1 and PD-L1 inhibitors market. This, in turn, will aid Agilent to solidify its footing in the global cancer diagnostics market. Per a Mordor Intelligence report, the global PD-1 and PD-L1 inhibitors market is expected to hit $45.8 billion in 2023 and reach $104.6 billion by 2028, witnessing a CAGR of 18% between 2023 and 2028. A Future Market Insights report indicates that the global cancer diagnostics market will reach $126 billion by 2033, exhibiting a CAGR of 8.5% during the forecast period of 2023-2033. We believe the company’s solid prospects in these promising markets are expected to instill investor optimism in the stock. However, it has been suffering from macroeconomic uncertainties, weak momentum in China, rising inflationary pressure and geo-political tensions. Agilent has lost 24.1% in the year-to-date period, underperforming the industry’s decline of 4.6%. Expanding DGG Segment Apart from the latest move, Agilent released the enhanced xCELLigence RTCA Software Pro Version 2.8, a software package for real-time cell analysis in GMP-regulated facilities, ensuring data authenticity and compliance. Further, Agilent launched the Agilent SureSelect Cancer CGP Assay, a pan-cancer assay designed for somatic variant profiling of solid tumor types, utilizing an NGS panel of 679 genes. We note that all the above-mentioned endeavors will likely act as a catalyst for its customer base expansion. Notably, Agilent signed a Research Collaboration Agreement with the National Cancer Centre Singapore to expedite translational cancer research on Asian-prevalent cancer genomics over two years. Further, the agreement involves the provision of an Agilent Magnis NGS Preparation System for investigating specific details in Asian cancer cohorts, where tissue samples are limited locally and regionally. Moreover, Agilent signed a Memorandum of Understanding with Advanced Cell Therapy and Research Institute, Singapore, to install and operate its xCELLigence real-time cell analyzer, aiming to advance cell and gene therapy over the next three years. All these endeavors are likely to aid the performance of the DGG segment in the days ahead. For third-quarter fiscal 2023, revenues in the underlined segment increased 3% from the prior-year fiscal quarter’s figure on a reported as well as a core basis to $349 million. Our model estimate for DGG revenues for fiscal 2023 is pegged at $1.41 billion, indicating growth of 1.5% from the 2022 level. The same for fiscal 2024 and fiscal 2025 stands at $1.48 billion and $1.58 billion, suggesting year-over-year growth of 5% and 7%, respectively. Zacks Rank & Stocks to Consider Currently, Agilent carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader technology sector are Badger Meter BMI, Arista Networks ANET and Salesforce CRM. While Badger Meter sports a Zacks Rank #1 (Strong Buy), Arista Networks and Salesforce carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here. Badger Meter shares have gained 35.9% in the year-to-date period. BMI’s long-term earnings growth rate is currently projected at 20.39%. Arista Networks shares have gained 71.2% in the year-to-date period. The long-term earnings growth rate for ANET is currently projected at 20.4% Salesforce shares have gained 65.5% in the year-to-date period. CRM’s long-term earnings growth rate is currently projected at 22.54%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Salesforce Inc. (CRM) : Free Stock Analysis Report Badger Meter, Inc. (BMI) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notably, Agilent received FDA approval for its PD-L1 IHC 22C3 pharmDx diagnostic tool, which helps in Gastric or Gastroesophageal Junction Adenocarcinoma diagnosis. Additionally, PD-L1 IHC 22C3 pharmDx aids in identifying patients with non-small cell lung, esophageal, cervical, head and neck and triple-negative breast cancer who may be eligible for KEYTRUDA treatment. Further, the agreement involves the provision of an Agilent Magnis NGS Preparation System for investigating specific details in Asian cancer cohorts, where tissue samples are limited locally and regionally.

Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote Growth Prospects The latest announcement bodes well for the company’s deepening focus to strengthen its footprint in the PD-1 and PD-L1 inhibitors market. While Badger Meter sports a Zacks Rank #1 (Strong Buy), Arista Networks and Salesforce carry a Zacks Rank #2 (Buy) each. Click to get this free report Salesforce Inc. (CRM) : Free Stock Analysis Report Badger Meter, Inc. (BMI) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report To read this article on Zacks.com click here.

Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote Growth Prospects The latest announcement bodes well for the company’s deepening focus to strengthen its footprint in the PD-1 and PD-L1 inhibitors market. Notably, Agilent signed a Research Collaboration Agreement with the National Cancer Centre Singapore to expedite translational cancer research on Asian-prevalent cancer genomics over two years. Click to get this free report Salesforce Inc. (CRM) : Free Stock Analysis Report Badger Meter, Inc. (BMI) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report To read this article on Zacks.com click here.

Per a Mordor Intelligence report, the global PD-1 and PD-L1 inhibitors market is expected to hit $45.8 billion in 2023 and reach $104.6 billion by 2028, witnessing a CAGR of 18% between 2023 and 2028. Some better-ranked stocks in the broader technology sector are Badger Meter BMI, Arista Networks ANET and Salesforce CRM. See them now >> Want the latest recommendations from Zacks Investment Research?

21.0

2023-11-14 00:00:00 UTC

Agilent Technologies Announces FDA Approval For PD-L1 IHC 22C3 PharmDx - Quick Facts

A

https://www.nasdaq.com/articles/agilent-technologies-announces-fda-approval-for-pd-l1-ihc-22c3-pharmdx-quick-facts

(RTTNews) - Agilent Technologies Inc. (A) has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal Junction Adenocarcinoma who may be eligible for treatment with KEYTRUDA, Merck's anti-PD-1 therapy. The company noted that this marks the sixth cancer type for which PD-L1 IHC 22C3 pharmDx has gained FDA approval. PD-L1 IHC 22C3 pharmDx was developed by Agilent in partnership with Merck as a companion diagnostic for KEYTRUDA. For More Such Health News, visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

(RTTNews) - Agilent Technologies Inc. (A) has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal Junction Adenocarcinoma who may be eligible for treatment with KEYTRUDA, Merck's anti-PD-1 therapy. The company noted that this marks the sixth cancer type for which PD-L1 IHC 22C3 pharmDx has gained FDA approval. PD-L1 IHC 22C3 pharmDx was developed by Agilent in partnership with Merck as a companion diagnostic for KEYTRUDA.

(RTTNews) - Agilent Technologies Inc. (A) has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal Junction Adenocarcinoma who may be eligible for treatment with KEYTRUDA, Merck's anti-PD-1 therapy. The company noted that this marks the sixth cancer type for which PD-L1 IHC 22C3 pharmDx has gained FDA approval. PD-L1 IHC 22C3 pharmDx was developed by Agilent in partnership with Merck as a companion diagnostic for KEYTRUDA.

(RTTNews) - Agilent Technologies Inc. (A) has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal Junction Adenocarcinoma who may be eligible for treatment with KEYTRUDA, Merck's anti-PD-1 therapy. For More Such Health News, visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

(RTTNews) - Agilent Technologies Inc. (A) has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal Junction Adenocarcinoma who may be eligible for treatment with KEYTRUDA, Merck's anti-PD-1 therapy. The company noted that this marks the sixth cancer type for which PD-L1 IHC 22C3 pharmDx has gained FDA approval. PD-L1 IHC 22C3 pharmDx was developed by Agilent in partnership with Merck as a companion diagnostic for KEYTRUDA.

22.0

2023-11-13 00:00:00 UTC

Analysts Estimate Agilent Technologies (A) to Report a Decline in Earnings: What to Look Out for

A

https://www.nasdaq.com/articles/analysts-estimate-agilent-technologies-a-to-report-a-decline-in-earnings%3A-what-to-look-out

Wall Street expects a year-over-year decline in earnings on lower revenues when Agilent Technologies (A) reports results for the quarter ended October 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 20. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. Zacks Consensus Estimate This scientific instrument maker is expected to post quarterly earnings of $1.34 per share in its upcoming report, which represents a year-over-year change of -12.4%. Revenues are expected to be $1.67 billion, down 9.7% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 0.19% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). How Have the Numbers Shaped Up for Agilent? For Agilent, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.53%. On the other hand, the stock currently carries a Zacks Rank of #4. So, this combination makes it difficult to conclusively predict that Agilent will beat the consensus EPS estimate. Does Earnings Surprise History Hold Any Clue? While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Agilent would post earnings of $1.37 per share when it actually produced earnings of $1.43, delivering a surprise of +4.38%. Over the last four quarters, the company has beaten consensus EPS estimates three times. Bottom Line An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Agilent doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold." Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For Agilent, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 20. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 0.19% lower over the last 30 days to the current level. For the last reported quarter, it was expected that Agilent would post earnings of $1.37 per share when it actually produced earnings of $1.43, delivering a surprise of +4.38%.

23.0

2023-11-08 00:00:00 UTC

Agilent Technologies (A) Stock Dips While Market Gains: Key Facts

A

https://www.nasdaq.com/articles/agilent-technologies-a-stock-dips-while-market-gains%3A-key-facts-0

In the latest trading session, Agilent Technologies (A) closed at $109.39, marking a -1.04% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.1%. At the same time, the Dow lost 0.12%, and the tech-heavy Nasdaq gained 0.08%. Shares of the scientific instrument maker have depreciated by 2.43% over the course of the past month, underperforming the Computer and Technology sector's gain of 1.55% and the S&P 500's gain of 1.72%. Market participants will be closely following the financial results of Agilent Technologies in its upcoming release. The company plans to announce its earnings on November 20, 2023. The company is expected to report EPS of $1.34, down 12.42% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $1.67 billion, indicating a 9.65% downward movement from the same quarter last year. Investors might also notice recent changes to analyst estimates for Agilent Technologies. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.09% downward. At present, Agilent Technologies boasts a Zacks Rank of #4 (Sell). Investors should also note Agilent Technologies's current valuation metrics, including its Forward P/E ratio of 19.55. Its industry sports an average Forward P/E of 23.35, so one might conclude that Agilent Technologies is trading at a discount comparatively. Meanwhile, A's PEG ratio is currently 1.96. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. A's industry had an average PEG ratio of 2.24 as of yesterday's close. The Electronics - Testing Equipment industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 95, finds itself in the top 38% echelons of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Alongside, our most recent consensus estimate is anticipating revenue of $1.67 billion, indicating a 9.65% downward movement from the same quarter last year. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

In the latest trading session, Agilent Technologies (A) closed at $109.39, marking a -1.04% move from the previous day. Over the past month, the Zacks Consensus EPS estimate has shifted 1.09% downward. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. This industry, currently bearing a Zacks Industry Rank of 95, finds itself in the top 38% echelons of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups.

In the latest trading session, Agilent Technologies (A) closed at $109.39, marking a -1.04% move from the previous day. Shares of the scientific instrument maker have depreciated by 2.43% over the course of the past month, underperforming the Computer and Technology sector's gain of 1.55% and the S&P 500's gain of 1.72%. Investors might also notice recent changes to analyst estimates for Agilent Technologies.

24.0

2023-11-07 00:00:00 UTC

A Quantitative Stock Analysis

A

https://www.nasdaq.com/articles/a-quantitative-stock-analysis-0

Below is Validea's guru fundamental report for AGILENT TECHNOLOGIES INC (A). Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. AGILENT TECHNOLOGIES INC (A) is a large-cap growth stock in the Scientific & Technical Instr. industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: FAIL CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.

Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends.

Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends.

Below is Validea's guru fundamental report for AGILENT TECHNOLOGIES INC (A). Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing.

25.0

2023-11-01 00:00:00 UTC

Agilent Technologies (A) Stock Dips While Market Gains: Key Facts

A

https://www.nasdaq.com/articles/agilent-technologies-a-stock-dips-while-market-gains%3A-key-facts

Agilent Technologies (A) closed at $102.86 in the latest trading session, marking a -0.49% move from the prior day. This change lagged the S&P 500's 1.05% gain on the day. On the other hand, the Dow registered a gain of 0.67%, and the technology-centric Nasdaq increased by 1.64%. Shares of the scientific instrument maker have depreciated by 6.25% over the course of the past month, underperforming the Computer and Technology sector's loss of 2.51% and the S&P 500's loss of 2.21%. Analysts and investors alike will be keeping a close eye on the performance of Agilent Technologies in its upcoming earnings disclosure. The company's earnings report is set to go public on November 20, 2023. The company is expected to report EPS of $1.37, down 10.46% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $1.67 billion, reflecting a 9.65% fall from the equivalent quarter last year. Investors should also note any recent changes to analyst estimates for Agilent Technologies. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.05% lower. At present, Agilent Technologies boasts a Zacks Rank of #4 (Sell). Investors should also note Agilent Technologies's current valuation metrics, including its Forward P/E ratio of 19.1. This indicates a discount in contrast to its industry's Forward P/E of 24.31. It's also important to note that A currently trades at a PEG ratio of 1.91. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Electronics - Testing Equipment industry had an average PEG ratio of 2.45. The Electronics - Testing Equipment industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 34, finds itself in the top 14% echelons of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Analysts and investors alike will be keeping a close eye on the performance of Agilent Technologies in its upcoming earnings disclosure. At the same time, our most recent consensus estimate is projecting a revenue of $1.67 billion, reflecting a 9.65% fall from the equivalent quarter last year. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

Investors should also note Agilent Technologies's current valuation metrics, including its Forward P/E ratio of 19.1. By the end of yesterday's trading, the Electronics - Testing Equipment industry had an average PEG ratio of 2.45. This industry, currently bearing a Zacks Industry Rank of 34, finds itself in the top 14% echelons of all 250+ industries.

This industry, currently bearing a Zacks Industry Rank of 34, finds itself in the top 14% echelons of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys.

Investors should also note any recent changes to analyst estimates for Agilent Technologies. Investors should also note Agilent Technologies's current valuation metrics, including its Forward P/E ratio of 19.1. This industry, currently bearing a Zacks Industry Rank of 34, finds itself in the top 14% echelons of all 250+ industries.

26.0

2023-10-31 00:00:00 UTC

Ametek (AME) Q3 Earnings Surpass Estimates

A

https://www.nasdaq.com/articles/ametek-ame-q3-earnings-surpass-estimates

Ametek (AME) came out with quarterly earnings of $1.64 per share, beating the Zacks Consensus Estimate of $1.58 per share. This compares to earnings of $1.45 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.80%. A quarter ago, it was expected that this maker of electronic instruments and electromechanical devices would post earnings of $1.52 per share when it actually produced earnings of $1.57, delivering a surprise of 3.29%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Ametek, which belongs to the Zacks Electronics - Testing Equipment industry, posted revenues of $1.62 billion for the quarter ended September 2023, missing the Zacks Consensus Estimate by 1.55%. This compares to year-ago revenues of $1.55 billion. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Ametek shares have added about 0.3% since the beginning of the year versus the S&P 500's gain of 8.5%. What's Next for Ametek? While Ametek has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Ametek: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.62 on $1.72 billion in revenues for the coming quarter and $6.26 on $6.61 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Electronics - Testing Equipment is currently in the top 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Agilent Technologies (A), has yet to report results for the quarter ended October 2023. The results are expected to be released on November 20. This scientific instrument maker is expected to post quarterly earnings of $1.34 per share in its upcoming report, which represents a year-over-year change of -12.4%. The consensus EPS estimate for the quarter has been revised 0.3% lower over the last 30 days to the current level. Agilent Technologies' revenues are expected to be $1.67 billion, down 9.7% from the year-ago quarter. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AMETEK, Inc. (AME) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. This scientific instrument maker is expected to post quarterly earnings of $1.34 per share in its upcoming report, which represents a year-over-year change of -12.4%.

Ametek, which belongs to the Zacks Electronics - Testing Equipment industry, posted revenues of $1.62 billion for the quarter ended September 2023, missing the Zacks Consensus Estimate by 1.55%. The current consensus EPS estimate is $1.62 on $1.72 billion in revenues for the coming quarter and $6.26 on $6.61 billion in revenues for the current fiscal year. Click to get this free report AMETEK, Inc. (AME) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here.

Ametek (AME) came out with quarterly earnings of $1.64 per share, beating the Zacks Consensus Estimate of $1.58 per share. Ametek, which belongs to the Zacks Electronics - Testing Equipment industry, posted revenues of $1.62 billion for the quarter ended September 2023, missing the Zacks Consensus Estimate by 1.55%. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock.

Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research?

27.0

2023-10-30 00:00:00 UTC

Oversold Conditions For Agilent Technologies (A)

A

https://www.nasdaq.com/articles/oversold-conditions-for-agilent-technologies-a

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Agilent Technologies, Inc. (Symbol: A) entered into oversold territory, hitting an RSI reading of 25.5, after changing hands as low as $96.80 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 30.8. A bullish investor could look at A's 25.5 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of A shares: Looking at the chart above, A's low point in its 52 week range is $96.80 per share, with $160.265 as the 52 week high point — that compares with a last trade of $98.86. Find out what 9 other oversold stocks you need to know about » Also see: • Cheap Materials Shares • SI Stock Predictions • TPL Stock Predictions The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In trading on Monday, shares of Agilent Technologies, Inc. (Symbol: A) entered into oversold territory, hitting an RSI reading of 25.5, after changing hands as low as $96.80 per share. A bullish investor could look at A's 25.5 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of A shares: Looking at the chart above, A's low point in its 52 week range is $96.80 per share, with $160.265 as the 52 week high point — that compares with a last trade of $98.86.

By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 30.8. The chart below shows the one year performance of A shares: Looking at the chart above, A's low point in its 52 week range is $96.80 per share, with $160.265 as the 52 week high point — that compares with a last trade of $98.86. Find out what 9 other oversold stocks you need to know about » Also see: • Cheap Materials Shares • SI Stock Predictions • TPL Stock Predictions The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In trading on Monday, shares of Agilent Technologies, Inc. (Symbol: A) entered into oversold territory, hitting an RSI reading of 25.5, after changing hands as low as $96.80 per share. The chart below shows the one year performance of A shares: Looking at the chart above, A's low point in its 52 week range is $96.80 per share, with $160.265 as the 52 week high point — that compares with a last trade of $98.86. Find out what 9 other oversold stocks you need to know about » Also see: • Cheap Materials Shares • SI Stock Predictions • TPL Stock Predictions The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

28.0

2023-10-24 00:00:00 UTC

A Quantitative Stock Analysis

A

https://www.nasdaq.com/articles/a-quantitative-stock-analysis

Below is Validea's guru fundamental report for AGILENT TECHNOLOGIES INC (A). Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. AGILENT TECHNOLOGIES INC (A) is a large-cap growth stock in the Scientific & Technical Instr. industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: FAIL CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.

Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends.

Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends.

Below is Validea's guru fundamental report for AGILENT TECHNOLOGIES INC (A). Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing.

29.0

2023-10-24 00:00:00 UTC

Danaher beats profit estimates on respiratory testing demand

A

https://www.nasdaq.com/articles/danaher-beats-profit-estimates-on-respiratory-testing-demand

Oct 24 (Reuters) - Danaher DHR.N on Tuesday beat Wall Street estimates for third-quarter profit as strong demand for its diagnostic tests for respiratory diseases helped soften the blow from weaker sales at the healthcare conglomerate's life-sciences unit. The diagnostics unit, which makes kits, also used for COVID-19 testing, as well as reagents and other tools, reported sales of $2.25 billion, beating the average analyst estimate of $2.12 billion, according to LSEG data. However, the life sciences unit, which provides reagents and lab equipment used in the discovery of new drugs and vaccines, posted sales of $1.71 billion, missing estimates of $1.78 billion. "Revenue in the third quarter came in ahead of our expectations, with Biotechnology performing as anticipated, and higher respiratory testing revenue more than offsetting slightly softer-than-anticipated demand in Life Sciences," Danaher CEO Rainer Blair said in a statement. Shares of the Washington D.C.-based company rose 1.2% to $206.50 before the bell. Danaher now expects a slight decline in adjusted core sales for the year, compared with its previous expectation of a low single-digit rise. Life sciences companies such as Danaher, Agilent A.N and Thermo Fisher TMO.N cut their annual profit forecasts earlier this year as some clients slashed their budgets for biopharma services due to a funding crunch. Rising interest rates squeezed funding needed for drug development programs, weighing on demand for contract research services offered by Danaher and rival Thermo Fisher. Danaher's forecast excludes the impact of the spinoff of its Environmental & Applied Solutions unit, Veralto VLTO.N, which began trading on Oct. 2. On an adjusted basis, Danaher reported a profit per share of $2.02, beating analysts' expectations of $1.87. Third-quarter sales of $6.87 billion also topped estimates of $6.63 billion. (Reporting by Christy Santhosh; Editing by Krishna Chandra Eluri and Sriraj Kalluvila) ((Christy.Santhosh@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Oct 24 (Reuters) - Danaher DHR.N on Tuesday beat Wall Street estimates for third-quarter profit as strong demand for its diagnostic tests for respiratory diseases helped soften the blow from weaker sales at the healthcare conglomerate's life-sciences unit. Life sciences companies such as Danaher, Agilent A.N and Thermo Fisher TMO.N cut their annual profit forecasts earlier this year as some clients slashed their budgets for biopharma services due to a funding crunch. Rising interest rates squeezed funding needed for drug development programs, weighing on demand for contract research services offered by Danaher and rival Thermo Fisher.

"Revenue in the third quarter came in ahead of our expectations, with Biotechnology performing as anticipated, and higher respiratory testing revenue more than offsetting slightly softer-than-anticipated demand in Life Sciences," Danaher CEO Rainer Blair said in a statement. Life sciences companies such as Danaher, Agilent A.N and Thermo Fisher TMO.N cut their annual profit forecasts earlier this year as some clients slashed their budgets for biopharma services due to a funding crunch. On an adjusted basis, Danaher reported a profit per share of $2.02, beating analysts' expectations of $1.87.

Oct 24 (Reuters) - Danaher DHR.N on Tuesday beat Wall Street estimates for third-quarter profit as strong demand for its diagnostic tests for respiratory diseases helped soften the blow from weaker sales at the healthcare conglomerate's life-sciences unit. The diagnostics unit, which makes kits, also used for COVID-19 testing, as well as reagents and other tools, reported sales of $2.25 billion, beating the average analyst estimate of $2.12 billion, according to LSEG data. However, the life sciences unit, which provides reagents and lab equipment used in the discovery of new drugs and vaccines, posted sales of $1.71 billion, missing estimates of $1.78 billion.

The diagnostics unit, which makes kits, also used for COVID-19 testing, as well as reagents and other tools, reported sales of $2.25 billion, beating the average analyst estimate of $2.12 billion, according to LSEG data. On an adjusted basis, Danaher reported a profit per share of $2.02, beating analysts' expectations of $1.87. Third-quarter sales of $6.87 billion also topped estimates of $6.63 billion.

30.0

2023-10-19 00:00:00 UTC

December 15th Options Now Available For Agilent Technologies (A)

A

https://www.nasdaq.com/articles/december-15th-options-now-available-for-agilent-technologies-a

Investors in Agilent Technologies, Inc. (Symbol: A) saw new options become available today, for the December 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the A options chain for the new December 15th contracts and identified one put and one call contract of particular interest. The put contract at the $105.00 strike price has a current bid of $2.75. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $105.00, but will also collect the premium, putting the cost basis of the shares at $102.25 (before broker commissions). To an investor already interested in purchasing shares of A, that could represent an attractive alternative to paying $109.28/share today. Because the $105.00 strike represents an approximate 4% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 2.62% return on the cash commitment, or 16.76% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for Agilent Technologies, Inc., and highlighting in green where the $105.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $110.00 strike price has a current bid of $4.50. If an investor was to purchase shares of A stock at the current price level of $109.28/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $110.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 4.78% if the stock gets called away at the December 15th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if A shares really soar, which is why looking at the trailing twelve month trading history for Agilent Technologies, Inc., as well as studying the business fundamentals becomes important. Below is a chart showing A's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 4.12% boost of extra return to the investor, or 26.35% annualized, which we refer to as the YieldBoost. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $109.28) to be 27%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of Stocks Analysts Like » Also see: • GIC Options Chain • Institutional Holders of CING • PACW Insider Buying The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Because the $105.00 strike represents an approximate 4% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Of course, a lot of upside could potentially be left on the table if A shares really soar, which is why looking at the trailing twelve month trading history for Agilent Technologies, Inc., as well as studying the business fundamentals becomes important.

The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Below is a chart showing the trailing twelve month trading history for Agilent Technologies, Inc., and highlighting in green where the $105.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $110.00 strike price has a current bid of $4.50. Investors in Agilent Technologies, Inc. (Symbol: A) saw new options become available today, for the December 15th expiration.

The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Below is a chart showing the trailing twelve month trading history for Agilent Technologies, Inc., and highlighting in green where the $105.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $110.00 strike price has a current bid of $4.50. Below is a chart showing A's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected.

At Stock Options Channel, our YieldBoost formula has looked up and down the A options chain for the new December 15th contracts and identified one put and one call contract of particular interest. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Should the contract expire worthless, the premium would represent a 2.62% return on the cash commitment, or 16.76% annualized — at Stock Options Channel we call this the YieldBoost.

31.0

2023-10-17 00:00:00 UTC

Carl Icahn sues Illumina board for violating 'fiduciary duties'

A

https://www.nasdaq.com/articles/carl-icahn-sues-illumina-board-for-violating-fiduciary-duties

Changes source in headline, recasts paragraph 1, adds background in paragraphs 4-6 Oct 17 (Reuters) - Activist-investor Carl Icahn sued the board of directors at genetic testing company Illumina ILMN.O and accused them of breaching their fiduciary duties, according to a sealed copy of the complaint on Tuesday. The publicly available version of the complaint did not contain further details, but Icahn told the 13D investor conference in New York on Tuesday that the lawsuit pertained to Illumina completing its acquisition of cancer detection test maker Grail. Illumina said it is reviewing the complaint, while Icahn and Grail did not immediately respond to Reuters requests for a comment. The gene-sequencing machine maker had repurchased Grail in 2021 despite opposition from U.S. and European antitrust regulators - a decision that prompted Icahn to pursue a proxy fight at Illumina, arguing Grail should be divested as it had cost investors billions of dollars. Last week, Illumina said it would divest cancer test maker Grail in 12 months according to the terms of the European Commission's order, if the life sciences company does not win its challenge in court. (Reporting by Mrinmay Dey and Shivani Tanna in Bengaluru; Editing by Sherry Jacob-Phillips) ((Mrinmay.Dey@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Changes source in headline, recasts paragraph 1, adds background in paragraphs 4-6 Oct 17 (Reuters) - Activist-investor Carl Icahn sued the board of directors at genetic testing company Illumina ILMN.O and accused them of breaching their fiduciary duties, according to a sealed copy of the complaint on Tuesday. The publicly available version of the complaint did not contain further details, but Icahn told the 13D investor conference in New York on Tuesday that the lawsuit pertained to Illumina completing its acquisition of cancer detection test maker Grail. Last week, Illumina said it would divest cancer test maker Grail in 12 months according to the terms of the European Commission's order, if the life sciences company does not win its challenge in court.

Changes source in headline, recasts paragraph 1, adds background in paragraphs 4-6 Oct 17 (Reuters) - Activist-investor Carl Icahn sued the board of directors at genetic testing company Illumina ILMN.O and accused them of breaching their fiduciary duties, according to a sealed copy of the complaint on Tuesday. The publicly available version of the complaint did not contain further details, but Icahn told the 13D investor conference in New York on Tuesday that the lawsuit pertained to Illumina completing its acquisition of cancer detection test maker Grail. Last week, Illumina said it would divest cancer test maker Grail in 12 months according to the terms of the European Commission's order, if the life sciences company does not win its challenge in court.

Changes source in headline, recasts paragraph 1, adds background in paragraphs 4-6 Oct 17 (Reuters) - Activist-investor Carl Icahn sued the board of directors at genetic testing company Illumina ILMN.O and accused them of breaching their fiduciary duties, according to a sealed copy of the complaint on Tuesday. The publicly available version of the complaint did not contain further details, but Icahn told the 13D investor conference in New York on Tuesday that the lawsuit pertained to Illumina completing its acquisition of cancer detection test maker Grail. The gene-sequencing machine maker had repurchased Grail in 2021 despite opposition from U.S. and European antitrust regulators - a decision that prompted Icahn to pursue a proxy fight at Illumina, arguing Grail should be divested as it had cost investors billions of dollars.

Changes source in headline, recasts paragraph 1, adds background in paragraphs 4-6 Oct 17 (Reuters) - Activist-investor Carl Icahn sued the board of directors at genetic testing company Illumina ILMN.O and accused them of breaching their fiduciary duties, according to a sealed copy of the complaint on Tuesday. The publicly available version of the complaint did not contain further details, but Icahn told the 13D investor conference in New York on Tuesday that the lawsuit pertained to Illumina completing its acquisition of cancer detection test maker Grail. Illumina said it is reviewing the complaint, while Icahn and Grail did not immediately respond to Reuters requests for a comment.

32.0

2023-10-10 00:00:00 UTC

Agilent (A) Bolsters NTD Research With SIDC Partnership

A

https://www.nasdaq.com/articles/agilent-a-bolsters-ntd-research-with-sidc-partnership

Agilent Technologies A signed a Memorandum of Understanding with the Sarawak Infectious Disease Centre (SIDC) to provide its 6475 triple quadrupole LC/MS system for neglected tropical diseases (NTD) research. Notably, Agilent's 6475 LC/MS, which utilizes iFunnel technologies, will aid SIDC's research on tropical medicines and infectious diseases, enabling rapid outbreak response through extensive research and diagnostic capabilities. Further, the 6475 LC/MS system enhances signal response and optimizes research outcomes through technology and knowledge transfer, capacity building, research programs and human capital development. SIDC plans to use Agilent's capabilities as it prepares for facility completion by December 2025. We note that the latest move has expanded the customer base of Agilent’s liquid chromatography mass spectrometry (LC/MS) systems. This, in turn, will strengthen Agilent’s Life Sciences & Applied Markets Group (LSAG) segment. Moreover, the deal will also strengthen Agilent’s footprint in Asian markets. Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote Growth Prospects We believe that the latest move will strengthen the company’s footing in the global neglected tropical diseases diagnosis market. Per an MMR research report, the global NTD diagnosis market size is expected to reach $8.97 billion by 2029, exhibiting a CAGR of 4.5% between 2022 and 2029. A Grand View Research report predicts the global NTD diagnosis market size to witness a CAGR of 4.5% during the forecast period of 2023-2030. We believe the company’s solid prospects in the promising NTD diagnosis market are expected to instill investor optimism in the stock. However, it has been suffering from macroeconomic uncertainties, weak momentum in China, rising inflationary pressure and geo-political tensions. Agilent has lost 25.6% in the year-to-date period, underperforming the industry’s growth of 0.8%. LSAG Segment in Focus The latest move is in sync with the company’s growing efforts toward bolstering its LSAG segment. Apart from the latest move, Agilent Technologies showcased its expanded InfinityLab GPC/SEC Solution at the HPLC Conference 2023 in Düsseldorf. The solution includes a dedicated column thermostat, multi-angle light scattering detector, GPC/SEC-Ready Kit, and WinGPC Software for advanced material characterization. Additionally, Agilent's 1260 Infinity II Hybrid Multisampler, 1290 Infinity II Bio Online Sample Manager and Revident Quadrupole Time-of-Flight LC/MS System were also displayed at the HPLC 2023 conference. Further, Agilent Technologies introduced new liquid chromatography mass spectrometry systems, Agilent 6495D LC/TQ and Revident LC/Q-TOF, along with new software for profiling and library management, ensuring high analytical sensitivity and efficiency for fast, high-quality data and early maintenance feedback for optimal performance. Also, Agilent launched the Agilent 8697 Headspace Sampler -XL Tray, offering 120 vial capacity and enhanced instrument intelligence features for increased uptime and operator ease of use compared to its predecessor. All these endeavors are likely to aid the performance of the LSAG segment in the days ahead. However, the sluggish pharma market continues to remain a concern. Our model estimate for LSAG revenues for fiscal 2023 is pegged at $3.85 billion, indicating a decline of 3.9% from the fiscal 2022 level. Zacks Rank & Stocks to Consider Currently, Agilent carries a Zacks Rank #5 (Strong Sell). Some better-ranked stocks in the broader technology sector are Asure Software ASUR, Applied Materials AMAT and Arista Networks ANET. While Asure Software and Applied Materials sport a Zacks Rank #1 (Strong Buy) each, Arista Networks carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Asure Software shares have lost 2% in the year-to-date period. ASUR’s long-term earnings growth rate is currently projected at 27%. Applied Materials shares have gained 43.9% in the year-to-date period. AMAT’s long-term earnings growth rate is currently projected at 6.10%. Arista Networks shares have gained 61.8% in the year-to-date period. The long-term earnings growth rate for ANET is currently projected at 18.75% Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Applied Materials, Inc. (AMAT) : Free Stock Analysis Report Asure Software Inc (ASUR) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Per an MMR research report, the global NTD diagnosis market size is expected to reach $8.97 billion by 2029, exhibiting a CAGR of 4.5% between 2022 and 2029. A Grand View Research report predicts the global NTD diagnosis market size to witness a CAGR of 4.5% during the forecast period of 2023-2030. The solution includes a dedicated column thermostat, multi-angle light scattering detector, GPC/SEC-Ready Kit, and WinGPC Software for advanced material characterization.

Some better-ranked stocks in the broader technology sector are Asure Software ASUR, Applied Materials AMAT and Arista Networks ANET. While Asure Software and Applied Materials sport a Zacks Rank #1 (Strong Buy) each, Arista Networks carries a Zacks Rank #2 (Buy). Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Applied Materials, Inc. (AMAT) : Free Stock Analysis Report Asure Software Inc (ASUR) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report To read this article on Zacks.com click here.

Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote Growth Prospects We believe that the latest move will strengthen the company’s footing in the global neglected tropical diseases diagnosis market. Further, Agilent Technologies introduced new liquid chromatography mass spectrometry systems, Agilent 6495D LC/TQ and Revident LC/Q-TOF, along with new software for profiling and library management, ensuring high analytical sensitivity and efficiency for fast, high-quality data and early maintenance feedback for optimal performance. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Applied Materials, Inc. (AMAT) : Free Stock Analysis Report Asure Software Inc (ASUR) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report To read this article on Zacks.com click here.

Notably, Agilent's 6475 LC/MS, which utilizes iFunnel technologies, will aid SIDC's research on tropical medicines and infectious diseases, enabling rapid outbreak response through extensive research and diagnostic capabilities. Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote Growth Prospects We believe that the latest move will strengthen the company’s footing in the global neglected tropical diseases diagnosis market. Some better-ranked stocks in the broader technology sector are Asure Software ASUR, Applied Materials AMAT and Arista Networks ANET.

33.0

2023-10-05 00:00:00 UTC

Q4 Stock Predictions: 3 S&P 500 Stocks Ready to Soar

A

https://www.nasdaq.com/articles/q4-stock-predictions%3A-3-sp-500-stocks-ready-to-soar

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Stocks ended the third quarter on a sour note. The Federal Reserve’s aggressive posture against inflation combined with soaring interest rates have investors taking defensive measures. But it’s not time to give up on the stock market. In fact, thanks to the recent selling, bargains are springing up across many S&P 500 stocks. Let’s examine three that will benefit from current market conditions and rally heading into 2024. Wells Fargo (WFC) Source: Ken Wolter / Shutterstock.com Wells Fargo (NYSE:WFC) is one of the big banks that is thriving amid the industry’s correction. That’s because Wells Fargo did not aggressively expand its balance sheet or buy overvalued securities over the past few years. True, investors have shunned nearly all financials stocks this year amid unprecedented volatility in the interest rate markets. Banks that were positioned poorly, like First Republic and Silicon Valley, ended up going bust. And others are suffering from falling profitability and strained balance sheets at the present time. Meanwhile, Wells Fargo has positioned its balance sheet to earn far more profits as interest rates rise. And those rates are normally beneficial to the banking sector as a whole. For firms like Wells Fargo that managed their risks and exposures properly, that remains true in 2023. Specifically, Wells Fargo’s net interest margin (NIM), the spread between its loan interest and deposit payments, has soared from 2.2% in Q2 of last year to 3.1% today. With a near 50% jump in core profitability on its loan book, it’s no wonder that Wells Fargo is reporting rising earnings. WFC stock hasn’t yet snapped out of the industrywide doldrums. As a result, shares go for just eight times forward earnings today. Charles River Laboratories (CRL) Source: IgorGolovniov / Shutterstock.com Charles River Laboratories (NYSE:CRL) is a leading healthcare company focused on providing lab tools and services related to pharmaceutical drug development. Historically, it’s been the dominant player in animal models. Specifically, Charles River procures, breeds, and distributes lab rats, mice, rabbits, and non-human primates. The last one got Charles River in trouble, as the company was implicated in an investigation into alleged macaque smuggling in Cambodia. However, as of last quarter, Charles River has been able to resolve its sourcing issues around non-human primates. More broadly, CRL stock has slumped amid the slowdown in the biotech industry. With smaller biotech companies struggling to obtain funding, Charles River is experiencing less trials and revenue-generating business. Yet, it’s only a matter of time until biotech funding rises again, given the priority to find cures for rare diseases. CRL will inevitably be part of those future cures. In fact, the company was involved in developing more than 80% of all drugs that received FDA approval since 2020. In effect, Charles River is a tax on the entire biotech industry, with their consistent postings of compounded earnings per share growth rate in the teens since the turn of the century. Thanks to the recent scandal and biotech industry’s slump, CRL shares are now on sale at an unusually low 18 times forward earnings. Keysight Technologies (KEYS) Source: Funtap / Shutterstock.com Keysight Technologies (NYSE:KEYS) is a company that provides testing, product quality, and design solutions to technology companies. The firm has an interesting history. Keysight sprung up originally as Hewlett-Packard‘s Test & Measurement division more than half a century ago, and was ultimately spun off from Agilent (NYSE:A) into its own publicly-traded entity in 2014. KEYS stock has been incredibly successful over the past decade. Since 2014, shares jumped from $30 to a peak of more than $200. However, Keysight has fallen amid a slowdown in telecom and information technology spending over the past year. That has led KEYS stock to slide back to around $130 today. The weakness makes sense, as Keysight is heavily involved in quality control and testing for telecom companies. With 5G rollouts seeing an underwhelming debut as compared to expectations, that has cast a shadow on industry vendors. Other Keysight segments such as services for edge computing and RFID functions have slipped as demand levels off following an unusually robust 2021 and 2022. Indeed, the market is blowing the situation way out of proportion. KEYS stock is down to 16 times forward earnings, which is quite the discount for a tech company that has reliably posted double-digit earnings growth. It’s only a matter of time until telecom spending picks back up given the ever-growing demand for mobile data. Also, Keysight is active in emerging growth fields such as AI and next-generation semiconductors. Investors should take advantage of the current dip in KEYS stock. On the date of publication, Ian Bezek held a long position in KEYS, CRL, and WFC stock. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Ian Bezek has written more than 1,000 articles for InvestorPlace.com and Seeking Alpha. He also worked as a Junior Analyst for Kerrisdale Capital, a $300 million New York City-based hedge fund. You can reach him on Twitter at @irbezek. More From InvestorPlace Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. ChatGPT IPO Could Shock the World, Make This Move Before the Announcement The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors The post Q4 Stock Predictions: 3 S&P 500 Stocks Ready to Soar appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Federal Reserve’s aggressive posture against inflation combined with soaring interest rates have investors taking defensive measures. In effect, Charles River is a tax on the entire biotech industry, with their consistent postings of compounded earnings per share growth rate in the teens since the turn of the century. Keysight sprung up originally as Hewlett-Packard‘s Test & Measurement division more than half a century ago, and was ultimately spun off from Agilent (NYSE:A) into its own publicly-traded entity in 2014.

Wells Fargo (WFC) Source: Ken Wolter / Shutterstock.com Wells Fargo (NYSE:WFC) is one of the big banks that is thriving amid the industry’s correction. Charles River Laboratories (CRL) Source: IgorGolovniov / Shutterstock.com Charles River Laboratories (NYSE:CRL) is a leading healthcare company focused on providing lab tools and services related to pharmaceutical drug development. Keysight Technologies (KEYS) Source: Funtap / Shutterstock.com Keysight Technologies (NYSE:KEYS) is a company that provides testing, product quality, and design solutions to technology companies.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Stocks ended the third quarter on a sour note. Charles River Laboratories (CRL) Source: IgorGolovniov / Shutterstock.com Charles River Laboratories (NYSE:CRL) is a leading healthcare company focused on providing lab tools and services related to pharmaceutical drug development. Keysight Technologies (KEYS) Source: Funtap / Shutterstock.com Keysight Technologies (NYSE:KEYS) is a company that provides testing, product quality, and design solutions to technology companies.

But it’s not time to give up on the stock market. True, investors have shunned nearly all financials stocks this year amid unprecedented volatility in the interest rate markets. Meanwhile, Wells Fargo has positioned its balance sheet to earn far more profits as interest rates rise.

34.0

2023-09-29 00:00:00 UTC

Barclays Maintains Agilent Technologies (A) Underweight Recommendation

A

https://www.nasdaq.com/articles/barclays-maintains-agilent-technologies-a-underweight-recommendation-0

Fintel reports that on September 29, 2023, Barclays maintained coverage of Agilent Technologies (NYSE:A) with a Underweight recommendation. Analyst Price Forecast Suggests 26.87% Upside As of August 31, 2023, the average one-year price target for Agilent Technologies is 142.10. The forecasts range from a low of 111.10 to a high of $171.15. The average price target represents an increase of 26.87% from its latest reported closing price of 112.00. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.94%. The projected annual non-GAAP EPS is 5.77. What is the Fund Sentiment? There are 1926 funds or institutions reporting positions in Agilent Technologies. This is a decrease of 104 owner(s) or 5.12% in the last quarter. Average portfolio weight of all funds dedicated to A is 0.31%, a decrease of 19.13%. Total shares owned by institutions decreased in the last three months by 1.89% to 296,536K shares. The put/call ratio of A is 0.70, indicating a bullish outlook. What are Other Shareholders Doing? Massachusetts Financial Services holds 11,037K shares representing 3.77% ownership of the company. In it's prior filing, the firm reported owning 8,907K shares, representing an increase of 19.30%. The firm increased its portfolio allocation in A by 3.73% over the last quarter. T. Rowe Price Investment Management holds 9,968K shares representing 3.41% ownership of the company. In it's prior filing, the firm reported owning 9,277K shares, representing an increase of 6.93%. The firm decreased its portfolio allocation in A by 11.26% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,177K shares representing 3.14% ownership of the company. In it's prior filing, the firm reported owning 9,160K shares, representing an increase of 0.18%. The firm decreased its portfolio allocation in A by 19.66% over the last quarter. Wellington Management Group Llp holds 8,736K shares representing 2.99% ownership of the company. In it's prior filing, the firm reported owning 12,057K shares, representing a decrease of 38.01%. The firm decreased its portfolio allocation in A by 39.89% over the last quarter. Price T Rowe Associates holds 8,054K shares representing 2.75% ownership of the company. In it's prior filing, the firm reported owning 8,219K shares, representing a decrease of 2.05%. The firm increased its portfolio allocation in A by 78.88% over the last quarter. Agilent Technologies Background Information (This description is provided by the company.) Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits. Click to Learn More This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Fintel reports that on September 29, 2023, Barclays maintained coverage of Agilent Technologies (NYSE:A) with a Underweight recommendation. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

T. Rowe Price Investment Management holds 9,968K shares representing 3.41% ownership of the company. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,177K shares representing 3.14% ownership of the company. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,177K shares representing 3.14% ownership of the company. In it's prior filing, the firm reported owning 12,057K shares, representing a decrease of 38.01%. In it's prior filing, the firm reported owning 8,219K shares, representing a decrease of 2.05%.

The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.94%. Massachusetts Financial Services holds 11,037K shares representing 3.77% ownership of the company. T. Rowe Price Investment Management holds 9,968K shares representing 3.41% ownership of the company.

35.0

2023-09-28 00:00:00 UTC

Ex-Dividend Reminder: Upbound Group, Cardinal Health and Agilent Technologies

A

https://www.nasdaq.com/articles/ex-dividend-reminder%3A-upbound-group-cardinal-health-and-agilent-technologies

Looking at the universe of stocks we cover at Dividend Channel, on 10/2/23, Upbound Group Inc (Symbol: UPBD), Cardinal Health, Inc. (Symbol: CAH), and Agilent Technologies, Inc. (Symbol: A) will all trade ex-dividend for their respective upcoming dividends. Upbound Group Inc will pay its quarterly dividend of $0.34 on 10/24/23, Cardinal Health, Inc. will pay its quarterly dividend of $0.5006 on 10/15/23, and Agilent Technologies, Inc. will pay its quarterly dividend of $0.225 on 10/25/23. As a percentage of UPBD's recent stock price of $29.70, this dividend works out to approximately 1.14%, so look for shares of Upbound Group Inc to trade 1.14% lower — all else being equal — when UPBD shares open for trading on 10/2/23. Similarly, investors should look for CAH to open 0.57% lower in price and for A to open 0.20% lower, all else being equal. Below are dividend history charts for UPBD, CAH, and A, showing historical dividends prior to the most recent ones declared. Upbound Group Inc (Symbol: UPBD): Cardinal Health, Inc. (Symbol: CAH): Agilent Technologies, Inc. (Symbol: A): In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 4.58% for Upbound Group Inc, 2.27% for Cardinal Health, Inc., and 0.81% for Agilent Technologies, Inc.. Free Report: Top 8%+ Dividends (paid monthly) In Thursday trading, Upbound Group Inc shares are currently up about 0.9%, Cardinal Health, Inc. shares are up about 0.3%, and Agilent Technologies, Inc. shares are up about 0.3% on the day. Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen » Also see: • Institutional Holders of AX • IBTD YTD Return • CRG Split History The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. If they do continue, the current estimated yields on annualized basis would be 4.58% for Upbound Group Inc, 2.27% for Cardinal Health, Inc., and 0.81% for Agilent Technologies, Inc.. Free Report: Top 8%+ Dividends (paid monthly) In Thursday trading, Upbound Group Inc shares are currently up about 0.9%, Cardinal Health, Inc. shares are up about 0.3%, and Agilent Technologies, Inc. shares are up about 0.3% on the day. dividend stocks should be on your radar screen » Also see: • Institutional Holders of AX • IBTD YTD Return • CRG Split History The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Looking at the universe of stocks we cover at Dividend Channel, on 10/2/23, Upbound Group Inc (Symbol: UPBD), Cardinal Health, Inc. (Symbol: CAH), and Agilent Technologies, Inc. (Symbol: A) will all trade ex-dividend for their respective upcoming dividends. Upbound Group Inc will pay its quarterly dividend of $0.34 on 10/24/23, Cardinal Health, Inc. will pay its quarterly dividend of $0.5006 on 10/15/23, and Agilent Technologies, Inc. will pay its quarterly dividend of $0.225 on 10/25/23. Upbound Group Inc (Symbol: UPBD): Cardinal Health, Inc. (Symbol: CAH): Agilent Technologies, Inc. (Symbol: A): In general, dividends are not always predictable, following the ups and downs of company profits over time.

Looking at the universe of stocks we cover at Dividend Channel, on 10/2/23, Upbound Group Inc (Symbol: UPBD), Cardinal Health, Inc. (Symbol: CAH), and Agilent Technologies, Inc. (Symbol: A) will all trade ex-dividend for their respective upcoming dividends. Upbound Group Inc will pay its quarterly dividend of $0.34 on 10/24/23, Cardinal Health, Inc. will pay its quarterly dividend of $0.5006 on 10/15/23, and Agilent Technologies, Inc. will pay its quarterly dividend of $0.225 on 10/25/23. If they do continue, the current estimated yields on annualized basis would be 4.58% for Upbound Group Inc, 2.27% for Cardinal Health, Inc., and 0.81% for Agilent Technologies, Inc.. Free Report: Top 8%+ Dividends (paid monthly) In Thursday trading, Upbound Group Inc shares are currently up about 0.9%, Cardinal Health, Inc. shares are up about 0.3%, and Agilent Technologies, Inc. shares are up about 0.3% on the day.

As a percentage of UPBD's recent stock price of $29.70, this dividend works out to approximately 1.14%, so look for shares of Upbound Group Inc to trade 1.14% lower — all else being equal — when UPBD shares open for trading on 10/2/23. Upbound Group Inc (Symbol: UPBD): Cardinal Health, Inc. (Symbol: CAH): Agilent Technologies, Inc. (Symbol: A): In general, dividends are not always predictable, following the ups and downs of company profits over time. If they do continue, the current estimated yields on annualized basis would be 4.58% for Upbound Group Inc, 2.27% for Cardinal Health, Inc., and 0.81% for Agilent Technologies, Inc.. Free Report: Top 8%+ Dividends (paid monthly) In Thursday trading, Upbound Group Inc shares are currently up about 0.9%, Cardinal Health, Inc. shares are up about 0.3%, and Agilent Technologies, Inc. shares are up about 0.3% on the day.

36.0

2023-09-25 00:00:00 UTC

After Hours Most Active for Sep 25, 2023 : OKE, APO^A, ET, XPEV, BAC, FINV, MCHI, ARM, CSCO, CMCSA, QQQ, AAPL

A

https://www.nasdaq.com/articles/after-hours-most-active-for-sep-25-2023-%3A-oke-apo%5Ea-et-xpev-bac-finv-mchi-arm-csco-cmcsa

The NASDAQ 100 After Hours Indicator is up 13.01 to 14,781.91. The total After hours volume is currently 63,813,936 shares traded. The following are the most active stocks for the after hours session: ONEOK, Inc. (OKE) is +0.01 at $66.55, with 19,749,458 shares traded. OKE's current last sale is 91.16% of the target price of $73. Apollo Global Management, Inc. (APO^A) is unchanged at $56.25, with 3,816,895 shares traded. Energy Transfer L.P. (ET) is -0.02 at $13.99, with 3,668,019 shares traded. ET's current last sale is 82.29% of the target price of $17. XPeng Inc. (XPEV) is +0.11 at $16.80, with 3,072,662 shares traded. XPEV's current last sale is 98.53% of the target price of $17.05. Bank of America Corporation (BAC) is +0.01 at $27.61, with 1,936,137 shares traded. BAC's current last sale is 78.89% of the target price of $35. FinVolution Group (FINV) is unchanged at $5.00, with 1,855,555 shares traded. As reported by Zacks, the current mean recommendation for FINV is in the "strong buy range". iShares MSCI China ETF (MCHI) is -0.0345 at $43.38, with 1,662,357 shares traded. This represents a 23.86% increase from its 52 Week Low. Arm Holdings plc (ARM) is -0.14 at $54.30, with 1,625,772 shares traded. ARM's current last sale is 118.04% of the target price of $46. Cisco Systems, Inc. (CSCO) is unchanged at $53.48, with 1,352,499 shares traded. CSCO's current last sale is 92.21% of the target price of $58. Comcast Corporation (CMCSA) is unchanged at $44.87, with 1,323,937 shares traded. As reported by Zacks, the current mean recommendation for CMCSA is in the "buy range". Invesco QQQ Trust, Series 1 (QQQ) is +0.35 at $359.96, with 1,301,962 shares traded. This represents a 41.57% increase from its 52 Week Low. Apple Inc. (AAPL) is +0.12 at $176.20, with 1,151,926 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2024. The consensus EPS forecast is $1.56. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range". The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

As reported by Zacks, the current mean recommendation for FINV is in the "strong buy range". iShares MSCI China ETF (MCHI) is -0.0345 at $43.38, with 1,662,357 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2024.

Comcast Corporation (CMCSA) is unchanged at $44.87, with 1,323,937 shares traded. As reported by Zacks, the current mean recommendation for CMCSA is in the "buy range". As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".

The total After hours volume is currently 63,813,936 shares traded. Arm Holdings plc (ARM) is -0.14 at $54.30, with 1,625,772 shares traded. Comcast Corporation (CMCSA) is unchanged at $44.87, with 1,323,937 shares traded.

The NASDAQ 100 After Hours Indicator is up 13.01 to 14,781.91. Comcast Corporation (CMCSA) is unchanged at $44.87, with 1,323,937 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2024.

37.0

2023-09-21 00:00:00 UTC

Daily Dividend Report: CLX,CVX,A,SBUX,AMT

A

https://www.nasdaq.com/articles/daily-dividend-report%3A-clxcvxasbuxamt

Clorox announced today that its board of directors has declared a quarterly dividend of $1.20 per share on the company's common stock. The dividend is payable Nov. 9, 2023, to shareholders of record as of the close of business on Oct. 25, 2023. CVS Health has announced that its board of directors has approved a quarterly dividend of sixty and a half cents per share on the Common Stock. The dividend is payable on November 1, 2023, to holders of record on October 20, 2023. Agilent Technologies, today announced that a quarterly dividend of 22.5 cents per share of common stock will be paid on Oct. 25, 2023, to all shareholders of record as of the close of business on Oct. 3, 2023. Starbucks today announced that its Board of Directors approved an increase in the company's quarterly cash dividend from $0.53 to $0.57 per share of outstanding Common Stock. This increase will be effective with the dividend payable on November 24, 2023, to shareholders of record on November 10, 2023, and raises the company's annual dividend rate to $2.28 per share. Starbucks initiated its dividend in 2010 at $0.05 per share of outstanding Common Stock, and increased its dividend consecutively each year over the past 13 years at a CAGR of approximately 20%. American Tower today announced that its board of directors has declared its quarterly cash distribution of $1.62 per share on shares of the Company's common stock. The distribution is payable on October 27, 2023 to the stockholders of record at the close of business on October 11, 2023. VIDEO: Daily Dividend Report: CLX,CVX,A,SBUX,AMT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

CVS Health has announced that its board of directors has approved a quarterly dividend of sixty and a half cents per share on the Common Stock. Agilent Technologies, today announced that a quarterly dividend of 22.5 cents per share of common stock will be paid on Oct. 25, 2023, to all shareholders of record as of the close of business on Oct. 3, 2023. Starbucks today announced that its Board of Directors approved an increase in the company's quarterly cash dividend from $0.53 to $0.57 per share of outstanding Common Stock.

Clorox announced today that its board of directors has declared a quarterly dividend of $1.20 per share on the company's common stock. Starbucks today announced that its Board of Directors approved an increase in the company's quarterly cash dividend from $0.53 to $0.57 per share of outstanding Common Stock. American Tower today announced that its board of directors has declared its quarterly cash distribution of $1.62 per share on shares of the Company's common stock.

Agilent Technologies, today announced that a quarterly dividend of 22.5 cents per share of common stock will be paid on Oct. 25, 2023, to all shareholders of record as of the close of business on Oct. 3, 2023. Starbucks today announced that its Board of Directors approved an increase in the company's quarterly cash dividend from $0.53 to $0.57 per share of outstanding Common Stock. This increase will be effective with the dividend payable on November 24, 2023, to shareholders of record on November 10, 2023, and raises the company's annual dividend rate to $2.28 per share.

Agilent Technologies, today announced that a quarterly dividend of 22.5 cents per share of common stock will be paid on Oct. 25, 2023, to all shareholders of record as of the close of business on Oct. 3, 2023. Starbucks today announced that its Board of Directors approved an increase in the company's quarterly cash dividend from $0.53 to $0.57 per share of outstanding Common Stock. American Tower today announced that its board of directors has declared its quarterly cash distribution of $1.62 per share on shares of the Company's common stock.

38.0

2023-09-21 00:00:00 UTC

Agilent Technologies is Now Oversold (A)

A

https://www.nasdaq.com/articles/agilent-technologies-is-now-oversold-a

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of Agilent Technologies, Inc. (Symbol: A) entered into oversold territory, hitting an RSI reading of 26.2, after changing hands as low as $109.905 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 33.9. A bullish investor could look at A's 26.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of A shares: Looking at the chart above, A's low point in its 52 week range is $109 per share, with $160.265 as the 52 week high point — that compares with a last trade of $110.56. Find out what 9 other oversold stocks you need to know about » Also see: • Stocks Being Sold By Hedge Funds • LII Average Annual Return • ESP Past Earnings The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

A bullish investor could look at A's 26.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of A shares: Looking at the chart above, A's low point in its 52 week range is $109 per share, with $160.265 as the 52 week high point — that compares with a last trade of $110.56. Find out what 9 other oversold stocks you need to know about » Also see: • Stocks Being Sold By Hedge Funds • LII Average Annual Return • ESP Past Earnings The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 33.9. A bullish investor could look at A's 26.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of A shares: Looking at the chart above, A's low point in its 52 week range is $109 per share, with $160.265 as the 52 week high point — that compares with a last trade of $110.56.

In trading on Thursday, shares of Agilent Technologies, Inc. (Symbol: A) entered into oversold territory, hitting an RSI reading of 26.2, after changing hands as low as $109.905 per share. The chart below shows the one year performance of A shares: Looking at the chart above, A's low point in its 52 week range is $109 per share, with $160.265 as the 52 week high point — that compares with a last trade of $110.56. Find out what 9 other oversold stocks you need to know about » Also see: • Stocks Being Sold By Hedge Funds • LII Average Annual Return • ESP Past Earnings The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

39.0

2023-09-20 00:00:00 UTC

Agilent (A) Boosts Genomic Profiling With New Collaboration

A

https://www.nasdaq.com/articles/agilent-a-boosts-genomic-profiling-with-new-collaboration

Agilent Technologies A has entered into a research agreement with the National Cancer Centre Singapore, to bring advancement in Singapore’s genomic profiling on Asian-prevalent cancers. The research focuses on improving tumor genome characterization and utilizing this data in patient care to enhance clinical trials, oncology diagnostics and treatment decisions. Notably, this collaboration involves the provision of the Agilent Magnis NGS Preparation System, which is used to study details specific to Asian cancer cohorts where tissue samples are limited. This, in turn, will simplify gene assays and complex genetic aberrations for reproducible results. We believe that the latest agreement will accelerate the development of next-generation diagnostic tools to improve patient care. Moreover, the deal will also strengthen Agilent’s footprint in Asian markets. Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote Growth Prospects The latest partnership is in sync with the company’s efforts to strengthen its footprint in the global genomics market. Per a Towards Healthcare report, the global genomics market is expected to reach $127.16 billion by 2032, witnessing a CAGR of 16.1% between 2023 and 2032. A Grand View Research report predicts the global genomics market to witness a CAGR of 16.5% during the period of 2023-2030. We believe the company’s solid prospects in the promising genomics market are expected to instill investor optimism in the stock. Agilent has lost 25% in the year-to-date period against the industry’s growth of 1.7%. Notably, the company has been suffering from macroeconomic uncertainties, weak momentum in China, rising inflationary pressure and geo-political tensions. DGG Segment in Focus The latest move bodes well for the company’s growing efforts toward bolstering its Diagnostics and Genomics Group (DGG) segment. Recently, Agilent released the enhanced xCELLigence RTCA Software Pro Version 2.8, a software package for real-time cell analysis in GMP-regulated facilities, ensuring data authenticity and compliance. Further, it launched the Agilent SureSelect Cancer CGP Assay, a pan-cancer assay designed for somatic variant profiling of solid tumor types, utilizing an NGS panel of 679 genes. We note that the abovementioned endeavors will likely act as a catalyst for its customer base expansion. Notably, Agilent signed a Memorandum of Understanding with Advanced Cell Therapy and Research Institute, Singapore to install and operate its xCELLigence real-time cell analyzer, aiming to advance cell and gene therapy over the next three years The company also partnered with Theragen Bio to improve precision oncology in South Korea through advanced bioinformatic solutions, leveraging their combined expertise in cancer genomic profiling design and software knowledge. All these endeavors are likely to aid the performance of the DGG segment in the days ahead. For third-quarter fiscal 2023, revenues in the underlined segment increased 3% from the prior-year fiscal quarter’s figure on a reported, as well as a core basis to $349 million. Our model estimate for DGG revenues for fiscal 2023 is pegged at $1.41 billion, indicating growth of 1.5% from the 2022 level. The same for fiscal 2024 and fiscal 2025 stands at $1.48 billion and $1.58 billion, reflecting year-over-year growth of 5% and 7%, respectively. Zacks Rank & Stocks to Consider Currently, Agilent carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader technology sector are Asure Software ASUR, Arista Networks ANET and Applied Materials AMAT. While Asure Software sports a Zacks Rank #1 (Strong Buy), Arista Networks and Applied Materials carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here. Asure Software shares have lost 5.2% in the year-to-date period. ASUR’s long-term earnings growth rate is currently projected at 27%. Arista Networks shares have gained 52.3% in the year-to-date period. The long-term earnings growth rate for ANET is currently projected at 18.75% Applied Materials shares have gained 41.4% in the year-to-date period. AMAT’s long-term earnings growth rate is currently projected at 6.10%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Applied Materials, Inc. (AMAT) : Free Stock Analysis Report Asure Software Inc (ASUR) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The research focuses on improving tumor genome characterization and utilizing this data in patient care to enhance clinical trials, oncology diagnostics and treatment decisions. Notably, this collaboration involves the provision of the Agilent Magnis NGS Preparation System, which is used to study details specific to Asian cancer cohorts where tissue samples are limited. The company also partnered with Theragen Bio to improve precision oncology in South Korea through advanced bioinformatic solutions, leveraging their combined expertise in cancer genomic profiling design and software knowledge.

The research focuses on improving tumor genome characterization and utilizing this data in patient care to enhance clinical trials, oncology diagnostics and treatment decisions. While Asure Software sports a Zacks Rank #1 (Strong Buy), Arista Networks and Applied Materials carry a Zacks Rank #2 (Buy) each. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Applied Materials, Inc. (AMAT) : Free Stock Analysis Report Asure Software Inc (ASUR) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report To read this article on Zacks.com click here.

Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote Growth Prospects The latest partnership is in sync with the company’s efforts to strengthen its footprint in the global genomics market. While Asure Software sports a Zacks Rank #1 (Strong Buy), Arista Networks and Applied Materials carry a Zacks Rank #2 (Buy) each. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Applied Materials, Inc. (AMAT) : Free Stock Analysis Report Asure Software Inc (ASUR) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report To read this article on Zacks.com click here.

Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote Growth Prospects The latest partnership is in sync with the company’s efforts to strengthen its footprint in the global genomics market. Some better-ranked stocks in the broader technology sector are Asure Software ASUR, Arista Networks ANET and Applied Materials AMAT. While Asure Software sports a Zacks Rank #1 (Strong Buy), Arista Networks and Applied Materials carry a Zacks Rank #2 (Buy) each.

40.0

2023-09-15 00:00:00 UTC

Notable Friday Option Activity: PRGS, POOL, A

A

https://www.nasdaq.com/articles/notable-friday-option-activity%3A-prgs-pool-a

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Progress Software Corp (Symbol: PRGS), where a total of 1,216 contracts have traded so far, representing approximately 121,600 underlying shares. That amounts to about 53.8% of PRGS's average daily trading volume over the past month of 226,140 shares. Particularly high volume was seen for the $50 strike put option expiring October 20, 2023, with 502 contracts trading so far today, representing approximately 50,200 underlying shares of PRGS. Below is a chart showing PRGS's trailing twelve month trading history, with the $50 strike highlighted in orange: Pool Corp (Symbol: POOL) saw options trading volume of 1,502 contracts, representing approximately 150,200 underlying shares or approximately 53.3% of POOL's average daily trading volume over the past month, of 282,025 shares. Especially high volume was seen for the $360 strike put option expiring September 15, 2023, with 501 contracts trading so far today, representing approximately 50,100 underlying shares of POOL. Below is a chart showing POOL's trailing twelve month trading history, with the $360 strike highlighted in orange: And Agilent Technologies, Inc. (Symbol: A) saw options trading volume of 8,847 contracts, representing approximately 884,700 underlying shares or approximately 52.8% of A's average daily trading volume over the past month, of 1.7 million shares. Particularly high volume was seen for the $130 strike call option expiring October 20, 2023, with 1,666 contracts trading so far today, representing approximately 166,600 underlying shares of A. Below is a chart showing A's trailing twelve month trading history, with the $130 strike highlighted in orange: For the various different available expirations for PRGS options, POOL options, or A options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 » Also see: • Funds Holding ATOM • CTCT Videos • Funds Holding RTNB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Particularly high volume was seen for the $50 strike put option expiring October 20, 2023, with 502 contracts trading so far today, representing approximately 50,200 underlying shares of PRGS. Especially high volume was seen for the $360 strike put option expiring September 15, 2023, with 501 contracts trading so far today, representing approximately 50,100 underlying shares of POOL. Particularly high volume was seen for the $130 strike call option expiring October 20, 2023, with 1,666 contracts trading so far today, representing approximately 166,600 underlying shares of A.

Particularly high volume was seen for the $50 strike put option expiring October 20, 2023, with 502 contracts trading so far today, representing approximately 50,200 underlying shares of PRGS. Below is a chart showing PRGS's trailing twelve month trading history, with the $50 strike highlighted in orange: Pool Corp (Symbol: POOL) saw options trading volume of 1,502 contracts, representing approximately 150,200 underlying shares or approximately 53.3% of POOL's average daily trading volume over the past month, of 282,025 shares. Below is a chart showing POOL's trailing twelve month trading history, with the $360 strike highlighted in orange: And Agilent Technologies, Inc. (Symbol: A) saw options trading volume of 8,847 contracts, representing approximately 884,700 underlying shares or approximately 52.8% of A's average daily trading volume over the past month, of 1.7 million shares.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Progress Software Corp (Symbol: PRGS), where a total of 1,216 contracts have traded so far, representing approximately 121,600 underlying shares. Below is a chart showing PRGS's trailing twelve month trading history, with the $50 strike highlighted in orange: Pool Corp (Symbol: POOL) saw options trading volume of 1,502 contracts, representing approximately 150,200 underlying shares or approximately 53.3% of POOL's average daily trading volume over the past month, of 282,025 shares. Below is a chart showing POOL's trailing twelve month trading history, with the $360 strike highlighted in orange: And Agilent Technologies, Inc. (Symbol: A) saw options trading volume of 8,847 contracts, representing approximately 884,700 underlying shares or approximately 52.8% of A's average daily trading volume over the past month, of 1.7 million shares.

Below is a chart showing PRGS's trailing twelve month trading history, with the $50 strike highlighted in orange: Pool Corp (Symbol: POOL) saw options trading volume of 1,502 contracts, representing approximately 150,200 underlying shares or approximately 53.3% of POOL's average daily trading volume over the past month, of 282,025 shares. Especially high volume was seen for the $360 strike put option expiring September 15, 2023, with 501 contracts trading so far today, representing approximately 50,100 underlying shares of POOL. Below is a chart showing A's trailing twelve month trading history, with the $130 strike highlighted in orange: For the various different available expirations for PRGS options, POOL options, or A options, visit StockOptionsChannel.com.

41.0

2023-09-15 00:00:00 UTC

Friday Sector Leaders: Utilities, Healthcare

A

https://www.nasdaq.com/articles/friday-sector-leaders%3A-utilities-healthcare-2

Looking at the sectors faring best as of midday Friday, shares of Utilities companies are outperforming other sectors, not showing much of a loss. Within the sector, DTE Energy Co (Symbol: DTE) and CenterPoint Energy, Inc (Symbol: CNP) are two of the day's stand-outs, showing a gain of 0.8% and 0.8%, respectively. Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is down 0.1% on the day, and down 6.10% year-to-date. DTE Energy Co, meanwhile, is down 7.89% year-to-date, and CenterPoint Energy, Inc is up 0.76% year-to-date. Combined, DTE and CNP make up approximately 4.3% of the underlying holdings of XLU. The next best performing sector is the Healthcare sector, losing just 0.3%. Among large Healthcare stocks, Waters Corp. (Symbol: WAT) and Agilent Technologies, Inc. (Symbol: A) are the most notable, showing a gain of 2.3% and 2.0%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is down 0.5% in midday trading, and down 1.36% on a year-to-date basis. Waters Corp., meanwhile, is down 19.49% year-to-date, and Agilent Technologies, Inc., is down 21.61% year-to-date. Combined, WAT and A make up approximately 1.0% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Friday. As you can see, none of the sectors are up on the day, while eight sectors are down. SECTOR % CHANGE Utilities -0.0% Healthcare -0.3% Consumer Products -0.4% Financial -0.5% Industrial -0.6% Materials -0.9% Services -1.0% Energy -1.4% Technology & Communications -1.5% 25 Dividend Giants Widely Held By ETFs » Also see: • OUT Historical Stock Prices • AKRX market cap history • DQ Split History The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Combined, DTE and CNP make up approximately 4.3% of the underlying holdings of XLU. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Friday. Utilities -0.0% Healthcare -0.3% Consumer Products -0.4% Financial -0.5% Industrial -0.6% Materials -0.9% Services -1.0% Energy -1.4% Technology & Communications -1.5% 25 Dividend Giants Widely Held By ETFs » Also see: • OUT Historical Stock Prices • AKRX market cap history • DQ Split History The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Within the sector, DTE Energy Co (Symbol: DTE) and CenterPoint Energy, Inc (Symbol: CNP) are two of the day's stand-outs, showing a gain of 0.8% and 0.8%, respectively. Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is down 0.1% on the day, and down 6.10% year-to-date. Among large Healthcare stocks, Waters Corp. (Symbol: WAT) and Agilent Technologies, Inc. (Symbol: A) are the most notable, showing a gain of 2.3% and 2.0%, respectively.

Within the sector, DTE Energy Co (Symbol: DTE) and CenterPoint Energy, Inc (Symbol: CNP) are two of the day's stand-outs, showing a gain of 0.8% and 0.8%, respectively. Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is down 0.1% on the day, and down 6.10% year-to-date. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is down 0.5% in midday trading, and down 1.36% on a year-to-date basis.

Within the sector, DTE Energy Co (Symbol: DTE) and CenterPoint Energy, Inc (Symbol: CNP) are two of the day's stand-outs, showing a gain of 0.8% and 0.8%, respectively. Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is down 0.1% on the day, and down 6.10% year-to-date. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Friday.

42.0

2023-09-14 00:00:00 UTC

Agilent (A) Down 6.5% Since Last Earnings Report: Can It Rebound?

A

https://www.nasdaq.com/articles/agilent-a-down-6.5-since-last-earnings-report%3A-can-it-rebound

A month has gone by since the last earnings report for Agilent Technologies (A). Shares have lost about 6.5% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Agilent due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Agilent Q3 Earnings Beat Estimates Agilent Technologies delivered third-quarter fiscal 2023 earnings of $1.43 per share, which beat the Zacks Consensus Estimate by 4.4%. The bottom line increased by 7% from the year-ago fiscal quarter’s level. Revenues of $1.67 billion surpassed the Zacks Consensus Estimate of $1.66 billion. However, the top line was down 2.7% on a reported basis and 2.3% on a core basis from the respective year-ago fiscal quarter’s levels. The decline was attributed to sluggishness in Chemistry & Advanced Materials and Pharma & Biopharma markets due to weak momentum in China. Nevertheless, growth in Academia & Gov’t, Food, Environmental & Forensics and Diagnostics and Clinical markets remained a positive. Segmental Top Line Details Agilent has three reporting segments, namely, Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG) and Diagnostics and Genomics Group (DGG). LSAG: The segment accounted for $927 million or 55% of its total revenues, down 9% on a reported as well as on a core basis from the respective prior-year fiscal quarter’s levels. This was due to macroeconomic uncertainties, soft market conditions in China and a sluggish pharma market. The reported figure came below the Zacks Consensus Estimate of $929 million. ACG: Revenues from the segment were $396 million, accounting for 24% of total revenues. The figure surpassed the consensus mark of $377 million. The top line improved by 10% from the prior-year fiscal quarter’s reading on a reported basis and by 11% on a core basis, demonstrating solid momentum across all regions and end markets. A strong demand for the company’s services was a positive. DGG: Revenues increased 3% from the prior-year fiscal quarter’s figure on a reported as well as a core basis to $349 million, accounting for the remaining 21% of total revenues. The figure came slightly below the consensus mark of $3508 million. Segmental growth was attributed to strength in the NASD business. A solid demand for diagnostic tests contributed well to the company’s pathology business. However, weakness in genomics and Resolution Bioscience businesses was a negative. Operating Results For the fiscal third quarter, gross margin in the LSAG segment contracted by 50 basis points (bps) to 29.9% from the prior-year fiscal quarter’s number. ACG’s gross margin expanded by 390 bps to 50.9%. DGG’s gross margin contracted by 180 bps from the year-ago fiscal quarter’s actuals to 52.2%. Research & development (R&D) costs were $118 million, up 1.7% from the prior-year fiscal quarter’s number. Selling, general & administrative (SG&A) expenses were $407 million, down 1.2% from the year-earlier fiscal quarter’s figure. As a percentage of revenues, R&D expenses expanded by 35 bps year over year to 7.05%. SG&A expenses expanded by 40 bps year over year to 24.3%. Operating margin for the fiscal third quarter was 7.9%, which declined significantly from 23.9% in the year-earlier fiscal quarter’s figure. Segment-wise, the operating margin for LSAG was down 60 bps from the year-earlier fiscal quarter’s level of 29.9%. ACG’s operating margin was 32.7%, up 810 bps from the year-ago fiscal quarter’s level. DGG segment’s operating margin expanded 250 bps to 24% from the year-ago fiscal quarter’s figure. Balance Sheet & Cash Flow As of Jul 31, 2023, Agilent’s cash and cash equivalents were $1.33 billion, up from $1.18 billion on Apr 30, 2023. Accounts receivables were $1.3 billion at the end of third-quarter fiscal 2023, down from $1.4 billion at the end of second-quarter fiscal 2023. Long-term debt was $2.734 billion for the reported quarter compared with $2.733 billion in the prior fiscal quarter. Agilent generated $562 million in cash from operations during the reported quarter, up from $398 million generated in the previous quarter. It returned $401 million to shareholders, out of which dividend payments accounted for $66 million and share repurchases accounted for the remaining $335 million. Guidance For the fiscal fourth quarter of 2023, management expects revenues of $1.655-$1.705 billion, suggesting a decline between 12.2% and 9.5% on a core basis from the year-ago fiscal quarter’s actuals. Non-GAAP earnings per share are expected to be $1.33-$1.36. For fiscal 2023, management lowered its revenue guidance to the band of $6.80-$6.85 billion from $6.93-7.03 billion, implying growth of 0.8-1.5% on a core basis from the respective fiscal 2022 figures. Management also lowered the guidance for fiscal 2023 non-GAAP earnings per share downward from $5.60-$5.65 to $5.40-5.43. How Have Estimates Been Moving Since Then? It turns out, estimates review have trended downward during the past month. The consensus estimate has shifted -16.1% due to these changes. VGM Scores At this time, Agilent has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy. Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in. Outlook Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Agilent has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold." Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. The decline was attributed to sluggishness in Chemistry & Advanced Materials and Pharma & Biopharma markets due to weak momentum in China. LSAG: The segment accounted for $927 million or 55% of its total revenues, down 9% on a reported as well as on a core basis from the respective prior-year fiscal quarter’s levels.

Agilent Q3 Earnings Beat Estimates Agilent Technologies delivered third-quarter fiscal 2023 earnings of $1.43 per share, which beat the Zacks Consensus Estimate by 4.4%. Segmental Top Line Details Agilent has three reporting segments, namely, Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG) and Diagnostics and Genomics Group (DGG). Operating Results For the fiscal third quarter, gross margin in the LSAG segment contracted by 50 basis points (bps) to 29.9% from the prior-year fiscal quarter’s number.

DGG: Revenues increased 3% from the prior-year fiscal quarter’s figure on a reported as well as a core basis to $349 million, accounting for the remaining 21% of total revenues. Operating Results For the fiscal third quarter, gross margin in the LSAG segment contracted by 50 basis points (bps) to 29.9% from the prior-year fiscal quarter’s number. Guidance For the fiscal fourth quarter of 2023, management expects revenues of $1.655-$1.705 billion, suggesting a decline between 12.2% and 9.5% on a core basis from the year-ago fiscal quarter’s actuals.

A month has gone by since the last earnings report for Agilent Technologies (A). The reported figure came below the Zacks Consensus Estimate of $929 million. DGG segment’s operating margin expanded 250 bps to 24% from the year-ago fiscal quarter’s figure.

43.0

2023-09-12 00:00:00 UTC

Agilent To Sell Resolution Bioscience To Exact Sciences For Undisclosed Sum

A

https://www.nasdaq.com/articles/agilent-to-sell-resolution-bioscience-to-exact-sciences-for-undisclosed-sum

(RTTNews) - Agilent Technologies, Inc. (A) and Exact Sciences Corp. (EXAS) said on Tuesday that they have inked a deal for the sale of Resolution Bioscience to Exact Sciences., for an undisclosed sum. Resolution Bioscience is a developer of next-generation sequencing-based precision oncology solutions. Sam Raha, Senior Vice President at Agilent, said: "Exact is a leading centralized laboratory for advanced cancer diagnostic testing with significant capabilities and resources in this area, which makes Resolution Bioscience a strategic fit for them. This agreement will enable the talented Resolution Bioscience team to continue their work advancing diagnostic solutions for their customers and patients, a very positive outcome of this transaction." The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Resolution Bioscience is a developer of next-generation sequencing-based precision oncology solutions. Sam Raha, Senior Vice President at Agilent, said: "Exact is a leading centralized laboratory for advanced cancer diagnostic testing with significant capabilities and resources in this area, which makes Resolution Bioscience a strategic fit for them. This agreement will enable the talented Resolution Bioscience team to continue their work advancing diagnostic solutions for their customers and patients, a very positive outcome of this transaction."

(RTTNews) - Agilent Technologies, Inc. (A) and Exact Sciences Corp. (EXAS) said on Tuesday that they have inked a deal for the sale of Resolution Bioscience to Exact Sciences., for an undisclosed sum. Resolution Bioscience is a developer of next-generation sequencing-based precision oncology solutions. This agreement will enable the talented Resolution Bioscience team to continue their work advancing diagnostic solutions for their customers and patients, a very positive outcome of this transaction."

(RTTNews) - Agilent Technologies, Inc. (A) and Exact Sciences Corp. (EXAS) said on Tuesday that they have inked a deal for the sale of Resolution Bioscience to Exact Sciences., for an undisclosed sum. Sam Raha, Senior Vice President at Agilent, said: "Exact is a leading centralized laboratory for advanced cancer diagnostic testing with significant capabilities and resources in this area, which makes Resolution Bioscience a strategic fit for them. This agreement will enable the talented Resolution Bioscience team to continue their work advancing diagnostic solutions for their customers and patients, a very positive outcome of this transaction."

(RTTNews) - Agilent Technologies, Inc. (A) and Exact Sciences Corp. (EXAS) said on Tuesday that they have inked a deal for the sale of Resolution Bioscience to Exact Sciences., for an undisclosed sum. Resolution Bioscience is a developer of next-generation sequencing-based precision oncology solutions. Sam Raha, Senior Vice President at Agilent, said: "Exact is a leading centralized laboratory for advanced cancer diagnostic testing with significant capabilities and resources in this area, which makes Resolution Bioscience a strategic fit for them.

44.0

2023-09-05 00:00:00 UTC

Illumina names Agilent exec Jacob Thaysen as CEO

A

https://www.nasdaq.com/articles/illumina-names-agilent-exec-jacob-thaysen-as-ceo

Adds background in paragraphs 2-3 Sept 5 (Reuters) - Illumina Inc ILMN.O said on Tuesday its board has named Agilent Technologies' A.N executive Jacob Thaysen as the U.S. genetic testing company's CEO. Thaysen would replace ‍Charles Dadswell, who has been serving as Illumina's interim CEO since June. The appointment comes months after Illumina's former CEO Francis deSouza stepped down, marking a victory for activist investor Carl Icahn. Thaysen's appointment would become effective Sept. 25. (Reporting by Manas Mishra and Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Adds background in paragraphs 2-3 Sept 5 (Reuters) - Illumina Inc ILMN.O said on Tuesday its board has named Agilent Technologies' A.N executive Jacob Thaysen as the U.S. genetic testing company's CEO. Thaysen would replace ‍Charles Dadswell, who has been serving as Illumina's interim CEO since June. The appointment comes months after Illumina's former CEO Francis deSouza stepped down, marking a victory for activist investor Carl Icahn.

Thaysen would replace ‍Charles Dadswell, who has been serving as Illumina's interim CEO since June. Thaysen's appointment would become effective Sept. 25. (Reporting by Manas Mishra and Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Adds background in paragraphs 2-3 Sept 5 (Reuters) - Illumina Inc ILMN.O said on Tuesday its board has named Agilent Technologies' A.N executive Jacob Thaysen as the U.S. genetic testing company's CEO. The appointment comes months after Illumina's former CEO Francis deSouza stepped down, marking a victory for activist investor Carl Icahn. (Reporting by Manas Mishra and Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Adds background in paragraphs 2-3 Sept 5 (Reuters) - Illumina Inc ILMN.O said on Tuesday its board has named Agilent Technologies' A.N executive Jacob Thaysen as the U.S. genetic testing company's CEO. Thaysen would replace ‍Charles Dadswell, who has been serving as Illumina's interim CEO since June. The appointment comes months after Illumina's former CEO Francis deSouza stepped down, marking a victory for activist investor Carl Icahn.

45.0

2023-09-01 00:00:00 UTC

Do Options Traders Know Something About Agilent (A) Stock We Don't?

A

https://www.nasdaq.com/articles/do-options-traders-know-something-about-agilent-a-stock-we-dont

Investors in Agilent Technologies, Inc. A need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 19, 2024 $65.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. What do the Analysts Think? Clearly, options traders are pricing in a big move for Agilent shares, but what is the fundamental picture for the company? Currently, Agilent is a Zacks Rank #4 (Sell) in the Electronics - Testing Equipment industry that ranks in the Bottom 30% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while six analysts have revised their estimates downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.61 per share to $1.35 in that period. Given the way analysts feel about Agilent right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected. Looking to Trade Options? Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk. Click to see the trades now >> Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here.

Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. Click to see the trades now >> Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come.

Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. Given the way analysts feel about Agilent right now, this huge implied volatility could mean there’s a trade developing. Looking to Trade Options?

46.0

2023-08-31 00:00:00 UTC

Building Wealth with Spinoffs: How Adding These Gems Can Transform Your Portfolio

A

https://www.nasdaq.com/articles/building-wealth-with-spinoffs%3A-how-adding-these-gems-can-transform-your-portfolio

Imagine discovering a treasure map that leads to the chest containing the loot. Consider that the investment world has its own version of these concealed treasures: Spinoffs. These financial treasures have the potential to reshape your entire investment voyage, not just enhance your portfolio. The catch? You must look for them and do some work. A tough ask, I know. What is A Spinoff? In a Spinoff, a parent company separates one of its business entities or divisions into a standalone, independent company. By distributing shares of the spun-off company to the current proprietors of the parent, two separate publicly listed entities are created. The new enterprise that emerges because of a Spinoff is often referred to as a "Spinoff company." Spinoffs can increase shareholder value by allowing distinct companies to focus on their core competencies and releasing hidden value in specific business divisions. In addition, it offers investors the option to invest in various companies based on their investment preferences and risk tolerance. Or, alternatively, eradicate them. The media frequently gets it wrong when speaking about Spinoffs. This is a very important point to remember. A ‘true’ Spinoff only happens when a share of a division is distributed amongst existing shareholders that own the parent company. Contrary to the media, IPOs, Divestitures, carve-outs, split-offs, and split-ups are not Spinoffs and consequently, these transactions lose many of the value creating dynamics of the Spinoff corporate action. Cross-reference information from various trustworthy sources, particularly official business communication. To fully comprehend the Spinoff and its ramifications, investors should also look for information from reliable financial analysts, subject-matter experts, and formal regulatory filings, such as those with the Securities and Exchange Commission (SEC). Do Spinoffs Outperform? The “Spinoff” is an essentially inefficient method for distributing stock to the incorrect individuals. You receive shares whether you desire them or not. Typically, investors acquire these shares by default and sell them on the open market almost immediately, making them inexpensive companies that no one is interested in. They are occasionally referred to as "orphan securities." At this point, X marks the location, and digging should commence. Why the dynamics of Spinoffs make it an essential area for an investor to analyze: Studies have shown that Spinoffs have historically beaten the market by over 10 percent as the pure, newly focused business takes off. Compensation for executives can be more closely correlated with business performance. The company will become smaller, which will increase the executives' motivation and sense of ownership. Separating companies allows each entity to be properly valued and can sometimes unlock a “conglomerate discount." Due to the likelihood that the company would be small and lack a roadshow, it is under-followed. As a result, there are more chances for investors to discover returns greater than the index. The Edge Consulting Groups 20 year study shows that Spinoffs are likely to be taken over. Roughly 35 percent are acquired around the two-year mark post-Spinoff. Typically, there are hundreds of Spinoff situations a year. Around 40 have over $1 billion in market cap. This is a sweet spot where liquidity and “real” companies come together in my opinion. 5 Reasons Why You Should Be Looking For These Situations Including Spinoffs in your investment portfolio can provide a variety of benefits, including diversification, undervalued opportunities, and the potential for higher returns and enhanced performance. 1. Enhanced Diversification: Incorporating Spinoffs introduces a new layer of diversification. Since Spinoff companies often operate in different sectors than their parent companies, they can provide exposure to industries that might not have been represented in your portfolio. This helps spread risk and reduces the impact of negative events within a specific sector. 2. Undervalued Opportunities: Spinoffs are sometimes overlooked by the market, leading to potential undervaluation. This presents an opportunity for investors to purchase shares of promising companies at a lower price compared to their intrinsic value. As the market gradually recognizes their worth, these undervalued gems can yield substantial returns. 3. Focused Management: Spinoff companies can streamline operations and focus on their core competencies, which often leads to improved efficiency and performance. The management teams of these newly independent entities tend to be more agile and dedicated to the success of their specific business, potentially translating into better growth prospects. 4. Catalyst for Change: The newfound independence of a Spinoff can lead to strategic changes, such as cost-cutting initiatives, innovation, and targeted expansion plans. These changes can drive improved financial performance and boost shareholder value over time. 5. Potential for Outperformance: Historical data indicates that Spinoffs often outperform the broader market indices. This outperformance can be attributed to a combination of factors, including improved focus, better capital allocation decisions, and the market's eventual recognition of the Spinoff's value proposition. Why isn’t Everybody Looking At Them? I asked the legendary investor Joel Greenblatt this question once and he didn’t hesitate to give me the answer. ‘No one wants to do the work.’ Spinoffs analysis takes a lot of effort and, surprise, surprise, not many want to do it. However, as an investment veteran of over 30 years, I can categorically say that some of my most profitable ideas come from doing a hell of a lot of work and finding the angle and edge in the situation in this area. Furthermore, they are not promoted by brokers. Unlike an IPO there is no stock to sell you. You gain the Spinoff from holding the parent company whether you like it or not. This opens a whole range of dynamics that are interesting for investing. Recent Spinoffs That You May Know AbbVie (ABBV) (formerly known as Abbott Laboratories' biopharmaceutical business) was spun off from Abbott Laboratories in 2013. AbbVie has outperformed the S&P 500 by more than 200% since the spinoff. Visa (V) was spun off from Bank of America (BAC) in 2008. Visa has outperformed the S&P 500 by more than 400% since Spinoff. Mastercard (MA) was spun off from American Express (AXP) in 2006. Mastercard has outperformed the S&P 500 by more than 300% since Spinoff. Agilent Technologies (A) was spun off from Hewlett-Packard (HPQ) in 1999. Agilent Technologies has outperformed the S&P 500 by more than 200% since the spinoff. Johnson & Johnson's (JNJ) Life Sciences division was spun off as a separate company called Janssen Pharmaceutical Companies in 2017. Janssen Pharmaceutical Companies has outperformed the S&P 500 by more than 50% since the spinoff. These are just a few examples of successful stock Spinoffs. There are many other examples, and the success of a spinoff can vary depending on several factors, such as the underlying business, the management team, and the market condition. In Summary If you are after hidden value where no one else is looking, look no further than this area of the market. There are services out there that can help, but ultimately a little hard work in a proven area will get you to some positive wealth creation a lot faster than competing with the masses. On the date of publication, Jim Osman did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

To fully comprehend the Spinoff and its ramifications, investors should also look for information from reliable financial analysts, subject-matter experts, and formal regulatory filings, such as those with the Securities and Exchange Commission (SEC). The management teams of these newly independent entities tend to be more agile and dedicated to the success of their specific business, potentially translating into better growth prospects. This outperformance can be attributed to a combination of factors, including improved focus, better capital allocation decisions, and the market's eventual recognition of the Spinoff's value proposition.

Why the dynamics of Spinoffs make it an essential area for an investor to analyze: Studies have shown that Spinoffs have historically beaten the market by over 10 percent as the pure, newly focused business takes off. 5 Reasons Why You Should Be Looking For These Situations Including Spinoffs in your investment portfolio can provide a variety of benefits, including diversification, undervalued opportunities, and the potential for higher returns and enhanced performance. Focused Management: Spinoff companies can streamline operations and focus on their core competencies, which often leads to improved efficiency and performance.

In a Spinoff, a parent company separates one of its business entities or divisions into a standalone, independent company. The new enterprise that emerges because of a Spinoff is often referred to as a "Spinoff company." Why the dynamics of Spinoffs make it an essential area for an investor to analyze: Studies have shown that Spinoffs have historically beaten the market by over 10 percent as the pure, newly focused business takes off.

What is A Spinoff? In a Spinoff, a parent company separates one of its business entities or divisions into a standalone, independent company. Typically, investors acquire these shares by default and sell them on the open market almost immediately, making them inexpensive companies that no one is interested in.

47.0

2023-08-25 00:00:00 UTC

EXCLUSIVE-Danaher in the lead to acquire biomedical equipment vendor Abcam -sources

A

https://www.nasdaq.com/articles/exclusive-danaher-in-the-lead-to-acquire-biomedical-equipment-vendor-abcam-sources-0

By David Carnevali NEW YORK, Aug 25 (Reuters) - Danaher Corp DHR.N is in the lead to acquire Abcam Plc ABCM.O, a provider of supplies to life science researchers with a market value of $5.4 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday. Abcam believes that Danaher's all-cash offer is superior to a rival bid from Agilent Technologies Inc A.N, the sources said. The exact price that Danaher is offering could not be learned. One of the sources said the deal price would be close to Abcam's current valuation, given that its stock has already risen more than 20% after Bloomberg News reported on June 16 that the company was fielding takeover interest. If the negotiations conclude successfully, a deal could be announced as early as next week, the sources said, cautioning that no agreement is certain and that the outcome could still change. They asked not to be identified because the matter is confidential. Abcam, Danaher and Agilent did not immediately respond to requests for comment. Abcam shares rose as much as 9% in afternoon trading in New York on Friday to $24.52. Danaher shares were up 1.3% at $256.76. Based in Cambridge, England, Abcam supplies antibodies, reagents and other products used in medical research. The company serves roughly 750,000 research scientists at academic, research, government and biopharmaceutical organizations. Abcam has come under pressure from activist shareholders to sell itself, including its founder Jonathan Milner who owns 6.1% of the company, as well as hedge fund Starboard Value LP, complaining about the company's stock underperforming for most of the last two years. Danaher, one of the world's largest suppliers of diagnostic tools with a market value of $190 billion, has turned to dealmaking to expand in the sector. Abcam's antibody and reagent solutions could help Danaher win more and bigger contracts with some customers. Danaher acquired General Electric Co's GE.N biopharma solution business for $21.4 billion in 2019 and contract development and manufacturing organization Aldevron for $9.6 billion in 2021. (Reporting by David Carnevali in New York Editing by Greg Roumeliotis and Nick Zieminski) ((Greg.Roumeliotis@thomsonreuters.com; +1 646 223 6022; Reuters Messaging: greg.roumeliotis.thomsonreuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

By David Carnevali NEW YORK, Aug 25 (Reuters) - Danaher Corp DHR.N is in the lead to acquire Abcam Plc ABCM.O, a provider of supplies to life science researchers with a market value of $5.4 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday. One of the sources said the deal price would be close to Abcam's current valuation, given that its stock has already risen more than 20% after Bloomberg News reported on June 16 that the company was fielding takeover interest. Danaher, one of the world's largest suppliers of diagnostic tools with a market value of $190 billion, has turned to dealmaking to expand in the sector.

By David Carnevali NEW YORK, Aug 25 (Reuters) - Danaher Corp DHR.N is in the lead to acquire Abcam Plc ABCM.O, a provider of supplies to life science researchers with a market value of $5.4 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday. Based in Cambridge, England, Abcam supplies antibodies, reagents and other products used in medical research. Abcam's antibody and reagent solutions could help Danaher win more and bigger contracts with some customers.

By David Carnevali NEW YORK, Aug 25 (Reuters) - Danaher Corp DHR.N is in the lead to acquire Abcam Plc ABCM.O, a provider of supplies to life science researchers with a market value of $5.4 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday. Abcam believes that Danaher's all-cash offer is superior to a rival bid from Agilent Technologies Inc A.N, the sources said. One of the sources said the deal price would be close to Abcam's current valuation, given that its stock has already risen more than 20% after Bloomberg News reported on June 16 that the company was fielding takeover interest.

By David Carnevali NEW YORK, Aug 25 (Reuters) - Danaher Corp DHR.N is in the lead to acquire Abcam Plc ABCM.O, a provider of supplies to life science researchers with a market value of $5.4 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday. Abcam believes that Danaher's all-cash offer is superior to a rival bid from Agilent Technologies Inc A.N, the sources said. Based in Cambridge, England, Abcam supplies antibodies, reagents and other products used in medical research.

48.0

2023-08-25 00:00:00 UTC

EXCLUSIVE-Danaher in the lead to acquire biomedical equipment vendor Abcam-sources

A

https://www.nasdaq.com/articles/exclusive-danaher-in-the-lead-to-acquire-biomedical-equipment-vendor-abcam-sources

By David Carnevali NEW YORK, Aug 25 (Reuters) - Danaher Corp DHR.N is in the lead to acquire Abcam Plc ABCM.O, a provider of supplies to life science researchers with a market value of $5.1 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday. Abcam believes that Danaher's all-cash offer is superior to a rival bid from Agilent Technologies Inc A.N, the sources said. The exact price that Danaher is offering could not be learned. One of the sources said the deal price would be close to Abcam's current valuation, given that its stock has already risen close to 20% after Bloomberg News reported on June 16 that the company was fielding takeover interest. If the negotiations conclude successfully, a deal could be announced as early as next week, the sources said, cautioning that no agreement is certain and that the outcome could still change. They asked not to be identified because the matter is confidential. Abcam, Danaher and Agilent did not immediately respond to requests for comment. Based in Cambridge, England, Abcam supplies antibodies, reagents and other products used in medical research. The company serves roughly 750,000 research scientists at academic, research, government and biopharmaceutical organisations. (Reporting by David Carnevali in New York Editing by Greg Roumeliotis) ((Greg.Roumeliotis@thomsonreuters.com; +1 646 223 6022; Reuters Messaging: greg.roumeliotis.thomsonreuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

By David Carnevali NEW YORK, Aug 25 (Reuters) - Danaher Corp DHR.N is in the lead to acquire Abcam Plc ABCM.O, a provider of supplies to life science researchers with a market value of $5.1 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday. Abcam believes that Danaher's all-cash offer is superior to a rival bid from Agilent Technologies Inc A.N, the sources said. If the negotiations conclude successfully, a deal could be announced as early as next week, the sources said, cautioning that no agreement is certain and that the outcome could still change.

By David Carnevali NEW YORK, Aug 25 (Reuters) - Danaher Corp DHR.N is in the lead to acquire Abcam Plc ABCM.O, a provider of supplies to life science researchers with a market value of $5.1 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday. One of the sources said the deal price would be close to Abcam's current valuation, given that its stock has already risen close to 20% after Bloomberg News reported on June 16 that the company was fielding takeover interest. (Reporting by David Carnevali in New York Editing by Greg Roumeliotis) ((Greg.Roumeliotis@thomsonreuters.com; +1 646 223 6022; Reuters Messaging: greg.roumeliotis.thomsonreuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

By David Carnevali NEW YORK, Aug 25 (Reuters) - Danaher Corp DHR.N is in the lead to acquire Abcam Plc ABCM.O, a provider of supplies to life science researchers with a market value of $5.1 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday. Abcam believes that Danaher's all-cash offer is superior to a rival bid from Agilent Technologies Inc A.N, the sources said. One of the sources said the deal price would be close to Abcam's current valuation, given that its stock has already risen close to 20% after Bloomberg News reported on June 16 that the company was fielding takeover interest.

By David Carnevali NEW YORK, Aug 25 (Reuters) - Danaher Corp DHR.N is in the lead to acquire Abcam Plc ABCM.O, a provider of supplies to life science researchers with a market value of $5.1 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday. Abcam believes that Danaher's all-cash offer is superior to a rival bid from Agilent Technologies Inc A.N, the sources said. One of the sources said the deal price would be close to Abcam's current valuation, given that its stock has already risen close to 20% after Bloomberg News reported on June 16 that the company was fielding takeover interest.

49.0

2023-08-21 00:00:00 UTC

Buy the Drop: 3 Stocks to Snag After This Month’s 20% Tumble

A

https://www.nasdaq.com/articles/buy-the-drop%3A-3-stocks-to-snag-after-this-months-20-tumble

InvestorPlace - Stock Market News, Stock Advice & Trading Tips August has been a great month for investors looking for bargain stocks to buy on the dip. The S&P 500, Dow Jones Industrial Average, and the Nasdaq 100 were down 2,1%, 2.0%, and 2.4%, respectively, for the week of Aug. 14-18. Barron’s believes that September could be worse. If the past week is any indication, they could be on to something. Fundstrat analyst Tom Lee thinks August has been its typical mercurial self where gains are hard to come by and that the good times should return soon. Baron’s reported Lee’s comments from his Aug. 18 note to clients: “[T]he month’s declines haven’t shaken Lee’s core bullish thesis. ‘We see this more as ‘it’s August’ rather than the start of a larger rout…we are not in the camp this spills over into a wider selloff. That could happen, but more bad things need to emerge. In fact, there are some signs that we could see the stocks begin to stabilize soon.’” So, if you’re a risk-averse investor, you might want to wait a couple of weeks to see if the markets bottom. In the meantime, a quick screen of S&P 500 stocks down more than 20% over the past month gives bargain-hunting investors 14 stocks to choose from. Here are three undervalued due to their 20%, including one name from three different sectors. Sealed Air (SEE) Source: Shutterstock Sealed Air (NYSE:SEE) represents the materials sector. Its stock is down 25% for the past month and 31% year-to-date. Analysts are moderately optimistic about the stock, with 7 of the 15 rating it as Overweight or an outright Buy. It’s target price is $45 which is 31% higher than its current share price. One of the things that I use to assess value is free cash flow yield. If it’s over 8%, it’s definitely value. Between 4% and 8%, it’s reasonable value, if not dirt cheap. In the trailing 12 months ended June 30, its free cash flow was $152 million. Based on an enterprise value of $9.78 billion, it has a free cash flow yield of 1.6%, which suggests it’s not cheap. Before you toss the company best known for bubble wrap packaging overboard, consider its historical FCF yield. In 2020, it had a free cash flow of $556 million. Based on an enterprise value of $10.6 billion. At first glance, it appears Sealed Air’s business has deteriorated. And to a certain extent, it has, which is why it’s moving forwqard with SEE 2.0. This revitalization plan should deliver $150 million in annual cost savings by the end of 2025 and a return to its historical earnings and sales growth in 2024. Its stock hasn’t been this low since June 2020. Get ready for a revival in the waning months of 2023 and into 2024. Keysight Technologies (KEYS) Source: fantasyform/Shutterstock.com Keysight Technologies (NYSE:KEYS) represents the tech sector. Its stock is down 23% for the past month and 24% year-to-date. Like Sealed Air, it hasn’t traded this low since 2020. Keysight is a relatively new company by S&P 500 standards, incorporated in 2013. However, its history dates back to 1939 and Hewlett-Packard’s founding by Bill Hewlett and Dave Packard. Their first product was an audio oscillator. Electronic measurement was their business. In 1999, Agilent Technologies (NYSE:A) was formed to operate HP’s Medical Products and Instrument Group. In 2013, Agilent was split into two pure-play electronic measurement companies. Keysight was the one of the two, going public on November 1, 2014 after separating from Agilent. Agilent shareholders got one share of Keysight for two held by the parent. KEYS stock is up 335% since it began trading in November 2014. Agilent is up 191% over the same period. Shares have lost their mojo recently because the company reported Q3 2023 results on August 18th that included a downward revision of its guidance. It now expects fourth-quarter sales and earnings to decline by 10% and 13%, respectively. Currently trading at 4.16x sales — less than its five-year average of 5.1x — its enterprise value of $22.5 billion is 12.87x its earnings before interest, taxes, depreciation and amortization (EBITDA). That’s lower than it’s been since 2016. ResMed (RMD) Source: Vitalii Vodolazskyi / Shutterstock ResMed (NYSE:RMD) represents the healthcare sector. Its stock is down 25% for the past month and 21% year-to-date. Like the other two, it hasn’t traded this low since 2020. Interestingly, ResMed’s business is probably doing the best in terms of top-line growth among the trio, up 23% in Q4 2023 and 18% for all of 2023 to $4.2 billion. However, investors began to abandon the stock after hearing its gross margin (56.5%) and operating margin (29.0%) dropped for the year. All of its stock losses in 2023 are post-earnings. Investors have rightly or wrongly decided that the contraction of its margins in light of double-digit revenue growth suggests the quality of the sales increase for the maker of sleep apnea equipment is suspect. ResMed CEO Mick Farrell is very confident about the future. He stated in the Q4 2023 conference call: “Patient demand continues to drive increased adoption and utilization of our mask resupply programs, augmenting a steady cadence of new patient setups. We continue to see strong growth in both the U.S. business where provider resupply programs have augmented growth and in our markets outside the U.S. where our consumer outreach and subscription programs are also driving mass replenishment directly with those end user patients.” Of the 24 analysts covering the stock, 18 rate it Overweight or an outright Buy with a $240 median price, 45% higher than its current share price. I see ResMed as the best long-term hold of the trio, although all three should make you money over 3-5 years. On the date of publication, Will Ashworth did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Will Ashworth has written about investments full-time since 2008. Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors The post Buy the Drop: 3 Stocks to Snag After This Month’s 20% Tumble appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Investors have rightly or wrongly decided that the contraction of its margins in light of double-digit revenue growth suggests the quality of the sales increase for the maker of sleep apnea equipment is suspect. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors The post Buy the Drop: 3 Stocks to Snag After This Month’s 20% Tumble appeared first on InvestorPlace.

Sealed Air (SEE) Source: Shutterstock Sealed Air (NYSE:SEE) represents the materials sector. Keysight Technologies (KEYS) Source: fantasyform/Shutterstock.com Keysight Technologies (NYSE:KEYS) represents the tech sector. We continue to see strong growth in both the U.S. business where provider resupply programs have augmented growth and in our markets outside the U.S. where our consumer outreach and subscription programs are also driving mass replenishment directly with those end user patients.” Of the 24 analysts covering the stock, 18 rate it Overweight or an outright Buy with a $240 median price, 45% higher than its current share price.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips August has been a great month for investors looking for bargain stocks to buy on the dip. In the meantime, a quick screen of S&P 500 stocks down more than 20% over the past month gives bargain-hunting investors 14 stocks to choose from. We continue to see strong growth in both the U.S. business where provider resupply programs have augmented growth and in our markets outside the U.S. where our consumer outreach and subscription programs are also driving mass replenishment directly with those end user patients.” Of the 24 analysts covering the stock, 18 rate it Overweight or an outright Buy with a $240 median price, 45% higher than its current share price.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips August has been a great month for investors looking for bargain stocks to buy on the dip. Keysight was the one of the two, going public on November 1, 2014 after separating from Agilent. Interestingly, ResMed’s business is probably doing the best in terms of top-line growth among the trio, up 23% in Q4 2023 and 18% for all of 2023 to $4.2 billion.

50.0

2023-08-18 00:00:00 UTC

These 3 Unusually Active Options Have 1 Thing in Common

A

https://www.nasdaq.com/articles/these-3-unusually-active-options-have-1-thing-in-common

As I write this, it’s approaching noon Friday on the east coast. The major indexes are either down or flat on the day. Stocks appear headed for their worst week since March. Investors are worried about many subjects, including further interest rate hikes, higher bond yields, and a faltering Chinese economy. While I can’t promise you a rose garden regarding these subjects, I can tell you that it can always be worse. Think March 2009 or March 2020. My task on Fridays is to discuss unusual options activities that I find particularly interesting. The three options that have caught my attention today have one thing in common. By the end, you ought to know what it is. Happy Weekend! Agilent Technologies The first to catch my attention involves selling Agilent Technologies (A) put options. As I write this, one put and one call exhibits unusual options activity. While the call gives you a low ask price, I'm going with the Nov. 17 $115 put. The bid price on this Agilent put is $3.70. Based on a share price of $119.63, we’re looking at an annualized yield of 12.4%. With 91 days to expiry, the volume is 828, or 2.55x open interest. Currently, $4.63 above the strike, there is a real possibility that the put buyer will make you buy the shares at the strike. In that case, you’re not losing money until it falls to $111.30. Over the past year, Agilent stock hasn’t traded that low, with a 52-week low of $113.28. The last time its shares consistently traded below $111 was in late 2020. The odds are good that it might hit $115, but $111.30 is much less likely. I’m no technical analysis guru, but it does appear its shares bottomed in June. I know what you’re thinking: Didn’t the company give its guidance on China concerns? It sure did. On Wednesday, it said it expects revenue of $6.80 billion for its fiscal year, down from its previous guidance of $6.93 billion. On the bottom line, its earnings per share estimate has dropped by 20 cents to $5.40 at the low end of its guidance. There you have it: approximately $130 million less revenue and 20 cents per share. The EPS estimate revision translates to less than a 4% cut in earnings. Currently trading at 22.5x earnings, the maker of lab instruments is in value territory. Having traded near $180 as recently as September 2021, this is a good entry point. Ford Another stock that’s fallen out of favor with investors is Ford (F). Its shares are down 26% over the past year. Investors might be skeptical about its electric vehicle plans. On Aug. 17, it announced that it and a consortium of companies would invest $887 million to build a plant in Becancour, Quebec, to produce EV battery materials. When the plant gets up to speed, it will be capable of producing 45,000 tonnes of cathode active materials (CAM). “This cathode facility will supply the material that goes into Ford’s future EVs in North America, specifically some of our future trucks,” Lisa Drake, Ford vice president for EVs, told reporters. As part of the investment, the Canadian government will make a CAD$322 million condition loan, while the Quebec government will kick in a similar amount on a forgivable basis. The plant’s expected to open in 2026. I mention this because Ford recently reported healthy Q2 2023 earnings of $1.9 billion, a three-fold increase from a year ago. However, the iconic Detroit automaker said its EV business lost $1.1 billion on an EBIT basis during the quarter, more than double its loss in Q2 2022. In 2023, it expects EBIT losses of $4.5 billion, $1.5 billion more than expected. Ford isn’t alone here. Almost every company with a presence in EVs is losing money and ratcheting their production outputs lower to recognize that the uptake by consumers, especially in North America, will be slower than anticipated. As soon as the charging networks are up to snuff in North America, EV production will rocket higher. It will take patience from investors. The put to sell is the Sept. 8 $12 strike with a bid price of $0.38 for a net price of $11.62. That’s an annualized yield of 55.6% should its share price fail to remain under $12 by September. With a 52-week low of $10.90, you aren’t likely to lose much on the trade, even if it falls into the low $11s. Long-term, Ford’s going to be a player in EVs. U.S. Steel The iconic but oft-struggled U.S. steelmaker is possibly in the final throes of being sold to one of its competitors. Who it will be, we still don’t know. However, one thing is sure: U.S. Steel’s (X) final sale price will increase. Cleveland-Cliffs (CLF) has already offered $35 in cash and stock. That was rejected. Privately held Esmark has also made an unsolicited bid that’s been rejected by the company. Where this goes is anyone’s guess. However, if you sell the Aug. 25 $28.50 put, you’re looking at an annualized yield of almost 20%, with virtually no chance you’ll be asked to buy the shares. Keep selling puts weekly at a sub-$30 strike until the deal is done. Sure, if everything goes away and there is no sale, the stock price could crater into the $20s, but by then, you might have rolled the dice on three or four occasions, pocketing more than enough premium income to account for any decline. Consider this my M&A arbitrage bet. Have you figured out the one thing these three stocks have in common? They all have single-letter stock symbols. More Options News from Barchart Walmart's Better Than Expected Earnings and FCF Could Push WMT Stock Higher Here’s the Real Lowdown of Ross Stores’ (ROST) Q2 Report Somebody Really Must Like Suncor Given Its Unusual Options Activity Attention Speculators: Going Long Discover Financial Services (DFS) Might Not Be a Bad Idea On the date of publication, Will Ashworth did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Investors are worried about many subjects, including further interest rate hikes, higher bond yields, and a faltering Chinese economy. Almost every company with a presence in EVs is losing money and ratcheting their production outputs lower to recognize that the uptake by consumers, especially in North America, will be slower than anticipated. More Options News from Barchart Walmart's Better Than Expected Earnings and FCF Could Push WMT Stock Higher Here’s the Real Lowdown of Ross Stores’ (ROST) Q2 Report Somebody Really Must Like Suncor Given Its Unusual Options Activity Attention Speculators: Going Long Discover Financial Services (DFS) Might Not Be a Bad Idea On the date of publication, Will Ashworth did not have (either directly or indirectly) positions in any of the securities mentioned in this article.

Agilent Technologies The first to catch my attention involves selling Agilent Technologies (A) put options. Over the past year, Agilent stock hasn’t traded that low, with a 52-week low of $113.28. On Aug. 17, it announced that it and a consortium of companies would invest $887 million to build a plant in Becancour, Quebec, to produce EV battery materials.

Over the past year, Agilent stock hasn’t traded that low, with a 52-week low of $113.28. “This cathode facility will supply the material that goes into Ford’s future EVs in North America, specifically some of our future trucks,” Lisa Drake, Ford vice president for EVs, told reporters. More Options News from Barchart Walmart's Better Than Expected Earnings and FCF Could Push WMT Stock Higher Here’s the Real Lowdown of Ross Stores’ (ROST) Q2 Report Somebody Really Must Like Suncor Given Its Unusual Options Activity Attention Speculators: Going Long Discover Financial Services (DFS) Might Not Be a Bad Idea On the date of publication, Will Ashworth did not have (either directly or indirectly) positions in any of the securities mentioned in this article.

On the bottom line, its earnings per share estimate has dropped by 20 cents to $5.40 at the low end of its guidance. “This cathode facility will supply the material that goes into Ford’s future EVs in North America, specifically some of our future trucks,” Lisa Drake, Ford vice president for EVs, told reporters. The put to sell is the Sept. 8 $12 strike with a bid price of $0.38 for a net price of $11.62.

51.0

2023-08-17 00:00:00 UTC

Stocks Move Higher Before the Open as Investors Weigh Fed Minutes, Walmart Earnings on Tap

A

https://www.nasdaq.com/articles/stocks-move-higher-before-the-open-as-investors-weigh-fed-minutes-walmart-earnings-on-tap

September S&P 500 futures (ESU23) are up +0.22%, and September Nasdaq 100 E-Mini futures (NQU23) are up +0.19% this morning as market participants digested the minutes of the Federal Reserve’s latest meeting while watching for fresh indications of weakness in China. The minutes of the Federal Open Market Committee’s July 25-26 meeting revealed a split among Fed officials regarding the necessity for further interest rate hikes, as “some participants” voiced concerns about potential economic risks from excessive rate increases, while “most” policymakers continued to prioritize the battle against inflation. Also, during the policy outlook discussion, officials emphasized the significance of closely observing incoming economic data “to determine the extent of additional policy firming that may be appropriate to return inflation to 2% over time.” “Most participants continued to see significant upside risks to inflation, which could require further tightening of monetary policy,” according to the FOMC minutes released Wednesday. “The FOMC minutes reiterated many of the core themes that Powell delivered at the July press conference. There was nothing here to derail our assumption that September will be another ‘skip,’ although another hike in November or December is firmly on the table if the data warrants,” said Ben Jeffery, a strategist at BMO Capital Markets. In Wednesday’s trading session, the benchmark S&P 500 dropped to a 5-week low, the blue-chip Dow posted a 4-week low, and the tech-heavy Nasdaq 100 notched a 1-1/2 month low. Progressive Corp (PGR) surged over +8% and was the top percentage gainer on the S&P 500 after reporting net premiums written for July rose +21% y/y to $5.95 billion. Also, TJX Companies Inc (TJX) climbed more than +4% after the company posted upbeat Q2 results and lifted its annual comparable sales forecast. In addition, Target Corporation (TGT) gained over +2% after the big-box retailer reported stronger-than-expected Q2 margins and adjusted EPS. On the bearish side, chip stocks retreated after the 10-year Treasury yield rose to a 9-1/2 month high, with Advanced Micro Devices Inc (AMD) dropping more than -3% and Marvell Technology (MRVL) slumping over -2%. Also, Agilent Technologies Inc (A) fell more than -3% after cutting its FY23 guidance amid a “softer macroeconomic environment.” Economic data on Wednesday showed U.S. July Building Permits, a proxy for future construction, came in at 1.442M compared to a consensus of 1.463M. At the same time, U.S. Housing Starts rose +3.9% m/m to 1.452M, stronger than expectations of 1.448M. In addition, U.S. Industrial Production stood at +1.0% m/m in July, stronger than expectations of +0.3% m/m. Meanwhile, U.S. rate futures have priced in an 86.5% probability of no hike and a 13.5% chance of a 25 basis point rate increase at the next central bank meeting in September. On the earnings front, major companies like Walmart (WMT), Applied Materials (AMAT), and Ross Stores (ROST) are slated to release their quarterly results today. Today, all eyes are focused on the U.S. Philadelphia Fed manufacturing index in a couple of hours. Economists, on average, forecast that the August Philadelphia Fed manufacturing index will stand at -10.0, compared to the previous value of -13.5. Also, investors will likely focus on U.S. Initial Jobless Claims data. Economists estimate this figure to be 240K, compared to last week’s value of 248K. In the bond markets, United States 10-Year rates are at 4.298%, up +0.94%. The Euro Stoxx 50 futures are down -0.40% this morning as the minutes of the U.S. Federal Reserve’s July meeting sparked concerns the central bank will continue to raise interest rates to contain inflation while downbeat earnings also hurt risk appetite. Losses in construction and materials stocks are leading the overall market lower. Meanwhile, bond yields across Europe surged, with significant jumps observed in Italy and Germany, exerting pressure on equities. In corporate news, Bae Systems Plc (BA.L.EB) fell over -3% after Britain’s largest defense company agreed to acquire Ball Corp’s aerospace assets for about $5.55 billion in cash. Also, Adyen NV (ADYEN.A.DX) tumbled more than -23% after the Dutch payments processor reported weaker-than-expected first-half earnings. Eurozone’s Trade Balance data was released today. Eurozone June Trade Balance stood at 23.0B, stronger than expectations of 18.3B. Asian stock markets today closed mixed. China’s Shanghai Composite Index (SHCOMP) closed up +0.43%, and Japan’s Nikkei 225 Stock Index (NIK) closed down -0.44%. China’s Shanghai Composite today closed higher, supported by the robust performance of technology stocks. The People’s Bank of China intensified its efforts to stem losses in the yuan Thursday by providing the most forceful guidance since October through its daily reference rate for the managed currency. Meanwhile, concerns over China’s economy and its precarious debt burden persisted. Reuters reported on Thursday that Zhongzhi Enterprise Group informed its investors about a liquidity crisis and its intention to conduct debt restructuring as the Chinese asset manager contends with a worsening property market downturn. Also, a unit of China Evergrande Group stated that the Chinese securities regulator had built a case against it regarding suspected violations of information disclosure. In other news, the ratings agency Fitch told Bloomberg on Wednesday that any extension of government debt was likely to prompt a reassessment of China’s A+ credit rating. Japan’s Nikkei 225 Stock Index closed lower today as worries about more U.S. Federal Reserve interest rate hikes and a gloomy outlook for China’s economy weighed on market sentiment. Data on Thursday revealed that the country logged an unexpected trade deficit in July. Also, Japan’s exports experienced a decline in July for the first time in almost 2-1/2 years, underscoring worries about a potential global recession. Meanwhile, Japan's 20-year bond yield experienced a sharp increase following an auction of debt that received lackluster investor demand. In corporate news, tourism-related stocks retreated even after data showed that the number of visitors to Japan in July reached its highest level since the pandemic. The Nikkei Volatility, which takes into account the implied volatility of Nikkei 225 options, closed down -2.05% to 19.56. “Investors were reacting only to negative market cues - rising global yields and ongoing worries about China's economy,” said Takehiko Masuzawa, a trading head at Phillip Securities Japan. The Japanese July Trade Balance has been reported at -78.7B, weaker than expectations of +24.6B. The Japanese July Exports came in at -0.3% y/y, stronger than expectations of -0.8% y/y. The Japanese July Imports stood at -13.5% y/y, stronger than expectations of -14.7% y/y. The Japanese June Core Machinery Orders arrived at +2.7% m/m and -5.8% y/y, weaker than expectations of +3.6% m/m and -5.5% y/y. Pre-Market U.S. Stock Movers Wolfspeed Inc (WOLF) plunged over -12% in pre-market trading after the company reported mixed Q4 results and provided weaker-than-expected Q1 guidance. Cisco Systems Inc (CSCO) gained more than +2% in pre-market trading after the networking giant reported upbeat Q4 results. Chegg Inc (CHGG) rose over +1% in pre-market trading after the company announced its board of directors had authorized an increase of $200 million as part of its securities repurchase program. The Lovesac Company (LOVE) fell more than -2% in pre-market trading after the company disclosed in an SEC filing Wednesday that it identified errors related to last mile freight expenses. Avnet Inc (AVT) climbed about +6% in pre-market trading after reporting upbeat Q4 results and issuing a solid Q1 outlook. Adobe Systems Incorporated (ADBE) rose over +2% in pre-market trading after BofA upgraded the stock to Buy from Neutral. You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Thursday - August 17th Walmart (WMT), Applied Materials (AMAT), Ross Stores (ROST), Bill Com (BILL), Tapestry (TPR), Globant SA (GLOB), Bilibili (BILI), Lumentum Holdings Inc (LITE), Arcos Dorados (ARCO), Corporacion America Airports (CAAP), Farfetch A (FTCH), SFLoration Ltd (SFL), SGHC Limited (SGHC), Dole (DOLE), Ehang (EH), SpartanNash Co (SPTN), Despegar.com (DESP), Nano X (NNOX), Gambling.com Group (GAMB), LSI Industries (LYTS). More Stock Market News from Barchart 3 Dividend Kings To Buy And Hold Forever in a Retirement PortfolioStocks Fall and Bond Yields Climb as Fed Remains Hawkish2 Energy Stocks Wall Street Predicts Will Rally 25% or MoreUnusual Activity in DraftKings Put Options Shows Traders Are Bullish On the date of publication, Oleksandr Pylypenko did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Euro Stoxx 50 futures are down -0.40% this morning as the minutes of the U.S. Federal Reserve’s July meeting sparked concerns the central bank will continue to raise interest rates to contain inflation while downbeat earnings also hurt risk appetite. Reuters reported on Thursday that Zhongzhi Enterprise Group informed its investors about a liquidity crisis and its intention to conduct debt restructuring as the Chinese asset manager contends with a worsening property market downturn. You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Thursday - August 17th Walmart (WMT), Applied Materials (AMAT), Ross Stores (ROST), Bill Com (BILL), Tapestry (TPR), Globant SA (GLOB), Bilibili (BILI), Lumentum Holdings Inc (LITE), Arcos Dorados (ARCO), Corporacion America Airports (CAAP), Farfetch A (FTCH), SFLoration Ltd (SFL), SGHC Limited (SGHC), Dole (DOLE), Ehang (EH), SpartanNash Co (SPTN), Despegar.com (DESP), Nano X (NNOX), Gambling.com Group (GAMB), LSI Industries (LYTS).

On the earnings front, major companies like Walmart (WMT), Applied Materials (AMAT), and Ross Stores (ROST) are slated to release their quarterly results today. Japan’s Nikkei 225 Stock Index closed lower today as worries about more U.S. Federal Reserve interest rate hikes and a gloomy outlook for China’s economy weighed on market sentiment. You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Thursday - August 17th Walmart (WMT), Applied Materials (AMAT), Ross Stores (ROST), Bill Com (BILL), Tapestry (TPR), Globant SA (GLOB), Bilibili (BILI), Lumentum Holdings Inc (LITE), Arcos Dorados (ARCO), Corporacion America Airports (CAAP), Farfetch A (FTCH), SFLoration Ltd (SFL), SGHC Limited (SGHC), Dole (DOLE), Ehang (EH), SpartanNash Co (SPTN), Despegar.com (DESP), Nano X (NNOX), Gambling.com Group (GAMB), LSI Industries (LYTS).

The minutes of the Federal Open Market Committee’s July 25-26 meeting revealed a split among Fed officials regarding the necessity for further interest rate hikes, as “some participants” voiced concerns about potential economic risks from excessive rate increases, while “most” policymakers continued to prioritize the battle against inflation. Japan’s Nikkei 225 Stock Index closed lower today as worries about more U.S. Federal Reserve interest rate hikes and a gloomy outlook for China’s economy weighed on market sentiment. More Stock Market News from Barchart 3 Dividend Kings To Buy And Hold Forever in a Retirement PortfolioStocks Fall and Bond Yields Climb as Fed Remains Hawkish2 Energy Stocks Wall Street Predicts Will Rally 25% or MoreUnusual Activity in DraftKings Put Options Shows Traders Are Bullish On the date of publication, Oleksandr Pylypenko did not have (either directly or indirectly) positions in any of the securities mentioned in this article.

Japan’s Nikkei 225 Stock Index closed lower today as worries about more U.S. Federal Reserve interest rate hikes and a gloomy outlook for China’s economy weighed on market sentiment. Pre-Market U.S. Stock Movers Wolfspeed Inc (WOLF) plunged over -12% in pre-market trading after the company reported mixed Q4 results and provided weaker-than-expected Q1 guidance. Cisco Systems Inc (CSCO) gained more than +2% in pre-market trading after the networking giant reported upbeat Q4 results.

52.0

2023-08-16 00:00:00 UTC

TD Cowen Maintains Agilent Technologies (A) Outperform Recommendation

A

https://www.nasdaq.com/articles/td-cowen-maintains-agilent-technologies-a-outperform-recommendation-0

Fintel reports that on August 16, 2023, TD Cowen maintained coverage of Agilent Technologies (NYSE:A) with a Outperform recommendation. Analyst Price Forecast Suggests 14.32% Upside As of August 2, 2023, the average one-year price target for Agilent Technologies is 143.65. The forecasts range from a low of 116.15 to a high of $171.15. The average price target represents an increase of 14.32% from its latest reported closing price of 125.65. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.94%. The projected annual non-GAAP EPS is 5.77. Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). Shareholders of record as of July 3, 2023 received the payment on July 26, 2023. Previously, the company paid $0.22 per share. At the current share price of $125.65 / share, the stock's dividend yield is 0.72%. Looking back five years and taking a sample every week, the average dividend yield has been 0.73%, the lowest has been 0.44%, and the highest has been 1.14%. The standard deviation of yields is 0.15 (n=235). The current dividend yield is 0.10 standard deviations below the historical average. Additionally, the company's dividend payout ratio is 0.23. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5. The company's 3-Year dividend growth rate is 0.25%, demonstrating that it has increased its dividend over time. What is the Fund Sentiment? There are 1956 funds or institutions reporting positions in Agilent Technologies. This is a decrease of 54 owner(s) or 2.69% in the last quarter. Average portfolio weight of all funds dedicated to A is 0.34%, a decrease of 14.86%. Total shares owned by institutions decreased in the last three months by 0.02% to 302,000K shares. The put/call ratio of A is 0.98, indicating a bullish outlook. What are Other Shareholders Doing? Massachusetts Financial Services holds 11,037K shares representing 3.74% ownership of the company. In it's prior filing, the firm reported owning 8,907K shares, representing an increase of 19.30%. The firm decreased its portfolio allocation in A by 84.09% over the last quarter. T. Rowe Price Investment Management holds 9,968K shares representing 3.37% ownership of the company. In it's prior filing, the firm reported owning 9,277K shares, representing an increase of 6.93%. The firm decreased its portfolio allocation in A by 11.26% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,160K shares representing 3.10% ownership of the company. In it's prior filing, the firm reported owning 8,971K shares, representing an increase of 2.07%. The firm decreased its portfolio allocation in A by 12.83% over the last quarter. Wellington Management Group Llp holds 8,736K shares representing 2.96% ownership of the company. In it's prior filing, the firm reported owning 12,057K shares, representing a decrease of 38.01%. The firm decreased its portfolio allocation in A by 91.52% over the last quarter. Price T Rowe Associates holds 8,054K shares representing 2.73% ownership of the company. In it's prior filing, the firm reported owning 8,219K shares, representing a decrease of 2.05%. The firm decreased its portfolio allocation in A by 20.72% over the last quarter. Agilent Technologies Background Information (This description is provided by the company.) Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. JPMORGAN CHASE BANK, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3. Second Amended and Restated Certificate of Incorporation Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits. Click to Learn More This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3. Second Amended and Restated Certificate of Incorporation Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more.

Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,160K shares representing 3.10% ownership of the company. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3.

The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.94%. At the current share price of $125.65 / share, the stock's dividend yield is 0.72%. There are 1956 funds or institutions reporting positions in Agilent Technologies.

53.0

2023-08-16 00:00:00 UTC

Stocks Mixed as Markets Await Minutes of the July FOMC Meeting

A

https://www.nasdaq.com/articles/stocks-mixed-as-markets-await-minutes-of-the-july-fomc-meeting

What you need to know… The S&P 500 Index ($SPX) (SPY) today is down -0.17%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.03%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.46%. Stocks this morning are mixed. Lower T-note yields and a decline in inflation expectations support stocks today. The 10-year U.S. breakeven inflation rate fell to a 3-1/2 week low today at 2.308%. The markets are awaiting this afternoon’s release of the minutes of the July 25-26 FOMC meeting for clues as to the future direction of Fed policy. This morning’s U.S. economic news was mixed as July housing starts and Jul manufacturing production rose more than expected, but July building permits rose less than expected. China’s economic woes continue to weigh on global markets. The yuan fell to a 9-1/4 month low today, and the Shanghai Composite closed down -0.82% after China’s July home sales fell for the second month by the most in 7 months. Also, liquidity concerns in China’s shadow banking system have intensified after Zhongrong International Trust missed payments on dozens of its investment products. JPMorgan Chase cut its China 2023 GDP forecast to 4.8% from a 6.4% estimate in May. Barclays cut its China 2023 GDP forecast to 4.5% from a prior forecast of 4.9%. Zhongrong International Trust, China's ninth-biggest trust with about 600 billion yuan in assets, missed payments on 30 investment products and halted redemptions on some short-term instruments. The firm said liquidity has dried up "unexpectedly," making it hard to meet short-term debt obligations as most of the underlying assets are long-term and illiquid. The firm has 270 high-yield products totaling 39.5 billion yuan ($5.4 billion) due this year. Weekly data from the Mortgage Bankers Association showed mortgage applications fell -0.8% w/w, the fifth straight week of declines. The U.S. 30-year mortgage rate rose to 7.16% last week, matching the highest since 2001. U.S. Jul housing starts rose +3.9% m/m to 1.452 million, stronger than expectations of 1.450 million. However, Jul building permits, a proxy for future construction, rose +0.1% m/m to 1.442 million, weaker than expectations of 1.463 million. U.S. Jul manufacturing production unexpectedly rose +0.5% m/m, stronger than expectations of no change. The markets are discounting the odds at 11% for a +25 bp rate hike at the September 20 FOMC meeting and 38% for that +25 bp rate hike at the November 1 FOMC meeting. Global bond yields are mixed. The 10-year T-note yield is down -1.0 bp to 4.201%. The 10-year German bund yield is down -2.6 bp at 2.646%. The 10-year UK gilt yield is up +4.2 bp at 4.631%. Overseas stock markets are lower. The Euro Stoxx 50 is down -0.03%. China’s Shanghai Composite Index today closed down -0.82%. Japan’s Nikkei Stock Index closed down -1.46%. Today’s stock movers… Progressive Corp (PGR) is up more than +8% to lead gainers in the S&P 500 after reporting net premiums written for July rose +21% y/y to $5.95 billion. Target (TGT) is up more than +4% after reporting Q2 Ebitda of $1.90 billion, better than the consensus of $1.58 billion. TJX Cos (TJX) is up more than +3% after reporting Q2 net sales of $12.80 billion, stronger than the consensus of $12.44 billion, and raising its full-year comparable sales estimate to +3% to +4% from a prior view of +2% to +3%, better than the consensus of +3.01%. H&R Block (HRB) is up more than +7% after reporting Q4 adjusted EPS from continuing operations of $2.05, better than the consensus of $1.88. MarketAxcess Holdings (MKTX) is up more than +3% on signs of insider buying after an SEC filing showed CEO Concannon purchased $1.02 million of shares on Monday. Coinbase Global (COIN) is up more than +2% after it won approval from the National Futures Association to operate as a Futures Commission Merchant and offer access to crypto futures. Keurig Dr Pepper (KDP) is up more than +1% after UBS upgraded the stock to buy from neutral with a price target of $42. GE Healthcare (GEHC) is up more than +1% after Wells Fargo Securities initiated coverage of the stock with a recommendation of overweight and a price target of $90. MarketAxcess Holdings (MKTX) is up more than +3% on signs of insider buying after an SEC filing showed CEO Concannon purchased $1.02 million of shares on Monday. Jack Henry & Associates (JKHY) is down more than -7% to lead losers in the S&P 500 after forecasting 2024 EPS of $4.92-$4.99, weaker than the consensus of $5.34. Trucking stocks are under pressure on signs of weakness in freight demand after data from the Cass Freight Shipment Index showed U.S. July freight volume fell -8.9% y/y, the sixth consecutive monthly decline. As a result, JB Hunt Transport Services (JBHT) is down more than -2%. Also, Knight-Swift Transportation Holdings (KNX) and Werner Enterprises (WERN) are down more than -1%. In addition, Schneider National (SNDR) and CH Robinson Worldwide (CHRW) are down more than -0.5%. Agilent Technologies (A) is down more than -3% after cutting its full-year revenue forecast to $6.80 billion-$6.85 billion from a previous forecast of $6.93 billion-$7.03 billion. Intel (INTC) is down more than -1% to lead losers in the Down Jones Industrial after it agreed to terminate its previously disclosed agreement to buy Tower Semiconductor for $5.4 billion. Coherent (COHR) is down more than -34% after forecasting 2024 revenue of $4.5 billion-$4.7 billion, weaker than the consensus of $4.88 billion. Tesla (TSLA) is down more than -1% after it cut its vehicle prices in China for the second time in three days. Across the markets… September 10-year T-notes (ZNU23) today are up +5 ticks, and the 10-year T-note yield is down -1.0 bp at 4.201%. Sep T-notes today are slightly higher on a decline in inflation expectations after the 10-year breakeven inflation rate fell to a 3-1/2 week low today at 2.308%. Gains in T-notes are limited due to today’s stronger-than-expected economic news on July housing starts and Jul manufacturing production. The dollar index (DXY00) today is down by -0.06%. The dollar today is slightly weaker, weighed down by lower T-note yields. Also, today’s stronger-than-expected report on Jun Eurozone industrial production boosted the euro against the dollar. Losses in the dollar were contained on weakness in the yuan, which dropped to a 9-1/4 month low against the dollar on Chinese economic concerns. EUR/USD (^EURUSD) today is up by +0.16%. The euro is moderately higher today on a weaker dollar. Also, today’s stronger-than-expected report on Eurozone Jun industrial production gave the euro a boost. Eurozone Jun industrial production unexpectedly rose +0.5% m/m, stronger than expectations of no change. USD/JPY (^USDJPY) is up by +0.16%. The yen today is moving lower for the eighth consecutive session and posted a new 9-month against the dollar. Central bank divergence is weighing on the yen, with the BOE, ECB, and Fed in the middle of their rate hiking cycles while the BOJ maintains QE and record-low interest rates. Lower T-note yields today are limiting losses in the yen. October gold (GCV3) today is up +1.8 (+0.09%), and Sep silver (SIU23) is up +0.064 (+0.28%). Precious metals prices this morning are slightly higher. A weaker dollar today is giving metals prices a boost. Also, T-note yields are supportive of precious metals. In addition, the deepening liquidity crisis in China has boosted safe-haven demand for precious metals after Zhongrong International Trust missed payments on dozens of its investment products. Silver prices are finding support on signs of strength in industrial metals demand after today’s news showed Eurozone Jun industrial production and U.S. Jul manufacturing production rose more than expected. Gains in silver were limited after JPMorgan Chase and Barclays cut their China 2023 GDP estimates, a bearish factor for industrial metals demand. Also, fund liquidation in gold continues after long gold holdings in ETFs fell to a 3-1/3 year low on Tuesday. More Stock Market News from Barchart How Did This EV Company's CFO Amass an Incredible $590 Million Fortune?Supersize Your McDonald’s (MCD) Holdings Before the Market Realizes the Discount on TapDisney or Netflix: Which Streaming Stock is a Better Buy?Markets Today: Stocks Slightly Lower on Chinese Economic Woes On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

MarketAxcess Holdings (MKTX) is up more than +3% on signs of insider buying after an SEC filing showed CEO Concannon purchased $1.02 million of shares on Monday. In addition, the deepening liquidity crisis in China has boosted safe-haven demand for precious metals after Zhongrong International Trust missed payments on dozens of its investment products. What you need to know… The S&P 500 Index ($SPX) (SPY) today is down -0.17%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.03%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.46%.

This morning’s U.S. economic news was mixed as July housing starts and Jul manufacturing production rose more than expected, but July building permits rose less than expected. MarketAxcess Holdings (MKTX) is up more than +3% on signs of insider buying after an SEC filing showed CEO Concannon purchased $1.02 million of shares on Monday. Gains in T-notes are limited due to today’s stronger-than-expected economic news on July housing starts and Jul manufacturing production.

MarketAxcess Holdings (MKTX) is up more than +3% on signs of insider buying after an SEC filing showed CEO Concannon purchased $1.02 million of shares on Monday. Sep T-notes today are slightly higher on a decline in inflation expectations after the 10-year breakeven inflation rate fell to a 3-1/2 week low today at 2.308%. Silver prices are finding support on signs of strength in industrial metals demand after today’s news showed Eurozone Jun industrial production and U.S. Jul manufacturing production rose more than expected.

MarketAxcess Holdings (MKTX) is up more than +3% on signs of insider buying after an SEC filing showed CEO Concannon purchased $1.02 million of shares on Monday. The dollar today is slightly weaker, weighed down by lower T-note yields. EUR/USD (^EURUSD) today is up by +0.16%.

54.0

2023-08-16 00:00:00 UTC

Jefferies Maintains Agilent Technologies (A) Buy Recommendation

A

https://www.nasdaq.com/articles/jefferies-maintains-agilent-technologies-a-buy-recommendation

Fintel reports that on August 16, 2023, Jefferies maintained coverage of Agilent Technologies (NYSE:A) with a Buy recommendation. Analyst Price Forecast Suggests 14.32% Upside As of August 2, 2023, the average one-year price target for Agilent Technologies is 143.65. The forecasts range from a low of 116.15 to a high of $171.15. The average price target represents an increase of 14.32% from its latest reported closing price of 125.65. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.94%. The projected annual non-GAAP EPS is 5.77. Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). Shareholders of record as of July 3, 2023 received the payment on July 26, 2023. Previously, the company paid $0.22 per share. At the current share price of $125.65 / share, the stock's dividend yield is 0.72%. Looking back five years and taking a sample every week, the average dividend yield has been 0.73%, the lowest has been 0.44%, and the highest has been 1.14%. The standard deviation of yields is 0.15 (n=235). The current dividend yield is 0.10 standard deviations below the historical average. Additionally, the company's dividend payout ratio is 0.23. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5. The company's 3-Year dividend growth rate is 0.25%, demonstrating that it has increased its dividend over time. What is the Fund Sentiment? There are 1956 funds or institutions reporting positions in Agilent Technologies. This is a decrease of 54 owner(s) or 2.69% in the last quarter. Average portfolio weight of all funds dedicated to A is 0.34%, a decrease of 14.86%. Total shares owned by institutions decreased in the last three months by 0.02% to 302,000K shares. The put/call ratio of A is 0.98, indicating a bullish outlook. What are Other Shareholders Doing? Massachusetts Financial Services holds 11,037K shares representing 3.74% ownership of the company. In it's prior filing, the firm reported owning 8,907K shares, representing an increase of 19.30%. The firm decreased its portfolio allocation in A by 84.09% over the last quarter. T. Rowe Price Investment Management holds 9,968K shares representing 3.37% ownership of the company. In it's prior filing, the firm reported owning 9,277K shares, representing an increase of 6.93%. The firm decreased its portfolio allocation in A by 11.26% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,160K shares representing 3.10% ownership of the company. In it's prior filing, the firm reported owning 8,971K shares, representing an increase of 2.07%. The firm decreased its portfolio allocation in A by 12.83% over the last quarter. Wellington Management Group Llp holds 8,736K shares representing 2.96% ownership of the company. In it's prior filing, the firm reported owning 12,057K shares, representing a decrease of 38.01%. The firm decreased its portfolio allocation in A by 91.52% over the last quarter. Price T Rowe Associates holds 8,054K shares representing 2.73% ownership of the company. In it's prior filing, the firm reported owning 8,219K shares, representing a decrease of 2.05%. The firm decreased its portfolio allocation in A by 20.72% over the last quarter. Agilent Technologies Background Information (This description is provided by the company.) Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. JPMORGAN CHASE BANK, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits. Click to Learn More This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more.

Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,160K shares representing 3.10% ownership of the company. Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A.

The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.94%. At the current share price of $125.65 / share, the stock's dividend yield is 0.72%. Additionally, the company's dividend payout ratio is 0.23.

55.0

2023-08-16 00:00:00 UTC

Stocks Fall and Bond Yields Climb as Fed Remains Hawkish

A

https://www.nasdaq.com/articles/stocks-fall-and-bond-yields-climb-as-fed-remains-hawkish

What you need to know… The S&P 500 Index ($SPX) (SPY) Wednesday closed down -0.76%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.52%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -1.07%. Stocks on Wednesday gave up early gains and retreated, with the S&P 500 falling to a 5-week low, the Dow Jones Industrials falling to a 4-week low, and the Nasdaq 100 dropping to a 1-1/2 month low. Stock indexes came under pressure Wednesday afternoon when bond yields jumped after the minutes of the July 25-26 FOMC meeting stated that policymakers saw “significant” inflation risks that may merit more rate hikes. Wednesday’s U.S. economic news was mixed as July housing starts and Jul manufacturing production rose more than expected, but July building permits rose less than expected. China’s economic woes continue to weigh on global markets. The yuan fell to a 9-1/4 month low Wednesday, and the Shanghai Composite closed down -0.82% after China’s July home sales fell for the second month by the most in 7 months. Also, liquidity concerns in China’s shadow banking system have intensified after Zhongrong International Trust missed payments on dozens of its investment products. Zhongrong International Trust, China's ninth-biggest trust with about 600 billion yuan in assets, missed payments on 30 investment products and halted redemptions on some short-term instruments. The firm said liquidity has dried up "unexpectedly," making it hard to meet short-term debt obligations as most of the underlying assets are long-term and illiquid. The firm has 270 high-yield products totaling 39.5 billion yuan ($5.4 billion) due this year. JPMorgan Chase cut its China 2023 GDP forecast to 4.8% from a 6.4% estimate in May. Barclays cut its China 2023 GDP forecast to 4.5% from a prior forecast of 4.9%. Weekly data from the Mortgage Bankers Association showed mortgage applications fell -0.8% w/w, the fifth straight week of declines. The U.S. 30-year mortgage rate rose to 7.16% last week, matching the highest since 2001. U.S. Jul housing starts rose +3.9% m/m to 1.452 million, stronger than expectations of 1.450 million. However, Jul building permits, a proxy for future construction, rose +0.1% m/m to 1.442 million, weaker than expectations of 1.463 million. U.S. Jul manufacturing production unexpectedly rose +0.5% m/m, stronger than expectations of no change. The minutes of the July 25-26 FOMC meeting were hawkish for Fed policy and bearish for stocks as they stated, "most participants continued to see significant upside risks to inflation, which could require further tightening of monetary policy. " The markets are discounting the odds at 11% for a +25 bp rate hike at the September 20 FOMC meeting and 43% for that +25 bp rate hike at the November 1 FOMC meeting. Global bond yields Wednesday were mixed. The 10-year T-note yield rose to a 9-1/2 month high of 4.276% and finished up +5.5 bp to 4.266%. The 10-year German bund yield fell -2.2 bp to 2.650%. The 10-year UK gilt yield rose +5.7 bp to 4.646%. Overseas stock markets on Wednesday settled lower. The Euro Stoxx 50 closed down -0.103%. China’s Shanghai Composite Index today closed down -0.82%. Japan’s Nikkei Stock Index closed down -1.46%. Today’s stock movers… Jack Henry & Associates (JKHY) closed down more than -6% to lead losers in the S&P 500 after forecasting 2024 EPS of $4.92-$4.99, weaker than the consensus of $5.34. Chip stocks retreated Wednesday after the 10-year T-note yield rose to a 9-1/2 month high. As a result, Advanced Micro Devices (AMD) closed down more than -3% to lead losers in the Nasdaq 100. Also, Marvell Technology (MRVL), NXP Semiconductors NV (NXPI), Analog Devices (ADI), Globalfoundries (GFS), and ON Semiconductor (ON) closed down more than -2%. In addition, KLA Corp (KLAC), Micron Technology (MU), and Lam Research (LRCX) closed down more than -1%. Trucking stocks are under pressure on signs of weakness in freight demand after data from the Cass Freight Shipment Index showed U.S. July freight volume fell -8.9% y/y, the sixth consecutive monthly decline. As a result, JB Hunt Transport Services (JBHT) closed down more than -3%. Also, Knight-Swift Transportation Holdings (KNX), Werner Enterprises (WERN), and Marten Transport Ltd (MRTN) closed down more than -2%. In addition, Schneider National (SNDR) closed down more than -1%. Agilent Technologies (A) closed down more than -3% after cutting its full-year revenue forecast to $6.80 billion-$6.85 billion from a previous forecast of $6.93 billion-$7.03 billion. Intel (INTC) closed down more than -3% to lead losers in the Down Jones Industrial after it agreed to terminate its previously disclosed agreement to buy Tower Semiconductor for $5.4 billion. Coherent (COHR) closed down more than -29% after forecasting 2024 revenue of $4.5 billion-$4.7 billion, weaker than the consensus of $4.88 billion. Tesla (TSLA) closed down more than -3% after it cut its vehicle prices in China for the second time in three days. Insurance stocks rallied Wednesday after Progressive Corp reported net premiums written for July rose +21% y/y to $5.95 billion. As a result, Progressive Corp (PGR) closed up more than +8% to lead gainers in the S&P 500. Also, Allstate (ALL) closed up more than +4%, and Brown & Brown (BRO) closed up more than +2%. In addition, Travelers Cos (TRV) closed up more than +1% to lead gainers in the Dow Jones Industrials. MarketAxcess Holdings (MKTX) closed up more than +5% on signs of insider buying after an SEC filing showed CEO Concannon purchased $1.02 million of shares on Monday. TJX Cos (TJX) closed up more than +4% after reporting Q2 net sales of $12.80 billion, stronger than the consensus of $12.44 billion, and raising its full-year comparable sales estimate to +3% to +4% from a prior view of +2% to +3%, better than the consensus of +3.01%. Target (TGT) closed up more than +2% after reporting Q2 Ebitda of $1.90 billion, better than the consensus of $1.58 billion. H&R Block (HRB) closed up more than +9% after reporting Q4 adjusted EPS from continuing operations of $2.05, better than the consensus of $1.88. AES Corp (AES) closed up more than +2% on signs of inside buying after an SEC filing showed director Monie bought $500,598 of shares on Wednesday. Keurig Dr Pepper (KDP) closed up more than +1% after UBS upgraded the stock to buy from neutral with a price target of $42. Across the markets… September 10-year T-notes (ZNU23) Wednesday closed down -6.5 ticks, and the 10-year T-note yield rose +5.5 bp to 4.266%. Sep T-notes Wednesday gave up an early advance and turned lower, and the 10-year T-note yield Wednesday climbed to a 9-1/2 month high of 4.276%. Stronger-than-expected U.S. economic reports on July housing starts Wednesday, and Jul manufacturing production weighed on T-notes. Losses in T-notes accelerated Wednesday afternoon after the hawkish minutes of the July 25-26 FOMC meeting stated that policymakers saw “significant” inflation risks that may merit more rate hikes. T-note prices Wednesday morning initially rose after inflation expectations declined when the 10-year breakeven inflation rate fell to a 3-1/2 week low of 2.308%. Also, weakness in stocks sparked some safe-haven demand for T-notes. More Stock Market News from Barchart Dollar Advances after the Hawkish July FOMC Meeting Minutes Crude Prices Retreat on Chinese Growth Concerns Forecasts for Cooler U.S. Weather Undercut Nat-Gas Prices 2 Energy Stocks Wall Street Predicts Will Rally 25% or More On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stock indexes came under pressure Wednesday afternoon when bond yields jumped after the minutes of the July 25-26 FOMC meeting stated that policymakers saw “significant” inflation risks that may merit more rate hikes. More Stock Market News from Barchart Dollar Advances after the Hawkish July FOMC Meeting Minutes Crude Prices Retreat on Chinese Growth Concerns Forecasts for Cooler U.S. Weather Undercut Nat-Gas Prices 2 Energy Stocks Wall Street Predicts Will Rally 25% or More On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article.

Stock indexes came under pressure Wednesday afternoon when bond yields jumped after the minutes of the July 25-26 FOMC meeting stated that policymakers saw “significant” inflation risks that may merit more rate hikes. Wednesday’s U.S. economic news was mixed as July housing starts and Jul manufacturing production rose more than expected, but July building permits rose less than expected. Losses in T-notes accelerated Wednesday afternoon after the hawkish minutes of the July 25-26 FOMC meeting stated that policymakers saw “significant” inflation risks that may merit more rate hikes.

What you need to know… The S&P 500 Index ($SPX) (SPY) Wednesday closed down -0.76%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.52%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -1.07%. The yuan fell to a 9-1/4 month low Wednesday, and the Shanghai Composite closed down -0.82% after China’s July home sales fell for the second month by the most in 7 months. Across the markets… September 10-year T-notes (ZNU23) Wednesday closed down -6.5 ticks, and the 10-year T-note yield rose +5.5 bp to 4.266%.

Target (TGT) closed up more than +2% after reporting Q2 Ebitda of $1.90 billion, better than the consensus of $1.58 billion. T-note prices Wednesday morning initially rose after inflation expectations declined when the 10-year breakeven inflation rate fell to a 3-1/2 week low of 2.308%. For more information please view the Barchart Disclosure Policy here.

56.0

2023-08-16 00:00:00 UTC

Wednesday Sector Laggards: Healthcare, Consumer Products

A

https://www.nasdaq.com/articles/wednesday-sector-laggards%3A-healthcare-consumer-products-1

Looking at the sectors faring worst as of midday Wednesday, shares of Healthcare companies are underperforming other sectors, showing a 0.6% loss. Within that group, ResMed Inc. (Symbol: RMD) and Agilent Technologies, Inc. (Symbol: A) are two of the day's laggards, showing a loss of 3.9% and 2.6%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is flat on the day on the day, and up 0.85% year-to-date. ResMed Inc., meanwhile, is down 15.50% year-to-date, and Agilent Technologies, Inc., is down 18.14% year-to-date. Combined, RMD and A make up approximately 1.2% of the underlying holdings of XLV. The next worst performing sector is the Consumer Products sector, showing a 0.3% loss. Among large Consumer Products stocks, BorgWarner Inc (Symbol: BWA) and Ralph Lauren Corp (Symbol: RL) are the most notable, showing a loss of 2.5% and 1.4%, respectively. One ETF closely tracking Consumer Products stocks is the iShares U.S. Consumer Goods ETF (IYK), which is down 0.1% in midday trading, and down 0.41% on a year-to-date basis. BorgWarner Inc, meanwhile, is up 12.97% year-to-date, and Ralph Lauren Corp is up 9.49% year-to-date. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. As you can see, one sector is up on the day, while seven sectors are down. SECTOR % CHANGE Utilities +0.7% Financial -0.0% Consumer Products -0.3% Services -0.3% Technology & Communications -0.3% Industrial -0.3% Materials -0.3% Energy -0.3% Healthcare -0.6% 10 ETFs With Stocks That Insiders Are Buying » Also see: • STRT market cap history • Top Ten Hedge Funds Holding SGNT • CE YTD Return The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Combined, RMD and A make up approximately 1.2% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. Utilities +0.7% Financial -0.0% Consumer Products -0.3% Services -0.3% Technology & Communications -0.3% Industrial -0.3% Materials -0.3% Energy -0.3% Healthcare -0.6% 10 ETFs With Stocks That Insiders Are Buying » Also see: • STRT market cap history • Top Ten Hedge Funds Holding SGNT • CE YTD Return The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Within that group, ResMed Inc. (Symbol: RMD) and Agilent Technologies, Inc. (Symbol: A) are two of the day's laggards, showing a loss of 3.9% and 2.6%, respectively. The next worst performing sector is the Consumer Products sector, showing a 0.3% loss. Among large Consumer Products stocks, BorgWarner Inc (Symbol: BWA) and Ralph Lauren Corp (Symbol: RL) are the most notable, showing a loss of 2.5% and 1.4%, respectively.

Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is flat on the day on the day, and up 0.85% year-to-date. One ETF closely tracking Consumer Products stocks is the iShares U.S. Consumer Goods ETF (IYK), which is down 0.1% in midday trading, and down 0.41% on a year-to-date basis. Utilities +0.7% Financial -0.0% Consumer Products -0.3% Services -0.3% Technology & Communications -0.3% Industrial -0.3% Materials -0.3% Energy -0.3% Healthcare -0.6% 10 ETFs With Stocks That Insiders Are Buying » Also see: • STRT market cap history • Top Ten Hedge Funds Holding SGNT • CE YTD Return The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Within that group, ResMed Inc. (Symbol: RMD) and Agilent Technologies, Inc. (Symbol: A) are two of the day's laggards, showing a loss of 3.9% and 2.6%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is flat on the day on the day, and up 0.85% year-to-date. The next worst performing sector is the Consumer Products sector, showing a 0.3% loss.

57.0

2023-08-16 00:00:00 UTC

Credit Suisse Maintains Agilent Technologies (A) Outperform Recommendation

A

https://www.nasdaq.com/articles/credit-suisse-maintains-agilent-technologies-a-outperform-recommendation-0

Fintel reports that on August 16, 2023, Credit Suisse maintained coverage of Agilent Technologies (NYSE:A) with a Outperform recommendation. Analyst Price Forecast Suggests 14.32% Upside As of August 2, 2023, the average one-year price target for Agilent Technologies is 143.65. The forecasts range from a low of 116.15 to a high of $171.15. The average price target represents an increase of 14.32% from its latest reported closing price of 125.65. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.94%. The projected annual non-GAAP EPS is 5.77. Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). Shareholders of record as of July 3, 2023 received the payment on July 26, 2023. Previously, the company paid $0.22 per share. At the current share price of $125.65 / share, the stock's dividend yield is 0.72%. Looking back five years and taking a sample every week, the average dividend yield has been 0.73%, the lowest has been 0.44%, and the highest has been 1.14%. The standard deviation of yields is 0.15 (n=235). The current dividend yield is 0.10 standard deviations below the historical average. Additionally, the company's dividend payout ratio is 0.23. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5. The company's 3-Year dividend growth rate is 0.25%, demonstrating that it has increased its dividend over time. What is the Fund Sentiment? There are 1956 funds or institutions reporting positions in Agilent Technologies. This is a decrease of 54 owner(s) or 2.69% in the last quarter. Average portfolio weight of all funds dedicated to A is 0.34%, a decrease of 14.86%. Total shares owned by institutions decreased in the last three months by 0.02% to 302,000K shares. The put/call ratio of A is 0.98, indicating a bullish outlook. What are Other Shareholders Doing? Massachusetts Financial Services holds 11,037K shares representing 3.74% ownership of the company. In it's prior filing, the firm reported owning 8,907K shares, representing an increase of 19.30%. The firm decreased its portfolio allocation in A by 84.09% over the last quarter. T. Rowe Price Investment Management holds 9,968K shares representing 3.37% ownership of the company. In it's prior filing, the firm reported owning 9,277K shares, representing an increase of 6.93%. The firm decreased its portfolio allocation in A by 11.26% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,160K shares representing 3.10% ownership of the company. In it's prior filing, the firm reported owning 8,971K shares, representing an increase of 2.07%. The firm decreased its portfolio allocation in A by 12.83% over the last quarter. Wellington Management Group Llp holds 8,736K shares representing 2.96% ownership of the company. In it's prior filing, the firm reported owning 12,057K shares, representing a decrease of 38.01%. The firm decreased its portfolio allocation in A by 91.52% over the last quarter. Price T Rowe Associates holds 8,054K shares representing 2.73% ownership of the company. In it's prior filing, the firm reported owning 8,219K shares, representing a decrease of 2.05%. The firm decreased its portfolio allocation in A by 20.72% over the last quarter. Agilent Technologies Background Information (This description is provided by the company.) Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. JPMORGAN CHASE BANK, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3. Second Amended and Restated Certificate of Incorporation Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits. Click to Learn More This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3. Second Amended and Restated Certificate of Incorporation Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more.

Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,160K shares representing 3.10% ownership of the company. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3.

The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.94%. At the current share price of $125.65 / share, the stock's dividend yield is 0.72%. There are 1956 funds or institutions reporting positions in Agilent Technologies.

58.0

2023-08-16 00:00:00 UTC

Evercore ISI Group Maintains Agilent Technologies (A) In-Line Recommendation

A

https://www.nasdaq.com/articles/evercore-isi-group-maintains-agilent-technologies-a-in-line-recommendation

Fintel reports that on August 16, 2023, Evercore ISI Group maintained coverage of Agilent Technologies (NYSE:A) with a In-Line recommendation. Analyst Price Forecast Suggests 14.32% Upside As of August 2, 2023, the average one-year price target for Agilent Technologies is 143.65. The forecasts range from a low of 116.15 to a high of $171.15. The average price target represents an increase of 14.32% from its latest reported closing price of 125.65. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.94%. The projected annual non-GAAP EPS is 5.77. Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). Shareholders of record as of July 3, 2023 received the payment on July 26, 2023. Previously, the company paid $0.22 per share. At the current share price of $125.65 / share, the stock's dividend yield is 0.72%. Looking back five years and taking a sample every week, the average dividend yield has been 0.73%, the lowest has been 0.44%, and the highest has been 1.14%. The standard deviation of yields is 0.15 (n=235). The current dividend yield is 0.10 standard deviations below the historical average. Additionally, the company's dividend payout ratio is 0.23. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5. The company's 3-Year dividend growth rate is 0.25%, demonstrating that it has increased its dividend over time. What is the Fund Sentiment? There are 1956 funds or institutions reporting positions in Agilent Technologies. This is a decrease of 54 owner(s) or 2.69% in the last quarter. Average portfolio weight of all funds dedicated to A is 0.34%, a decrease of 14.86%. Total shares owned by institutions decreased in the last three months by 0.02% to 302,000K shares. The put/call ratio of A is 0.98, indicating a bullish outlook. What are Other Shareholders Doing? Massachusetts Financial Services holds 11,037K shares representing 3.74% ownership of the company. In it's prior filing, the firm reported owning 8,907K shares, representing an increase of 19.30%. The firm decreased its portfolio allocation in A by 84.09% over the last quarter. T. Rowe Price Investment Management holds 9,968K shares representing 3.37% ownership of the company. In it's prior filing, the firm reported owning 9,277K shares, representing an increase of 6.93%. The firm decreased its portfolio allocation in A by 11.26% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,160K shares representing 3.10% ownership of the company. In it's prior filing, the firm reported owning 8,971K shares, representing an increase of 2.07%. The firm decreased its portfolio allocation in A by 12.83% over the last quarter. Wellington Management Group Llp holds 8,736K shares representing 2.96% ownership of the company. In it's prior filing, the firm reported owning 12,057K shares, representing a decrease of 38.01%. The firm decreased its portfolio allocation in A by 91.52% over the last quarter. Price T Rowe Associates holds 8,054K shares representing 2.73% ownership of the company. In it's prior filing, the firm reported owning 8,219K shares, representing a decrease of 2.05%. The firm decreased its portfolio allocation in A by 20.72% over the last quarter. Agilent Technologies Background Information (This description is provided by the company.) Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. JPMORGAN CHASE BANK, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits. Click to Learn More This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Fintel reports that on August 16, 2023, Evercore ISI Group maintained coverage of Agilent Technologies (NYSE:A) with a In-Line recommendation. Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more.

Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,160K shares representing 3.10% ownership of the company. Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A.

The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.94%. At the current share price of $125.65 / share, the stock's dividend yield is 0.72%. Additionally, the company's dividend payout ratio is 0.23.

59.0

2023-08-16 00:00:00 UTC

Barclays Maintains Agilent Technologies (A) Underweight Recommendation

A

https://www.nasdaq.com/articles/barclays-maintains-agilent-technologies-a-underweight-recommendation

Fintel reports that on August 16, 2023, Barclays maintained coverage of Agilent Technologies (NYSE:A) with a Underweight recommendation. Analyst Price Forecast Suggests 14.32% Upside As of August 2, 2023, the average one-year price target for Agilent Technologies is 143.65. The forecasts range from a low of 116.15 to a high of $171.15. The average price target represents an increase of 14.32% from its latest reported closing price of 125.65. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.94%. The projected annual non-GAAP EPS is 5.77. Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). Shareholders of record as of July 3, 2023 received the payment on July 26, 2023. Previously, the company paid $0.22 per share. At the current share price of $125.65 / share, the stock's dividend yield is 0.72%. Looking back five years and taking a sample every week, the average dividend yield has been 0.73%, the lowest has been 0.44%, and the highest has been 1.14%. The standard deviation of yields is 0.15 (n=235). The current dividend yield is 0.10 standard deviations below the historical average. Additionally, the company's dividend payout ratio is 0.23. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5. The company's 3-Year dividend growth rate is 0.25%, demonstrating that it has increased its dividend over time. What is the Fund Sentiment? There are 1956 funds or institutions reporting positions in Agilent Technologies. This is a decrease of 54 owner(s) or 2.69% in the last quarter. Average portfolio weight of all funds dedicated to A is 0.34%, a decrease of 14.86%. Total shares owned by institutions decreased in the last three months by 0.02% to 302,000K shares. The put/call ratio of A is 0.98, indicating a bullish outlook. What are Other Shareholders Doing? Massachusetts Financial Services holds 11,037K shares representing 3.74% ownership of the company. In it's prior filing, the firm reported owning 8,907K shares, representing an increase of 19.30%. The firm decreased its portfolio allocation in A by 84.09% over the last quarter. T. Rowe Price Investment Management holds 9,968K shares representing 3.37% ownership of the company. In it's prior filing, the firm reported owning 9,277K shares, representing an increase of 6.93%. The firm decreased its portfolio allocation in A by 11.26% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,160K shares representing 3.10% ownership of the company. In it's prior filing, the firm reported owning 8,971K shares, representing an increase of 2.07%. The firm decreased its portfolio allocation in A by 12.83% over the last quarter. Wellington Management Group Llp holds 8,736K shares representing 2.96% ownership of the company. In it's prior filing, the firm reported owning 12,057K shares, representing a decrease of 38.01%. The firm decreased its portfolio allocation in A by 91.52% over the last quarter. Price T Rowe Associates holds 8,054K shares representing 2.73% ownership of the company. In it's prior filing, the firm reported owning 8,219K shares, representing a decrease of 2.05%. The firm decreased its portfolio allocation in A by 20.72% over the last quarter. Agilent Technologies Background Information (This description is provided by the company.) Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. JPMORGAN CHASE BANK, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3. Second Amended and Restated Certificate of Incorporation Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits. Click to Learn More This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3. Second Amended and Restated Certificate of Incorporation Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more.

Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,160K shares representing 3.10% ownership of the company. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3.

The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.94%. At the current share price of $125.65 / share, the stock's dividend yield is 0.72%. There are 1956 funds or institutions reporting positions in Agilent Technologies.

60.0

2023-08-16 00:00:00 UTC

Baird Maintains Agilent Technologies (A) Outperform Recommendation

A

https://www.nasdaq.com/articles/baird-maintains-agilent-technologies-a-outperform-recommendation-0

Fintel reports that on August 16, 2023, Baird maintained coverage of Agilent Technologies (NYSE:A) with a Outperform recommendation. Analyst Price Forecast Suggests 14.32% Upside As of August 2, 2023, the average one-year price target for Agilent Technologies is 143.65. The forecasts range from a low of 116.15 to a high of $171.15. The average price target represents an increase of 14.32% from its latest reported closing price of 125.65. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.94%. The projected annual non-GAAP EPS is 5.77. Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). Shareholders of record as of July 3, 2023 received the payment on July 26, 2023. Previously, the company paid $0.22 per share. At the current share price of $125.65 / share, the stock's dividend yield is 0.72%. Looking back five years and taking a sample every week, the average dividend yield has been 0.73%, the lowest has been 0.44%, and the highest has been 1.14%. The standard deviation of yields is 0.15 (n=235). The current dividend yield is 0.10 standard deviations below the historical average. Additionally, the company's dividend payout ratio is 0.23. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5. The company's 3-Year dividend growth rate is 0.25%, demonstrating that it has increased its dividend over time. What is the Fund Sentiment? There are 1956 funds or institutions reporting positions in Agilent Technologies. This is a decrease of 54 owner(s) or 2.69% in the last quarter. Average portfolio weight of all funds dedicated to A is 0.34%, a decrease of 14.86%. Total shares owned by institutions decreased in the last three months by 0.02% to 302,000K shares. The put/call ratio of A is 0.98, indicating a bullish outlook. What are Other Shareholders Doing? Massachusetts Financial Services holds 11,037K shares representing 3.74% ownership of the company. In it's prior filing, the firm reported owning 8,907K shares, representing an increase of 19.30%. The firm decreased its portfolio allocation in A by 84.09% over the last quarter. T. Rowe Price Investment Management holds 9,968K shares representing 3.37% ownership of the company. In it's prior filing, the firm reported owning 9,277K shares, representing an increase of 6.93%. The firm decreased its portfolio allocation in A by 11.26% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,160K shares representing 3.10% ownership of the company. In it's prior filing, the firm reported owning 8,971K shares, representing an increase of 2.07%. The firm decreased its portfolio allocation in A by 12.83% over the last quarter. Wellington Management Group Llp holds 8,736K shares representing 2.96% ownership of the company. In it's prior filing, the firm reported owning 12,057K shares, representing a decrease of 38.01%. The firm decreased its portfolio allocation in A by 91.52% over the last quarter. Price T Rowe Associates holds 8,054K shares representing 2.73% ownership of the company. In it's prior filing, the firm reported owning 8,219K shares, representing a decrease of 2.05%. The firm decreased its portfolio allocation in A by 20.72% over the last quarter. Agilent Technologies Background Information (This description is provided by the company.) Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. JPMORGAN CHASE BANK, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3. Second Amended and Restated Certificate of Incorporation Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits. Click to Learn More This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3. Second Amended and Restated Certificate of Incorporation Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more.

Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,160K shares representing 3.10% ownership of the company. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3.

The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.94%. At the current share price of $125.65 / share, the stock's dividend yield is 0.72%. There are 1956 funds or institutions reporting positions in Agilent Technologies.

61.0

2023-08-16 00:00:00 UTC

Stocks Slightly Higher as Markets Await Minutes of the July FOMC Meeting

A

https://www.nasdaq.com/articles/stocks-slightly-higher-as-markets-await-minutes-of-the-july-fomc-meeting

What you need to know… The S&P 500 Index ($SPX) (SPY) today is up +0.04%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.21%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.11%. Stocks this morning are slightly higher. Lower T-note yields and a decline in inflation expectations support stocks today. The 10-year U.S. breakeven inflation rate fell to a 3-1/2 week low today at 2.308%. The markets are awaiting this afternoon’s release of the minutes of the July 25-26 FOMC meeting for clues as to the future direction of Fed policy. This morning’s U.S. economic news was mixed as July housing starts and Jul manufacturing production rose more than expected, but July building permits rose less than expected. China’s economic woes continue to weigh on global markets. The yuan fell to a 9-1/4 month low today, and the Shanghai Composite closed down -0.82% after China’s July home sales fell for the second month by the most in 7 months. Also, liquidity concerns in China’s shadow banking system have intensified after Zhongrong International Trust missed payments on dozens of its investment products. JPMorgan Chase cut its China 2023 GDP forecast to 4.8% from a 6.4% estimate in May. Barclays cut its China 2023 GDP forecast to 4.5% from a prior forecast of 4.9%. Zhongrong International Trust, China's ninth-biggest trust with about 600 billion yuan in assets, missed payments on 30 investment products and halted redemptions on some short-term instruments. The firm said liquidity has dried up "unexpectedly," making it hard to meet short-term debt obligations as most of the underlying assets are long-term and illiquid. The firm has 270 high-yield products totaling 39.5 billion yuan ($5.4 billion) due this year. Weekly data from the Mortgage Bankers Association showed mortgage applications fell -0.8% w/w, the fifth straight week of declines. The U.S. 30-year mortgage rate rose to 7.16% last week, matching the highest since 2001. U.S. Jul housing starts rose +3.9% m/m to 1.452 million, stronger than expectations of 1.450 million. However, Jul building permits, a proxy for future construction, rose +0.1% m/m to 1.442 million, weaker than expectations of 1.463 million. U.S. Jul manufacturing production unexpectedly rose +0.5% m/m, stronger than expectations of no change. The markets are discounting the odds at 11% for a +25 bp rate hike at the September 20 FOMC meeting and 38% for that +25 bp rate hike at the November 1 FOMC meeting. Global bond yields are mixed. The 10-year T-note yield is down -1.0 bp to 4.201%. The 10-year German bund yield is down -2.6 bp at 2.646%. The 10-year UK gilt yield is up +4.2 bp at 4.631%. Overseas stock markets are lower. The Euro Stoxx 50 is down -0.03%. China’s Shanghai Composite Index today closed down -0.82%. Japan’s Nikkei Stock Index closed down -1.46%. Today’s stock movers… Progressive Corp (PGR) is up more than +8% to lead gainers in the S&P 500 after reporting net premiums written for July rose +21% y/y to $5.95 billion. Target (TGT) is up more than +4% after reporting Q2 Ebitda of $1.90 billion, better than the consensus of $1.58 billion. TJX Cos (TJX) is up more than +3% after reporting Q2 net sales of $12.80 billion, stronger than the consensus of $12.44 billion, and raising its full-year comparable sales estimate to +3% to +4% from a prior view of +2% to +3%, better than the consensus of +3.01%. H&R Block (HRB) is up more than +7% after reporting Q4 adjusted EPS from continuing operations of $2.05, better than the consensus of $1.88. MarketAxcess Holdings (MKTX) is up more than +3% on signs of insider buying after an SEC filing showed CEO Concannon purchased $1.02 million of shares on Monday. Coinbase Global (COIN) is up more than +2% after it won approval from the National Futures Association to operate as a Futures Commission Merchant and offer access to crypto futures. Keurig Dr Pepper (KDP) is up more than +1% after UBS upgraded the stock to buy from neutral with a price target of $42. GE Healthcare (GEHC) is up more than +1% after Wells Fargo Securities initiated coverage of the stock with a recommendation of overweight and a price target of $90. MarketAxcess Holdings (MKTX) is up more than +3% on signs of insider buying after an SEC filing showed CEO Concannon purchased $1.02 million of shares on Monday. Jack Henry & Associates (JKHY) is down more than -7% to lead losers in the S&P 500 after forecasting 2024 EPS of $4.92-$4.99, weaker than the consensus of $5.34. Trucking stocks are under pressure on signs of weakness in freight demand after data from the Cass Freight Shipment Index showed U.S. July freight volume fell -8.9% y/y, the sixth consecutive monthly decline. As a result, JB Hunt Transport Services (JBHT) is down more than -2%. Also, Knight-Swift Transportation Holdings (KNX) and Werner Enterprises (WERN) are down more than -1%. In addition, Schneider National (SNDR) and CH Robinson Worldwide (CHRW) are down more than -0.5%. Agilent Technologies (A) is down more than -3% after cutting its full-year revenue forecast to $6.80 billion-$6.85 billion from a previous forecast of $6.93 billion-$7.03 billion. Intel (INTC) is down more than -1% to lead losers in the Down Jones Industrial after it agreed to terminate its previously disclosed agreement to buy Tower Semiconductor for $5.4 billion. Coherent (COHR) is down more than -34% after forecasting 2024 revenue of $4.5 billion-$4.7 billion, weaker than the consensus of $4.88 billion. Tesla (TSLA) is down more than -1% after it cut its vehicle prices in China for the second time in three days. Across the markets… September 10-year T-notes (ZNU23) today are up +5 ticks, and the 10-year T-note yield is down -1.0 bp at 4.201%. Sep T-notes today are slightly higher on a decline in inflation expectations after the 10-year breakeven inflation rate fell to a 3-1/2 week low today at 2.308%. Gains in T-notes are limited due to today’s stronger-than-expected economic news on July housing starts and Jul manufacturing production. The dollar index (DXY00) today is down by -0.06%. The dollar today is slightly weaker, weighed down by lower T-note yields. Also, today’s stronger-than-expected report on Jun Eurozone industrial production boosted the euro against the dollar. Losses in the dollar were contained on weakness in the yuan, which dropped to a 9-1/4 month low against the dollar on Chinese economic concerns. EUR/USD (^EURUSD) today is up by +0.16%. The euro is moderately higher today on a weaker dollar. Also, today’s stronger-than-expected report on Eurozone Jun industrial production gave the euro a boost. Eurozone Jun industrial production unexpectedly rose +0.5% m/m, stronger than expectations of no change. USD/JPY (^USDJPY) is up by +0.16%. The yen today is moving lower for the eighth consecutive session and posted a new 9-month against the dollar. Central bank divergence is weighing on the yen, with the BOE, ECB, and Fed in the middle of their rate hiking cycles while the BOJ maintains QE and record-low interest rates. Lower T-note yields today are limiting losses in the yen. October gold (GCV3) today is up +1.8 (+0.09%), and Sep silver (SIU23) is up +0.064 (+0.28%). Precious metals prices this morning are slightly higher. A weaker dollar today is giving metals prices a boost. Also, T-note yields are supportive of precious metals. In addition, the deepening liquidity crisis in China has boosted safe-haven demand for precious metals after Zhongrong International Trust missed payments on dozens of its investment products. Silver prices are finding support on signs of strength in industrial metals demand after today’s news showed Eurozone Jun industrial production and U.S. Jul manufacturing production rose more than expected. Gains in silver were limited after JPMorgan Chase and Barclays cut their China 2023 GDP estimates, a bearish factor for industrial metals demand. Also, fund liquidation in gold continues after long gold holdings in ETFs fell to a 3-1/3 year low on Tuesday. More Stock Market News from Barchart How Did This EV Company's CFO Amass an Incredible $590 Million Fortune? Supersize Your McDonald’s (MCD) Holdings Before the Market Realizes the Discount on Tap Disney or Netflix: Which Streaming Stock is a Better Buy? Markets Today: Stocks Slightly Lower on Chinese Economic Woes On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

MarketAxcess Holdings (MKTX) is up more than +3% on signs of insider buying after an SEC filing showed CEO Concannon purchased $1.02 million of shares on Monday. In addition, the deepening liquidity crisis in China has boosted safe-haven demand for precious metals after Zhongrong International Trust missed payments on dozens of its investment products. Gains in silver were limited after JPMorgan Chase and Barclays cut their China 2023 GDP estimates, a bearish factor for industrial metals demand.

This morning’s U.S. economic news was mixed as July housing starts and Jul manufacturing production rose more than expected, but July building permits rose less than expected. MarketAxcess Holdings (MKTX) is up more than +3% on signs of insider buying after an SEC filing showed CEO Concannon purchased $1.02 million of shares on Monday. Gains in T-notes are limited due to today’s stronger-than-expected economic news on July housing starts and Jul manufacturing production.

Lower T-note yields and a decline in inflation expectations support stocks today. MarketAxcess Holdings (MKTX) is up more than +3% on signs of insider buying after an SEC filing showed CEO Concannon purchased $1.02 million of shares on Monday. Sep T-notes today are slightly higher on a decline in inflation expectations after the 10-year breakeven inflation rate fell to a 3-1/2 week low today at 2.308%.

However, Jul building permits, a proxy for future construction, rose +0.1% m/m to 1.442 million, weaker than expectations of 1.463 million. MarketAxcess Holdings (MKTX) is up more than +3% on signs of insider buying after an SEC filing showed CEO Concannon purchased $1.02 million of shares on Monday. The dollar today is slightly weaker, weighed down by lower T-note yields.

62.0

2023-08-16 00:00:00 UTC

JP Morgan Maintains Agilent Technologies (A) Overweight Recommendation

A

https://www.nasdaq.com/articles/jp-morgan-maintains-agilent-technologies-a-overweight-recommendation

Fintel reports that on August 16, 2023, JP Morgan maintained coverage of Agilent Technologies (NYSE:A) with a Overweight recommendation. Analyst Price Forecast Suggests 14.32% Upside As of August 2, 2023, the average one-year price target for Agilent Technologies is 143.65. The forecasts range from a low of 116.15 to a high of $171.15. The average price target represents an increase of 14.32% from its latest reported closing price of 125.65. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.94%. The projected annual non-GAAP EPS is 5.77. Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). Shareholders of record as of July 3, 2023 received the payment on July 26, 2023. Previously, the company paid $0.22 per share. At the current share price of $125.65 / share, the stock's dividend yield is 0.72%. Looking back five years and taking a sample every week, the average dividend yield has been 0.73%, the lowest has been 0.44%, and the highest has been 1.14%. The standard deviation of yields is 0.15 (n=235). The current dividend yield is 0.10 standard deviations below the historical average. Additionally, the company's dividend payout ratio is 0.23. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5. The company's 3-Year dividend growth rate is 0.25%, demonstrating that it has increased its dividend over time. What is the Fund Sentiment? There are 1956 funds or institutions reporting positions in Agilent Technologies. This is a decrease of 54 owner(s) or 2.69% in the last quarter. Average portfolio weight of all funds dedicated to A is 0.34%, a decrease of 14.86%. Total shares owned by institutions decreased in the last three months by 0.02% to 302,000K shares. The put/call ratio of A is 0.98, indicating a bullish outlook. What are Other Shareholders Doing? Massachusetts Financial Services holds 11,037K shares representing 3.74% ownership of the company. In it's prior filing, the firm reported owning 8,907K shares, representing an increase of 19.30%. The firm decreased its portfolio allocation in A by 84.09% over the last quarter. T. Rowe Price Investment Management holds 9,968K shares representing 3.37% ownership of the company. In it's prior filing, the firm reported owning 9,277K shares, representing an increase of 6.93%. The firm decreased its portfolio allocation in A by 11.26% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,160K shares representing 3.10% ownership of the company. In it's prior filing, the firm reported owning 8,971K shares, representing an increase of 2.07%. The firm decreased its portfolio allocation in A by 12.83% over the last quarter. Wellington Management Group Llp holds 8,736K shares representing 2.96% ownership of the company. In it's prior filing, the firm reported owning 12,057K shares, representing a decrease of 38.01%. The firm decreased its portfolio allocation in A by 91.52% over the last quarter. Price T Rowe Associates holds 8,054K shares representing 2.73% ownership of the company. In it's prior filing, the firm reported owning 8,219K shares, representing a decrease of 2.05%. The firm decreased its portfolio allocation in A by 20.72% over the last quarter. Agilent Technologies Background Information (This description is provided by the company.) Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. JPMORGAN CHASE BANK, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3. Second Amended and Restated Certificate of Incorporation Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits. Click to Learn More This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3. Second Amended and Restated Certificate of Incorporation Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Additional reading: Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3; adjusts full-year outlook to reflect softer market conditions CREDIT AGREEMENT dated as of June 7, 2023 AGILENT TECHNOLOGIES, INC., The LENDERS Party Hereto, BNP PARIBAS, as Administrative Agent, CITIBANK, N.A., BANK OF AMERICA, N.A. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more.

Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 9,160K shares representing 3.10% ownership of the company. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndicati Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results; adjusts full-year guidance in an increasingly challenging market Amended and Restated Bylaws of Agilent Technologies, Inc., incorporated by reference to Exhibit 3.

The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.94%. At the current share price of $125.65 / share, the stock's dividend yield is 0.72%. There are 1956 funds or institutions reporting positions in Agilent Technologies.

63.0

2023-08-15 00:00:00 UTC

Agilent Technologies Q3 23 Earnings Conference Call At 4:30 PM ET

A

https://www.nasdaq.com/articles/agilent-technologies-q3-23-earnings-conference-call-at-4%3A30-pm-et

(RTTNews) - Agilent Technologies (A) will host a conference call at 4:30 PM ET on August 15, 2023, to discuss Q3 23 earnings results. To access the live webcast, log on to https://www.investor.agilent.com/news-and-events/events/default.aspx The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

(RTTNews) - Agilent Technologies (A) will host a conference call at 4:30 PM ET on August 15, 2023, to discuss Q3 23 earnings results. To access the live webcast, log on to https://www.investor.agilent.com/news-and-events/events/default.aspx The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

(RTTNews) - Agilent Technologies (A) will host a conference call at 4:30 PM ET on August 15, 2023, to discuss Q3 23 earnings results. To access the live webcast, log on to https://www.investor.agilent.com/news-and-events/events/default.aspx The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

(RTTNews) - Agilent Technologies (A) will host a conference call at 4:30 PM ET on August 15, 2023, to discuss Q3 23 earnings results. To access the live webcast, log on to https://www.investor.agilent.com/news-and-events/events/default.aspx The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

(RTTNews) - Agilent Technologies (A) will host a conference call at 4:30 PM ET on August 15, 2023, to discuss Q3 23 earnings results. To access the live webcast, log on to https://www.investor.agilent.com/news-and-events/events/default.aspx The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

64.0

2023-08-15 00:00:00 UTC

Markets Remain Sold; H&R Block (HRB), Agilent (A) Beat

A

https://www.nasdaq.com/articles/markets-remain-sold-hr-block-hrb-agilent-a-beat

Market indices could not overcome early morning selloffs following stronger-than-expected prints on both July Retail Sales and Import Prices. After the opening bell, we saw Business Inventories flat month over month and North American Home Builders Confidence drop back down to 50, below the 57 expected and the 56 posted a month ago. Lower housing supply, higher mortgage rates and construction costs, and a depleted construction labor market added to a softening of this confidence survey. In all, the Dow slid -360 points, -1.02%, while the Nasdaq was down -157 points, -1.14%. The S&P 500 was in-line, -1.16% for the session, while the small-cap Russell 2000 fell the furthest of the major indices, -1.29%. For the S&P, the index has slipped beneath its 50-day moving average for the first time in roughly five months. Both the S&P and the Nasdaq currently see their five-month winning streaks in jeopardy halfway through August. H&R Block HRB beat earnings estimates for its fiscal Q4 this afternoon, reporting earnings of $2.05 per share on $1.03 billion which outpaced expectations of $1.89 per share and $1.01 billion, respectively. Full-year revenue guidance was posted at $3.47 billion, ahead of the $3.45 billion in the Zacks consensus. Shares of the well-known tax preparation service firm have gained +5.7% on the news. After its stock fell to year-to-date lows around Memorial Day, its now back above breakeven year to date. Agilent Technologies A also released better-than-expected results for its fiscal Q3 after today’s close, with earnings of $1.43 per share stepping beyond the $1.37 analysts were expecting (and better than the $1.34 per share reported in the year-ago quarter), and revenues of $1.67 billion squeaking past the $1.66 billion in the Zacks consensus. However, full-year guidance for both earnings and sales came in lower than current estimates in this afternoon’s report, which is likely why shares are trading down -2.1% in late trading. Agilent is down year-to-date by now more than -16%. Tomorrow we get another fairly eventful day, with Housing Starts and Building Permits, as well as Industrial Production and Capacity Utilization, all for the month of July coming out before the opening bell. Wednesday afternoon, we’ll get the minutes from the latest Federal Open Market Committee (FOMC) meeting, where interest rates were ratcheted up another 25 basis points after pausing during the FOMC’s June meeting. In the morning, we’ll see Q2 results from Target TGT and after the close Cisco Systems CSCO, both of which are expected to put up big earnings gains from the year-ago quarter. Questions or comments about this article and/or author? Click here>> Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Target Corporation (TGT) : Free Stock Analysis Report Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report H&R Block, Inc. (HRB) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tomorrow we get another fairly eventful day, with Housing Starts and Building Permits, as well as Industrial Production and Capacity Utilization, all for the month of July coming out before the opening bell. In the morning, we’ll see Q2 results from Target TGT and after the close Cisco Systems CSCO, both of which are expected to put up big earnings gains from the year-ago quarter. It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood.

H&R Block HRB beat earnings estimates for its fiscal Q4 this afternoon, reporting earnings of $2.05 per share on $1.03 billion which outpaced expectations of $1.89 per share and $1.01 billion, respectively. In the morning, we’ll see Q2 results from Target TGT and after the close Cisco Systems CSCO, both of which are expected to put up big earnings gains from the year-ago quarter. Click to get this free report Target Corporation (TGT) : Free Stock Analysis Report Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report H&R Block, Inc. (HRB) : Free Stock Analysis Report To read this article on Zacks.com click here.

H&R Block HRB beat earnings estimates for its fiscal Q4 this afternoon, reporting earnings of $2.05 per share on $1.03 billion which outpaced expectations of $1.89 per share and $1.01 billion, respectively. Agilent Technologies A also released better-than-expected results for its fiscal Q3 after today’s close, with earnings of $1.43 per share stepping beyond the $1.37 analysts were expecting (and better than the $1.34 per share reported in the year-ago quarter), and revenues of $1.67 billion squeaking past the $1.66 billion in the Zacks consensus. Click to get this free report Target Corporation (TGT) : Free Stock Analysis Report Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report H&R Block, Inc. (HRB) : Free Stock Analysis Report To read this article on Zacks.com click here.

H&R Block HRB beat earnings estimates for its fiscal Q4 this afternoon, reporting earnings of $2.05 per share on $1.03 billion which outpaced expectations of $1.89 per share and $1.01 billion, respectively. After its stock fell to year-to-date lows around Memorial Day, its now back above breakeven year to date. Agilent Technologies A also released better-than-expected results for its fiscal Q3 after today’s close, with earnings of $1.43 per share stepping beyond the $1.37 analysts were expecting (and better than the $1.34 per share reported in the year-ago quarter), and revenues of $1.67 billion squeaking past the $1.66 billion in the Zacks consensus.

65.0

2023-08-15 00:00:00 UTC

Agilent (A) Reports Q3 Earnings: What Key Metrics Have to Say

A

https://www.nasdaq.com/articles/agilent-a-reports-q3-earnings%3A-what-key-metrics-have-to-say

For the quarter ended July 2023, Agilent Technologies (A) reported revenue of $1.67 billion, down 2.7% over the same period last year. EPS came in at $1.43, compared to $1.34 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $1.66 billion, representing a surprise of +0.92%. The company delivered an EPS surprise of +4.38%, with the consensus EPS estimate being $1.37. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Revenue- Americas: $667 million versus the two-analyst average estimate of $628.95 million. The reported number represents a year-over-year change of -0.6%. Net Revenue- Asia Pacific: $573 million compared to the $630.99 million average estimate based on two analysts. The reported number represents a change of -10.5% year over year. Net Revenue- Europe: $432 million versus $395.70 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.1% change. Net Revenue- Life Sciences and Applied Markets Group: $927 million versus $929.24 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -9% change. Net Revenue- Agilent Crosslab Group: $396 million versus the four-analyst average estimate of $377.29 million. The reported number represents a year-over-year change of +10.3%. Net Revenue- Diagnostics and Genomics Group: $349 million versus $350.15 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +2.7% change. Revenue by End Markets- Food: $151 million versus the two-analyst average estimate of $148.74 million. Revenue by End Markets- Environmental and Forensics: $164 million versus the two-analyst average estimate of $160.83 million. Revenue by End Markets- Chemical and Energy: $378 million versus the two-analyst average estimate of $375.11 million. Revenue by End Markets- Academia and Government: $146 million compared to the $139.40 million average estimate based on two analysts. Revenue by End Markets- Pharmaceutical and Biopharmaceutical: $592 million versus the two-analyst average estimate of $593.87 million. Revenue by End Markets- Diagnostics and Clinical: $241 million versus $241.46 million estimated by two analysts on average. View all Key Company Metrics for Agilent here>>> Shares of Agilent have returned +7.1% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Revenue- Americas: $667 million versus the two-analyst average estimate of $628.95 million. Net Revenue- Diagnostics and Genomics Group: $349 million versus $350.15 million estimated by four analysts on average. Revenue by End Markets- Diagnostics and Clinical: $241 million versus $241.46 million estimated by two analysts on average.

Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Revenue- Americas: $667 million versus the two-analyst average estimate of $628.95 million. Revenue by End Markets- Academia and Government: $146 million compared to the $139.40 million average estimate based on two analysts. Revenue by End Markets- Diagnostics and Clinical: $241 million versus $241.46 million estimated by two analysts on average.

The reported revenue compares to the Zacks Consensus Estimate of $1.66 billion, representing a surprise of +0.92%. Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Revenue- Americas: $667 million versus the two-analyst average estimate of $628.95 million. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come.

66.0

2023-08-15 00:00:00 UTC

Agilent Technologies cuts annual forecasts on China weakness

A

https://www.nasdaq.com/articles/agilent-technologies-cuts-annual-forecasts-on-china-weakness

By Pratik Jain Aug 15 (Reuters) - Medical equipment maker Agilent Technologies A.N cut annual profit and sales forecasts for a second straight quarter as demand stays soft in major market China due to a slow economic recovery. Agilent expects full-year revenue to be between $6.80 billion and $6.85 billion, compared with $6.93 billion to $7.03 billion projected earlier. It expects annual adjusted profit per share between $5.40 and $5.43, compared with its prior forecast of $5.60 to $5.65. "In July, we saw a further (sales) deterioration in China, resulting in the 17% decline for the quarter," CFO Robert McMahon said in a post-earnings call. "While the Q3 decline in China was centered in pharma, which was down 30%, we did see weakness in other end markets as well. We expect the conditions we've seen in July to persist in China for Q4." For the third quarter ended July 31, the company's total sales fell 2.7% to $1.67 billion. Sales from its third-largest segment that offers genetic sequencing, contract manufacturing, research and development, among others, were $349 million, missing a Refinitiv estimate of $355.67 million. The sales miss was due to softness in genomics and the shutdown of its Resolution Bioscience business, which offered next-generation sequencing-based cancer diagnostics solutions. The company said on Tuesday it has taken a $291 million pre-tax charge in the quarter associated with the shutdown and expects the wind-down to continue through the fourth quarter and into early fiscal 2024. Agilent CEO Mike McMullen flagged performance of its largest unit that provides laboratory instruments, consumables and software continues to be affected by the market environment in China. "Our sales funnel remains healthy and are up year-on-year, but deal velocity continues to slow as customers remain cautious in making capital purchases," McMullen added. Its quarterly adjusted profit per share was $1.43, above expectations of $1.36. (Reporting by Pratik Jain in Bengaluru; Editing by Shilpi Majumdar) ((Pratik.Jain@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

By Pratik Jain Aug 15 (Reuters) - Medical equipment maker Agilent Technologies A.N cut annual profit and sales forecasts for a second straight quarter as demand stays soft in major market China due to a slow economic recovery. The sales miss was due to softness in genomics and the shutdown of its Resolution Bioscience business, which offered next-generation sequencing-based cancer diagnostics solutions. Agilent CEO Mike McMullen flagged performance of its largest unit that provides laboratory instruments, consumables and software continues to be affected by the market environment in China.

By Pratik Jain Aug 15 (Reuters) - Medical equipment maker Agilent Technologies A.N cut annual profit and sales forecasts for a second straight quarter as demand stays soft in major market China due to a slow economic recovery. It expects annual adjusted profit per share between $5.40 and $5.43, compared with its prior forecast of $5.60 to $5.65. For the third quarter ended July 31, the company's total sales fell 2.7% to $1.67 billion.

By Pratik Jain Aug 15 (Reuters) - Medical equipment maker Agilent Technologies A.N cut annual profit and sales forecasts for a second straight quarter as demand stays soft in major market China due to a slow economic recovery. Agilent expects full-year revenue to be between $6.80 billion and $6.85 billion, compared with $6.93 billion to $7.03 billion projected earlier. The company said on Tuesday it has taken a $291 million pre-tax charge in the quarter associated with the shutdown and expects the wind-down to continue through the fourth quarter and into early fiscal 2024.

It expects annual adjusted profit per share between $5.40 and $5.43, compared with its prior forecast of $5.60 to $5.65. "In July, we saw a further (sales) deterioration in China, resulting in the 17% decline for the quarter," CFO Robert McMahon said in a post-earnings call. For the third quarter ended July 31, the company's total sales fell 2.7% to $1.67 billion.

67.0

2023-08-15 00:00:00 UTC

After-Hours Earnings Report for August 15, 2023 : ALC, A, NU, JKHY, HRB, DLO, MRCY, LRN, DADA, KTCC, GBNH

A

https://www.nasdaq.com/articles/after-hours-earnings-report-for-august-15-2023-%3A-alc-a-nu-jkhy-hrb-dlo-mrcy-lrn-dada-ktcc

The following companies are expected to report earnings after hours on 08/15/2023. Visit our Earnings Calendar for a full list of expected earnings releases. Alcon Inc. (ALC)is reporting for the quarter ending June 30, 2023. The medical instruments company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.62. This value represents a 1.59% decrease compared to the same quarter last year. In the past year ALC has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ALC is 30.88 vs. an industry ratio of -60.00, implying that they will have a higher earnings growth than their competitors in the same industry. Agilent Technologies, Inc. (A)is reporting for the quarter ending July 31, 2023. The electrical test equipment company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.37. This value represents a 2.24% increase compared to the same quarter last year. In the past year A has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2023 Price to Earnings ratio for A is 22.58 vs. an industry ratio of 37.90. Nu Holdings Ltd. (NU)is reporting for the quarter ending June 30, 2023. The technology services company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.04. This value represents a 500.00% increase compared to the same quarter last year. In the past year NU has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2023 Price to Earnings ratio for NU is 46.71 vs. an industry ratio of -3.60, implying that they will have a higher earnings growth than their competitors in the same industry. Jack Henry & Associates, Inc. (JKHY)is reporting for the quarter ending June 30, 2023. The electrical company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.19. This value represents a 8.18% increase compared to the same quarter last year. JKHY missed the consensus earnings per share in the 4th calendar quarter of 2022 by -0.9%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for JKHY is 35.38 vs. an industry ratio of 17.90, implying that they will have a higher earnings growth than their competitors in the same industry. H&R Block, Inc. (HRB)is reporting for the quarter ending June 30, 2023. The business services company's consensus earnings per share forecast from the 3 analysts that follow the stock is $1.89. This value represents a 32.17% increase compared to the same quarter last year. HRB missed the consensus earnings per share in the 1st calendar quarter of 2023 by -6.87%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for HRB is 9.45 vs. an industry ratio of 13.60. DLocal Limited (DLO)is reporting for the quarter ending June 30, 2023. The financial transactions company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.13. This value represents a 30.00% increase compared to the same quarter last year. The "days to cover" for this stock exceeds 11 days. Zacks Investment Research reports that the 2023 Price to Earnings ratio for DLO is 23.98 vs. an industry ratio of 17.40, implying that they will have a higher earnings growth than their competitors in the same industry. Mercury Systems Inc (MRCY)is reporting for the quarter ending June 30, 2023. The computer paraphernalia company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.34. This value represents a 47.69% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for MRCY is 49.35 vs. an industry ratio of -0.10, implying that they will have a higher earnings growth than their competitors in the same industry. Stride, Inc. (LRN)is reporting for the quarter ending June 30, 2023. The education (school) company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.86. This value represents a 30.30% increase compared to the same quarter last year. LRN missed the consensus earnings per share in the 3rd calendar quarter of 2022 by -200%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for LRN is 13.79 vs. an industry ratio of 14.70. Dada Nexus Limited (DADA)is reporting for the quarter ending June 30, 2023. The technology services company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.08. This value represents a 78.95% increase compared to the same quarter last year. DADA missed the consensus earnings per share in the 2nd calendar quarter of 2022 by -40.74%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for DADA is -133.25 vs. an industry ratio of -3.60. Key Tronic Corporation (KTCC)is reporting for the quarter ending June 30, 2023. The electrical instrument company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.15. This value represents a 66.67% increase compared to the same quarter last year. The last two quarters KTCC had negative earnings surprises; the latest report they missed by -10%. Zacks Investment Research reports that the Price to Earnings ratio for KTCC is 0.00 vs. an industry ratio of -4.10, implying that they will have a higher earnings growth than their competitors in the same industry. Greenbrook TMS Inc. (GBNH)is reporting for the quarter ending June 30, 2023. The medical (outpatient/home care) company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.29. This value represents a 29.27% increase compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for GBNH is -0.31 vs. an industry ratio of 15.00. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The medical instruments company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.62. The electrical test equipment company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.37. The electrical instrument company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.15.

Zacks Investment Research reports that the 2023 Price to Earnings ratio for ALC is 30.88 vs. an industry ratio of -60.00, implying that they will have a higher earnings growth than their competitors in the same industry. Zacks Investment Research reports that the 2023 Price to Earnings ratio for NU is 46.71 vs. an industry ratio of -3.60, implying that they will have a higher earnings growth than their competitors in the same industry. Zacks Investment Research reports that the 2023 Price to Earnings ratio for JKHY is 35.38 vs. an industry ratio of 17.90, implying that they will have a higher earnings growth than their competitors in the same industry.

Zacks Investment Research reports that the 2023 Price to Earnings ratio for ALC is 30.88 vs. an industry ratio of -60.00, implying that they will have a higher earnings growth than their competitors in the same industry. Zacks Investment Research reports that the 2023 Price to Earnings ratio for NU is 46.71 vs. an industry ratio of -3.60, implying that they will have a higher earnings growth than their competitors in the same industry. Zacks Investment Research reports that the 2023 Price to Earnings ratio for JKHY is 35.38 vs. an industry ratio of 17.90, implying that they will have a higher earnings growth than their competitors in the same industry.

JKHY missed the consensus earnings per share in the 4th calendar quarter of 2022 by -0.9%. HRB missed the consensus earnings per share in the 1st calendar quarter of 2023 by -6.87%. DADA missed the consensus earnings per share in the 2nd calendar quarter of 2022 by -40.74%.

68.0

2023-08-15 00:00:00 UTC

Stock Index Futures Plunge on Pressure from Rising Bond Yields, China Data Disappoints

A

https://www.nasdaq.com/articles/stock-index-futures-plunge-on-pressure-from-rising-bond-yields-china-data-disappoints

September S&P 500 futures (ESU23) are down -0.61%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.48% this morning as market participants digested the latest U.K. employment data, which fueled concerns about inflationary pressures and consequently pushed U.S. Treasury yields higher, while disappointing economic data from China also weighed on sentiment ahead of crucial U.S. retail sales data. In Monday’s trading session, Wall Street’s major averages closed higher. NVIDIA Corporation (NVDA) climbed over +7% and was the top percentage gainer on the tech-heavy Nasdaq 100 after Morgan Stanley said the recent decline in the stock is a “good entry point” ahead of its Q2 results next week. Also, United States Steel Corporation (X) surged more than +36% after the company rejected a $7.25 billion cash and stock takeover offer from Cleveland-Cliffs and said it would initiate a formal review of its strategic options. In addition, Monday.Com Ltd (MNDY) rose over +8% after reporting upbeat Q2 results and raising its full-year revenue guidance. On the bearish side, Tesla Inc (TSLA) dropped more than -1% after the automaker said it had cut prices in China for Model Y Long Range and Performance versions. Regional bank stocks also retreated, with KeyCorp (KEY) plunging over -4% and Comerica Inc (CMA) falling more than -3%. “It’s the first day in a while that tech has really significantly outperformed. I think that’s indicative of the fact that you have this blockbuster Nvidia report coming up, and that could support the tech market pretty substantially,” said Jay Hatfield, CEO of Infrastructure Capital Advisors. Meanwhile, U.S. rate futures have priced in an 88.5% probability of no hike and an 11.5% chance of a 25 basis point rate increase at September’s monetary policy meeting. On the earnings front, major companies like Home Depot (HD), Suncor Energy (SU), Alcon (ALC), and Agilent Technologies (A) are slated to release their quarterly results today. Today, all eyes are focused on U.S. Retail Sales data in a couple of hours. Economists, on average, forecast that July Retail Sales will stand at +0.4% m/m, compared to the previous value of +0.2% m/m. Also, investors will likely focus on U.S. Core Retail Sales data, which came in at +0.2% m/m in June. Economists foresee the new figure to be -0.3% m/m. U.S. Export and Import Price Indexes for July will also be in focus today. Economists anticipate Export Price Index to be at +0.2% m/m and Import Price Index to stand at +0.2% m/m. U.S. NY Empire State Manufacturing Index will be reported today as well. Economists foresee this figure to stand at -1.00 in August, compared to the previous number of +1.10. In the bond markets, United States 10-Year rates are at 4.228%, up +1.02%. The Euro Stoxx 50 futures are down -0.78% this morning as apprehensions about inflation have led to speculation that interest rates will remain elevated for an extended period. Bond yields surged across Europe, with U.K. gilts experiencing a notable spike after a record-high wage growth spurred worries about inflationary pressures. Real estate and insurance stocks underperformed on Tuesday, while retail stocks gained ground. In corporate news, Marks and Spencer Group Plc (MKS.LN) soared over +6% after the retailer lifted its profit forecast. U.K.’s Average Earnings Index +Bonus, U.K.’s Claimant Count Change, U.K.’s Employment Change 3M/3M, U.K.’s Unemployment Rate, Germany’s ZEW Economic Sentiment, and Eurozone’s ZEW Economic Sentiment data were released today. U.K. June Average Earnings Index +Bonus has been reported at 8.2%, stronger than expectations of 7.3%. U.K. July Claimant Count Change stood at +29.0K, weaker than expectations of -7.3K. U.K. June Employment Change 3M/3M came in at -66K, weaker than expectations of +75K. U.K. June Unemployment Rate was at 4.2%, weaker than expectations of 4.0%. The German August ZEW Economic Sentiment stood at -12.3, stronger than expectations of -14.7. Eurozone August ZEW Economic Sentiment arrived at -5.5, stronger than expectations of -12.0. Asian stock markets today closed mixed. China’s Shanghai Composite Index (SHCOMP) closed down -0.07%, and Japan’s Nikkei 225 Stock Index (NIK) closed up +0.56%. China’s Shanghai Composite today closed lower even after the central bank unexpectedly cut a key interest rate to bolster growth, following the latest data indicating a further slowdown in the country’s economic activity. Data released by the National Bureau of Statistics showed on Tuesday that China’s industrial production and retail sales growth decelerated and fell short of expectations in July. The People’s Bank of China lowered the rate on 401 billion yuan worth of one-year medium-term lending facility loans to some financial institutions by 15 basis points to 2.50%. Also, the central bank conducted a 204 billion yuan injection through seven-day reverse repos while cutting borrowing costs by 10 basis points to 1.80%. Meanwhile, the yuan declined to the weakest level since November, and China’s government bonds experienced a rally following the central bank’s decision to lower interest rates. “The weak dataset continues to paint a bearish picture of China after the Politburo meeting. Most investors are in wait-and-see mode, only willing to allocate tactically to China on expectations of stimulus,” said UBS analysts in a note. The Chinese July Industrial Production stood at +3.7% y/y, weaker than expectations of +4.4% y/y. The Chinese July Retail Sales came in at +2.5% y/y, weaker than expectations of +4.5% y/y. The Chinese July Fixed Asset Investment arrived at +3.4% y/y, weaker than expectations of +3.8% y/y. The Chinese July Unemployment Rate was at 5.3%, in line with expectations. At the same time, Japan’s Nikkei 225 Stock Index closed higher today, tracking Wall Street’s firm overnight finish, and market sentiment was additionally lifted by stronger-than-expected economic growth data. According to government data released on Tuesday, Japan’s economy expanded for a third consecutive quarter in April-June, as robust exports countered the impact of a decelerating post-COVID recovery in consumption. In corporate news, Japan Post Holdings climbed over +4% after the conglomerate of banks and insurance businesses revealed plans to repurchase up to 8.4% of its own shares, totaling 300 billion yen. At the same time, Dentsu Group plunged more than -7% after the advertising firm slashed its full-year net profit guidance. The Nikkei Volatility, which takes into account the implied volatility of Nikkei 225 options, closed down -4.31% to 18.85. The Japanese GDP has been reported at +1.5% q/q and +6.0% y/y in the second quarter, stronger than expectations of +0.8% q/q and +3.1% y/y. The Japanese June Industrial Production came in at +2.4% m/m, stronger than expectations of +2.0% m/m. Pre-Market U.S. Stock Movers DR Horton Inc (DHI) and Lennar Corporation (LEN) climbed about +2% in pre-market trading after Warren Buffett’s Berkshire Hathaway revealed new positions in the stocks. LL Flooring Holdings Inc (LL) surged over +12% in pre-market trading after the company announced that it had planned to explore strategic alternatives, including a potential sale of the company. Arena Group Holdings Inc (AREN) soared about +18% in pre-market trading after the company signed a binding letter of intent with Simplify Inventions, LLC and its founder, Manoj Bhargava, to acquire certain assets of its subsidiary Bridge Media Networks. Getty Images Holdings Inc (GETY) tumbled more than -18% in pre-market trading after the company reported downbeat Q2 results and cut its FY23 revenue guidance. Delcath Systems Inc (DCTH) spiked about +66% in pre-market trading after announcing that the U.S. Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma. Caredx Inc (CDNA) rose over +5% in pre-market trading after Raymond James upgraded the stock to Outperform from Market Perform. You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Tuesday - August 15th Home Depot (HD), Suncor Energy (SU), Alcon (ALC), Agilent Technologies (A), Nu Holdings (NU), Sea (SE), Cardinal Health (CAH), Legend Bio (LEGN), Jack Henry&Associates (JKHY), Tencent Music Entertainment Group (TME), Coherent (COHR), CAVA Group (CAVA), H&R Block (HRB), Dlocal (DLO), IHS Holding (IHS), Mercury (MRCY), Stride (LRN), Dada Nexus (DADA), Riskified (RSKD), HUYA (HUYA), Eagle Point Cred (ECC), Mondee Holdings (MOND), International General Insurance (IGIC), GigaCloud Technology (GCT), Terran Orbital (LLAP), Rekor Systems (REKR). More Stock Market News from Barchart Strength in Chip Stocks Lifts the Overall MarketGeneral Mills vs. Kraft Heinz: Which is the Better Consumer Defensive Stock?Should You Buy the Dip in Apple Stock?Why Is Warren Buffett Selling U.S. Stocks? The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

China’s Shanghai Composite today closed lower even after the central bank unexpectedly cut a key interest rate to bolster growth, following the latest data indicating a further slowdown in the country’s economic activity. At the same time, Japan’s Nikkei 225 Stock Index closed higher today, tracking Wall Street’s firm overnight finish, and market sentiment was additionally lifted by stronger-than-expected economic growth data. Arena Group Holdings Inc (AREN) soared about +18% in pre-market trading after the company signed a binding letter of intent with Simplify Inventions, LLC and its founder, Manoj Bhargava, to acquire certain assets of its subsidiary Bridge Media Networks.

U.K.’s Average Earnings Index +Bonus, U.K.’s Claimant Count Change, U.K.’s Employment Change 3M/3M, U.K.’s Unemployment Rate, Germany’s ZEW Economic Sentiment, and Eurozone’s ZEW Economic Sentiment data were released today. At the same time, Japan’s Nikkei 225 Stock Index closed higher today, tracking Wall Street’s firm overnight finish, and market sentiment was additionally lifted by stronger-than-expected economic growth data. You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Tuesday - August 15th Home Depot (HD), Suncor Energy (SU), Alcon (ALC), Agilent Technologies (A), Nu Holdings (NU), Sea (SE), Cardinal Health (CAH), Legend Bio (LEGN), Jack Henry&Associates (JKHY), Tencent Music Entertainment Group (TME), Coherent (COHR), CAVA Group (CAVA), H&R Block (HRB), Dlocal (DLO), IHS Holding (IHS), Mercury (MRCY), Stride (LRN), Dada Nexus (DADA), Riskified (RSKD), HUYA (HUYA), Eagle Point Cred (ECC), Mondee Holdings (MOND), International General Insurance (IGIC), GigaCloud Technology (GCT), Terran Orbital (LLAP), Rekor Systems (REKR).

September S&P 500 futures (ESU23) are down -0.61%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.48% this morning as market participants digested the latest U.K. employment data, which fueled concerns about inflationary pressures and consequently pushed U.S. Treasury yields higher, while disappointing economic data from China also weighed on sentiment ahead of crucial U.S. retail sales data. You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Tuesday - August 15th Home Depot (HD), Suncor Energy (SU), Alcon (ALC), Agilent Technologies (A), Nu Holdings (NU), Sea (SE), Cardinal Health (CAH), Legend Bio (LEGN), Jack Henry&Associates (JKHY), Tencent Music Entertainment Group (TME), Coherent (COHR), CAVA Group (CAVA), H&R Block (HRB), Dlocal (DLO), IHS Holding (IHS), Mercury (MRCY), Stride (LRN), Dada Nexus (DADA), Riskified (RSKD), HUYA (HUYA), Eagle Point Cred (ECC), Mondee Holdings (MOND), International General Insurance (IGIC), GigaCloud Technology (GCT), Terran Orbital (LLAP), Rekor Systems (REKR). More Stock Market News from Barchart Strength in Chip Stocks Lifts the Overall MarketGeneral Mills vs. Kraft Heinz: Which is the Better Consumer Defensive Stock?Should You Buy the Dip in Apple Stock?Why Is Warren Buffett Selling U.S. Stocks?

U.K. June Average Earnings Index +Bonus has been reported at 8.2%, stronger than expectations of 7.3%. China’s Shanghai Composite today closed lower even after the central bank unexpectedly cut a key interest rate to bolster growth, following the latest data indicating a further slowdown in the country’s economic activity. At the same time, Japan’s Nikkei 225 Stock Index closed higher today, tracking Wall Street’s firm overnight finish, and market sentiment was additionally lifted by stronger-than-expected economic growth data.

69.0

2023-08-15 00:00:00 UTC

Agilent Technologies Q3 Profit Decreases, but beats estimates

A

https://www.nasdaq.com/articles/agilent-technologies-q3-profit-decreases-but-beats-estimates

(RTTNews) - Agilent Technologies (A) revealed a profit for third quarter that decreased from last year but beat the Street estimates. The company's earnings came in at $111 million, or $0.38 per share. This compares with $329 million, or $1.10 per share, in last year's third quarter. Excluding items, Agilent Technologies reported adjusted earnings of $422 million or $1.43 per share for the period. Analysts on average had expected the company to earn $1.36 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items. The company's revenue for the quarter fell 2.9% to $1.67 billion from $1.72 billion last year. Agilent Technologies earnings at a glance (GAAP) : -Earnings (Q3): $111 Mln. vs. $329 Mln. last year. -EPS (Q3): $0.38 vs. $1.10 last year. -Analyst Estimates: $1.36 -Revenue (Q3): $1.67 Bln vs. $1.72 Bln last year. -Guidance: Full year EPS guidance: $5.40 - $5.43 Full year revenue guidance: $6.80 - $6.85 Bln The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

(RTTNews) - Agilent Technologies (A) revealed a profit for third quarter that decreased from last year but beat the Street estimates. Excluding items, Agilent Technologies reported adjusted earnings of $422 million or $1.43 per share for the period. Analysts on average had expected the company to earn $1.36 per share, according to figures compiled by Thomson Reuters.

Excluding items, Agilent Technologies reported adjusted earnings of $422 million or $1.43 per share for the period. -Analyst Estimates: $1.36 -Revenue (Q3): $1.67 Bln vs. $1.72 Bln last year. -Guidance: Full year EPS guidance: $5.40 - $5.43 Full year revenue guidance: $6.80 - $6.85 Bln The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

(RTTNews) - Agilent Technologies (A) revealed a profit for third quarter that decreased from last year but beat the Street estimates. Excluding items, Agilent Technologies reported adjusted earnings of $422 million or $1.43 per share for the period. -Guidance: Full year EPS guidance: $5.40 - $5.43 Full year revenue guidance: $6.80 - $6.85 Bln The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The company's earnings came in at $111 million, or $0.38 per share. This compares with $329 million, or $1.10 per share, in last year's third quarter. Agilent Technologies earnings at a glance (GAAP) : -Earnings (Q3): $111 Mln.

70.0

2023-08-14 00:00:00 UTC

Validea Detailed Fundamental Analysis - A

A

https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-a-1

Below is Validea's guru fundamental report for AGILENT TECHNOLOGIES INC (A). Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. AGILENT TECHNOLOGIES INC (A) is a large-cap growth stock in the Scientific & Technical Instr. industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: FAIL CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.

Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends.

Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends.

Below is Validea's guru fundamental report for AGILENT TECHNOLOGIES INC (A). Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing.

71.0

2023-08-14 00:00:00 UTC

Stocks Set to Open Lower as Investors Await FOMC Minutes, Retail Earnings

A

https://www.nasdaq.com/articles/stocks-set-to-open-lower-as-investors-await-fomc-minutes-retail-earnings

September S&P 500 futures (ESU23) are down -0.09%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.05% this morning as market participants looked ahead to the release of the minutes of the Federal Reserve’s latest policy meeting as well as quarterly earnings reports from high-profile retailers. In Friday’s trading session, Wall Street’s major averages closed mixed, with the benchmark S&P 500 and tech-heavy Nasdaq 100 dropping to 1-month lows. Wynn Resorts Limited (WYNN) slid over -3% after the company announced the closure of its sports betting app in eight states. Chip stocks also slumped, with Lam Research Corp (LRCX) falling about -5% and NVIDIA Corporation (NVDA) dropping more than -3%. In addition, U.S.-listed Chinese technology stocks plunged on concerns surrounding the state of China’s economy. As a result, JD.com Inc (JD) closed down over -5%, and Baidu Inc (BIDU) closed down more than -4%. On the bullish side, News Corp (NWSA) climbed over +4% and was the top percentage gainer on the S&P 500 after the Rupert Murdoch-owned media conglomerate topped quarterly profit estimates. Data on Friday showed the U.S. July producer price index stood at +0.8% y/y compared to +0.2% y/y in June, stronger than expectations of +0.7% y/y. Also, U.S. Core PPI arrived at +2.4% y/y in July, stronger than expectations of +2.3% y/y. In addition, the University of Michigan’s consumer sentiment reading came in at 71.2 in August, stronger than expectations of 71.0, while year-ahead inflation expectations unexpectedly eased to +3.3%. “We think there’s some reassessment of inflation going on with investors looking further under the hood. Disinflation has been very rapid in the past months at the top level, but that may be leveling out here a little,” said Paul Christopher, head ofglobal marketstrategy at Wells Fargo Investment Institut. Second-quarter earnings season winds down, with investors anticipating fresh reports from major global companies this week, including Home Depot (HD), Agilent Technologies (A), Cisco (CSCO), TJX (TJX), Target (TGT), Walmart (WMT), Applied Materials (AMAT), Ross Stores (ROST), Deere&Company (DE), Palo Alto Networks (PANW), and Estee Lauder (EL). In the coming week, investors will be monitoring a spate of economic data, including U.S. Retail Sales, Core Retail Sales, Export Price Index, Import Price Index, NY Empire State Manufacturing Index, Building Permits (preliminary), Housing Starts, Industrial Production, Manufacturing Production, Crude Oil Inventories, Philadelphia Fed Manufacturing Index, and Initial Jobless Claims. In addition, investors will be closely watching the release of the Federal Reserve’s minutes from the July meeting on Wednesday, seeking additional insights into the trajectory of interest rates after the July CPI reading calmed some nerves. U.S. rate futures have priced in an 88.5% probability of no hike and an 11.5% chance of a 25 basis point rate increase at the next central bank meeting in September. The U.S. economic data slate is mainly empty on Monday. In the bond markets, United States 10-Year rates are at 4.158%, down -0.24%. The Euro Stoxx 50 futures are up +0.35% this morning as investors digested better-than-expected Germany’s inflation data while awaiting the release of Federal Reserve policy minutes later in the week. Telecom and bank stocks gained ground on Monday, while mining and energy stocks underperformed. Data released by the Federal Statistical Office on Monday indicated that German wholesale prices fell by -2.8% year-on-year in July, marking the fourth consecutive month of decline. In corporate news, Kon.Philips N.V. (PHIA.NA) surged over +4% after Exor NV bought a 15% stake in the Dutch medical technology company. Also, Talanx Ag (TLX.D.DX) rose more than +2% after boosting its profit guidance. Germany’s WPI data was released today. The German July WPI has been reported at -0.2% m/m and -2.8% y/y, compared to expectations of -1.4% m/m and -2.6% y/y. Asian stock markets today settled in the red. China’s Shanghai Composite Index (SHCOMP) closed down -0.34%, and Japan’s Nikkei 225 Stock Index (NIK) closed down -1.27%. China’s Shanghai Composite today closed lower amid persistent concerns over slowing economic growth. Recent data showed that China’s new bank loans plunged in July, with other key credit gauges also showing signs of weakening, despite policymakers’ efforts to mitigate the economic slowdown through interest rate cuts and pledges of further support. Meanwhile, Country Garden Holdings Co Ltd tumbled over -18% after the country’s top private property developer said it would suspend trading in onshore bonds of 11 of its units amid growing debt problems. Also, shares of Chinese electric vehicle makers listed in Hong Kong plunged amid worries about further price cuts after Tesla cut prices again in China for some Model Y versions, with Li Auto Inc falling more than -2% and Xpeng Inc slumping about -3%. In other news, two clients of Chinese trust company Zhongrong International Trust Co said over the weekend that they had not received payment on maturing investment products. On the ground of this, China’s banking regulator announced it would set up a task force dedicated to assessing risks associated with Zhongzhi Enterprise Group Co. Investor attention is now squarely on Chinese retail sales and industrial production data due on Tuesday. Japan’s Nikkei 225 Stock Index closed sharply lower today, weighed down by losses in chip and energy stocks, while concerns over the Chinese economy also dampened market sentiment. Chip-related stocks slumped on Monday, with chip-making equipment maker Tokyo Electron falling about -1% and chip-testing equipment maker Advantest dropping more than -3%. Meanwhile, Nippon Sheet Glass climbed over +10% after reporting better-than-expected quarterly results. In other news, Reuters reported that SoftBank Group Corp is engaged in discussions to purchase the remaining 25% stake in Arm Ltd from Vision Fund 1, a $100 billion investment fund it raised in 2017. The Nikkei Volatility, which takes into account the implied volatility of Nikkei 225 options, closed up +2.44% to 19.70. Pre-Market U.S. Stock Movers Tesla Inc (TSLA) fell over -1% in pre-market trading after the automaker reduced the prices for Model Y Long Range and Performance versions in China. Okta Inc (OKTA) climbed more than +4% in pre-market trading after Goldman Sachs upgraded the stock to Buy from Sell. United States Steel Corporation (X) surged over +22% in pre-market trading as the company initiated a formal review of its strategic options after rejecting a $7.25 billion cash and stock takeover offer from Cleveland-Cliffs Inc. CF Industries Holdings Inc (CF) slid more than -1% in pre-market trading after Barclays downgraded the stock to Equal Weight from Overweight. Nikola Corp (NKLA) plunged over -15% in pre-market trading after the company announced a recall of all battery-powered electric trucks it had previously delivered due to two battery fires, and it also temporarily suspended sales of new battery-electric vehicles. Marriott International Inc (MAR) dropped about -3% in pre-market trading after Bernstein downgraded the stock to Market Perform from Outperform. You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Monday - August 14th Roivant Sciences (ROIV), Monday.Com (MNDY), Natura & Co (NTCO), Beach Energy (BCHEY), Rumble (RUM), Getty Images Holdings (GETY), JinkoSolar (JKS), Definitive Healthcare (DH), Navitas Semiconductor (NVTS), Altus Power (AMPS), Ast Spacemobile (ASTS), Ferroglobe (GSM), Yalla (YALA), Hut 8 Mining (HUT), Terawulf (WULF), CompoSecure (CMPO). More Stock Market News from Barchart Retail Data, FOMC and Other Can't Miss Items this WeekDomino's Pizza Stock Looks Cheap To Traders Who Sell Short OTM PutsCracking the Currency Code: Analyzing Seasonal Patterns and the Future of the British PoundStocks Weighed Down by Stronger U.S. PPI and Higher Bond Yields On the date of publication, Oleksandr Pylypenko did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

On the ground of this, China’s banking regulator announced it would set up a task force dedicated to assessing risks associated with Zhongzhi Enterprise Group Co. Investor attention is now squarely on Chinese retail sales and industrial production data due on Tuesday. Nikola Corp (NKLA) plunged over -15% in pre-market trading after the company announced a recall of all battery-powered electric trucks it had previously delivered due to two battery fires, and it also temporarily suspended sales of new battery-electric vehicles. You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Monday - August 14th Roivant Sciences (ROIV), Monday.Com (MNDY), Natura & Co (NTCO), Beach Energy (BCHEY), Rumble (RUM), Getty Images Holdings (GETY), JinkoSolar (JKS), Definitive Healthcare (DH), Navitas Semiconductor (NVTS), Altus Power (AMPS), Ast Spacemobile (ASTS), Ferroglobe (GSM), Yalla (YALA), Hut 8 Mining (HUT), Terawulf (WULF), CompoSecure (CMPO).

In the coming week, investors will be monitoring a spate of economic data, including U.S. Retail Sales, Core Retail Sales, Export Price Index, Import Price Index, NY Empire State Manufacturing Index, Building Permits (preliminary), Housing Starts, Industrial Production, Manufacturing Production, Crude Oil Inventories, Philadelphia Fed Manufacturing Index, and Initial Jobless Claims. The Euro Stoxx 50 futures are up +0.35% this morning as investors digested better-than-expected Germany’s inflation data while awaiting the release of Federal Reserve policy minutes later in the week. Japan’s Nikkei 225 Stock Index closed sharply lower today, weighed down by losses in chip and energy stocks, while concerns over the Chinese economy also dampened market sentiment.

In the coming week, investors will be monitoring a spate of economic data, including U.S. Retail Sales, Core Retail Sales, Export Price Index, Import Price Index, NY Empire State Manufacturing Index, Building Permits (preliminary), Housing Starts, Industrial Production, Manufacturing Production, Crude Oil Inventories, Philadelphia Fed Manufacturing Index, and Initial Jobless Claims. United States Steel Corporation (X) surged over +22% in pre-market trading as the company initiated a formal review of its strategic options after rejecting a $7.25 billion cash and stock takeover offer from Cleveland-Cliffs Inc. CF Industries Holdings Inc (CF) slid more than -1% in pre-market trading after Barclays downgraded the stock to Equal Weight from Overweight. More Stock Market News from Barchart Retail Data, FOMC and Other Can't Miss Items this WeekDomino's Pizza Stock Looks Cheap To Traders Who Sell Short OTM PutsCracking the Currency Code: Analyzing Seasonal Patterns and the Future of the British PoundStocks Weighed Down by Stronger U.S. PPI and Higher Bond Yields On the date of publication, Oleksandr Pylypenko did not have (either directly or indirectly) positions in any of the securities mentioned in this article.

In addition, investors will be closely watching the release of the Federal Reserve’s minutes from the July meeting on Wednesday, seeking additional insights into the trajectory of interest rates after the July CPI reading calmed some nerves. In the bond markets, United States 10-Year rates are at 4.158%, down -0.24%. Japan’s Nikkei 225 Stock Index closed sharply lower today, weighed down by losses in chip and energy stocks, while concerns over the Chinese economy also dampened market sentiment.

72.0

2023-08-14 00:00:00 UTC

Stocks Set to Open Higher as Investors Await FOMC Minutes, Retail Earnings

A

https://www.nasdaq.com/articles/stocks-set-to-open-higher-as-investors-await-fomc-minutes-retail-earnings

September S&P 500 futures (ESU23) are up +0.12%, and September Nasdaq 100 E-Mini futures (NQU23) are up +0.15% this morning as market participants looked ahead to the release of the minutes of the Federal Reserve’s latest policy meeting as well as quarterly earnings reports from high-profile retailers. In Friday’s trading session, Wall Street’s major averages closed mixed, with the benchmark S&P 500 and tech-heavy Nasdaq 100 dropping to 1-month lows. Wynn Resorts Limited (WYNN) slid over -3% after the company announced the closure of its sports betting app in eight states. Chip stocks also slumped, with Lam Research Corp (LRCX) falling about -5% and NVIDIA Corporation (NVDA) dropping more than -3%. In addition, U.S.-listed Chinese technology stocks plunged on concerns surrounding the state of China’s economy. As a result, JD.com Inc (JD) closed down over -5%, and Baidu Inc (BIDU) closed down more than -4%. On the bullish side, News Corp (NWSA) climbed over +4% and was the top percentage gainer on the S&P 500 after the Rupert Murdoch-owned media conglomerate topped quarterly profit estimates. Data on Friday showed the U.S. July producer price index stood at +0.8% y/y compared to +0.2% y/y in June, stronger than expectations of +0.7% y/y. Also, U.S. Core PPI arrived at +2.4% y/y in July, stronger than expectations of +2.3% y/y. In addition, the University of Michigan’s consumer sentiment reading came in at 71.2 in August, stronger than expectations of 71.0, while year-ahead inflation expectations unexpectedly eased to +3.3%. “We think there’s some reassessment of inflation going on with investors looking further under the hood. Disinflation has been very rapid in the past months at the top level, but that may be leveling out here a little,” said Paul Christopher, head ofglobal marketstrategy at Wells Fargo Investment Institut. Second-quarter earnings season winds down, with investors anticipating fresh reports from major global companies this week, including Home Depot (HD), Agilent Technologies (A), Cisco (CSCO), TJX (TJX), Target (TGT), Walmart (WMT), Applied Materials (AMAT), Ross Stores (ROST), Deere&Company (DE), Palo Alto Networks (PANW), and Estee Lauder (EL). In the coming week, investors will be monitoring a spate of economic data, including U.S. Retail Sales, Core Retail Sales, Export Price Index, Import Price Index, NY Empire State Manufacturing Index, Building Permits (preliminary), Housing Starts, Industrial Production, Manufacturing Production, Crude Oil Inventories, Philadelphia Fed Manufacturing Index, and Initial Jobless Claims. In addition, investors will be closely watching the release of the Federal Reserve’s minutes from the July meeting on Wednesday, seeking additional insights into the trajectory of interest rates after the July CPI reading calmed some nerves. U.S. rate futures have priced in an 88.5% probability of no hike and an 11.5% chance of a 25 basis point rate increase at the next central bank meeting in September. The U.S. economic data slate is mainly empty on Monday. In the bond markets, United States 10-Year rates are at 4.158%, down -0.24%. The Euro Stoxx 50 futures are up +0.35% this morning as investors digested better-than-expected Germany’s inflation data while awaiting the release of Federal Reserve policy minutes later in the week. Telecom and bank stocks gained ground on Monday, while mining and energy stocks underperformed. Data released by the Federal Statistical Office on Monday indicated that German wholesale prices fell by -2.8% year-on-year in July, marking the fourth consecutive month of decline. In corporate news, Kon.Philips N.V. (PHIA.NA) surged over +4% after Exor NV bought a 15% stake in the Dutch medical technology company. Also, Talanx Ag (TLX.D.DX) rose more than +2% after boosting its profit guidance. Germany’s WPI data was released today. The German July WPI has been reported at -0.2% m/m and -2.8% y/y, compared to expectations of -1.4% m/m and -2.6% y/y. Asian stock markets today settled in the red. China’s Shanghai Composite Index (SHCOMP) closed down -0.34%, and Japan’s Nikkei 225 Stock Index (NIK) closed down -1.27%. China’s Shanghai Composite today closed lower amid persistent concerns over slowing economic growth. Recent data showed that China’s new bank loans plunged in July, with other key credit gauges also showing signs of weakening, despite policymakers’ efforts to mitigate the economic slowdown through interest rate cuts and pledges of further support. Meanwhile, Country Garden Holdings Co Ltd tumbled over -18% after the country’s top private property developer said it would suspend trading in onshore bonds of 11 of its units amid growing debt problems. Also, shares of Chinese electric vehicle makers listed in Hong Kong plunged amid worries about further price cuts after Tesla cut prices again in China for some Model Y versions, with Li Auto Inc falling more than -2% and Xpeng Inc slumping about -3%. In other news, two clients of Chinese trust company Zhongrong International Trust Co said over the weekend that they had not received payment on maturing investment products. On the ground of this, China’s banking regulator announced it would set up a task force dedicated to assessing risks associated with Zhongzhi Enterprise Group Co. Investor attention is now squarely on Chinese retail sales and industrial production data due on Tuesday. Japan’s Nikkei 225 Stock Index closed sharply lower today, weighed down by losses in chip and energy stocks, while concerns over the Chinese economy also dampened market sentiment. Chip-related stocks slumped on Monday, with chip-making equipment maker Tokyo Electron falling about -1% and chip-testing equipment maker Advantest dropping more than -3%. Meanwhile, Nippon Sheet Glass climbed over +10% after reporting better-than-expected quarterly results. In other news, Reuters reported that SoftBank Group Corp is engaged in discussions to purchase the remaining 25% stake in Arm Ltd from Vision Fund 1, a $100 billion investment fund it raised in 2017. The Nikkei Volatility, which takes into account the implied volatility of Nikkei 225 options, closed up +2.44% to 19.70. Pre-Market U.S. Stock Movers Tesla Inc (TSLA) fell over -1% in pre-market trading after the automaker reduced the prices for Model Y Long Range and Performance versions in China. Okta Inc (OKTA) climbed more than +4% in pre-market trading after Goldman Sachs upgraded the stock to Buy from Sell. United States Steel Corporation (X) surged over +22% in pre-market trading as the company initiated a formal review of its strategic options after rejecting a $7.25 billion cash and stock takeover offer from Cleveland-Cliffs Inc. CF Industries Holdings Inc (CF) slid more than -1% in pre-market trading after Barclays downgraded the stock to Equal Weight from Overweight. Nikola Corp (NKLA) plunged over -15% in pre-market trading after the company announced a recall of all battery-powered electric trucks it had previously delivered due to two battery fires, and it also temporarily suspended sales of new battery-electric vehicles. Marriott International Inc (MAR) dropped about -3% in pre-market trading after Bernstein downgraded the stock to Market Perform from Outperform. You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Monday - August 14th Roivant Sciences (ROIV), Monday.Com (MNDY), Natura & Co (NTCO), Beach Energy (BCHEY), Rumble (RUM), Getty Images Holdings (GETY), JinkoSolar (JKS), Definitive Healthcare (DH), Navitas Semiconductor (NVTS), Altus Power (AMPS), Ast Spacemobile (ASTS), Ferroglobe (GSM), Yalla (YALA), Hut 8 Mining (HUT), Terawulf (WULF), CompoSecure (CMPO). More Stock Market News from Barchart Retail Data, FOMC and Other Can't Miss Items this WeekDomino's Pizza Stock Looks Cheap To Traders Who Sell Short OTM PutsCracking the Currency Code: Analyzing Seasonal Patterns and the Future of the British PoundStocks Weighed Down by Stronger U.S. PPI and Higher Bond Yields On the date of publication, Oleksandr Pylypenko did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

On the ground of this, China’s banking regulator announced it would set up a task force dedicated to assessing risks associated with Zhongzhi Enterprise Group Co. Investor attention is now squarely on Chinese retail sales and industrial production data due on Tuesday. Nikola Corp (NKLA) plunged over -15% in pre-market trading after the company announced a recall of all battery-powered electric trucks it had previously delivered due to two battery fires, and it also temporarily suspended sales of new battery-electric vehicles. You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Monday - August 14th Roivant Sciences (ROIV), Monday.Com (MNDY), Natura & Co (NTCO), Beach Energy (BCHEY), Rumble (RUM), Getty Images Holdings (GETY), JinkoSolar (JKS), Definitive Healthcare (DH), Navitas Semiconductor (NVTS), Altus Power (AMPS), Ast Spacemobile (ASTS), Ferroglobe (GSM), Yalla (YALA), Hut 8 Mining (HUT), Terawulf (WULF), CompoSecure (CMPO).

In the coming week, investors will be monitoring a spate of economic data, including U.S. Retail Sales, Core Retail Sales, Export Price Index, Import Price Index, NY Empire State Manufacturing Index, Building Permits (preliminary), Housing Starts, Industrial Production, Manufacturing Production, Crude Oil Inventories, Philadelphia Fed Manufacturing Index, and Initial Jobless Claims. The Euro Stoxx 50 futures are up +0.35% this morning as investors digested better-than-expected Germany’s inflation data while awaiting the release of Federal Reserve policy minutes later in the week. Japan’s Nikkei 225 Stock Index closed sharply lower today, weighed down by losses in chip and energy stocks, while concerns over the Chinese economy also dampened market sentiment.

In the coming week, investors will be monitoring a spate of economic data, including U.S. Retail Sales, Core Retail Sales, Export Price Index, Import Price Index, NY Empire State Manufacturing Index, Building Permits (preliminary), Housing Starts, Industrial Production, Manufacturing Production, Crude Oil Inventories, Philadelphia Fed Manufacturing Index, and Initial Jobless Claims. United States Steel Corporation (X) surged over +22% in pre-market trading as the company initiated a formal review of its strategic options after rejecting a $7.25 billion cash and stock takeover offer from Cleveland-Cliffs Inc. CF Industries Holdings Inc (CF) slid more than -1% in pre-market trading after Barclays downgraded the stock to Equal Weight from Overweight. More Stock Market News from Barchart Retail Data, FOMC and Other Can't Miss Items this WeekDomino's Pizza Stock Looks Cheap To Traders Who Sell Short OTM PutsCracking the Currency Code: Analyzing Seasonal Patterns and the Future of the British PoundStocks Weighed Down by Stronger U.S. PPI and Higher Bond Yields On the date of publication, Oleksandr Pylypenko did not have (either directly or indirectly) positions in any of the securities mentioned in this article.

In addition, investors will be closely watching the release of the Federal Reserve’s minutes from the July meeting on Wednesday, seeking additional insights into the trajectory of interest rates after the July CPI reading calmed some nerves. In the bond markets, United States 10-Year rates are at 4.158%, down -0.24%. Japan’s Nikkei 225 Stock Index closed sharply lower today, weighed down by losses in chip and energy stocks, while concerns over the Chinese economy also dampened market sentiment.

73.0

2023-08-11 00:00:00 UTC

Agilent Technologies (A) to Post Q3 Earnings: What's in Store?

A

https://www.nasdaq.com/articles/agilent-technologies-a-to-post-q3-earnings%3A-whats-in-store

Agilent Technologies A is set to report its third-quarter fiscal 2023 results on Aug 15. For the fiscal third quarter, A expects revenues of $1.640-$1.675 billion, suggesting growth between 4.5% and 2.5% on a core basis from the year-ago fiscal quarter’s actuals. The Zacks Consensus Estimate for the same is pegged at $1.66 billion, implying a decline of 3.6% from the year-ago fiscal quarter’s reported figure. Agilent’s non-GAAP earnings are expected to be $1.36-$1.38 per share. The Zacks Consensus Estimate for earnings is pegged at $1.37 per share, indicating growth of 2.2% from the year-ago fiscal quarter’s reported figure. Agilent’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average being 6.58%. Agilent Technologies, Inc. Price and EPS Surprise Agilent Technologies, Inc. price-eps-surprise | Agilent Technologies, Inc. Quote Key Factors to Note The company is expected to have gained from growing momentum across Agilent’s Cross Lab Group (ACG) and Diagnostics and Genomics Group (DGG) segments during the fiscal third quarter. Notably, the ACG segment is likely to have benefited from robust portfolio offerings. Moreover, strength in services attached to new instrument installations, as well as expanding service offerings for the existing instrument base, are likely to have contributed well. The Zacks Consensus Estimate for ACG is pegged at $377 million, implying growth of 5% from the year-ago fiscal quarter’s reported figure. Further, Agilent’s strength in NASD (Nucleic Acid Solutions Division) business is expected to have continued benefiting the DGG segment’s performance in the fiscal third quarter. Also, solid momentum in the pathology business and companion diagnostics pharma services are likely to have been positives. The Zacks Consensus Estimate for DGG is pegged at $350 million, implying growth of 2.9% from the year-ago fiscal quarter’s reported figure. Additionally, strength in liquid chromatography and liquid chromatography-mass spectrometry and lab consumables is expected to have benefited Agilent’s Life Sciences & Applied Markets Group (LSAG) segment in the quarter under review. However, the weakening of biotech and small molecule businesses is likely to have scaled down the LSAG segment’s revenues in the fiscal third quarter. The Zacks Consensus Estimate for LSAG is pegged at $929 million, implying a decline of 8.8% from the year-ago fiscal quarter’s reported figure. Furthermore, mounting expenses, geopolitical tensions and rising inflation are likely to have remained headwinds in the quarter under review. What Our Model Says Our proven model does not conclusively predict an earnings beat for Agilent this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Agilent has an Earnings ESP of 0.00% and a Zacks Rank #3. Other Stocks to Consider Here are some stocks worth considering as our model shows that these have the right combination of elements to beat on earnings this season. Workday WDAY has an Earnings ESP of +2.39% and has a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here. WDAY is scheduled to release fiscal second-quarter 2024 results on Aug 24. The Zacks Consensus Estimate for WDAY’s earnings is pegged at $1.24 per share, suggesting a rise of 49.4% year over year. NVIDIA NVDA has an Earnings ESP of +5.56% and carries a Zacks Rank #1 at present. NVDA is slated to report second-quarter fiscal 2024 results on Aug 23. The Zacks Consensus Estimate for NVDA’s second-quarter earnings is pegged at $2.06 per share, up from the prior-year quarter’s figure of 51 cents. Bilibili BILI has an Earnings ESP of +2.44% and a Zacks Rank #3 at present. BILI is scheduled to report second-quarter 2023 results on Aug 17. The Zacks Consensus Estimate for BILI’s earnings is pegged at a quarterly loss of 41 cents per share, suggesting an increase of 45.33% from the prior-year quarter’s reported figure. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NVIDIA Corporation (NVDA) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Workday, Inc. (WDAY) : Free Stock Analysis Report Bilibili Inc. Sponsored ADR (BILI) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Zacks Consensus Estimate for earnings is pegged at $1.37 per share, indicating growth of 2.2% from the year-ago fiscal quarter’s reported figure. The Zacks Consensus Estimate for ACG is pegged at $377 million, implying growth of 5% from the year-ago fiscal quarter’s reported figure. Further, Agilent’s strength in NASD (Nucleic Acid Solutions Division) business is expected to have continued benefiting the DGG segment’s performance in the fiscal third quarter.

The Zacks Consensus Estimate for ACG is pegged at $377 million, implying growth of 5% from the year-ago fiscal quarter’s reported figure. The Zacks Consensus Estimate for DGG is pegged at $350 million, implying growth of 2.9% from the year-ago fiscal quarter’s reported figure. Click to get this free report NVIDIA Corporation (NVDA) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Workday, Inc. (WDAY) : Free Stock Analysis Report Bilibili Inc.

The Zacks Consensus Estimate for earnings is pegged at $1.37 per share, indicating growth of 2.2% from the year-ago fiscal quarter’s reported figure. The Zacks Consensus Estimate for BILI’s earnings is pegged at a quarterly loss of 41 cents per share, suggesting an increase of 45.33% from the prior-year quarter’s reported figure. Click to get this free report NVIDIA Corporation (NVDA) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Workday, Inc. (WDAY) : Free Stock Analysis Report Bilibili Inc.

Agilent has an Earnings ESP of 0.00% and a Zacks Rank #3. The Zacks Consensus Estimate for WDAY’s earnings is pegged at $1.24 per share, suggesting a rise of 49.4% year over year. The Zacks Consensus Estimate for NVDA’s second-quarter earnings is pegged at $2.06 per share, up from the prior-year quarter’s figure of 51 cents.

74.0

2023-08-09 00:00:00 UTC

Agilent Technologies (A) Stock Moves -0.56%: What You Should Know

A

https://www.nasdaq.com/articles/agilent-technologies-a-stock-moves-0.56%3A-what-you-should-know

Agilent Technologies (A) closed at $127.63 in the latest trading session, marking a -0.56% move from the prior day. This change was narrower than the S&P 500's daily loss of 0.7%. Meanwhile, the Dow lost 0.54%, and the Nasdaq, a tech-heavy index, lost 1.17%. Coming into today, shares of the scientific instrument maker had gained 8.33% in the past month. In that same time, the Computer and Technology sector gained 1.4%, while the S&P 500 gained 2.35%. Investors will be hoping for strength from Agilent Technologies as it approaches its next earnings release, which is expected to be August 15, 2023. The company is expected to report EPS of $1.37, up 2.24% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $1.66 billion, down 3.56% from the prior-year quarter. For the full year, our Zacks Consensus Estimates are projecting earnings of $5.61 per share and revenue of $6.99 billion, which would represent changes of +7.47% and +2.07%, respectively, from the prior year. It is also important to note the recent changes to analyst estimates for Agilent Technologies. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.05% lower within the past month. Agilent Technologies is currently a Zacks Rank #3 (Hold). Digging into valuation, Agilent Technologies currently has a Forward P/E ratio of 22.87. This represents a discount compared to its industry's average Forward P/E of 25.76. It is also worth noting that A currently has a PEG ratio of 2.08. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Electronics - Testing Equipment stocks are, on average, holding a PEG ratio of 2.87 based on yesterday's closing prices. The Electronics - Testing Equipment industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 50, which puts it in the top 20% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Zacks Reveals ChatGPT "Sleeper" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Electronics - Testing Equipment stocks are, on average, holding a PEG ratio of 2.87 based on yesterday's closing prices. Zacks Reveals ChatGPT "Sleeper" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys."

Electronics - Testing Equipment stocks are, on average, holding a PEG ratio of 2.87 based on yesterday's closing prices. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research?

This industry currently has a Zacks Industry Rank of 50, which puts it in the top 20% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here.

Agilent Technologies is currently a Zacks Rank #3 (Hold). This industry currently has a Zacks Industry Rank of 50, which puts it in the top 20% of all 250+ industries. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research?

75.0

2023-08-07 00:00:00 UTC

Interesting A Put And Call Options For June 2024

A

https://www.nasdaq.com/articles/interesting-a-put-and-call-options-for-june-2024

Investors in Agilent Technologies, Inc. (Symbol: A) saw new options begin trading today, for the June 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 319 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the A options chain for the new June 2024 contracts and identified one put and one call contract of particular interest. The put contract at the $125.00 strike price has a current bid of $9.30. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $125.00, but will also collect the premium, putting the cost basis of the shares at $115.70 (before broker commissions). To an investor already interested in purchasing shares of A, that could represent an attractive alternative to paying $127.50/share today. Because the $125.00 strike represents an approximate 2% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 7.44% return on the cash commitment, or 8.51% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for Agilent Technologies, Inc., and highlighting in green where the $125.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $130.00 strike price has a current bid of $14.00. If an investor was to purchase shares of A stock at the current price level of $127.50/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $130.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 12.94% if the stock gets called away at the June 2024 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if A shares really soar, which is why looking at the trailing twelve month trading history for Agilent Technologies, Inc., as well as studying the business fundamentals becomes important. Below is a chart showing A's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 10.98% boost of extra return to the investor, or 12.56% annualized, which we refer to as the YieldBoost. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 250 trading day closing values as well as today's price of $127.50) to be 30%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of Stocks Analysts Like » Also see: • CIO Dividend Growth Rate • DRYS YTD Return • Union Pacific Stock Split History The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Because the $125.00 strike represents an approximate 2% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Of course, a lot of upside could potentially be left on the table if A shares really soar, which is why looking at the trailing twelve month trading history for Agilent Technologies, Inc., as well as studying the business fundamentals becomes important.

The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Below is a chart showing the trailing twelve month trading history for Agilent Technologies, Inc., and highlighting in green where the $125.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $130.00 strike price has a current bid of $14.00. Investors in Agilent Technologies, Inc. (Symbol: A) saw new options begin trading today, for the June 2024 expiration.

The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Below is a chart showing the trailing twelve month trading history for Agilent Technologies, Inc., and highlighting in green where the $125.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $130.00 strike price has a current bid of $14.00. Below is a chart showing A's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected.

At Stock Options Channel, our YieldBoost formula has looked up and down the A options chain for the new June 2024 contracts and identified one put and one call contract of particular interest. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Should the contract expire worthless, the premium would represent a 7.44% return on the cash commitment, or 8.51% annualized — at Stock Options Channel we call this the YieldBoost.

76.0

2023-08-03 00:00:00 UTC

Cognex Corporation (CGNX) Beats Q2 Earnings and Revenue Estimates

A

https://www.nasdaq.com/articles/cognex-corporation-cgnx-beats-q2-earnings-and-revenue-estimates

Cognex Corporation (CGNX) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 28%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.13, delivering a surprise of 44.44%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Cognex Corporation, which belongs to the Zacks Electronics - Testing Equipment industry, posted revenues of $242.51 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 4.99%. This compares to year-ago revenues of $274.63 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Cognex Corporation shares have added about 8.3% since the beginning of the year versus the S&P 500's gain of 17.6%. What's Next for Cognex Corporation? While Cognex Corporation has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Cognex Corporation: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.29 on $248.76 million in revenues for the coming quarter and $0.95 on $934.45 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Electronics - Testing Equipment is currently in the top 23% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Agilent Technologies (A), is yet to report results for the quarter ended July 2023. The results are expected to be released on August 15. This scientific instrument maker is expected to post quarterly earnings of $1.37 per share in its upcoming report, which represents a year-over-year change of +2.2%. The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level. Agilent Technologies' revenues are expected to be $1.66 billion, down 3.6% from the year-ago quarter. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cognex Corporation (CGNX) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. This scientific instrument maker is expected to post quarterly earnings of $1.37 per share in its upcoming report, which represents a year-over-year change of +2.2%. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things.

Cognex Corporation, which belongs to the Zacks Electronics - Testing Equipment industry, posted revenues of $242.51 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 4.99%. The current consensus EPS estimate is $0.29 on $248.76 million in revenues for the coming quarter and $0.95 on $934.45 million in revenues for the current fiscal year. Click to get this free report Cognex Corporation (CGNX) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here.

Cognex Corporation (CGNX) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.25 per share. Cognex Corporation, which belongs to the Zacks Electronics - Testing Equipment industry, posted revenues of $242.51 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 4.99%. Click to get this free report Cognex Corporation (CGNX) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here.

The company has topped consensus revenue estimates three times over the last four quarters. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock.

77.0

2023-07-31 00:00:00 UTC

Stocks See Support from Global Economic Optimism

A

https://www.nasdaq.com/articles/stocks-see-support-from-global-economic-optimism

What you need to know… The S&P 500 Index ($SPX) (SPY) today is up +0.12%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.08%. Stocks are slightly higher, with the Nasdaq 100 climbing to a 1-1/2 week high. Stocks are slightly higher amid another busy week of earnings results, with Apple and Amazon.com among those reporting this week. A rally in WTI crude to a 3-1/2 month high today is lifting energy stocks in pre-market trading and is boosting the overall market. U.S. stocks have some positive carryover from strength in global bourses. China’s Shanghai Composite rallied to a 2-1/2 month high today after economic news showed China’s manufacturing activity unexpectedly rose this month. Also, the Euro Stoxx 50 climbed to a 15-year high today as recession concerns receded after Eurozone Q2 GDP expanded more than expected. Today’s minor U.S. economic reports were mixed for stocks. On the positive side, the Jul Dallas Fed manufacturing outlook level of general business activity rose +3.2 to -20.0, stronger than expectations of -22.5. Conversely, the Jul MNI Chicago PMI rose +1.3 to 42.8, weaker than expectations of 43.5. Upbeat Fed comments were supportive of stocks. On Sunday, Minneapolis Fed President Kashkari said the inflation outlook in the U.S. is "quite positive" and that "the base case scenario seems to be that we'll have a slowing economy, but that we would avoid a recession." Also, Chicago Fed President Goolsbee said today that monthly inflation readings are coming in "quite good," but he hasn't yet decided on whether to support pausing interest-rate increases at the next FOMC meeting. The markets are discounting the odds at 20% for a +25 bp rate hike at the September 20 FOMC meeting. Global bond yields are lower. The 10-year T-note yield is down -0.2 bp at 3.949%. The 10-year German bund yield is down -0.8 bp at 2.485%. The 10-year UK Gilt yield is down -1.8 at 4.308%. Overseas stock markets are higher. The Euro Stoxx 50 is up +0.20%. China’s Shanghai Composite Index today closed up +0.46%. Japan’s Nikkei Stock Index closed up +1.26%. Today’s stock movers… ON Semiconductor (ON) is up more than +3% after reporting Q2 revenue of $2.09 billion, above the consensus of $2.02 billion. Adobe (ADBE) is up more than +3% after Morgan Stanley upgraded the stock to overweight from equal weight. Hasbro (HAS) is up more than +2% after Bank of America upgraded the stock to buy from neutral with a price target of $85. Energy stocks are climbing today, with the price of WTI crude up more than +1% at a 3-1/2 month high. As a result, Chevron (CVX) and Exxon Mobil (XOM) are up more than +2%. Also, ConocoPhillips (COP), Devon Energy (DVN), Haliburton (HAL), Occidental Petroleum (OXY), Marathon Petroleum (MPC), Schlumberger (SLB), Marathon Oil (MRO), and Valero Energy (VLO) are up more than +1%. Newell Brands (NWL) is up more than +2%, adding to last Friday’s 8% gain after it reported a Q2 normalized operating profit of $201 million, stronger than the consensus of $144.8 million. Warner Bros Discovery (WBD) is up more than +2% after the company’s “Barbie” movie grossed more than $500 million in global sales in its first week. Johnson & Johnson (JNJ) is down more than -4% to lead losers in the S&P 500 and Dow Jones Industrials after a judge dismissed the company’s second attempt at using its bankruptcy case to press thousands of cancer victims to drop their lawsuits and accept a $8.9 billion settlement. Baxter International (BAX) is down more than -2% after it issued an Urgent Medical Device Correction for its Spectrum V8 and Spectrum IQ infusion pumps in the U.S. and Puerto Rico, due to an increase in reported false upstream occlusion alarms following software upgrades. Agilent Technologies (A) is down more than -2% after Barclays downgraded the stock to underweight from equal weight. Waters (WAT) is down more than -2% after Barclays downgraded the stock to equal weight from overweight. CSX Corp (CSX) is down more than -1% after RBC Capital Markets downgraded the stock to sector perform from outperform. Ford Motor (F) is down more than -1% after Jeffries downgraded the stock to hold from buy. Across the markets… September 10-year T-notes (ZNU23) today are up +3 ticks, and the 10-year T-note yield is down -0.2 bp at 3.949%. Sep T-notes today are slightly higher on some positive Fed comments on inflation. Minneapolis Fed President Kashkari said the inflation outlook in the U.S. is "quite positive," and Chicago Fed President Goolsbee said monthly inflation readings are coming in "quite good." Also, a weaker-than-expected Jul MNI Chicago PMI report was bullish for T-notes. Gains are limited by supply pressures as the Treasury is expected to boost its quarterly refunding of longer-term Treasuries to $102 billion from $96 billion at Wednesday’s quarterly refunding announcement. The dollar index (DXY00) today is down by -0.06%. The dollar today is slightly lower on strength in the euro after today’s news that the Eurozone Q2 GDP and core CPI rose more than expected. Losses in the dollar were contained by weakness in the yen, which fell to a 3-week low against the dollar after the BOJ announced unscheduled bond purchases. EUR/USD (^EURUSD) today is up by +0.22%. The euro today garnered support from stronger-than-expected Eurozone GDP and core CPI reports. Also, comments from ECB President Lagarde gave the euro a boost when she said the ECB could raise interest rates again, even if it pauses at its next meeting in September. A weaker-than-expected German Jun retail sales report today limited the upside in EUR/USD. The Eurozone Jul CPI eased to +5.3% y/y from +5.5% y/y in June, right on expectations and the smallest increase in 1-1/2 years. However, Jul core CPI rose +5.5% y/y, unchanged from Jun and stronger than expectations of +5.4% y/y. Eurozone Q2 GDP rose +0.3% q/q and +0.6% y/y, stronger than expectations of +0.2% q/q and +0.5% y/y. German Jun retail sales fell -0.8% m/m, weaker than expectations of -0.3% m/m. USD/JPY (^USDJPY) is up by +0.68%. The yen today dropped to a 3-week high low against the dollar after the BOJ announced an unscheduled bond-purchase operation in an attempt to keep 10-year JGB bond yields from climbing. The BOJ announced that it would buy the equivalent of more than $2 billion of bonds at market rates after the 10-year JGB bond yield climbed to a 9-year high of 0.614%. Bond yields have surged since last Friday when the BOJ tweaked its yield curve control program and effectively raised the upper limit of its 10-year JGB yield target to 1.0% from 0.5%. Today’s Japanese economic news was mixed for the yen. On the negative side, Jun industrial production rose +2.0% m/m, the most in 4 months but weaker than expectations of +2.4% m/m. Conversely, the Jul consumer confidence index rose +0.9 to a 19-month high of 37.2, stronger than expectations of 36.2. Also, Jun retail sales fell -0.4% m/m, stronger than expectations of -0.7% m/m. August gold (GCQ3) today is up +6.5 (+0.33%), and Sep silver (SIU23) is up +0.440 (+1.80%). Precious metals prices this morning are moderately higher. A weaker dollar today is bullish for metals prices. Precious metals also rose on favorable inflation comments from Minneapolis Fed President Kashkari and Chicago Fed President Goolsbee, suggesting they may favor a pause in Fed rate hikes. Gains in gold are limited as fund liquidation of long gold holdings weighs on gold prices after long gold holdings in ETFs fell to a new 3-year low last Friday. Also, hawkish comments from ECB President Lagarde were bearish for precious metals when she said the ECB could raise interest rates again, even if it pauses at its next meeting in September. More Stock Market News from Barchart Cheap Stock Alert: Microsoft and Its Huge Free Cash Flow - Options Plays Look Attractive Markets Today: Stocks Push Higher on Strength in China and Europe Option Volatility and Earnings Report for July 31 – August 4 Stocks Set to Open Higher as Investors Await U.S. Payrolls Data and More Big Tech Earnings On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

On Sunday, Minneapolis Fed President Kashkari said the inflation outlook in the U.S. is "quite positive" and that "the base case scenario seems to be that we'll have a slowing economy, but that we would avoid a recession." Also, Chicago Fed President Goolsbee said today that monthly inflation readings are coming in "quite good," but he hasn't yet decided on whether to support pausing interest-rate increases at the next FOMC meeting. The yen today dropped to a 3-week high low against the dollar after the BOJ announced an unscheduled bond-purchase operation in an attempt to keep 10-year JGB bond yields from climbing.

China’s Shanghai Composite rallied to a 2-1/2 month high today after economic news showed China’s manufacturing activity unexpectedly rose this month. The yen today dropped to a 3-week high low against the dollar after the BOJ announced an unscheduled bond-purchase operation in an attempt to keep 10-year JGB bond yields from climbing. Precious metals also rose on favorable inflation comments from Minneapolis Fed President Kashkari and Chicago Fed President Goolsbee, suggesting they may favor a pause in Fed rate hikes.

The dollar today is slightly lower on strength in the euro after today’s news that the Eurozone Q2 GDP and core CPI rose more than expected. Precious metals also rose on favorable inflation comments from Minneapolis Fed President Kashkari and Chicago Fed President Goolsbee, suggesting they may favor a pause in Fed rate hikes. More Stock Market News from Barchart Cheap Stock Alert: Microsoft and Its Huge Free Cash Flow - Options Plays Look Attractive Markets Today: Stocks Push Higher on Strength in China and Europe Option Volatility and Earnings Report for July 31 – August 4 Stocks Set to Open Higher as Investors Await U.S. Payrolls Data and More Big Tech Earnings On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article.

Sep T-notes today are slightly higher on some positive Fed comments on inflation. The dollar today is slightly lower on strength in the euro after today’s news that the Eurozone Q2 GDP and core CPI rose more than expected. EUR/USD (^EURUSD) today is up by +0.22%.

78.0

2023-07-31 00:00:00 UTC

Validea Detailed Fundamental Analysis - A

A

https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-a-0

Below is Validea's guru fundamental report for AGILENT TECHNOLOGIES INC (A). Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. AGILENT TECHNOLOGIES INC (A) is a large-cap growth stock in the Scientific & Technical Instr. industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: FAIL CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.

Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends.

Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends.

Below is Validea's guru fundamental report for AGILENT TECHNOLOGIES INC (A). Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing.

79.0

2023-07-26 00:00:00 UTC

Agilent Technologies (A) Gains As Market Dips: What You Should Know

A

https://www.nasdaq.com/articles/agilent-technologies-a-gains-as-market-dips%3A-what-you-should-know-2

In the latest trading session, Agilent Technologies (A) closed at $128.47, marking a +0.91% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.02%. Meanwhile, the Dow gained 0.23%, and the Nasdaq, a tech-heavy index, lost 0.12%. Prior to today's trading, shares of the scientific instrument maker had gained 8.77% over the past month. This has outpaced the Computer and Technology sector's gain of 3.63% and the S&P 500's gain of 5.14% in that time. Investors will be hoping for strength from Agilent Technologies as it approaches its next earnings release, which is expected to be August 15, 2023. The company is expected to report EPS of $1.37, up 2.24% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $1.66 billion, down 3.56% from the prior-year quarter. For the full year, our Zacks Consensus Estimates are projecting earnings of $5.61 per share and revenue of $6.99 billion, which would represent changes of +7.47% and +2.07%, respectively, from the prior year. Any recent changes to analyst estimates for Agilent Technologies should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.04% lower within the past month. Agilent Technologies is holding a Zacks Rank of #3 (Hold) right now. Valuation is also important, so investors should note that Agilent Technologies has a Forward P/E ratio of 22.69 right now. Its industry sports an average Forward P/E of 25.96, so we one might conclude that Agilent Technologies is trading at a discount comparatively. It is also worth noting that A currently has a PEG ratio of 2.06. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Electronics - Testing Equipment stocks are, on average, holding a PEG ratio of 2.86 based on yesterday's closing prices. The Electronics - Testing Equipment industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 59, putting it in the top 24% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.” Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. Electronics - Testing Equipment stocks are, on average, holding a PEG ratio of 2.86 based on yesterday's closing prices. Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests.

The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Electronics - Testing Equipment stocks are, on average, holding a PEG ratio of 2.86 based on yesterday's closing prices. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.” Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research?

This has outpaced the Computer and Technology sector's gain of 3.63% and the S&P 500's gain of 5.14% in that time. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. This group has a Zacks Industry Rank of 59, putting it in the top 24% of all 250+ industries.

80.0

2023-07-20 00:00:00 UTC

Healthcare Prime Destination for Bargains, Quality

A

https://www.nasdaq.com/articles/healthcare-prime-destination-for-bargains-quality

With the hoopla surrounding mega-cap growth stocks this year, some slower-moving sectors may not be getting the attention they deserve. Arguably, healthcare is part of that group. That’s saying something when considering that is the sector is the second-largest behind technology in the S&P 500. Part of the issue confounding healthcare stocks this year is that the cap-weighted version of the S&P 500 Health Care Index is pointing lower. Meanwhile, more glamorous fare (growth sectors) and the broader market are soaring. Some of that boils down to lethargy among large-cap biopharma stocks. Still, some analysts remain encouraged by the long-term outlook for the sector. The Invesco S&P 500® Equal Weight Health Care ETF (RSPH) could be one of the ideal exchange traded funds with which to access a potential healthcare rebound in the second half of 2023 owing to the fund’s exposure to the sector’s defensive, growth, and quality traits. As things stand today, RSPH is sharply outperforming its cap-weighted rivals year-to-date while sporting less annualized volatility than the S&P 500. RSPH Ready for Healthy Second Half The healthcare sector is home to a plethora of wide moat companies, and RSPH in particular has them in spades. Wide moat traits include intangible assets, high switching costs, cost advantages, efficient scale, and the network effect. Broadly speaking, the network effect is more relevant in the tech and internet realms. However, the other four wide moat attributes are widely visible in the healthcare arena, including among RSPH member firms. That includes Pfizer (NYSE: PFE). “Pfizer’s patent-protected drugs carry strong pricing power that enables the firm to generate returns on invested capital in excess of its cost of capital,” observed Morningstar sector director Damien Conover. “The patents give the company time to develop the next generation of drugs before generic competition arises.” RSPH’s exposure to medical device makers, which account for nearly 32% of the ETF’s portfolio, is another wide moat positive thanks to the likes of Agilent Technologies (NYSE: A), Thermo Fisher Scientific (NYSE: TMO), and Waters (NYSE: WAT). The Invesco ETF carries an allocation to this group 1,100 basis points over those found in equivalent cap-weighted ETFs. For more news, information, and analysis, visit the Portfolio Strategies Channel. Read more on ETFtrends.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

With the hoopla surrounding mega-cap growth stocks this year, some slower-moving sectors may not be getting the attention they deserve. Part of the issue confounding healthcare stocks this year is that the cap-weighted version of the S&P 500 Health Care Index is pointing lower. As things stand today, RSPH is sharply outperforming its cap-weighted rivals year-to-date while sporting less annualized volatility than the S&P 500.

The Invesco S&P 500® Equal Weight Health Care ETF (RSPH) could be one of the ideal exchange traded funds with which to access a potential healthcare rebound in the second half of 2023 owing to the fund’s exposure to the sector’s defensive, growth, and quality traits. Wide moat traits include intangible assets, high switching costs, cost advantages, efficient scale, and the network effect. However, the other four wide moat attributes are widely visible in the healthcare arena, including among RSPH member firms.

The Invesco S&P 500® Equal Weight Health Care ETF (RSPH) could be one of the ideal exchange traded funds with which to access a potential healthcare rebound in the second half of 2023 owing to the fund’s exposure to the sector’s defensive, growth, and quality traits. RSPH Ready for Healthy Second Half The healthcare sector is home to a plethora of wide moat companies, and RSPH in particular has them in spades. “The patents give the company time to develop the next generation of drugs before generic competition arises.” RSPH’s exposure to medical device makers, which account for nearly 32% of the ETF’s portfolio, is another wide moat positive thanks to the likes of Agilent Technologies (NYSE: A), Thermo Fisher Scientific (NYSE: TMO), and Waters (NYSE: WAT).

Part of the issue confounding healthcare stocks this year is that the cap-weighted version of the S&P 500 Health Care Index is pointing lower. RSPH Ready for Healthy Second Half The healthcare sector is home to a plethora of wide moat companies, and RSPH in particular has them in spades. However, the other four wide moat attributes are widely visible in the healthcare arena, including among RSPH member firms.

81.0

2023-07-17 00:00:00 UTC

Validea Detailed Fundamental Analysis - A

A

https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-a

Below is Validea's guru fundamental report for AGILENT TECHNOLOGIES INC (A). Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. AGILENT TECHNOLOGIES INC (A) is a large-cap growth stock in the Scientific & Technical Instr. industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: FAIL CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.

Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends.

Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Additional Research Links Top NASDAQ 100 Stocks Top Technology Stocks Top Large-Cap Growth Stocks High Momentum Stocks High Insider Ownership Stocks Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends.

Below is Validea's guru fundamental report for AGILENT TECHNOLOGIES INC (A). Of the 22 guru strategies we follow, A rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing.

82.0

2023-07-06 00:00:00 UTC

Agilent Technologies (A) Dips More Than Broader Markets: What You Should Know

A

https://www.nasdaq.com/articles/agilent-technologies-a-dips-more-than-broader-markets%3A-what-you-should-know-4

In the latest trading session, Agilent Technologies (A) closed at $118.43, marking a -0.9% move from the previous day. This move lagged the S&P 500's daily loss of 0.79%. At the same time, the Dow lost 1.07%, and the tech-heavy Nasdaq lost 2.71%. Prior to today's trading, shares of the scientific instrument maker had gained 2.5% over the past month. This has lagged the Computer and Technology sector's gain of 2.73% and the S&P 500's gain of 4.16% in that time. Wall Street will be looking for positivity from Agilent Technologies as it approaches its next earnings report date. The company is expected to report EPS of $1.37, up 2.24% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.66 billion, down 3.5% from the year-ago period. A's full-year Zacks Consensus Estimates are calling for earnings of $5.61 per share and revenue of $6.99 billion. These results would represent year-over-year changes of +7.47% and +2.04%, respectively. Investors might also notice recent changes to analyst estimates for Agilent Technologies. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.11% lower. Agilent Technologies is currently a Zacks Rank #4 (Sell). Valuation is also important, so investors should note that Agilent Technologies has a Forward P/E ratio of 21.29 right now. For comparison, its industry has an average Forward P/E of 25.92, which means Agilent Technologies is trading at a discount to the group. Investors should also note that A has a PEG ratio of 1.94 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Electronics - Testing Equipment industry currently had an average PEG ratio of 2.84 as of yesterday's close. The Electronics - Testing Equipment industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 182, which puts it in the bottom 28% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Zacks.com. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.2% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In the latest trading session, Agilent Technologies (A) closed at $118.43, marking a -0.9% move from the previous day. For comparison, its industry has an average Forward P/E of 25.92, which means Agilent Technologies is trading at a discount to the group. The Electronics - Testing Equipment industry currently had an average PEG ratio of 2.84 as of yesterday's close.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here.

Agilent Technologies is currently a Zacks Rank #4 (Sell). This industry currently has a Zacks Industry Rank of 182, which puts it in the bottom 28% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups.

This has lagged the Computer and Technology sector's gain of 2.73% and the S&P 500's gain of 4.16% in that time. Within the past 30 days, our consensus EPS projection has moved 0.11% lower. Agilent Technologies is currently a Zacks Rank #4 (Sell).

83.0

2023-07-03 00:00:00 UTC

Validea's Top 5 Health Care Stocks Based On Joel Greenblatt - 7/3/2023

A

https://www.nasdaq.com/articles/valideas-top-5-health-care-stocks-based-on-joel-greenblatt-7-3-2023

The following are the top rated Health Care stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields. GILEAD SCIENCES, INC. (GILD) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Joel Greenblatt is 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company's other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. EARNINGS YIELD: NEUTRAL RETURN ON TANGIBLE CAPITAL: NEUTRAL FINAL RANKING: FAIL Detailed Analysis of GILEAD SCIENCES, INC. GILD Guru Analysis GILD Fundamental Analysis JOHNSON & JOHNSON (JNJ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Joel Greenblatt is 20% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: Johnson & Johnson is a diversified healthcare products company. The Company is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer Health, Pharmaceutical and MedTech. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women's health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The MedTech segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. EARNINGS YIELD: NEUTRAL RETURN ON TANGIBLE CAPITAL: NEUTRAL FINAL RANKING: FAIL Detailed Analysis of JOHNSON & JOHNSON JNJ Guru Analysis JNJ Fundamental Analysis AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Major Drugs industry. The rating according to our strategy based on Joel Greenblatt is 0% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: AmerisourceBergen Corporation is a global pharmaceutical sourcing and distribution services company. The Company's U.S. Healthcare Solutions segment distributes an offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. This segment consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty. The Company also focuses on specialty services and a global platform of pharma manufacturer services capabilities. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. Detailed Analysis of AMERISOURCEBERGEN CORP. ABC Guru Analysis ABC Fundamental Analysis UNITEDHEALTH GROUP INC (UNH) is a large-cap growth stock in the Insurance (Accident & Health) industry. The rating according to our strategy based on Joel Greenblatt is 0% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: UnitedHealth Group Incorporated is a diversified health care company that operates Optum and UnitedHealthcare platforms. Its segments include Optum Health, Optum Insight, Optum Rx and UnitedHealthcare. Optum Health segment is focused on care delivery, care management, wellness and consumer engagement, and health financial services. Optum Insight segment serves the needs of hospital systems, physicians, health plans, governments and life sciences companies. Optum Rx segment offers pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, purchasing and clinical capabilities, and develops programs in areas such as step therapy, formulary management, drug adherence and disease/drug therapy management. UnitedHealthcare includes the combined results of operations of UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement, UnitedHealthcare Community & State and UnitedHealthcare Global. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. Detailed Analysis of UNITEDHEALTH GROUP INC UNH Guru Analysis UNH Fundamental Analysis AGILENT TECHNOLOGIES INC (A) is a large-cap growth stock in the Scientific & Technical Instr. industry. The rating according to our strategy based on Joel Greenblatt is 0% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: Agilent Technologies, Inc. is engaged in providing application-focused solutions that include instruments, software, services, and consumables for the entire laboratory workflow. The Company's life sciences and applied markets segment provides application-focused solutions, which include instruments, consumables and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Its diagnostics and genomics segment includes the genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership and biomolecular analysis businesses. The Company's Agilent CrossLab segment offers services portfolio, which consists of repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and various other custom services to support the customers' laboratory operations. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. EARNINGS YIELD: NEUTRAL RETURN ON TANGIBLE CAPITAL: NEUTRAL FINAL RANKING: FAIL Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis Joel Greenblatt Portfolio Top Joel Greenblatt Stocks About Joel Greenblatt: In his 2005 bestseller The Little Book That Beats The Market, hedge fund manager Joel Greenblatt laid out a stunningly simple way to beat the market using two -- and only two -- fundamental variables. The "Magic Formula," as he called it, produced back-tested returns of 30.8 percent per year from 1988 through 2004, more than doubling the S&P 500's 12.4 percent return during that time. Greenblatt also produced exceptional returns as managing partner at Gotham Capital, a New York City-based hedge fund he founded. The firm averaged a remarkable 40 percent annualized return over more than two decades. About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

84.0

2023-06-28 00:00:00 UTC

Ex-Dividend Reminder: Agilent Technologies, Cardinal Health and Encompass Health

A

https://www.nasdaq.com/articles/ex-dividend-reminder%3A-agilent-technologies-cardinal-health-and-encompass-health

Looking at the universe of stocks we cover at Dividend Channel, on 6/30/23, Agilent Technologies, Inc. (Symbol: A), Cardinal Health, Inc. (Symbol: CAH), and Encompass Health Corp (Symbol: EHC) will all trade ex-dividend for their respective upcoming dividends. Agilent Technologies, Inc. will pay its quarterly dividend of $0.225 on 7/26/23, Cardinal Health, Inc. will pay its quarterly dividend of $0.5006 on 7/15/23, and Encompass Health Corp will pay its quarterly dividend of $0.15 on 7/17/23. As a percentage of A's recent stock price of $116.20, this dividend works out to approximately 0.19%, so look for shares of Agilent Technologies, Inc. to trade 0.19% lower — all else being equal — when A shares open for trading on 6/30/23. Similarly, investors should look for CAH to open 0.54% lower in price and for EHC to open 0.23% lower, all else being equal. Below are dividend history charts for A, CAH, and EHC, showing historical dividends prior to the most recent ones declared. Agilent Technologies, Inc. (Symbol: A): Cardinal Health, Inc. (Symbol: CAH): Encompass Health Corp (Symbol: EHC): In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 0.77% for Agilent Technologies, Inc., 2.15% for Cardinal Health, Inc., and 0.91% for Encompass Health Corp. In Wednesday trading, Agilent Technologies, Inc. shares are currently down about 0.7%, Cardinal Health, Inc. shares are up about 0.1%, and Encompass Health Corp shares are off about 0.2% on the day. Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen » Also see: • Institutional Holders of UVCL • UGI Historical Stock Prices • FTI Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

As a percentage of A's recent stock price of $116.20, this dividend works out to approximately 0.19%, so look for shares of Agilent Technologies, Inc. to trade 0.19% lower — all else being equal — when A shares open for trading on 6/30/23. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. dividend stocks should be on your radar screen » Also see: • Institutional Holders of UVCL • UGI Historical Stock Prices • FTI Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Looking at the universe of stocks we cover at Dividend Channel, on 6/30/23, Agilent Technologies, Inc. (Symbol: A), Cardinal Health, Inc. (Symbol: CAH), and Encompass Health Corp (Symbol: EHC) will all trade ex-dividend for their respective upcoming dividends. Agilent Technologies, Inc. will pay its quarterly dividend of $0.225 on 7/26/23, Cardinal Health, Inc. will pay its quarterly dividend of $0.5006 on 7/15/23, and Encompass Health Corp will pay its quarterly dividend of $0.15 on 7/17/23. Agilent Technologies, Inc. (Symbol: A): Cardinal Health, Inc. (Symbol: CAH): Encompass Health Corp (Symbol: EHC): In general, dividends are not always predictable, following the ups and downs of company profits over time.

Looking at the universe of stocks we cover at Dividend Channel, on 6/30/23, Agilent Technologies, Inc. (Symbol: A), Cardinal Health, Inc. (Symbol: CAH), and Encompass Health Corp (Symbol: EHC) will all trade ex-dividend for their respective upcoming dividends. Agilent Technologies, Inc. will pay its quarterly dividend of $0.225 on 7/26/23, Cardinal Health, Inc. will pay its quarterly dividend of $0.5006 on 7/15/23, and Encompass Health Corp will pay its quarterly dividend of $0.15 on 7/17/23. Agilent Technologies, Inc. (Symbol: A): Cardinal Health, Inc. (Symbol: CAH): Encompass Health Corp (Symbol: EHC): In general, dividends are not always predictable, following the ups and downs of company profits over time.

As a percentage of A's recent stock price of $116.20, this dividend works out to approximately 0.19%, so look for shares of Agilent Technologies, Inc. to trade 0.19% lower — all else being equal — when A shares open for trading on 6/30/23. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 0.77% for Agilent Technologies, Inc., 2.15% for Cardinal Health, Inc., and 0.91% for Encompass Health Corp.

85.0

2023-06-23 00:00:00 UTC

Agilent Technologies (A) Gains As Market Dips: What You Should Know

A

https://www.nasdaq.com/articles/agilent-technologies-a-gains-as-market-dips%3A-what-you-should-know-1

Agilent Technologies (A) closed at $119.42 in the latest trading session, marking a +0.62% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.77%. At the same time, the Dow lost 0.65%, and the tech-heavy Nasdaq lost 2.23%. Coming into today, shares of the scientific instrument maker had lost 0.68% in the past month. In that same time, the Computer and Technology sector gained 6.75%, while the S&P 500 gained 4.66%. Wall Street will be looking for positivity from Agilent Technologies as it approaches its next earnings report date. In that report, analysts expect Agilent Technologies to post earnings of $1.37 per share. This would mark year-over-year growth of 2.24%. Our most recent consensus estimate is calling for quarterly revenue of $1.66 billion, down 3.5% from the year-ago period. A's full-year Zacks Consensus Estimates are calling for earnings of $5.61 per share and revenue of $6.99 billion. These results would represent year-over-year changes of +7.47% and +2.04%, respectively. Investors should also note any recent changes to analyst estimates for Agilent Technologies. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.15% lower. Agilent Technologies is currently a Zacks Rank #4 (Sell). Looking at its valuation, Agilent Technologies is holding a Forward P/E ratio of 21.14. This valuation marks a discount compared to its industry's average Forward P/E of 25.53. We can also see that A currently has a PEG ratio of 1.92. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. A's industry had an average PEG ratio of 2.78 as of yesterday's close. The Electronics - Testing Equipment industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 61, which puts it in the top 25% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow An in the coming trading sessions, be sure to utilize Zacks.com. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Agilent Technologies (A) closed at $119.42 in the latest trading session, marking a +0.62% move from the prior day. It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here.

This industry currently has a Zacks Industry Rank of 61, which puts it in the top 25% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Agilent Technologies (A) closed at $119.42 in the latest trading session, marking a +0.62% move from the prior day. Investors should also note any recent changes to analyst estimates for Agilent Technologies. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research?

86.0

2023-06-22 00:00:00 UTC

Agilent (A) Down 2.2% Since Last Earnings Report: Can It Rebound?

A

https://www.nasdaq.com/articles/agilent-a-down-2.2-since-last-earnings-report%3A-can-it-rebound

A month has gone by since the last earnings report for Agilent Technologies (A). Shares have lost about 2.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Agilent due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Agilent Q2 Earnings Match Estimates Agilent Technologies reported second-quarter fiscal 2023 earnings of $1.27 per share, which came in line with the Zacks Consensus Estimate. The bottom line increased by 12.4% from the year-ago fiscal quarter’s level. Revenues of $1.72 billion surpassed the Zacks Consensus Estimate of $1.67 billion. The top line was up 6.8% on a reported basis and 9.5% on a core basis from the respective year-ago fiscal quarter’s levels. Top-line growth was driven by strong momentum across Food, Academia & Gov’t and Chemistry & Advanced Materials markets. A strong performance in China also contributed well. Segmental Top Line Details Agilent has three reporting segments, namely, Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG) and Diagnostics and Genomics Group (DGG). LSAG: The segment accounted for $968 million or 56% of its total revenues, up 8% on a reported basis and 10% on a core basis from the respective prior-year fiscal quarter’s levels. This was driven by strong performance in the Chemical & Advanced Materials, Food and Academic & Gov’t markets. Strength in LC and LCMS and lab consumables also aided results. ACG: Revenues from the segment were $387 million, accounting for 23% of total revenues. Also, the top line improved by 10% from the prior-year fiscal quarter’s reading on a reported basis and 13% on a core basis, driven by strength in services attached to new instrument installations as well as expanding service offerings for the existing instrument base. DGG: Revenues increased 1% from the prior-year fiscal quarter’s figure on a reported basis and 3% on a core basis to $362 million, accounting for the remaining 21% of total revenues. Segmental growth was attributed to strength in the NASD and pathology businesses. Also, solid momentum in companion diagnostics pharma services contributed well. Operating Results For the fiscal second quarter, gross margin in the LSAG segment expanded by 90 basis points (bps) to 59.9% from the prior-year fiscal quarter’s number. ACG’s gross margin contracted 10 bps to 47%. DGG’s gross margin contracted 420 bps from the year-ago fiscal quarter’s actuals to 51.8%. Research & development (R&D) costs were $126 million, up 9.6% from the prior-year fiscal quarter’s number. Selling, general & administrative (SG&A) expenses were $415 million, up 7.5% from the year-earlier fiscal quarter’s figure. As a percentage of revenues, R&D expenses expanded 10 bps year over year to 7.3%. Meanwhile, SG&A expenses expanded 20 bps year over year to 24.2%. Operating margin for the fiscal first quarter was 22.3%, which contracted 10 bps from the year-earlier fiscal quarter’s figure. Segment-wise, the operating margin for LSAG was up 180 bps from the year-earlier fiscal quarter’s level of 27.3%. ACG’s operating margin was 26.6%, up 200 bps from the year-ago fiscal quarter’s level. DGG segment’s operating margin contracted 530 bps to 20.2% from the year-ago fiscal quarter’s figure. Balance Sheet & Cash Flow As of Apr 30, 2023, Agilent’s cash and cash equivalents were $1.18 billion, down from $1.25 billion on Jan 31, 2023. Accounts receivables were $1.4 billion at the end of second-quarter fiscal 2023, down from $1.5 billion at the end of first-quarter fiscal 2023. Long-term debt was $2.733 billion for the reported quarter, which remained flat as compared with the prior fiscal quarter. Agilent generated $398 million in cash from operations during the reported quarter, up from $296 million generated in the previous quarter. Further, it returned $151 million to shareholders, out of which dividend payments accounted for $66 million and share repurchases accounted for the remaining $85 million. Guidance For the fiscal third quarter of 2023, management expects revenues of $1.640-$1.675 billion, suggesting growth between 4.5% and 2.5% on a core basis from the year-ago fiscal quarter’s actuals. Non-GAAP earnings per share are expected to be $1.36-$1.38. For fiscal 2023, management lowered its revenue guidance from the band of $7.03-$7.1 billion to $6.93-7.03 billion, implying a growth of 1.2-2.7% on a reported basis and 3-4.5% on a core basis from the respective fiscal 2022 figures. Management also updated the guidance for fiscal 2023 non-GAAP earnings per share downward from $5.65-$5.70 to $5.60-$5.65. How Have Estimates Been Moving Since Then? In the past month, investors have witnessed a downward trend in fresh estimates. VGM Scores At this time, Agilent has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy. Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in. Outlook Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Agilent has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Will the recent negative trend continue leading up to its next earnings release, or is Agilent due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Top-line growth was driven by strong momentum across Food, Academia & Gov’t and Chemistry & Advanced Materials markets.

Agilent Q2 Earnings Match Estimates Agilent Technologies reported second-quarter fiscal 2023 earnings of $1.27 per share, which came in line with the Zacks Consensus Estimate. DGG: Revenues increased 1% from the prior-year fiscal quarter’s figure on a reported basis and 3% on a core basis to $362 million, accounting for the remaining 21% of total revenues. Operating Results For the fiscal second quarter, gross margin in the LSAG segment expanded by 90 basis points (bps) to 59.9% from the prior-year fiscal quarter’s number.

Agilent Q2 Earnings Match Estimates Agilent Technologies reported second-quarter fiscal 2023 earnings of $1.27 per share, which came in line with the Zacks Consensus Estimate. Operating Results For the fiscal second quarter, gross margin in the LSAG segment expanded by 90 basis points (bps) to 59.9% from the prior-year fiscal quarter’s number. Guidance For the fiscal third quarter of 2023, management expects revenues of $1.640-$1.675 billion, suggesting growth between 4.5% and 2.5% on a core basis from the year-ago fiscal quarter’s actuals.

A month has gone by since the last earnings report for Agilent Technologies (A). Agilent Q2 Earnings Match Estimates Agilent Technologies reported second-quarter fiscal 2023 earnings of $1.27 per share, which came in line with the Zacks Consensus Estimate. Operating Results For the fiscal second quarter, gross margin in the LSAG segment expanded by 90 basis points (bps) to 59.9% from the prior-year fiscal quarter’s number.

87.0

2023-06-21 00:00:00 UTC

Agilent Technologies Stock: Ready to Rise off the Floor

A

https://www.nasdaq.com/articles/agilent-technologies-stock%3A-ready-to-rise-off-the-floor

Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down 19% year-to-date. Agilent is a leading global provider of laboratory technologies and equipment. It counts some of the most well-known biotechnology, healthcare, diagnostic and applied materials companies in the world as clients, including Abbott Laboratories (NYSE: ABT), Thermo Fisher Scientific Inc. (NYSE: TMO) and Roche Holding AG (OTCMKTS: RHHBY). While shares were punished for their lowered guidance, the company is still very profitable. The company has stated that has seen longer sales cycles, especially with startup biotechs tightening their wallets in the uncertain macroeconomic climate. Core Growth On May 23, Agilent released its fiscal second-quarter 2023 results for the quarter ending April 2023. The company reported a non-GAAP earnings-per-share (EPS) profit of $1.27 versus consensus analyst estimates of $1.26, beating estimates by one cent. GAAP net income was $302 million, up from $274 million in the year-ago period. Revenues rose 6.8% year-over-year (YoY) to $1.72 billion, beating analyst estimates of $1.67 billion. Revenues were up 9.5% core with growth across all end markets and regions. Revenues by Segment Agilent has several divisions focused on each respective product and service. Its life sciences and applied markets group (LSAG) grew 8% year-over-year (YoY) revenue to $968 million. The operating margin was 27.3%. This division provides instruments and services to enable researchers and scientists to perform life science applications like DNA sequencing, metabolomics and protein analysis. It also provides products for applied markets like food safety, forensics and environmental testing. Its Agilent cross-lab group (ACG) segment saw 10% YoY revenue growth with 26.6% operating margins. This division provides equipment, instruments, software and services to laboratories in various industries, including healthcare, pharmaceuticals, food and beverage, environmental and forensics. Its diagnostics and genome group (DGG) had a 1% YoY revenue increase to $362 million and a 20.2% operating margin. This division provides products and services for clients to perform clinical diagnostics and genomic research. Cutting Down Guidance Agilent issues downside guidance for fiscal quarter three 2023 EPS between $1.36 to $1.38 versus $1.44 consensus analyst estimates. Revenues are expected between $1.64 billion to $1.77 billion versus $1.77 billion. Fiscal full-year 2023 EPS is expected between $5.60 to $5.65 versus $5.69 consensus analyst estimates on revenues between $6.93 billion to $7.03 billion versus $7.09 billion consensus analyst estimates. Analysts Piling into the Clown Car At least 10 analysts reiterated their existing ratings and lowered price targets. Key Banc lowered its analyst rating to "sector weight" from "overweight." Key Banc’s analyst Paul Knight commented that the company's emerging biotech (3% of historical revenue) was at zero level of activity while large biopharma (33% of revenue) was more conservative on spending. Agilent cited no slowdown in its bioprocess business and more normalized China growth. He explained that a recovery needed in margins and a lack of revenue catalysts in the back half the analyst downgraded Agilent to "sector weight." You can find Agilent Technologies analyst ratings and price targets on MarketBeat. Weekly Descending Triangle The weekly candlestick chart illustrates a weekly triangle with a clear descending trendline and flat-bottom trendline at $113.28. The triangle commenced after peaking at $159.33 in January and selling off, making lower highs on the descending trendline. A fell to a low of $113.28 in May. Shares continued to fall, forming consecutive lower-body lows. A weekly market structure low (MSL) trigger forms on a breakout through $122.22. The weekly RSI is bouncing off the oversold 30-band indicating the weekly reversal in momentum back to the upside. The weekly 20-period exponential moving average (EMA) resistance falls at $131.64, followed by the weekly 50-period MA at $136.75. Pullback support levels are at $117.51, $115.51, $113.28 triangle low and $110.65. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This division provides instruments and services to enable researchers and scientists to perform life science applications like DNA sequencing, metabolomics and protein analysis. This division provides equipment, instruments, software and services to laboratories in various industries, including healthcare, pharmaceuticals, food and beverage, environmental and forensics. He explained that a recovery needed in margins and a lack of revenue catalysts in the back half the analyst downgraded Agilent to "sector weight."

The company reported a non-GAAP earnings-per-share (EPS) profit of $1.27 versus consensus analyst estimates of $1.26, beating estimates by one cent. Cutting Down Guidance Agilent issues downside guidance for fiscal quarter three 2023 EPS between $1.36 to $1.38 versus $1.44 consensus analyst estimates. Fiscal full-year 2023 EPS is expected between $5.60 to $5.65 versus $5.69 consensus analyst estimates on revenues between $6.93 billion to $7.03 billion versus $7.09 billion consensus analyst estimates.

Revenues rose 6.8% year-over-year (YoY) to $1.72 billion, beating analyst estimates of $1.67 billion. Fiscal full-year 2023 EPS is expected between $5.60 to $5.65 versus $5.69 consensus analyst estimates on revenues between $6.93 billion to $7.03 billion versus $7.09 billion consensus analyst estimates. Weekly Descending Triangle The weekly candlestick chart illustrates a weekly triangle with a clear descending trendline and flat-bottom trendline at $113.28.

Its life sciences and applied markets group (LSAG) grew 8% year-over-year (YoY) revenue to $968 million. Its Agilent cross-lab group (ACG) segment saw 10% YoY revenue growth with 26.6% operating margins. Key Banc lowered its analyst rating to "sector weight" from "overweight."

88.0

2023-06-21 00:00:00 UTC

Validea's Top 5 Health Care Stocks Based On Martin Zweig - 6/21/2023

A

https://www.nasdaq.com/articles/valideas-top-5-health-care-stocks-based-on-martin-zweig-6-21-2023

The following are the top rated Health Care stocks according to Validea's Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt. NOVO NORDISK A/S (ADR) (NVO) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Martin Zweig is 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. P/E RATIO: PASS REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS SALES GROWTH RATE: PASS CURRENT QUARTER EARNINGS: PASS QUARTERLY EARNINGS ONE YEAR AGO: PASS POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS EARNINGS PERSISTENCE: PASS LONG-TERM EPS GROWTH: FAIL TOTAL DEBT/EQUITY RATIO: PASS INSIDER TRANSACTIONS: PASS Detailed Analysis of NOVO NORDISK A/S (ADR) NVO Guru Analysis NVO Fundamental Analysis ZIMMER BIOMET HOLDINGS INC (ZBH) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Martin Zweig is 69% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, EMEA, and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. P/E RATIO: FAIL REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS SALES GROWTH RATE: PASS CURRENT QUARTER EARNINGS: PASS QUARTERLY EARNINGS ONE YEAR AGO: PASS POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS EARNINGS PERSISTENCE: FAIL LONG-TERM EPS GROWTH: FAIL TOTAL DEBT/EQUITY RATIO: PASS INSIDER TRANSACTIONS: PASS Detailed Analysis of ZIMMER BIOMET HOLDINGS INC ZBH Guru Analysis ZBH Fundamental Analysis ELEVANCE HEALTH INC (ELV) is a large-cap growth stock in the Insurance (Accident & Health) industry. The rating according to our strategy based on Martin Zweig is 69% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefit, CarelonRx, Carelon Services, and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to individual, employer group risk-based, employer group fee-based, BlueCard, Medicare, Medicaid and federal employees health benefits (FEHB) program members. The CarelonRx segment includes its pharmacy business. CarelonRx markets and offers pharmacy services to affiliated health plan customers, as well as to external customers outside of the health plans. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. P/E RATIO: PASS REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL SALES GROWTH RATE: PASS CURRENT QUARTER EARNINGS: PASS QUARTERLY EARNINGS ONE YEAR AGO: PASS POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: FAIL EARNINGS PERSISTENCE: FAIL LONG-TERM EPS GROWTH: PASS INSIDER TRANSACTIONS: PASS Detailed Analysis of ELEVANCE HEALTH INC ELV Guru Analysis ELV Fundamental Analysis AGILENT TECHNOLOGIES INC (A) is a large-cap growth stock in the Scientific & Technical Instr. industry. The rating according to our strategy based on Martin Zweig is 66% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: Agilent Technologies, Inc. is engaged in providing application-focused solutions that include instruments, software, services, and consumables for the entire laboratory workflow. The Company's life sciences and applied markets segment provides application-focused solutions, which include instruments, consumables and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Its diagnostics and genomics segment includes the genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership and biomolecular analysis businesses. The Company's Agilent CrossLab segment offers services portfolio, which consists of repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and various other custom services to support the customers' laboratory operations. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. P/E RATIO: PASS REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL SALES GROWTH RATE: PASS CURRENT QUARTER EARNINGS: PASS QUARTERLY EARNINGS ONE YEAR AGO: PASS POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: FAIL EARNINGS PERSISTENCE: FAIL LONG-TERM EPS GROWTH: PASS TOTAL DEBT/EQUITY RATIO: PASS INSIDER TRANSACTIONS: PASS Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis SELECT MEDICAL HOLDINGS CORP (SEM) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Martin Zweig is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: Select Medical Holdings Corporation operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The Company operates through four business segments: Critical Illness Recovery Hospital, which consists of hospitals that serves the needs of patients recovering from critical illnesses; Rehabilitation Hospital, which consists of hospitals that serves patients that require intensive physical rehabilitation care; Outpatient Rehabilitation, which consists of clinics that provide physical, occupational, and speech rehabilitation services, and Concentra, which consists of occupational health centers that provides workers' compensation injury care, physical therapy, and consumer health services and onsite clinics. It operates approximately 103 critical illness recovery hospitals in 28 states, 31 rehabilitation hospitals in 12 states, and over 1,928 outpatient rehabilitation clinics in 39 states. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. P/E RATIO: PASS REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL SALES GROWTH RATE: PASS CURRENT QUARTER EARNINGS: PASS QUARTERLY EARNINGS ONE YEAR AGO: PASS POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS EARNINGS PERSISTENCE: FAIL LONG-TERM EPS GROWTH: FAIL TOTAL DEBT/EQUITY RATIO: FAIL INSIDER TRANSACTIONS: PASS Detailed Analysis of SELECT MEDICAL HOLDINGS CORP SEM Guru Analysis SEM Fundamental Analysis Martin Zweig Portfolio About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Zweig has managed both mutual and hedge funds during his career, and he's put the fortune he's compiled to some interesting uses. He has owned what Forbes reported was the most expensive apartment in New York, a $70 million penthouse that sits atop Manhattan's Pierre Hotel, and he is a collector of all sorts of pop culture and historical memorabilia -- among his purchases are the gun used by Clint Eastwood in "Dirty Harry", a stock certificate signed by Commodore Vanderbilt, and even two old-fashioned gas pumps similar to those he'd seen at a nearby gas station while growing up in Cleveland, according to published reports. About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

89.0

2023-06-20 00:00:00 UTC

Medical Stocks Waters, Agilent, Illumina Show Growth Potential

A

https://www.nasdaq.com/articles/medical-stocks-waters-agilent-illumina-show-growth-potential

Investors seeking growth often have no choice other than paying up for a stock with strong potential. However, there are some stocks that appear to be trading at low valuations relative to their growth potential. Waters Corp. (NYSE: WAT), Agilent Technologies Inc. (NYSE: A) and Illumina Inc. (NASDAQ: ILMN) are S&P 500 stocks from the medical sector that have been trending lower, despite promising earnings outlooks. These companies develop technologies used by medical and pharmaceutical researchers, as well as in the detection of conditions. As a whole, the healthcare sector, as tracked by the Health Care Select Sector SPDR Fund (NYSEARCA: XLV), has languished throughout 2023, following a strong performance in 2020 and 2021. That sets the stage for several companies within that sector to be trading at a value relative to their growth prospects. Growth at a reasonable price (GARP) is an investment strategy that seeks to find stocks with a balance between growth potential and valuation. It combines elements of both growth investing and value investing. GARP investors look for companies that have the potential for above-average earnings increases but at a reasonable price relative to their earnings or other fundamental measures. Identifying Undervalued Companies This approach aims to identify companies that are undervalued by the market but have strong growth prospects. GARP focuses on factors such as earnings growth rates, price-to-earnings ratios, and other valuation metrics to assess the investment potential of a company. Other considerations include the company's competitive position, industry trends, and financial health. Here’s a look at three medical research and equipment stocks and the traits that make them GARP candidates. Waters: Analysts See Growth Waters makes analytical instruments and software. It specializes in liquid chromatography and mass spectrometry technologies. These are analytical techniques used to separate, identify, and quantify chemical compounds in a sample. Waters has a growth-y P/E of 23, even with a year-to-date decline of 21.42%. Analysts expect earnings to grow 5% this year and 11% next year. That’s very healthy for a long-established company that’s no longer growing at red-hot rates. The company has a relatively new CEO, Udit Batra, who took the helm in September 2020. A new CEO can frequently be a catalyst for further gains in a stock, as he or she brings in fresh ideas and renewed energy for growth. MarketBeat’s Waters analyst ratings show a price target of $335.27, an upside of 24.54%. Agilent Technologies: Stock May Have Bottomed The Agilent Technologies chart shows that the stock may have bottomed out in recent weeks after dropping 18.91% so far this year. Agilent provides scientific instruments, software, services, and lab supplies for laboratory analysis and diagnostics. The company has a long history of profitability, and MarketBeat’s Agilent Technologies dividend data show that it pays a yield of 0.74%. That’s not a spectacular yield, but it somewhat offsets price losses. Earnings have grown steadily, with a three-year earnings growth rate is a healthy 23%. Analysts expect earnings to grow 8% this year and 9% next year. The return on equity is 29%, indicating an efficiently managed company. Agilent Technologies analyst ratings show a consensus view of “moderate buy” on the stock, with a price target of $151.35 and an upside of 24.95%. Illumina: Good Estimates Despite Challenges Illumina has been in the news recently as its CEO resigned amid pressure from hedge fund manager Carl Icahn, an activist investor. The board is currently conducting a search for a new CEO. As noted above, when that new CEO is named, it could eventually result in a strong round of earnings and price gains for the stock. Illumina is a biotechnology company specializing in genetic sequencing and technologies for genomic research and clinical applications. Illumina's CEO resignation coincides with an ongoing dispute with activist investor Carl Icahn regarding Illumina’s acquisition of Grail. The Federal Trade Commission issued an order requiring Illumina to divest Grail, which makes a multi-cancer early detection test. The FTC said the deal would stifle competition and innovation in the U.S. market for life-saving cancer tests. Although that all sounds messy, analysts still have confidence that the stock has plenty of growth potential. MarketBeat’s Illumina analyst ratings show a consensus rating of “hold” with a price target of $253.70, an upside of 23.23%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

GARP focuses on factors such as earnings growth rates, price-to-earnings ratios, and other valuation metrics to assess the investment potential of a company. Agilent Technologies analyst ratings show a consensus view of “moderate buy” on the stock, with a price target of $151.35 and an upside of 24.95%. The Federal Trade Commission issued an order requiring Illumina to divest Grail, which makes a multi-cancer early detection test.

Waters: Analysts See Growth Waters makes analytical instruments and software. Agilent Technologies analyst ratings show a consensus view of “moderate buy” on the stock, with a price target of $151.35 and an upside of 24.95%. MarketBeat’s Illumina analyst ratings show a consensus rating of “hold” with a price target of $253.70, an upside of 23.23%.

Growth at a reasonable price (GARP) is an investment strategy that seeks to find stocks with a balance between growth potential and valuation. Agilent Technologies: Stock May Have Bottomed The Agilent Technologies chart shows that the stock may have bottomed out in recent weeks after dropping 18.91% so far this year. Agilent Technologies analyst ratings show a consensus view of “moderate buy” on the stock, with a price target of $151.35 and an upside of 24.95%.

Growth at a reasonable price (GARP) is an investment strategy that seeks to find stocks with a balance between growth potential and valuation. Waters: Analysts See Growth Waters makes analytical instruments and software. The company has a long history of profitability, and MarketBeat’s Agilent Technologies dividend data show that it pays a yield of 0.74%.

90.0

2023-06-14 00:00:00 UTC

Agilent (A) Boosts LSAG Segment With New GPC/SEC Solutions

A

https://www.nasdaq.com/articles/agilent-a-boosts-lsag-segment-with-new-gpc-sec-solutions

Agilent Technologies A is constantly gaining traction in molecular analyses on the back of its strength in liquid chromatography mass spectrometry (LCMS) offerings. This is evident from its latest InfinityLab Gel Permeation Chromatography/Size Exclusion Chromatography (GPC/SEC) solutions, which the company is gearing up to showcase at the HPLC 2023 conference. With the new solutions, which are designed for advanced material characterization, the company strengthened its Agilent InfinityLab GPC/SEC portfolio. Moreover, the portfolio now includes the benefits of the Polymer Standard Service acquisition. Notably, the new additions include the likes GPC/SEC column thermostat, the GPC/SEC-Ready Kit, a multi-angle light scattering detector and the powerful WinGPC Software. The combined portfolio of InfinityLab GPC/SEC and Polymer Standard Service will help Agilent cater well to the needs of scientists in macromolecular analysis. Also, it will aid its momentum across the chemical, food, pharmaceutical and biopharmaceutical industries. Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote LSAG Segment in Focus The latest move bodes well for the company’s growing efforts toward bolstering its Life Sciences & Applied Markets Group (LSAG) segment, which contributes the most to total revenues. Apart from the expansion of the Agilent InfinityLab GPC/SEC portfolio, the company recently launched the 6495 Triple Quadrupole LC/MS (LC/TQ) System and the Revident Quadrupole Time-of-Flight LC/MS (LC/QTOF) System. Notably, 6495 LC/TQ is designed to take care of the critical transition between the discovery phase of research and the translational phase to generate meaningful scientific insights on the back of its intelligence features. Meanwhile, Revident LC/Q-TOF features instrument intelligence for maximized operation time and productivity and a novel detection system that boosts spectral purity. To Conclude The abovementioned endeavors are expected to continue aiding the performance of the LSAG segment. In second-quarter fiscal 2023, the underlined segment generated $968 million in revenues, which accounted for 56% of the total revenues. The figure was up 8% on a reported basis and 10% on a core basis from the prior-year fiscal quarter’s levels. We believe the company’s strong focus on bolstering the LSAG segment will benefit its overall performance. For fiscal 2023, Agilent expects revenues between $6.93 billion and $7.03 billion, implying growth of 1.2-2.7% on a reported basis and 3-4.5% on a core basis from the respective fiscal 2022 figures. The Zacks Consensus Estimate for Agilent's fiscal 2023 revenues is pegged at $6.99 billion, indicating growth of 2% from 2022. However, mounting expenses do not bode well for the company’s profitability. Further, macroeconomic headwinds and uncertainties in the demand environment remain concerns. Coming to price performance, Agilent has lost 20% in the year-to-date period against the industry’s growth of 4.5%. Zacks Rank & Stocks to Consider Currently, Agilent Technologies carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader technology sector are Palo Alto Networks PANW, NVIDIA NVDA and AMETEK AME. While Palo Alto Networks and NVIDIA sport a Zacks Rank #1 (Strong Buy) each, AME carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Palo Alto Networks shares have gained 65% in the year-to-date period. The long-term earnings growth rate for PANW is currently projected at 31.5%. NVIDIA shares rallied 173.8% in the year-to-date period. Its long-term earnings growth rate is presently projected at 23.02%. AMETEK shares have increased by 10.2% in the year-to-date period. The long-term earnings growth rate for AME is currently projected at 8.95%. Zacks Reveals ChatGPT "Sleeper" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NVIDIA Corporation (NVDA) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report AMETEK, Inc. (AME) : Free Stock Analysis Report Palo Alto Networks, Inc. (PANW) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Agilent Technologies A is constantly gaining traction in molecular analyses on the back of its strength in liquid chromatography mass spectrometry (LCMS) offerings. This is evident from its latest InfinityLab Gel Permeation Chromatography/Size Exclusion Chromatography (GPC/SEC) solutions, which the company is gearing up to showcase at the HPLC 2023 conference. Notably, the new additions include the likes GPC/SEC column thermostat, the GPC/SEC-Ready Kit, a multi-angle light scattering detector and the powerful WinGPC Software.

Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote LSAG Segment in Focus The latest move bodes well for the company’s growing efforts toward bolstering its Life Sciences & Applied Markets Group (LSAG) segment, which contributes the most to total revenues. While Palo Alto Networks and NVIDIA sport a Zacks Rank #1 (Strong Buy) each, AME carries a Zacks Rank #2 (Buy). Click to get this free report NVIDIA Corporation (NVDA) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report AMETEK, Inc. (AME) : Free Stock Analysis Report Palo Alto Networks, Inc. (PANW) : Free Stock Analysis Report To read this article on Zacks.com click here.

Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote LSAG Segment in Focus The latest move bodes well for the company’s growing efforts toward bolstering its Life Sciences & Applied Markets Group (LSAG) segment, which contributes the most to total revenues. Zacks Rank & Stocks to Consider Currently, Agilent Technologies carries a Zacks Rank #4 (Sell). Click to get this free report NVIDIA Corporation (NVDA) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report AMETEK, Inc. (AME) : Free Stock Analysis Report Palo Alto Networks, Inc. (PANW) : Free Stock Analysis Report To read this article on Zacks.com click here.

Some better-ranked stocks in the broader technology sector are Palo Alto Networks PANW, NVIDIA NVDA and AMETEK AME. Palo Alto Networks shares have gained 65% in the year-to-date period. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research?

91.0

2023-06-07 00:00:00 UTC

Agilent (A) Boosts LCMS Portfolio With New Systems Launch

A

https://www.nasdaq.com/articles/agilent-a-boosts-lcms-portfolio-with-new-systems-launch

Agilent Technologies A expanded its liquid chromatography mass spectrometry (LCMS) offerings with the launch of the 6495 Triple Quadrupole LC/MS (LC/TQ) System and the Revident Quadrupole Time-of-Flight LC/MS (LC/QTOF) System. Notably, 6495 LC/TQ is designed to take care of the critical transition between the discovery phase of research and the translational phase to generate meaningful scientific insights on the back of its intelligence features. Thus, Agilent is likely to gain momentum among the targeted analysis applications that require the highest analytical sensitivity. Meanwhile, Revident LC/Q-TOF features instrument intelligence for maximized operation time and productivity and a novel detection system that boosts spectral purity. In addition to the new LCMS systems, Agilent unveiled MassHunter Explorer Profiling software and the new ChemVista library manager software, both of which are integrated with Revident LC/Q-TOF for delivering meaningful scientific insights. With Revident LC/Q-TO, the company is set to gain traction across food safety and environmental analysis and applications in other small molecule markets. Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote LSAG Segment in Focus The latest move bodes well for the company’s growing efforts toward bolstering its Life Sciences & Applied Markets Group (LSAG) segment, which contributes the most to total revenues. In second-quarter fiscal 2023, the segment generated $968 million in revenues, which accounted for 56% of the total revenues. The figure was up 8% on a reported basis and 10% on a core basis from the prior-year fiscal quarter’s levels. We believe the company’s strong focus on bolstering the LSAG segment is expected to contribute well to its overall performance, which in turn is likely to aid it in winning investors’ confidence in the days ahead. For fiscal 2023, Agilent expects revenues between $6.93 billion and $7.03 billion, implying growth of 1.2-2.7% on a reported basis and 3-4.5% on a core basis from the respective fiscal 2022 figures. The Zacks Consensus Estimate for Agilent's 2023 revenues is pegged at $6.99 billion, indicating growth of 2.1% from 2022. Coming to the price performance, Agilent has lost 21.4% in the year-to-date period against the industry’s growth of 2.3%. Expanding Portfolio Apart from the latest LCMS systems, the company rolled out the Cary 3500 Flexible UV-Vis System to strengthen its OpenLab software suite. The new spectrophotometer is ideal for analyzing liquid samples and characterizing solid samples as it features a large sample compartment with a small footprint. Further, the company announced the acquisition of e-Msion, which is known for an innovative electron capture dissociation (ECD) technology called the ExD cell. As part of the deal, the ExD cell will be integrated into Agilent’s advanced workflows, instruments and analytical solutions, which in turn will drive Agilent’s momentum across laboratories as well as among biological researchers. Also, Agilent announced the acquisition of Avida Biomed, which develops high-performance target enrichment workflows to aid clinical researchers using next-generation sequencing (NGS) approaches in studying cancer. The solutions of Avida Biomed highly complement Agilent’s SureSelect portfolio and NGS offerings. It has added strength to A’s portfolio of clinical research solutions. The acquisition is expected to help Agilent strengthen its Diagnostics and Genomics Group (DGG) segment. We believe that the growing portfolio offerings will continue to help Agilent strengthen its presence across various end markets. Zacks Rank & Stocks to Consider Currently, Agilent Technologies carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader technology sector are Palo Alto Networks PANW, NVIDIA NVDA and AMETEK AME. While Palo Alto Networks and NVIDIA sport a Zacks Rank #1 (Strong Buy), AME carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Palo Alto Networks shares have gained 61.9% in the year-to-date period. The long-term earnings growth rate for PANW is currently projected at 31.5%. NVIDIA shares have gained 166.1% in the year-to-date period. Its long-term earnings growth rate is presently projected at 23.02%. AMTEK shares have gained 7% in the year-to-date period. The long-term earnings growth rate for AME is currently projected at 8.95%. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is “Will you get into the right stocks early when their growth potential is greatest?” Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How To Profit From Trillions On Spending For Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NVIDIA Corporation (NVDA) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report AMETEK, Inc. (AME) : Free Stock Analysis Report Palo Alto Networks, Inc. (PANW) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

We believe the company’s strong focus on bolstering the LSAG segment is expected to contribute well to its overall performance, which in turn is likely to aid it in winning investors’ confidence in the days ahead. Also, Agilent announced the acquisition of Avida Biomed, which develops high-performance target enrichment workflows to aid clinical researchers using next-generation sequencing (NGS) approaches in studying cancer. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.

Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote LSAG Segment in Focus The latest move bodes well for the company’s growing efforts toward bolstering its Life Sciences & Applied Markets Group (LSAG) segment, which contributes the most to total revenues. While Palo Alto Networks and NVIDIA sport a Zacks Rank #1 (Strong Buy), AME carries a Zacks Rank #2 (Buy). Click to get this free report NVIDIA Corporation (NVDA) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report AMETEK, Inc. (AME) : Free Stock Analysis Report Palo Alto Networks, Inc. (PANW) : Free Stock Analysis Report To read this article on Zacks.com click here.

Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote LSAG Segment in Focus The latest move bodes well for the company’s growing efforts toward bolstering its Life Sciences & Applied Markets Group (LSAG) segment, which contributes the most to total revenues. Zacks Rank & Stocks to Consider Currently, Agilent Technologies carries a Zacks Rank #3 (Hold). Click to get this free report NVIDIA Corporation (NVDA) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report AMETEK, Inc. (AME) : Free Stock Analysis Report Palo Alto Networks, Inc. (PANW) : Free Stock Analysis Report To read this article on Zacks.com click here.

Agilent Technologies, Inc. Price and Consensus Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote LSAG Segment in Focus The latest move bodes well for the company’s growing efforts toward bolstering its Life Sciences & Applied Markets Group (LSAG) segment, which contributes the most to total revenues. Download FREE: How To Profit From Trillions On Spending For Infrastructure >> Want the latest recommendations from Zacks Investment Research? Click to get this free report NVIDIA Corporation (NVDA) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report AMETEK, Inc. (AME) : Free Stock Analysis Report Palo Alto Networks, Inc. (PANW) : Free Stock Analysis Report To read this article on Zacks.com click here.

92.0

2023-06-02 00:00:00 UTC

After Hours Most Active for Jun 2, 2023 : UPWK, QQQ, LCID, INTC, GOOGL, AAPL, BAC, T, NEE, VZ, PFE, AI

A

https://www.nasdaq.com/articles/after-hours-most-active-for-jun-2-2023-%3A-upwk-qqq-lcid-intc-googl-aapl-bac-t-nee-vz-pfe-ai

The NASDAQ 100 After Hours Indicator is down -7.37 to 14,539.27. The total After hours volume is currently 105,543,465 shares traded. The following are the most active stocks for the after hours session: Upwork Inc. (UPWK) is unchanged at $8.78, with 7,140,025 shares traded. As reported by Zacks, the current mean recommendation for UPWK is in the "buy range". Invesco QQQ Trust, Series 1 (QQQ) is +0.14 at $354.79, with 3,754,345 shares traded., following a 52-week high recorded in today's regular session. Lucid Group, Inc. (LCID) is -0.01 at $6.59, with 3,043,255 shares traded. As reported in the last short interest update the days to cover for LCID is 9.268482; this calculation is based on the average trading volume of the stock. Intel Corporation (INTC) is +0.01 at $31.32, with 2,563,384 shares traded. INTC's current last sale is 102.69% of the target price of $30.5. Alphabet Inc. (GOOGL) is +0.09 at $124.76, with 2,473,385 shares traded. As reported by Zacks, the current mean recommendation for GOOGL is in the "buy range". Apple Inc. (AAPL) is +0.05 at $181.00, with 2,408,686 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2023. The consensus EPS forecast is $1.18. , following a 52-week high recorded in today's regular session. Bank of America Corporation (BAC) is -0.02 at $28.69, with 1,906,940 shares traded. BAC's current last sale is 81.97% of the target price of $35. AT&T Inc. (T) is +0.01 at $15.22, with 1,793,938 shares traded. T's current last sale is 69.18% of the target price of $22. NextEra Energy, Inc. (NEE) is unchanged at $73.85, with 1,568,172 shares traded. As reported by Zacks, the current mean recommendation for NEE is in the "buy range". Verizon Communications Inc. (VZ) is -0.02 at $34.56, with 1,460,961 shares traded. VZ's current last sale is 82.29% of the target price of $42. Pfizer, Inc. (PFE) is -0.14 at $38.22, with 1,241,563 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2023. The consensus EPS forecast is $0.8. PFE's current last sale is 84.93% of the target price of $45. C3.ai, Inc. (AI) is -0.28 at $31.98, with 979,581 shares traded. AI's current last sale is 188.12% of the target price of $17. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

As reported in the last short interest update the days to cover for LCID is 9.268482; this calculation is based on the average trading volume of the stock. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2023. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2023.

The total After hours volume is currently 105,543,465 shares traded. Invesco QQQ Trust, Series 1 (QQQ) is +0.14 at $354.79, with 3,754,345 shares traded., following a 52-week high recorded in today's regular session. , following a 52-week high recorded in today's regular session.

The total After hours volume is currently 105,543,465 shares traded. AT&T Inc. (T) is +0.01 at $15.22, with 1,793,938 shares traded. C3.ai, Inc. (AI) is -0.28 at $31.98, with 979,581 shares traded.

The following are the most active stocks for the after hours session: AT&T Inc. (T) is +0.01 at $15.22, with 1,793,938 shares traded. C3.ai, Inc. (AI) is -0.28 at $31.98, with 979,581 shares traded.

93.0

2023-05-29 00:00:00 UTC

Validea's Top 5 Health Care Stocks Based On Martin Zweig - 5/29/2023

A

https://www.nasdaq.com/articles/valideas-top-5-health-care-stocks-based-on-martin-zweig-5-29-2023

The following are the top rated Health Care stocks according to Validea's Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt. BRUKER CORPORATION (BRKR) is a large-cap growth stock in the Scientific & Technical Instr. industry. The rating according to our strategy based on Martin Zweig is 69% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: Bruker Corporation is a developer, manufacturer and distributor of scientific instruments and analytical and diagnostic solutions. The Company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano and Bruker Energy & Supercon Technologies (BEST). The BSI BioSpin segment designs, manufactures, and distributes enabling life science tools based on magnetic resonance technology. The BSI CALID segment designs, manufactures and distributes life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions. The BSI Nano segment designs, manufactures and distributes advanced X-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, and others. BEST segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. P/E RATIO: PASS REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL SALES GROWTH RATE: PASS CURRENT QUARTER EARNINGS: PASS QUARTERLY EARNINGS ONE YEAR AGO: PASS POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS EARNINGS PERSISTENCE: FAIL LONG-TERM EPS GROWTH: PASS TOTAL DEBT/EQUITY RATIO: PASS INSIDER TRANSACTIONS: PASS Detailed Analysis of BRUKER CORPORATION BRKR Guru Analysis BRKR Fundamental Analysis ZIMMER BIOMET HOLDINGS INC (ZBH) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Martin Zweig is 69% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, EMEA, and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. P/E RATIO: FAIL REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS SALES GROWTH RATE: PASS CURRENT QUARTER EARNINGS: PASS QUARTERLY EARNINGS ONE YEAR AGO: PASS POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS EARNINGS PERSISTENCE: FAIL LONG-TERM EPS GROWTH: FAIL TOTAL DEBT/EQUITY RATIO: PASS INSIDER TRANSACTIONS: PASS Detailed Analysis of ZIMMER BIOMET HOLDINGS INC ZBH Guru Analysis ZBH Fundamental Analysis CENTENE CORP (CNC) is a large-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Martin Zweig is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: Centene Corporation is a healthcare company. The Company provides services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. It provides a range of managed healthcare products and services, primarily through Medicaid, Medicare, and commercial products. Its segments include Medicaid, Medicare, Commercial and Other. It offers Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace and the TRICARE program. It also contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Medicaid program provides health insurance to low-income families and individuals with disabilities. Medicare is a federal health insurance program for people ages 65 and over, which also covers people under 65 with certain disabilities and people with end-stage renal diseases. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. P/E RATIO: PASS REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS SALES GROWTH RATE: FAIL CURRENT QUARTER EARNINGS: PASS QUARTERLY EARNINGS ONE YEAR AGO: PASS POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS EARNINGS PERSISTENCE: FAIL LONG-TERM EPS GROWTH: FAIL TOTAL DEBT/EQUITY RATIO: PASS INSIDER TRANSACTIONS: PASS Detailed Analysis of CENTENE CORP CNC Guru Analysis CNC Fundamental Analysis AGILENT TECHNOLOGIES INC (A) is a large-cap growth stock in the Scientific & Technical Instr. industry. The rating according to our strategy based on Martin Zweig is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: Agilent Technologies, Inc. is engaged in providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. It operates in the life sciences, diagnostics and applied chemical markets. Its life sciences and applied markets business offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Its diagnostics and genomics businesses are comprised of six areas of activity, providing active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software, and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. Its product categories include liquid chromatography systems and components and liquid chromatography mass spectrometry systems. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. P/E RATIO: PASS REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL SALES GROWTH RATE: PASS CURRENT QUARTER EARNINGS: PASS QUARTERLY EARNINGS ONE YEAR AGO: PASS POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: FAIL EARNINGS PERSISTENCE: FAIL LONG-TERM EPS GROWTH: PASS TOTAL DEBT/EQUITY RATIO: PASS INSIDER TRANSACTIONS: PASS Detailed Analysis of AGILENT TECHNOLOGIES INC A Guru Analysis A Fundamental Analysis SIMULATIONS PLUS INC (SLP) is a small-cap growth stock in the Software & Programming industry. The rating according to our strategy based on Martin Zweig is 54% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: Simulations Plus, Inc. is a developer of drug discovery and development software for mechanistic modeling and simulation, for machine-learning-based prediction of properties of molecules from their structure, and is exploring the application of its machine-learning technologies in other industries, including aerospace/military and general healthcare. The Company offers its products and services through two business segments, which include Simulations Plus, Inc. and Cognigen Corporation. Cognigen Corporation is the subsidiary of the Company. Its pharmaceutical/chemistry software is used by various companies, such as pharmaceutical, biotechnology, agrochemical, and food industry companies and to regulatory agencies for use in the conduct of industry-based research. Its clinical-pharmacology-based consulting services include pharmacokinetic and pharmacodynamics modeling, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. P/E RATIO: FAIL REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS SALES GROWTH RATE: PASS CURRENT QUARTER EARNINGS: PASS QUARTERLY EARNINGS ONE YEAR AGO: PASS POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: FAIL EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: FAIL EARNINGS PERSISTENCE: FAIL LONG-TERM EPS GROWTH: FAIL TOTAL DEBT/EQUITY RATIO: PASS INSIDER TRANSACTIONS: PASS Detailed Analysis of SIMULATIONS PLUS INC SLP Guru Analysis SLP Fundamental Analysis Martin Zweig Portfolio About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Zweig has managed both mutual and hedge funds during his career, and he's put the fortune he's compiled to some interesting uses. He has owned what Forbes reported was the most expensive apartment in New York, a $70 million penthouse that sits atop Manhattan's Pierre Hotel, and he is a collector of all sorts of pop culture and historical memorabilia -- among his purchases are the gun used by Clint Eastwood in "Dirty Harry", a stock certificate signed by Commodore Vanderbilt, and even two old-fashioned gas pumps similar to those he'd seen at a nearby gas station while growing up in Cleveland, according to published reports. About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

94.0

2023-05-24 00:00:00 UTC

Stifel Maintains Agilent Technologies (A) Hold Recommendation

A

https://www.nasdaq.com/articles/stifel-maintains-agilent-technologies-a-hold-recommendation

Fintel reports that on May 24, 2023, Stifel maintained coverage of Agilent Technologies (NYSE:A) with a Hold recommendation. Analyst Price Forecast Suggests 29.29% Upside As of May 11, 2023, the average one-year price target for Agilent Technologies is 166.32. The forecasts range from a low of 146.45 to a high of $182.70. The average price target represents an increase of 29.29% from its latest reported closing price of 128.64. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.28%. The projected annual non-GAAP EPS is 5.77. Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). Shareholders of record as of July 3, 2023 will receive the payment on July 26, 2023. Previously, the company paid $0.22 per share. At the current share price of $128.64 / share, the stock's dividend yield is 0.70%. Looking back five years and taking a sample every week, the average dividend yield has been 0.74%, the lowest has been 0.44%, and the highest has been 1.14%. The standard deviation of yields is 0.16 (n=236). The current dividend yield is 0.26 standard deviations below the historical average. Additionally, the company's dividend payout ratio is 0.20. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5. The company's 3-Year dividend growth rate is 0.25%, demonstrating that it has increased its dividend over time. What is the Fund Sentiment? There are 2012 funds or institutions reporting positions in Agilent Technologies. This is an increase of 53 owner(s) or 2.71% in the last quarter. Average portfolio weight of all funds dedicated to A is 0.40%, a decrease of 8.32%. Total shares owned by institutions increased in the last three months by 0.70% to 302,422K shares. The put/call ratio of A is 1.12, indicating a bearish outlook. What are Other Shareholders Doing? Wellington Management Group Llp holds 12,057K shares representing 4.08% ownership of the company. In it's prior filing, the firm reported owning 13,408K shares, representing a decrease of 11.21%. The firm decreased its portfolio allocation in A by 17.85% over the last quarter. T. Rowe Price Investment Management holds 9,277K shares representing 3.14% ownership of the company. In it's prior filing, the firm reported owning 9,304K shares, representing a decrease of 0.29%. The firm decreased its portfolio allocation in A by 13.88% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,971K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 8,825K shares, representing an increase of 1.62%. The firm increased its portfolio allocation in A by 15.57% over the last quarter. Massachusetts Financial Services holds 8,907K shares representing 3.01% ownership of the company. In it's prior filing, the firm reported owning 7,868K shares, representing an increase of 11.66%. The firm increased its portfolio allocation in A by 2.60% over the last quarter. Price T Rowe Associates holds 8,219K shares representing 2.78% ownership of the company. In it's prior filing, the firm reported owning 7,707K shares, representing an increase of 6.23%. The firm decreased its portfolio allocation in A by 8.26% over the last quarter. Agilent Technologies Background Information (This description is provided by the company.) Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Key filings for this company: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. Key filings for this company: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K This story originally appeared on Fintel.

In it's prior filing, the firm reported owning 13,408K shares, representing a decrease of 11.21%. T. Rowe Price Investment Management holds 9,277K shares representing 3.14% ownership of the company. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,971K shares representing 3.03% ownership of the company.

Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,971K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 8,825K shares, representing an increase of 1.62%.

The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.28%. At the current share price of $128.64 / share, the stock's dividend yield is 0.70%. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend.

95.0

2023-05-24 00:00:00 UTC

B of A Securities Maintains Agilent Technologies (A) Buy Recommendation

A

https://www.nasdaq.com/articles/b-of-a-securities-maintains-agilent-technologies-a-buy-recommendation

Fintel reports that on May 24, 2023, B of A Securities maintained coverage of Agilent Technologies (NYSE:A) with a Buy recommendation. Analyst Price Forecast Suggests 29.29% Upside As of May 11, 2023, the average one-year price target for Agilent Technologies is 166.32. The forecasts range from a low of 146.45 to a high of $182.70. The average price target represents an increase of 29.29% from its latest reported closing price of 128.64. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.28%. The projected annual non-GAAP EPS is 5.77. Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). Shareholders of record as of July 3, 2023 will receive the payment on July 26, 2023. Previously, the company paid $0.22 per share. At the current share price of $128.64 / share, the stock's dividend yield is 0.70%. Looking back five years and taking a sample every week, the average dividend yield has been 0.74%, the lowest has been 0.44%, and the highest has been 1.14%. The standard deviation of yields is 0.16 (n=236). The current dividend yield is 0.26 standard deviations below the historical average. Additionally, the company's dividend payout ratio is 0.20. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5. The company's 3-Year dividend growth rate is 0.25%, demonstrating that it has increased its dividend over time. What is the Fund Sentiment? There are 2012 funds or institutions reporting positions in Agilent Technologies. This is an increase of 53 owner(s) or 2.71% in the last quarter. Average portfolio weight of all funds dedicated to A is 0.40%, a decrease of 8.32%. Total shares owned by institutions increased in the last three months by 0.70% to 302,422K shares. The put/call ratio of A is 1.12, indicating a bearish outlook. What are Other Shareholders Doing? Wellington Management Group Llp holds 12,057K shares representing 4.08% ownership of the company. In it's prior filing, the firm reported owning 13,408K shares, representing a decrease of 11.21%. The firm decreased its portfolio allocation in A by 17.85% over the last quarter. T. Rowe Price Investment Management holds 9,277K shares representing 3.14% ownership of the company. In it's prior filing, the firm reported owning 9,304K shares, representing a decrease of 0.29%. The firm decreased its portfolio allocation in A by 13.88% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,971K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 8,825K shares, representing an increase of 1.62%. The firm increased its portfolio allocation in A by 15.57% over the last quarter. Massachusetts Financial Services holds 8,907K shares representing 3.01% ownership of the company. In it's prior filing, the firm reported owning 7,868K shares, representing an increase of 11.66%. The firm increased its portfolio allocation in A by 2.60% over the last quarter. Price T Rowe Associates holds 8,219K shares representing 2.78% ownership of the company. In it's prior filing, the firm reported owning 7,707K shares, representing an increase of 6.23%. The firm decreased its portfolio allocation in A by 8.26% over the last quarter. Agilent Technologies Background Information (This description is provided by the company.) Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Key filings for this company: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. Key filings for this company: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K This story originally appeared on Fintel.

In it's prior filing, the firm reported owning 13,408K shares, representing a decrease of 11.21%. T. Rowe Price Investment Management holds 9,277K shares representing 3.14% ownership of the company. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,971K shares representing 3.03% ownership of the company.

Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,971K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 8,825K shares, representing an increase of 1.62%.

The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.28%. At the current share price of $128.64 / share, the stock's dividend yield is 0.70%. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend.

96.0

2023-05-24 00:00:00 UTC

Wells Fargo Maintains Agilent Technologies (A) Overweight Recommendation

A

https://www.nasdaq.com/articles/wells-fargo-maintains-agilent-technologies-a-overweight-recommendation

Fintel reports that on May 24, 2023, Wells Fargo maintained coverage of Agilent Technologies (NYSE:A) with a Overweight recommendation. Analyst Price Forecast Suggests 29.29% Upside As of May 11, 2023, the average one-year price target for Agilent Technologies is 166.32. The forecasts range from a low of 146.45 to a high of $182.70. The average price target represents an increase of 29.29% from its latest reported closing price of 128.64. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.28%. The projected annual non-GAAP EPS is 5.77. Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). Shareholders of record as of July 3, 2023 will receive the payment on July 26, 2023. Previously, the company paid $0.22 per share. At the current share price of $128.64 / share, the stock's dividend yield is 0.70%. Looking back five years and taking a sample every week, the average dividend yield has been 0.74%, the lowest has been 0.44%, and the highest has been 1.14%. The standard deviation of yields is 0.16 (n=236). The current dividend yield is 0.26 standard deviations below the historical average. Additionally, the company's dividend payout ratio is 0.20. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5. The company's 3-Year dividend growth rate is 0.25%, demonstrating that it has increased its dividend over time. What is the Fund Sentiment? There are 2012 funds or institutions reporting positions in Agilent Technologies. This is an increase of 53 owner(s) or 2.71% in the last quarter. Average portfolio weight of all funds dedicated to A is 0.40%, a decrease of 8.32%. Total shares owned by institutions increased in the last three months by 0.70% to 302,422K shares. The put/call ratio of A is 1.12, indicating a bearish outlook. What are Other Shareholders Doing? Wellington Management Group Llp holds 12,057K shares representing 4.08% ownership of the company. In it's prior filing, the firm reported owning 13,408K shares, representing a decrease of 11.21%. The firm decreased its portfolio allocation in A by 17.85% over the last quarter. T. Rowe Price Investment Management holds 9,277K shares representing 3.14% ownership of the company. In it's prior filing, the firm reported owning 9,304K shares, representing a decrease of 0.29%. The firm decreased its portfolio allocation in A by 13.88% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,971K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 8,825K shares, representing an increase of 1.62%. The firm increased its portfolio allocation in A by 15.57% over the last quarter. Massachusetts Financial Services holds 8,907K shares representing 3.01% ownership of the company. In it's prior filing, the firm reported owning 7,868K shares, representing an increase of 11.66%. The firm increased its portfolio allocation in A by 2.60% over the last quarter. Price T Rowe Associates holds 8,219K shares representing 2.78% ownership of the company. In it's prior filing, the firm reported owning 7,707K shares, representing an increase of 6.23%. The firm decreased its portfolio allocation in A by 8.26% over the last quarter. Agilent Technologies Background Information (This description is provided by the company.) Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Key filings for this company: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. Key filings for this company: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K This story originally appeared on Fintel.

In it's prior filing, the firm reported owning 13,408K shares, representing a decrease of 11.21%. T. Rowe Price Investment Management holds 9,277K shares representing 3.14% ownership of the company. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,971K shares representing 3.03% ownership of the company.

Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,971K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 8,825K shares, representing an increase of 1.62%.

The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.28%. At the current share price of $128.64 / share, the stock's dividend yield is 0.70%. There are 2012 funds or institutions reporting positions in Agilent Technologies.

97.0

2023-05-24 00:00:00 UTC

Baird Maintains Agilent Technologies (A) Outperform Recommendation

A

https://www.nasdaq.com/articles/baird-maintains-agilent-technologies-a-outperform-recommendation

Fintel reports that on May 24, 2023, Baird maintained coverage of Agilent Technologies (NYSE:A) with a Outperform recommendation. Analyst Price Forecast Suggests 29.29% Upside As of May 11, 2023, the average one-year price target for Agilent Technologies is 166.32. The forecasts range from a low of 146.45 to a high of $182.70. The average price target represents an increase of 29.29% from its latest reported closing price of 128.64. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.28%. The projected annual non-GAAP EPS is 5.77. Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). Shareholders of record as of July 3, 2023 will receive the payment on July 26, 2023. Previously, the company paid $0.22 per share. At the current share price of $128.64 / share, the stock's dividend yield is 0.70%. Looking back five years and taking a sample every week, the average dividend yield has been 0.74%, the lowest has been 0.44%, and the highest has been 1.14%. The standard deviation of yields is 0.16 (n=236). The current dividend yield is 0.26 standard deviations below the historical average. Additionally, the company's dividend payout ratio is 0.20. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5. The company's 3-Year dividend growth rate is 0.25%, demonstrating that it has increased its dividend over time. What is the Fund Sentiment? There are 2012 funds or institutions reporting positions in Agilent Technologies. This is an increase of 53 owner(s) or 2.71% in the last quarter. Average portfolio weight of all funds dedicated to A is 0.40%, a decrease of 8.32%. Total shares owned by institutions increased in the last three months by 0.70% to 302,422K shares. The put/call ratio of A is 1.12, indicating a bearish outlook. What are Other Shareholders Doing? Wellington Management Group Llp holds 12,057K shares representing 4.08% ownership of the company. In it's prior filing, the firm reported owning 13,408K shares, representing a decrease of 11.21%. The firm decreased its portfolio allocation in A by 17.85% over the last quarter. T. Rowe Price Investment Management holds 9,277K shares representing 3.14% ownership of the company. In it's prior filing, the firm reported owning 9,304K shares, representing a decrease of 0.29%. The firm decreased its portfolio allocation in A by 13.88% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,971K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 8,825K shares, representing an increase of 1.62%. The firm increased its portfolio allocation in A by 15.57% over the last quarter. Massachusetts Financial Services holds 8,907K shares representing 3.01% ownership of the company. In it's prior filing, the firm reported owning 7,868K shares, representing an increase of 11.66%. The firm increased its portfolio allocation in A by 2.60% over the last quarter. Price T Rowe Associates holds 8,219K shares representing 2.78% ownership of the company. In it's prior filing, the firm reported owning 7,707K shares, representing an increase of 6.23%. The firm decreased its portfolio allocation in A by 8.26% over the last quarter. Agilent Technologies Background Information (This description is provided by the company.) Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Key filings for this company: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. Key filings for this company: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K This story originally appeared on Fintel.

In it's prior filing, the firm reported owning 13,408K shares, representing a decrease of 11.21%. T. Rowe Price Investment Management holds 9,277K shares representing 3.14% ownership of the company. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,971K shares representing 3.03% ownership of the company.

Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,971K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 8,825K shares, representing an increase of 1.62%.

The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.28%. At the current share price of $128.64 / share, the stock's dividend yield is 0.70%. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend.

98.0

2023-05-24 00:00:00 UTC

Why Agilent Technologies Stock Is Sinking Today

A

https://www.nasdaq.com/articles/why-agilent-technologies-stock-is-sinking-today

What happened Shares of Agilent Technologies (NYSE: A) were sinking 7.9% lower as of 11:34 a.m. ET on Wednesday. The decline came after the life sciences company announced its fiscal 2023 second-quarter results following the market close on Tuesday. Agilent reported fiscal Q2 revenue of $1.72 billion, up 6.8% year over year. It posted net income of $302 million, or $1.02 per share, based on generally accepted accounting principles (GAAP). The company's non-GAAP earnings were $377 million, or $1.27 per share. Although Agilent narrowly topped the consensus Wall Street earnings estimate for the latest quarter, the company's guidance fell short. Agilent projects fiscal Q3 revenue of between $1.64 billion and $1.675 billion. Analysts' average third-quarter revenue estimate is $1.77 billion. The company expects fiscal Q3 non-GAAP earnings per share of $1.36 to $1.38, lower than the consensus estimate of $1.43. The company's full-year outlook also disappointed investors. Agilent forecasts full-year revenue of between $6.93 billion and $7.03 billion. Analysts' average revenue estimate is $7.57 billion. Agilent expects full-year non-GAAP earnings per share of $5.60 to $5.65. The consensus estimate is $6.29. So what Agilent attributed its lower-than-expected guidance to "increased market uncertainties." CEO Mike McMullen also pointed to the "increasingly challenging market environment." The main problems for the company are largely beyond its control. McMullen noted in Agilent's quarterly conference call that "continued macroeconomic uncertainty coupled with stresses in the banking system have accelerated a more conservative approach from our customers." Now what Agilent remains in solid financial shape to weather its current headwinds. The company should be able to deliver stronger growth once the economy gets on a firmer footing. 10 stocks we like better than Agilent Technologies When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Agilent Technologies wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of May 22, 2023 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

It posted net income of $302 million, or $1.02 per share, based on generally accepted accounting principles (GAAP). Although Agilent narrowly topped the consensus Wall Street earnings estimate for the latest quarter, the company's guidance fell short. McMullen noted in Agilent's quarterly conference call that "continued macroeconomic uncertainty coupled with stresses in the banking system have accelerated a more conservative approach from our customers."

The company expects fiscal Q3 non-GAAP earnings per share of $1.36 to $1.38, lower than the consensus estimate of $1.43. Analysts' average revenue estimate is $7.57 billion. Agilent expects full-year non-GAAP earnings per share of $5.60 to $5.65.

Agilent projects fiscal Q3 revenue of between $1.64 billion and $1.675 billion. The company expects fiscal Q3 non-GAAP earnings per share of $1.36 to $1.38, lower than the consensus estimate of $1.43. 10 stocks we like better than Agilent Technologies When our analyst team has a stock tip, it can pay to listen.

The company's non-GAAP earnings were $377 million, or $1.27 per share. The company expects fiscal Q3 non-GAAP earnings per share of $1.36 to $1.38, lower than the consensus estimate of $1.43. 10 stocks we like better than Agilent Technologies When our analyst team has a stock tip, it can pay to listen.

99.0

2023-05-24 00:00:00 UTC

Credit Suisse Maintains Agilent Technologies (A) Outperform Recommendation

A

https://www.nasdaq.com/articles/credit-suisse-maintains-agilent-technologies-a-outperform-recommendation

Fintel reports that on May 24, 2023, Credit Suisse maintained coverage of Agilent Technologies (NYSE:A) with a Outperform recommendation. Analyst Price Forecast Suggests 29.29% Upside As of May 11, 2023, the average one-year price target for Agilent Technologies is 166.32. The forecasts range from a low of 146.45 to a high of $182.70. The average price target represents an increase of 29.29% from its latest reported closing price of 128.64. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.28%. The projected annual non-GAAP EPS is 5.77. Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). Shareholders of record as of July 3, 2023 will receive the payment on July 26, 2023. Previously, the company paid $0.22 per share. At the current share price of $128.64 / share, the stock's dividend yield is 0.70%. Looking back five years and taking a sample every week, the average dividend yield has been 0.74%, the lowest has been 0.44%, and the highest has been 1.14%. The standard deviation of yields is 0.16 (n=236). The current dividend yield is 0.26 standard deviations below the historical average. Additionally, the company's dividend payout ratio is 0.20. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5. The company's 3-Year dividend growth rate is 0.25%, demonstrating that it has increased its dividend over time. What is the Fund Sentiment? There are 2012 funds or institutions reporting positions in Agilent Technologies. This is an increase of 53 owner(s) or 2.71% in the last quarter. Average portfolio weight of all funds dedicated to A is 0.40%, a decrease of 8.32%. Total shares owned by institutions increased in the last three months by 0.70% to 302,422K shares. The put/call ratio of A is 1.12, indicating a bearish outlook. What are Other Shareholders Doing? Wellington Management Group Llp holds 12,057K shares representing 4.08% ownership of the company. In it's prior filing, the firm reported owning 13,408K shares, representing a decrease of 11.21%. The firm decreased its portfolio allocation in A by 17.85% over the last quarter. T. Rowe Price Investment Management holds 9,277K shares representing 3.14% ownership of the company. In it's prior filing, the firm reported owning 9,304K shares, representing a decrease of 0.29%. The firm decreased its portfolio allocation in A by 13.88% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,971K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 8,825K shares, representing an increase of 1.62%. The firm increased its portfolio allocation in A by 15.57% over the last quarter. Massachusetts Financial Services holds 8,907K shares representing 3.01% ownership of the company. In it's prior filing, the firm reported owning 7,868K shares, representing an increase of 11.66%. The firm increased its portfolio allocation in A by 2.60% over the last quarter. Price T Rowe Associates holds 8,219K shares representing 2.78% ownership of the company. In it's prior filing, the firm reported owning 7,707K shares, representing an increase of 6.23%. The firm decreased its portfolio allocation in A by 8.26% over the last quarter. Agilent Technologies Background Information (This description is provided by the company.) Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Key filings for this company: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. Key filings for this company: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K This story originally appeared on Fintel.

In it's prior filing, the firm reported owning 13,408K shares, representing a decrease of 11.21%. T. Rowe Price Investment Management holds 9,277K shares representing 3.14% ownership of the company. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,971K shares representing 3.03% ownership of the company.

Agilent Technologies Declares $0.22 Dividend On May 17, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.90 annualized). VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,971K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 8,825K shares, representing an increase of 1.62%.

The projected annual revenue for Agilent Technologies is 7,130MM, an increase of 1.28%. At the current share price of $128.64 / share, the stock's dividend yield is 0.70%. There are 2012 funds or institutions reporting positions in Agilent Technologies.